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Abstract 
Bacterial lipoproteins feature an N-terminal Type II signal peptide, containing a lipobox motif which 
targets these proteins for post-translational lipidation. Following secretion, pre-prolipoprotein 
diacylglyceryl transferase (Lgt) catalyses the addition of an S-diacylglyceryl moiety to the lipobox 
cysteine thiol. The signal peptide sequence is then cleaved by a lipoprotein signal peptidase (Lsp), 
leaving the modified cysteine as the N-terminal residue of the mature Gram-positive lipoprotein. 
Lipoproteins are surface exposed and play an important role at the host-pathogen interface, as well 
as being implicated in nutrient uptake, sporulation and antibiotic resistance. Clostridium difficile is a 
Gram-positive, spore forming, obligate anaerobe which causes severe gastrointestinal disease in 
humans. Spores are the transmissible agent of C. difficile, with infection typically occurring via the 
faecal-oral route. Lipoproteins of C. difficile are known to function in nutrient uptake and adhesion 
and the lipoproteome is likely to be important in transmission and colonisation. 
Bacterial lipidation is difficult to study by traditional methods, however, metabolic tagging with 
bioothogonally-tagged lipid analogues has recently emerged as a powerful method to study lipidated 
proteins. This thesis describes the development and optimisation of metabolic tagging and 
quantitative chemical proteomics to investigate lipidation in C. difficile. The application of this 
approach to profile the lipoproteomes of 630 Δerm and the clinically relevant “hypervirulent” strain 
R20291 is described. This work includes the use of these probes, in combination with genetic and 
chemical inactivation of lgt, lspA and lspA2, to investigate lipoprotein biogenesis in C. difficile and to 
demonstrate the presence of two active Lsps. A combination of quantitative proteomics and 
phenotypic analysis has identified new functions for the C. difficile lipoproteome, including a role in 
the regulation of flagella and toxin production and in the initiation of sporulation. 
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Chapter 1: Introduction 
This chapter provides an introduction to the topics covered in this thesis and the biological processes 
studied. This chapter is divided into three main parts; the first will discuss the bacterium studied, 
Clostridium difficile, including its characteristics and the tools available to study C. difficile. The 
second section will discuss bacterial lipoproteins, the biosynthesis of lipoproteins by Gram-positive 
and Gram-negative bacteria and the functions of known bacterial lipoproteins. The third section will 
describe the use of metabolic chemical tagging to study Post-Translation Modification (PTM), 
including its application to study lipidation. Finally, the aims and objectives of this thesis will be 
described. 
1.1 Clostridium difficile 
1.1.1 Clostridium difficile Infection 
C. difficile is a Gram-positive, spore forming, obligate anaerobe, and an important nosocomial 
pathogen1. C. difficile infection (CDI) typically occurs following admission to a healthcare facility and 
treatment for an unrelated condition with broad spectrum antibiotics, such as cephalosporins, 
clindamycin, fluoroquinolines or broad–spectrum penicillins2. This depletes the natural gut flora3, 
enabling colonisation by C. difficile4. Transmission typically occurs via the faecal-oral route, although 
infection from spores in the environment is possible. C. difficile spores are highly resistant to 
desiccation, chemical treatment, heat shock and oxygen exposure and can persist in the 
environment for months to years5. Following ingestion spores germinate in response to certain bile 
salts, including cholate derivatives and glycine, in the anaerobic environment of the large intestine6. 
Patients suffering from CDI shed spores in their stools, which contributes to contamination of the 
environment and can lead to outbreaks of C. difficile. A challenging aspect of CDI is recurrent 
disease, with up to 35 % of patients suffering a relapse within 12 weeks of the initial infection. 
Retention of spores from the original infection can lead to relapse, however, it has been found that 
40 to 50 % of such cases are due to re-infection with a different strain of C. difficile3a, 7. 
Although CDI was initially identified as the causative agent of antibiotic associated diarrhoea and 
pseudomembranous colitis8. CDI is now known to include asymptomatic colonization9, as well as a 
spectrum of symptoms from mild self-limiting diarrhoea to more severe disease, including 
pseudomembranous colitis, toxic megacolon, sepsis, and death10. The mortality rate and outcomes 
for CDI patients vary depending on age and co-morbidity, with patients over 65  years of age 
11 
typically suffering worse outcomes11, however, mortality rates are from 3 to 30 % with a mortality of 
rate in the absence of contributing factors of 1.5 %12, rising to 6.9 % in the case of the highly virulent 
NAP1/027 strains such as R2029113. 
Hospitalisation combines multiple risk factors for CDI, including an environment contaminated with 
spores, a susceptible population and exposure to antibiotics; this has led to C. difficile being referred 
to as a “hospital superbug”3a. The associated healthcare cost of treating and managing C. difficile 
outbreaks in the United States has been estimated at $3.2 billion (2005 US dollars). Despite this, 
C. difficile has long been known to asymptomatically colonise 20 to 30 % of infants of less than 6 
months of age14; this figure decreases to 1 to 3 % as the “adult” gut flora becomes established by 1 
year of age. Additionally, a rise in community acquired infections has been reported with up to 36 % 
of cases having had no hospital admission or community contact with sufferers prior to admission9, 
11, 15. Measures adopted to reduce the incidence in CDI include isolation, increased hand hygiene 
measures and environmental decontamination16. These preventative strategies appear to have had 
measure of success with the number of CDI cases reported in the United Kingdom and Europe 
plateauing in recent years17; despite this C. difficile remains a significant burden in the United 
States18. Finally, so-called hypervirulent BI/NAP1 ribotype 027 strains have been increasing in 
prevalence15, 17, 19; these strains produce a binary toxin in addition to the Large Clostridial Toxins 
(LCT), feature a frameshift mutation in the LCT repressor gene tcdC and have acquired resistance to 
fluoroquinolones19. 
Current therapies for CDI depend on the severity of the infection and usually includes 
discontinuation of the inciting antibiotic20. In symptomatic cases, metronidazole is initially used and 
vancomycin is given for recurrent CDI, surgical intervention is required in the most severe cases12. 
Recently a number of novel antimicrobials have been reported to target CDI, with the aim of killing 
C. difficile without perturbing the normal microbiota21. A macrolide antibiotic fidaxomicin, also 
referred to as OPT-80, was approved by the FDA in 2011 and is the only new drug to enter the clinic 
for the treatment of CDI for 20 years; fidaxomicin acts by selectively inhibiting the σ subunit of 
Clostridial RNA polymerase and consequently blocks translation resulting in cell death22. 
While the work described in this thesis was being performed it was observed, on the basis of 
ribosomal and 16S RNA sequence conservation, that C. difficile along with several closely related 
species including C. paradoxum, C. sordelii, C. sticklandii, and Peptostreptococcus anaerobius, belong 
to a distinct family more closely related to the Peptostreptococcaceae23. To acknowledge the fact 
that C. difficile is substantially distinct from C. butyricum (the type species of the genus Clostridiales), 
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it has been suggested that these species be reclassified as Peptoclostridium spp, the type species of 
which is C. difficile23. Other pathogenic Clostridia, including C. botulinum, C. perfringens and C. tetani 
are close relatives of C. butyricum and as such remain members of the Clostridium genus. The new 
nomenclature has been adopted by the NCBI, the EBI and Uniprot, but has yet to achieve 
widespread usage; consequently the nomenclature C. difficile is retained in this thesis. 
1.1.2 The Toxins 
The pathogenicity of C. difficile derives from the action of the LCTs, Toxin A and Toxin B (TcdA and 
TcdB, respectively)24. The genes encoding the LCTs, along with negative (tcdC) and positive (tcdR) 
regulators of toxin expression and a putative pore-forming protein (tcdE) are located in a 19.6 kbp 
island, referred to as the Pathogenicity Locus or PaLoc25 (Figure 1 A). The PaLoc is variable between 
C. difficile strains26, with some strains featuring deletions in toxin A27 and “hypervirulent” ribotype 
027 strains feature a mutation in the repressor tcdC28; non-toxinogenic strains lack the entire 
PaLoc25c. In addition to the LCTs, some C. difficile strains produce a binary toxin composed of cdtA 
and cdtB29 however; these genes are present as pseudogenes in C. difficile 630, the strain used 
during this study30.   
The LCTs, which are of high MW (TcdA, 308 kDa and TcdB, 269 kDa), feature a similar four domain 
structure31, represented in Figure 1 B. The N-terminal region contains the cytotoxic 
glucosyltransferase domain32, which is followed by a conserved Cysteine Protease Domain (CPD) 
which is responsible for auto-proteolytic cleavage of the toxin33. The central domain of the LCTs, 
covering approximately 45 % of the protein, features a large hydrophobic region required for pore 
formation and membrane translocation of the LCTs25b, 34 and the C-terminal region of the LCTs is 
composed of Clostridial Repetitive Oligopeptides (CROPs), which bind to a carbohydrate displayed 
on the host cells surface in a multivalent manner35.  
The LCTs represent a highly evolved molecular system; delivery of the cytotoxic domain to host cells 
is a complex multi-step process, however, a mechanism of action has been proposed36 (Figure 1 C). 
The CROPs bind to a carbohydrate displayed on the host cell surface and the LCTs undergo receptor 
mediated endocytosis.  The LCTs undergo conformational changes in response to the low pH of the 
endosome37, extending the translocation domain and partially unfolding the N-terminal 
glycosyltransferase and CPD domains31b. The translocation domain inserts into the endosomal 
membrane and forms a pore38, it is proposed that the partially unfolded CPD and glucosyltransferase 
domains are passed into the cytoplasm, where they refold. The CPD is activated by a combination of 
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inositol hexaphosphate (Ins6P) binding
39 in the cytosol, which induces a conformational change40 
allowing autocatalytic cleavage releasing the glucosytransferase domain33a, 41. Release of the 
glucosyltransferase domain is required for activity of the LCTs, as catalytic triad mutants in the TcdB 
CPD show reduced cleavage and cytotoxicity25b. TcdA, TcdB and the binary toxin all function by 
inactivating Rho family small GTP-ases42; the LCT glucosyltransferase domain released mono-
glucosylates Rho family GTP-ases43, blocking GTP-ase activity and trapping the Rho family GTP-ases 
in the inactive, GDP bound form42, 44. This disrupts the function of their downstream effectors45, 
including epithelial barrier formation, membrane trafficking and cytoskeletal organisation46. In 
contrast to the LCTs, the binary toxin is composed of a binding (CdtB) and enzymatic (CdtA) 
components and inactivates Rho family GTP-ases by ADP-ribosylation in a manner analogous to the 
C. perfringens iota toxin29b. 
Toxin expression is controlled by a number of regulatory systems, including the transcriptional 
regulators CodY47 and CcpA48 which link toxin production to the nutritional status of the cell, 
repressing toxin production in the presence of Branched Chain Amino Acids (BCAAs) and sugars, 
respectively. It has also been shown that insertional inactivation of the flagella operon results in 
repression of the entire PaLoc49, indicating that motility and virulence are linked in C. difficile. The 
master regulator of sporulation, Spo0A, acts as a negative regulator of toxin production in ribotype 
027 strains50; however, the role of Spo0A in the regulation of toxin production in C. difficile 630 and 
related strains remains uncertain50-51. Finally, it has recently been demonstrated that toxin 
production in C. difficile is mediated by quorum sensing52, indicating that colonisation with C. difficile 
needs to reach a threshold level before toxin synthesis occurs during infection. However, the role of 
quorum sensing in CDI is by no means clear as, although all sequenced strains encode the 
autoinducer pre-peptide, some strains (including 630) are lacking genes encoding the quorum 
sensing response regulators; how these strains respond to the quorum sensing signal therefore 
remains uncertain. 
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Figure 1:  The large Clostridial Toxins. A) The genetic organisation of the C. difficile PaLoc; TcdA and TcdB are coloured white 
while the genes encoding the regulatory proteins, tcdR and tcdC, as well as the putative pore forming protein tcdE, are 
coloured blue. Distances are indicated in kbp. B) A representation of the domain structure of the LCTs, the length of each 
domain, in amino acids, and the catalytic residue annotations given for TcdB. The four domains are indicated. C) The 
proposed mechanism of action of the LCTs; binding to a carbohydrate receptor (1) is followed by endocytosis (2). The low pH 
in the endosome induces a conformational change in the toxin (3) allowing membrane insertion and translocation of the 
CPD and glucosyltransferase domains. The CPD and glucosyltransferase domains refold and InsP6 binds to the CPD, 
allosterically activating it (4). This leads to autocatalytic cleavage of the toxin, releasing the glucosyltransferase domain 
which glucosylates Rho family GTP-ases (5), causing cytotoxicity. 
1.1.3 The Surface Layer 
The surface of C. difficile is covered in a para-crystalline, proteinaceous array referred to as the 
Surface Layer (S-Layer). S-Layers are found in both Gram-negative and Gram-positive bacteria and 
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are particularly common in Archaea53; no single function as been ascribed for S-Layers, however, it 
has been proposed that they can play a role in pathogenesis, offer protection from the environment, 
act as molecular sieves or be important for maintenance of the cell envelope54. The C. difficile S-layer 
forms a regular lattice of two superimposed structures and is capable of self-assembly in vitro55. The 
major components of the C. difficile S-layer are the Low and High Molecular Weight (LMW and 
HMW, 32-38 kDa and 42-48 kDa respectively) Surface Layer Proteins (SLPs) which, unusually, are the 
product of a single gene, slpA56. slpA is located in a 37 kbp cluster of 17 genes57, which includes 11 
other cell wall proteins (Cwp) and the accessory secretory protein SecA2, which is required for S-
Layer translocation58. In addition to the HMW and LMW SLPs the cell surface of C. difficile features 
29 other proteins59 which contain cell wall binding 2 domains (CWB2) analogous to those found in 
the HMW SLP. The CWB2 domains are found as three repeats in all Cwps and are essential for 
anchoring the SLPs and Cwps to the cell surface, via binding to the anionic cell wall polymer PSII60. 
The Cwp family of proteins, summarised in Figure 2 A, have a number of functions the best studied 
of which are the cysteine protease Cwp84 and the adhesins Cwp6661 and CwpV62, the latter being 
expressed in a phase variable manner63 and undergoing autocatalytic cleavage64. 
Despite some variation in length the HMW SLP is highly conserved between strains of C. difficile; in 
contrast the LMW is highly variable56, 65 with the exception of the C-terminal 50 amino acids. The 
LMW SLP is surface exposed66 and the variation in LMW SLP sequence is proposed to be the result of 
pressure from the host immune response and implies a lack of functional constraints54, 56. The HMW 
and LMW SLPs are synthesised as a single polypeptide, SlpA, which is exported by the Sec apparatus 
and cleaved by the cysteine protease65b, Cwp84. Following export and cleavage by Cwp84 the HMW 
and LMW SLPs interact with each other via the 62 C-terminal residues of the LMW SLP and the N-
terminal 40 residues of the HMW SLP67, while the HMW SLP binds to the cell wall via an interaction 
between the CWB2 domains and PSII60. 
Cwp84 was demonstrated to be responsible for SlpA cleavage by an Activity-Based Protein Profiling 
(ABPP)68 approach. Treatment with an Activity Based Probe (ABP) derived from the cysteine 
protease inhibitor E-64 led to an accumulation of unprocessed SlpA in the S-Layer69; affinity 
enrichment of the target protein allowed it’s identification as Cwp84. An independent study 
insertionally inactivated the Cwp84 gene in C. difficile 630 Δerm which resulted in an inability to 
process immature SlpA, validating the role of Cwp84 in S-Layer processing70. Cwp84 has also been 
proposed to degrade extracellular matrix proteins71 and is shed into the media in a truncated, 47 
kDa, form that retains proteolytic activity; this truncated form is the product of autocatalytic 
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cleavage72. However, the major function of Cwp84 is the processing of SlpA into the HMW and LMW 
SLPs. 
C. difficile 630 encodes a paralog of cwp84, cwp13, which shares 63 % sequence identity with 
Cwp84. Cwp13 is encoded as an inactive zymogen and undergoes an autocatalytic cleavage to 
produce the active form73. Cwp13 does not process SlpA, but plays a role in the activation of Cwp84 
by proteolytic cleavage; mature Cwp84 is generated from its immature pro-protein by two 
proteolytic events, the removal of the Type I  signal peptide sequence on export from the cell 
produces a zymogen, which is then activated by cleavage by Cwp13 and another, unknown, 
mechanism73. In the absence of Cwp84, Cwp13 can cleave SlpA within the cell wall binding domains 
of the HMW SLP, providing a mechanism for release of incorrectly folded SlpA, and potentially 
misfolded Cwps in general, from the cell surface73. The proposed model for the processing of the S-
Layer by Cwp84 and Cwp13 is summarised in Figure 2 B. 
Glycosylation of S-Layer proteins is common in other bacterial strains54, 74, with only O-linked glycans 
being found in bacterial SLPs, despite the existence of N-linkages in other bacterial glycoproteins. 
C. difficile does not typically glycosylate the SLPs75, however, strains have recently been identified 
that encode a novel 24 kbp insertion in the S-Layer cassette which has high homology to S-layer 
glycosylation genes76. The function of this insertion and whether these strains have a glycosylated S-
Layer is currently unknown. 
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Figure 2: A) The members of the Cell Wall Binding (CWB2) protein family from C. difficile 630, domains identified using the 
Pfam database are highlighted. Image adapted from Fagan & Fairweather, Nature Reviews Microbiology (2014)
54
 with 
permission, under license number 3590290651549. B) The proposed model for S-Layer processing and activities of Cwp84 
and Cwp13 in C. difficile 630. SlpA, Cwp84 and Cwp13 are exported from the cell by the accessory sec system (SecA2, a) and 
the signal peptide sequence cleaved by a Type I signal peptidase. The proteases Cwp84 and Cwp13 are rendered 
catalytically active by pro-peptide cleavage (b); this occurs auto-catalytically for Cwp13 or via Cwp13 and an unknown 
mechanism in the case of Cwp84. Mature Cwp84 and Cwp13 are incorporated into the S-layer (c). Active Cwp84 cleaves 
SlpA to give the HMW and LMW-SLPs (d) which associate to form the H/L complex (e). Immature or misfolded proteins are 
recognised by Cwp13 and cleaved within their cell wall binding domain allowing release (f); this activity is expected to be 
tightly regulated to avoid unwanted SLP cleavage. Image adapted from de la Riva et al, Journal of Bacteriology (2011)
73
, 
with permission.  
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1.1.4 Sporulation in C. difficile 
In common with members of the Bacillus and Clostridium genera C. difficile is capable of forming 
non-replicating endospores; these spores are resistant to a range of environmental and chemical 
insults, including aerobic conditions, common disinfectants, desiccation, and extreme 
temperatures77. Spores are produced in the gastrointestinal tract of the host during infection and are 
shed in faeces78. Unusually for a pathogenic bacterium, spores are the transmissive agent of CDI and 
consequently are responsible for infection as well as persistence and recurrence79. Spores are a 
metabolically dormant form of the cell; on the initiation of sporulation cells undergo asymmetric cell 
division yielding two cells of unequal size, the mother cell and the smaller prespore.  
Initiation of sporulation commits the cell to form a spore, which requires asymmetric cell division 
and considerable morpohological changes to both the mother cell and the prespore. These cells 
contain identical chromosomes but express different subsets of genes which govern the 
morphological changes required for sporulation, which is arguably the simplest example of cellular 
differentiation80. Consequently, it is unsurprising that this is a tightly regulated process; the initiation 
of sporulation has been most extensively studied in Bacillus subtillis, which is described in 
comparison to C. difficile in this section. In both B. subtillis and C. difficile the transcription factor 
Spo0A is the master regulator of sporulation; Spo0A is activated by phosphorylation (Spo0A~P), 
which links extracellular signals to the initiation of sporulation via a phosphorelay system81. In 
B. subtilis there are five sensor kinases (KinA to KinE); these kinases catalyse the ATP dependant 
phosphorylation of a conserved histidine residue in response to an external signal. The phosphate is 
then transferred to a conserved aspartate of the response regulator Spo0F. Spo0F transfers the 
phosphate to a histidine side chain of phosphotransfer protein, Spo0B, which in turn phosphorylates 
an aspartate side chain of Spo0A, activating it82. To maintain control of the initiation of sporulation, 
specific response regulator aspartyl-phosphate phosphatases can counteract the phosphorelay by 
de-phosphorylation of Spo0F~P (Rap phosphatases)83 or Spo0A~P (Spo0E phosphatases)84.  
Active Spo0A~P binds to the DNA at consensus 0A boxes, repressing genes expressed during 
exponential and stationary growth and activating expression of those required for sporulation, 
mediating the switch to asymmetric cell division85. These include four downstream sporulation-
specific sigma factors, σF, σE, σG and σK; following the initiation of sporulation these are activated 
sequentially and sigma factors act as the key regulators of the sporulation pathway. These sigma 
factors coordinate gene expression between the mother cell and the forespore, with σF and σE being 
expressed during early development in the forespore and the mother cell respectively and σG and σK 
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being expressed during later stages of spore development in the forespore and mother cell, 
respectively85. In B. subtilis σE activity is dependent on σF and expression of σG is directly dependant 
on σF; σK expression depends on both σE and the excision of a sigK intervening (skin) sequence86. 
In C. difficile homologues of SigH, which transcribes spo0A, and Spo0A are present87, however, 
homologues of Spo0F and Spo0B are absent. It is believed that initiation of sporulation is controlled 
by a two-component signal transduction system, rather than the multi-component phosphorelay 
found in B. subtilis51. It has been shown that a KinA homologue in C. difficile, CD630_15790, is 
capable of directly phosphorylating Spo0A, supporting this hypothesis51. C. difficile encodes an 
additional 4 orphan histidine kinases with active site homology to KinA-E of B. subtilis and, although 
the ability of these to directly phosphorylate Spo0A has not been demonstrated, insertional 
inactivation of one of these, CD630_02492, results in a 3.6-fold reduction in sporualtion relative to 
the wild type51. Additionally, SigH activates transcription of CD630_02492 as well as Spo0A further 
implicating it in sporulation initiation87. 
The sporulation-specific sigma factors σF, σE, σG and σK are also conserved in C. difficile, however, it 
has become apparent that the regulation of spore development in C. difficile shows considerable 
differences to that in B. subtilis88. Although the main periods of sigma factor activity are conserved, 
during C. difficile sporulation gene expression is less tightly coupled between the forespore and the 
mother cell; the activity of σE is partially independent of σF and although σE is required for σK activity, 
σG is not required for σK activity and σE is not required for σG activity. Additionally, σK is not essential 
for the formation of heat resistant spores in C. difficile88b, although the loss of σK does lead to a 
reduction in spore formation. In common with B. subtilis, but in contrast to other sporogenous 
Clostridia, the sigK gene of C. difficile features an interrupting sequence (skin). Excision of the skin 
element is required for transcription of σK and is catalysed by SpoIVCA in both B. subtilis and 
C. difficile88b, 89. It has been proposed that, as anaerobic bacteria are considered to have evolved 
before aerobes, the sporulation pathway in C. difficile may reflect an ancestral version of the 
sporulation regulatory network and the more closely regulated system, with tighter coupling 
between gene expression and morphogenesis, observed for the Bacilli may have been gradually 
introduced during evolution90. 
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1.1.5 Genetic Tools to Study C. difficile 
1.1.5.1 ClosTron Mutagenesis 
The C. difficile features a large proportion of mobile genetic elements, predominantly conjugative 
transposons30. C. difficile has long been considered genetically recalcitrant; the first reported 
inactivation of C. difficile genes utilised the targeted insertion of an unstable plasmid into the gene 
of interest by homologous recombination. However, mutants generated using this method are 
unstable and, due to the lack of a selection method, the isolation of integrants inefficient91. Genetic 
manipulation of C. difficile was therefore revolutionised by the development of an efficient method 
for the production of stable mutants by insertional inactivation, referred to as the ClosTron92. 
The ClosTron system utilises a repurposed, constitutively expressed, group II intron from the 
Lactococcus lactis gene ltrB. Group II introns are self-splicing ribozymes93, typically composed of 6 
domains. Domain 4 encodes an Intron Encoded Protein (IEP, ltrA) which is required for mobility of 
the intron and minimally has reverse-transcriptase and maturase activity but can also have DNA 
binding and endonuclease functionality.  The main factors in determining intron site insertion have 
been determined94, making it possible to re-target the group II intron to any gene of interest by 
making specific changes to the intron sequence92a. For use as a genetic tool the ltrB intron has been 
further modified; relocation of the IEP encoding gene distally to the intron on the plasmid backbone 
ensures it will be lost along with the plasmid following mutagenesis, resulting in an extremely stable 
insertion92c, 95. Typically, the IEP encoding domain 4 is replaced with an antibiotic resistance marker 
to enable selection of integrants95. 
To enable positive selection for intron insertion at the gene of interest a retrotransposition-activated 
selectable marker (RAM) was developed. To provide a RAM the intron contains an antibiotic 
resistance gene, erythromycin resistance (ermB) in the case of C. difficile, which is inactivated by a 
nested group I intron. These elements are arranged such that, when the group II intron retro-homes 
to the target gene, the group I intron is lost via self-catalytic splicing restoring antibiotic resistance.  
ClosTron therefore presented considerable advantages over previous methods for inactivation of 
Clostridial genes by allowing the direct positive selection of integrants by erythromycin resistance92a. 
The ClosTron methodology has subsequently been optimised and refined; the latest generation of 
ClosTron plasmids are based on E. coli – Clostridial shuttle plasmids96 which has enabled numerous 
ClosTron plasmids to be created for application to diverse Clostridal species and to enable marker 
recycling92b. The ClosTron insertional mutagenesis methodology has been widely applied for the 
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genetic manipulation of the Clostridia and was utilised to create the first double knock out in 
C. difficile, which demonstrated that either TcdA or TcdB alone can cause CDI symptoms while the 
double knock out is non-virulent97. 
However, the ClosTron system has some limitations associated with it, including the requirement for 
an erythromycin sensitive strain of C. difficile, typically 630 Δerm, which was created from the 
reference strain 630 by serial passage and has consequently accumulated a number of mutations, as 
discussed in section 1.1.5.4, which can lead to different phenotypes being reported between the two 
strains. Additionally, the insertion of the ermB containing intron into the gene of interest can lead to 
polar effects on downstream genes and the strong thlA promoter which drives expression of ermB 
may cause transcriptional interference92a. 
1.1.5.2 Allelic Exchange Methodology 
Recently, allelic exchange methodologies for creating unmarked deletion or insertion mutations in 
the Clostridia have been reported and used to investigate the role of tcdC in regulation of toxin 
production, finding no link between tcdC genotype and toxin production98. Genetic manipulation by 
two-step allelic exchange requires both a positive selection marker for plasmid uptake and a counter 
selection marker for plasmid loss following excision from the chromosome.  Cytosine deaminase 
from E. coli (codA) was utilised as a counter selection marker in C. difficile.  CodA catalyzes the 
conversion of cytosine to uracil and is also capable of converting the harmless 5-fluorocytosine (FC) 
into the highly toxic 5-fluorouracil (FU). As C. difficile does not have a codA homologue, but does 
have a uracil phosphoribosyltransferase (upp) homologue, it was believed that C. difficile would be 
resistant to FC but sensitive to FU, which was confirmed by MIC assays98. 
Due to the low frequency of DNA transfer achieved by E. coli – C. difficile conjugation the use of 
replication deficient “suicide” plasmids was not possible; therefore the vectors used for allelic 
exchange in C. difficile featured an origin of replication derived from a different Gram-positive 
(C. botulinum in the case of C. difficile 630)96. These vectors replicate in C. difficile at a slower rate 
than the host chromosome and so, in the absence of selection, are segregationally unstable98. When 
the plasmid is maintained by antibiotic selection, cells for which the plasmid has integrated into the 
chromosome by allelic exchange will be enriched based on growth rate as the integrants are not 
limited by the rate of plasmid replication and segregation.  
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Figure 3: CodA mediated allelic exchange for a hypothetical gene Y, flanked by regions X and Z. A) A plasmid containing the 
modified form of the gene, Y*, flanked by homologous arms corresponding to X and Z is introduced by conjugation. The 
plasmid is replication deficient and features a positive selection marker (antibiotic resistance, +) and a counter selection 
marker (codA). When the plasmid is maintained by antibiotic the increased growth rate of single crossover integrants 
enables selection for clones in which a homologous recombination event at either X or Z (indicated by arrows) resulted in 
integration of the plasmid into the chromosome. B) Culturing in the absence of selection allows a rare second homologous 
recombination to occur; this can result in loss of either wild type Y (mutant) or Y* (wild type revertant). C) The excised 
plasmid is lost from the cell due to its instability and a counter screen can be performed for clones that have lost codA; the 
nature of the colony (wild type revertant or mutant) is assessed by PCR screening and sequencing. 
Allele exchange cassettes within the plasmids contain regions of homology, of a minimum of 500 bp, 
either side of the sequence to be altered and, following conjugation into C. difficile, single crossover 
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integrants were identified by their larger colony size when grown on antibiotic supplemented media. 
These clones were restreaked to purity and confirmed by PCR analysis; to allow a second crossover 
event to occur (double crossover) single crossover clones were grown on non-selective media for 
96 hours. All growth was then re-plated on defined media containing FC and FC resistant clones 
screened for plasmid loss by antibiotic selection98. Wild type revertants must be distinguished from 
double crossover mutants by PCR analysis. 
Shortly after the use of CodA mediated allelic exchange in C. difficile was first described, a counter 
selection marker free method for integrating DNA into the C. difficile chromosome was reported99.  
The C. difficile pyrE gene encodes orotate phosphoribosyltransferase which is required for 
pyrimidine biosynthesis and, as it renders 5-fluoro-orotate (FOA) toxic to cells, can be utilised as a 
counter selection marker. Ng and co-workers99 exploited this by creating pyrE null mutants of 
C. difficile 630 Δerm and R20291; plasmids encoding pyrE from C. sporogenes, to avoid 
recombination with the native pyrE locus, can therefore be used for counter selection in the creation 
of mutants by allelic exchange in an analogous manner to that described for codA above. The 
advantage of pyrE mediated allelic exchange over codA lies in the ability to use the pyrE null strain 
to, via Allelic Coupled Exchange (ACE), introduce a wild type copy of the deleted gene into the 
chromosome at the pyrE locus concomitant with restoration of the pyrE allele to the wild type – 
restoration of pyrE can then be used as a selection marker for complementation99. This method 
presents several advantages over complementation in trans as it restores a single copy of the gene 
on the chromosome at the pyrE locus, removing the need to maintain the plasmid, and therefore the 
complement, with antibiotics and prevents overexpression in the complement due to the use of 
multicopy plasmids. 
Finally, both codA and pyrE allelic exchange have been further developed for use in C. difficile by the 
use of longer homologous arms of 1,200 bp to improve the efficiency of homologous recombination 
and increasing the opportunity for this double crossover to occur by serial subculture, for up to 9 
days, of single crossover integrants100. Following this time period double crossover clones could be 
isolated without counter selection screening, other than for plasmid loss. This method was further 
extended to Streptococcus suis, demonstrating that the advantages conferred by these innovations 
are not unique to C. difficile100. 
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1.1.5.3 Transposon Mutagenesis Libraries 
A further use for the replication defective “pseudo-suicide” plasmids described in section 1.1.5.2 has 
been found in the generation of transposon mutagenesis libraries in C. difficile. Cartman and 
Minton101 utilised a mariner-transposable element Himar1 which inserts into the nucleotide 
sequence TA, making it appropriate for use in a low G-C content bacteria such as C. difficile. This 
transposon, containing an antibiotic resistance marker, was cloned into a E. coli – C. difficile shuttle 
plasmid and placed under the control of the tcdB promoter; as the plasmid features the C. botulinum 
replicon pBP1, which is replication defective in C. difficile R20291, when conjugated into R20291 the 
transposon inserted into the genome at random; for 98.3 % of mutants obtained the Himar1 
transposon was present as a single insertion101. 
This method has since been extended to C. difficile 630 and to conduct broader phenotypic screens 
in R20291102. Dembek and co-workers also utilised the Himar1 transposon but an alternative plasmid 
which places the transposon gene under the control of a tetracycline inducible promoter, in this 
plasmid the repressor tetR is directed towards the origin of replication and, on the addition of 
tetracycline, transcription of both the transposon gene and tetR increases. This causes dramatically 
increased read through from tetR into the pCD6 origin of replication resulting tetracycline 
dependent plasmid instability. On induction with tetracycline expression of the transposon is 
therefore activated and the plasmid lost102. The use of transposon-directed insertion site sequencing 
(TraDIS) allowed the identification of over 70,000 unique insertion sites in R20291 and the 
facilitated, by the lack or underrepresentation of mutants in these genes in the transposon library, 
the identification by  of a core set of 404 essential genes and a further 798 genes that are important 
for spore formation102. Recently, further developments to this system have created a conditional 
transposon for universal use in the Clostridia103.  
1.1.5.4 Erythromycin Sensitive C. difficile 630 Derivative 
The erythromycin sensitive derivative of C. difficile 630, 630 Δerm104, was used during this study for 
both the production of ClosTron mutants and for metabolic tagging and proteomic analysis, on the 
assumption that the genome of 630 Δerm was essentially identical to that of 630, for which a well 
annotated sequence is available105. However, it is worth noting that a recently reported sequence of 
the 630 Δerm genome106 found 71 differences between the two strains in addition to the 2.4 kbp 
deletion of the main erythromycin resistance genes, of which 21 occur intergenically106. The 
differences included a number of single nucleotide polymorphisms, an 18 bp duplication in spo0A 
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which is not reported to effect the spo0A::erm phenotype107, and the translocation of the CTn5 
transposon, which has been previously demonstrated to be capable of excision108, from a putative 
adhesin, CD630_18440, to rumA (CD630_33930) a uracil methylase that targets ribosomal RNA106. 
Despite this rearrangement, it is probable that the use of the 630 genome sequence during this 
study has not affected the outcomes. 
1.2 Bacterial Lipoproteins 
1.2.1 Bacterial Post-Translational Modifications 
Although it has long been though that protein Post-Translational Modifications (PTM) occurred 
rarely in prokaryotes, with some modifications only being found in higher organisms, it has recently 
become clear that “simpler” forms of life elaborate their proteome with a variety of PTMs109. PTMs 
play a critical role in modulating protein localisation, activity and the formation of protein 
complexes. Prokaryotes are capable of modifying their proteome with a range of PTMs including 
phosphorylation, glycosylation, acetylation, proteolytic cleavage, methylation, linkage to the 
peptidoglycan and lipidation109-110. Many of these PTM are extremely important for bacterial 
physiology and virulence109. Additionally, PTMs are important in host-pathogen interactions as 
bacterial proteins can be modified by the host PTM machinery111 or modify host proteins42, 112; this 
can enable pathogens evade the host immune response, as well as exerting cytotoxic effects113. 
Bacterial lipoproteins are an abundant and functionally diverse class of membrane associated 
proteins114. Protein lipidation by the addition of an N-terminal S-diacylglyceryl modification is a 
conserved PTM found in the vast majority of prokaryotes, including archaea110. This PTM anchors 
bacterial proteins to the membrane via a hydrophobic interaction between the acyl modification and 
cell membrane phospholipids115, providing a mechanism for hydrophilic proteins that perform 
functions within the cell envelope to be retained at the cell surface. In the case of Gram-positive 
bacteria, such as C. difficile, this anchor prevents their loss into the environment. 
1.2.2 Lipoprotein Biogenesis 
1.2.2.1 The Lipoprotein Structure, Export and Biogenesis 
Bacterial lipidation, in both Gram-positives and Gram-negatives, is characterised by the addition of 
an S-diacylglyceryl group to the cysteine side chain thiol at the N-terminus of the mature lipoprotein. 
In Gram-negatives and some Gram-positive bacteria this apolipoprotein is further modified by 
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N-acylation of the N-terminal cysteine, resulting in a triacylated protein. However, the Firmicutes do 
not encode a homologue of the enzyme that catalyses this PTM and the mature lipoprotein is 
historically considered to be diacylated116.  
Bacterial lipoproteins are translated in the cytoplasm as pre-prolipoproteins and have several 
conserved N-terminal features that signal for their export and modification by the lipoprotein 
biogenesis machinery, summarised in Figure 4 B. Other exported proteins feature an N-terminal 
signal peptide sequence, characterised by an N-terminal charged tail, a membrane spanning 
hydrophobic region and an AXA motif that is recognised for cleavage by Type I signal peptidases117. 
In contrast, lipoproteins feature a Type II signal peptide the C-terminus of which contains, in addition 
to the charged tail and hydrophobic region, a four amino acid lipobox motif; the lipobox is 
recognised by the enzyme prolipoprotein diacylglyceryl transferase (Lgt, discussed in detail in 
section 1.2.2.2) which catalyses the initial lipid modification118. The conserved lipobox sequence is 
typically represented as L-3[A/S/T]-2[G/A]-1C+1 where the +1 cysteine is the modified N-terminal 
residue in the mature lipoprotein. However, this canonical sequence has degenerated as more 
lipoproteins have been discovered and only the +1 cysteine is completely invariant119. In Gram-
negative bacteria the three amino acids following the +1 cysteine dictate the localisation of the 
mature lipoprotein and the presence of a +2 aspartate signals for Lipoprotein Outer membrane 
Localisation (Lol) avoidance (section 1.2.2.5) and retention at the cytoplasmic membrane118. The 
Type II signal peptide is separated from the functional fold of the protein by an intrinsically 
disordered tether domain. Tether lengths are highly variable between lipoproteins and are thought 
to act as a spacer between the folded protein and the lipid anchor, enabling proper positioning of 
the lipoprotein for correct function120. 
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Figure 4: A representation of the N-terminal features of exported proteins, including a positively charged tail (N-region) and 
hydrophobic region. A) An exported protein with an N-terminal type I signal peptide; the cleavage site for a Type I signal 
peptidase is indicated by , where X represents any amino acid. B) The N-terminus of a bacterial lipoprotein, featuring a 
Type II signal peptide. The lipobox motif is indicated and the cleavage site for a Type II signal peptidase (Lsp) indicated by 
; lipid modification occurs at the +1 cysteine. The Lol sorting sequence in Gram-negative bacteria is indicated, where X 
represents any amino acid – an aspartate at X+1 signals for retention at the cytoplasmic membrane. Finally, a non-
conserved flexible tether region separates the functional region of the lipoprotein from the lipid anchor.  
The Type II signal peptide sequence represented in Figure 4 B targets the pre-prolipoprotein for 
export via the General Secretory (Sec) pathway121, these proteins are exported in an unfolded 
conformation and fold on the trans side of the cytoplasmic membrane. It was originally assumed 
that all bacterial lipoproteins were exported via the Sec machinery, but it has recently become 
apparent that specific lipoproteins can be selectively exported by the SecA2-dependent accessory 
Sec system found in some Gram-positive bacteria114, 122. Additionally, export of lipoproteins via the 
Twin Arginine Translocation pathway (Tat), which exports folded and oligomeric proteins, has been 
shown to occur. Tat signal peptides are of variable length and feature a conserved SRRXFLK 
sequence in between the charged tail and hydrophobic regions; the twin arginine (RR) motif, which 
gives the pathway its name, is highly conserved114. Translocation of lipoproteins via the Tat pathway 
is particularly common in Mycobacteria123 and Streptomyces spp124 and the discovery of Tat exported 
lipoproteins has led to a re-evaluation of the assumption that only unfolded pre-prolipoproteins 
could be modified. Tat-dependent export of lipoproteins by the Firmicutes has not been reported 
and many Firmicutes lack a functional Tat export pathway. 
The bacterial lipoprotein biogenesis pathway, are described in detail in the following sections, is 
summarised here and in Figure 5. After export, typically by Sec, the N-terminal charged region of the 
signal peptide prevents complete translocation and the hydrophobic region remains embedded in 
the membrane. The lipobox motif, located at the C-terminus of the signal peptide, is recognised by 
prolipoprotein diacylglyceryl transferase (Lgt, section 1.2.2.2)125. Lgt catalyses the covalent 
attachment of a membrane phospholipid substrate to the conserved +1 cysteine side chain, forming 
a thioether linkage126. Following attachment of an S-diacylglyceryl to the cysteine side chain, the 
Type II signal peptide is then cleaved by a lipoprotein signal peptidase (Lsp, section 1.2.2.3) leaving 
the lipidated +1 cysteine as the new N-terminal residue127. The apolipoprotein remains anchored to 
the cytoplasmic membrane by the diacylglyceryl modification; in low G-C content Gram-positive 
bacteria this is the mature form of the lipoprotein. In Gram-negative and high G-C content Gram-
positive Actinobacteria the apolipoprotein is further modified by the enzyme lipoprotein N-acyl 
transferase (Lnt, section 1.2.2.4), which catalyses the acylation of the N-terminal cysteine amine128. 
The hololipoprotein produced is the mature form and is trafficked to the outer membrane by the Lol 
pathway (section 1.2.2.5) by default, unless an aspartate in the +2 position signals for Lol avoidance. 
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This pathway is generally believed to occur in sequence, although there is some evidence that Lsps 
can cleave unmodified pre-prolipoproteins in the absence of lgt129. Finally, unidentified transacylases 
and deacylases can reprocess and remodel apo and hololipoproteins in Staphylococcus aureus130, the 
ramifications of which will be discussed in section 1.2.2.6. 
 
Figure 5: Bacterial lipoprotein biogenesis; the pre-prolipoprotein (A) features an N-terminal Type II signal peptide sequence, 
containing a lipobox. The enzyme prolipoprotein diacylglyceryl transferase (Lgt) catalyses the addition of a diacylglyceryl 
fatty acid to the invariant lipobox cysteine side chain (B). The signal peptide is then cleaved within the lipobox, leaving the 
conserved cysteine as the N-terminal residue. The Apolipoprotein (C) remains anchored to the membrane via the lipid 
modification; this is the mature form in Gram-positive bacteria. (D) In Gram-negative and high G-C content Gram-positive 
bacteria the apolipoprotein is further modified by N-terminal acylation, catalysed by the enzyme Apolipoprotein N-Acyl 
transferase (Lnt). The mature hololipoprotein can potentially be trafficked to the outer membrane via the Lipoprotein 
Localisation (LoL) Pathway or the lipid modification remodelled by de- and trans-acylases.  
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1.2.2.2 Prolipoprotein Diacylglyceryl Transferase (Lgt) 
Prolipoprotein diacylglyceryl transferase (Lgt) catalyses the transfer of a diacylglyceryl moiety to the 
side chain of the lipobox cysteine, forming a thioether linkage125. Lgt activity was initially studied in 
E. coli using membrane extracts and in vitro using Braun’s lipoprotein131 and radioactive 
phospholipids as model substrates125. It was demonstrated that Lgt utilises membrane phospholipids 
as a substrate and that the signal peptide alone is sufficient for recognition and modification by 
Lgt125, 132. The gene encoding the enzyme responsible for lipidation (lgt) could not be identified in 
E. coli by traditional genetic methods as the lipoprotein biogenesis pathway is essential in Gram-
negative bacteria. It is believed that this is due to a combination of the essential nature of some 
outer membrane proteins and the toxic effects of accumulation of unmodified lipoproteins at the 
cytoplasmic membrane114, 133. The isolation of a mutant Salmonella typhimurium strain which 
accumulated unmodified  pre-prolipoproteins in a temperature sensitive manner enabled the 
identification of lgt134. The ability of the corresponding gene in E. coli to restore the lipidation defect 
in temperature sensitive mutants of both S. typhimurium and E. coli demonstrated its function135. In 
contrast, lgt has been found to be dispensable in all Gram-positive bacteria studied to date and a 
number of deletion mutants have been reported, including in the model Gram-positive B. subtilis136. 
The structure of E. coli Lgt has been investigated by comparison between E. coli lgt and the lgt genes 
from diverse bacterial species, including S. aureus, S. typhimurium and Haemophilus influenza137. Lgt 
features significant stretches of hydrophobic amino acids interrupted with hydrophilic regions, 
consistent with a transmembrane location, and a large number of conserved regions, the longest of 
which was proposed to contain a catalytic histidine137. Site directed mutagenesis studies identified 
conserved histidine residues (H103 and H196) and a conserved tyrosine (Y235), the hydroxyl group of 
which is essential, as being important for E. coli Lgt activity138. Recently, a more comprehensive 
study of the structure of E. coli Lgt revealed that it is an inner membrane protein with seven 
transmembrane domains, with the N-terminus located at the external face and the C-terminus at the 
cytoplasmic face of the membrane (Figure 6 A)139. This study also implicated arginine 143, arginine 
239 and glutamate 243 in catalysis and found that all residues required for activity are located in 
membrane spanning regions, indicating that lipid modification takes place within the membrane139. 
No studies of the structure of Lgt from a Gram-positive bacterium have been reported, however, it is 
assumed to be located in the membrane and to adopt a similar fold to that of E. coli. 
Lgt utilises membrane phospholipids as its substrates but exhibits very little selectivity with respect 
to the lipid type attached to phosphoglycerol head group116; the mollicute Archoleplasma laidlawii 
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incorporates myristic, palmitic and stearic acid into the diacylglyeryl anchor in similar proportion to 
that found in the membrane140. Mass spectrometry has identified a range of fatty acids incorporated 
into bacterial lipoproteins, varying between 14 and 20 carbons in length and typically being 
saturated or mono-unsaturated. The diacylglyceryl modification is typically heterogeneous with the 
two fatty acids attached being of different chain lengths116. 
As lgt is dispensable in Gram-positive bacteria, deletion mutants have been created in a number of 
species and are generally lipidation deficient. This has enabled the role of Lgt dependant lipidation in 
virulence to be assessed for a number of strains, however, the picture remains far from clear. In the 
case of Streptococcus pneumoniae, deletion of lgt attenuates virulence in a mouse model of 
infection, indicating that lipidation is required to fully establish infection141. Additionally, deletion of 
lgt in Bacillus anthracis reduces spore germination efficiency leading to attenuated virulence in a 
subcutaneous mouse model142. In contrast, S. aureus mutants lacking lgt display a hypervirulent 
phenotype143 and an lgt mutant in Streptococcus agalactiae, the causative agent of sepsis and 
meningitis in infants, displays increased lethality in a mouse model of infection144. Bacterial 
lipoglycans and lipopeptides featuring diacylglyceryl motifs are recognised by Toll-like Receptor 2 
(TLR2), triggering cytokine production and an immune response in macrophages145. In S. aureus and 
S. agalactiae lipoproteins, rather than lipoteichoic acids (LTA), trigger this immune response144, 146, 
indicating that Lgt dependant lipidation plays an important role in pathogen recognition and the 
host immune response143. Therefore, the effects of lgt mutation on virulence appear to be balanced, 
in a species and strain specific manner, between reduced immune activation and impaired fitness 
resulting from loss of lipidation.  
The majority of bacteria encode only a single copy of lgt but a limited number of Gram-positive 
bacteria, including Bacillus cereus, C. perfringens and the Gram-negative Coxiella burnetti encode 
two copies of lgt114-115.  The precise roles of these lgt paralogues remain unclear, however, it is 
possible that they process a specific subset of lipoproteins. 
1.2.2.3 Prolipoprotein Signal Peptidase (Lsp) 
Type II, or prolipoprotein, signal peptidase (Lsp) cleaves the signal peptide sequence from 
lipoproteins N-terminally to the +1 cysteine, typically following modification by Lgt147. The discovery 
that the cyclic peptide antibiotic globomycin is a specific inhibitor of Type II signal peptidases was an 
important breakthrough in the identification and analysis of Lsps148. Over expression of Lsps confers 
globomycin resistance on susceptible Gram-negative bacteria and this is frequently used to 
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demonstrate Lsp activity149. The genetic localisation of lspA in E. coli was found following the 
identification of an E. coli clone with globomycin resistance and a high level of Lsp activity150; the 
gene encoding lspA was sequenced and introducing insertional mutations demonstrated its Lsp 
activity151. 
E. coli Lsp features four transmembrane regions, with both the N- and C-termini facing the 
cytoplasm, as shown in Figure 6 B152. Lsps from other Gram-negative and Gram-positive bacteria are 
predicted to adopt a similar topology; the role of the 15 most conserved residues has been 
investigated by site directed mutagenesis in B. subtilis153. It was found that 5 of these residues were 
required for activity indicating a role in catalysis, active site geometry or substrate recognition. Of 
these 5, the only residues capable of participating in a known proteolytic mechanism were 
aspartate-102 and aspartate-129; Lsps are therefore believed to be aspartic proteases with Asp-102 
and Asp-129 being directly involved in catalysis153. 
As discussed for Lgt in section 1.2.2.2, Lsp is essential for Gram-negative bacteria, but dispensable in 
Gram-positives and deletion mutants have been used to investigate the role of Lsps in lipoprotein 
processing and virulence in a number of species. In B. subtilis loss of Lsp has no discernible effect on 
viability, competence, sporulation or germination but lsp mutants show increased temperature 
sensitivity127. In common with lgt mutants, defects in lipoprotein processing resulting from deletion 
of lsp have a mixed effect on virulence. Inactivation of lsp from S. suis has no effect on virulence in 
vivo149a; in contrast, lipoprotein functions are impaired on lsp deletion in S. pneumoniae and lsp is 
required for full virulence in mouse models of septicaemia and pneumonia149b. In Listeria 
monocytogenes, lsp expression is strongly induced when the bacteria are engulfed in the phagosome 
of infected macrophages; deletion of lsp results in a reduction in efficiency of phagosomal escape 
indicating that complete processing of lipoproteins is essential for virulence154. Complete lipoprotein 
processing is also required for virulence in Mycobacterium tuberculosis155. Retention of Type II signal 
peptides on inactivation of S. agalactiae lsp reduced the host immune response via TLR2 
activation144, however, this did not lead to an increase in lethality and there are few reports of lsp 
mutants that display increased virulence. 
In most bacteria lsp is present in a single copy although some bacteria possess more than one 
putative lsp paralogue, with examples including L. monocytogenes, Staphylococcus epidermidis and 
Nocardia farcinica114-115. In many cases the function of the second lsp is unclear, in L. monocytogenes 
the presence of a putative second lsp does not compensate for loss of lspA154. It is possible that not 
all accessory lsp genes function as Type II signal peptidases; the Gram-negative Myxococcus xanthus 
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is highly unusual in that it encodes four lsp homologues, lspA1 to lspA4. Individual over-expression of 
all four LspA proteins in E. coli confers globomycin resistance in a Braun’s lipoprotein null 
background, however, LspA1 provided limited resistance indicating that it functions poorly as an 
Lsp156. M. xanthus produces a cyclic macrolactam lactone antibiotic, TA, which inhibits Type II signal 
peptidases in an analogous manner to globomycin157. It was found that LspA3 confers resistance to 
TA when over-expressed in E. coli and deletion mutants in the individual lspA genes produce 
different levels of TA, with ΔlspA4 over producing TA156. It was proposed that LspA4 may play a role 
in sensing TA levels and LspA3 in TA resistance while LspA1 and LspA2 are “housekeeping” Type II 
signal peptidases156. Deletion of the lspA genes in this Gram-negative bacteria was only possible due 
to the existence of multiple, partially redundant, copies. 
It was originally believed that Lsps were only capable of cleaving lipid modified prolipoproteins, 
however, a number of studies have shown that Lsps can process unmodified pre-prolipoproteins in 
the absence of lgt114-115, 118. In S. agalactiae, Lsp cleaves the signal peptide sequence from pre-
prolipoproteins, while in a Δlgt Δlsp double knock out lipoprotein signal peptides are cleaved by a 
Type I signal peptidase144. Cleavage of pre-prolipoproteins by Lsp has also been observed for 
L. monocytogenes and this phenotype has enabled the characterisation of lipoproteins by proteomic 
identification of the lipoproteins shed into the media (discussed in section 1.2.4.2)129. Cleavage of 
pre-prolipoproteins in the absence of lgt has also been observed for Streptomyces coelicolor158 and 
Streptomyces scabies159. These studies indicate that an accumulation of unmodified lipoproteins in 
the cell membrane is unfavourable and alternative processing mechanisms exist to prevent this, but, 
as all reported studies observe Lsp cleavage of pre-prolipoproteins only in the absence of lgt, the 
physiological relevance of this is unknown. 
Finally, the signal peptides of some lipoproteins undergo further processing and, although they are 
often believed to be recycled, can have a significant “afterlife”118. Enterococcus faecalis releases an 8 
amino acid peptide pheromone which regulates the transfer of plasmid DNA by conjugation; this 
peptide is derived from the signal peptide sequence of the lipoprotein CcfA160. A transmembrane 
metalloprotease, Eep, was found to be responsible for processing of the CcfA signal peptide to 
produce the pheromone161. Eep cleaves lipoprotein signal peptides in S. uberis in the absence of 
Lsp162 and a large number of bacteria encode Eep homologues, raising the possibility that this is a 
common fate for lipoprotein signal peptides or that Eep plays a role in the maintenance of secretion 
pathways when lipoprotein processing is compromised162. 
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1.2.2.4 Apolipoprotein N-Acyl Transferase (Lnt)  
Lipoprotein N-acyl transferase (Lnt) catalyses the final step in lipoprotein biogenesis, attaching a 
fatty acid from the 1-position of membrane phospholipids to the N-terminal cysteine amine of the 
apolipoprotein163. Lnt is capable of utilising all available phospholipids as acyl donors, however, the 
kinetics of acylation vary with chain length and phospholipid head group, with phosphatidylglycerol 
being the preferred substrate164. Like Lgt and Lsp, Lnt is essential for Gram-negative bacteria; lnt was 
first identified from a S. typhimurium mutant which displayed temperature sensitive modification of 
apolipoproteins and could be complemented by a DNA fragment encoding the E. coli lnt gene165. 
BLAST analysis has enabled the identification of Lnt homologues in the vast majority of Gram-
negative bacteria and high G-C content Gram-positive bacteria; however, there is no evidence of Lnt 
homologues in low G-C content Gram-positives. Lnt was considered to be essential in all Gram-
negative bacteria but recent evidence has emerged that Lnt is dispensable in Francisella tularensis 
and Neisseria gonorrhoeae166. In the absence of lnt, lipoproteins still sort to the outer membrane in 
these species; this is due to altered Lol sorting complex (discussed in section 1.2.2.5) as these strains 
lack the inner membrane components LolE and LolC and instead feature a homologue LolF, which 
displays a degree of flexibility in the acylation status of lipoproteins recognised, allowing sorting of 
diacylated lipoproteins to the outer membrane166b. 
The membrane topology of Lnt has been investigated by the construction of LacZ and PhoA fusion 
proteins128. E. coli Lnt features 6 transmembrane regions with a large, conserved, periplasmic loop 
between transmembrane segments 5 and 6 (Figure 6 C). Lnt is a member of the CN hydrolase family 
and the essential residues have been identified; the presumed catalytic triad of E267-K355-C387 is 
required for E. coli Lnt activity and is located in the periplasmic loop167. In addition, a further four 
residues in this loop were identified that are essential for activity. A computer generated structural 
model for E. coli Lnt suggests that one pair of these residues may function in active site architecture 
while the other pair faces away from the active site and is anticipated to be involved in phospholipid 
and apolipoprotein binding167.  
Despite the lack of Lnt homologues in Gram-positive bacteria the modification state of Braun’s 
Lipoprotein, when expressed in B. subtilis, is consistent with some N-acylation occuring168. 
Additionally, S. coelicolor encodes two putative Lnt homologues, however, these failed to rescue Lnt 
deficient mutants in S. typhimurium167. Finally, both slow- and fast- growing Mycobacteria, including 
and M. bovis and M. smegmatis N-acylate their lipoproteins and the genes that encode their Lnt 
homologues have been identified169. There is an increasing body of experimental evidence indicating 
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that low G-C Gram-positive bacteria can also N-acylate apolipoproteins, despite the lack of an Lnt 
homologous to that of E. coli (discussed in section 1.2.2.6) and therefore there may be as yet 
unidentified enzymes capable of catalysing this modification116. 
 
Figure 6: A cartoon representation of the membrane topology of the enzymes that catalyse bacterial lipidation. Residues 
essential for activity are indicated in red boxes; residue numbers refer to E. coli. (A) Lgt; the residues required for catalytic 
activity are all located within transmembrane regions. (B) Lsp; the approximate location of conserved regions is given, the 
aspartate residues in transmembrane region 3 and loop 3 are believed to be the catalytic residues. (C) Lnt; the catalytic 
triad is located in the large 276 residue loop between transmembrane regions 5 and 6. 
1.2.2.5 Lipoprotein Localisation in Gram-Negatives 
Diderm (Gram-negative) bacteria modify their lipoproteins at the periplasmic membrane, however, 
many of these lipoproteins perform functions that are required at the outer membrane. Lipoproteins 
are transported between the two membranes by the Lipoprotein Outer membrane Localisation (Lol) 
machinery, an ABC-type transporter system, by default unless a Lol avoidance signal is present118. 
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Localisation is signalled by the amino acids in the +2 position following the Type II signal peptide; the 
presence of an aspartic acid in this position signal for Lol avoidance and retention at the inner 
membrane170. Although the presence of an Asp+2 signals for Lol avoidance, other residues can also 
signal for retention at the cytoplasmic membrane and the +3 and +4 positions have been found to 
play an important role; in Pseudomonas aeruginosa introduction of an artificial Asp+2 signals for Lol 
avoidance but the +3 and +4 positions are innately responsible for lipoprotein localisation171. 
The Lol transporter complex is composed of the periplasmic chaperone, LolA, an outer membrane 
receptor, LolB, and an inner membrane ABC transporter-like complex, which consists of the 
transmembrane proteins LolC, LolD and LolE in a 1:2:1 stoichiometry118. Translocation to the outer 
membrane is initiated by LolE which captures a lipoprotein from the inner membrane and 
simultaneously sequesters a vacant LolA chaperone172. Binding of a lipoprotein to LolE causes 
allosteric changes which increase the affinity of LolD for ATP; ATP binding to LolD then weakens the 
hydrophobic interactions between LolE and the lipoprotein173. ATP hydrolysis provides the energy 
required to extract the lipid groups from the membrane and the lipoprotein is transferred to LolA172. 
LolA binds to the acyl chains and transports the lipoprotein across the periplasm, passing it to LolB, 
which inserts the lipoprotein into the periplasmic face of the outer membrane. A “mouth-to-mouth” 
model for LolE-LolA-LolB interactions has been proposed, with the acyl chains occupying a 
hydrophobic pocket in all three proteins172. Translocation of lipoproteins across the outer membrane 
is rare in the majority of Gram-negative bacteria, but occurs commonly in some species, including 
Borellia burgdorferi118. 
1.2.2.6 Alternative Lipoprotein Processing in Gram-Positive Bacteria 
Due to their lack of an Lnt homologue, it has typically been thought that S-diacylglyceryl addition to 
the N-terminal cysteine is the mature lipoprotein modification in Gram-positive bacteria. Recently, 
MS based analysis has provided evidence for further remodelling of the lipid modification in low G-C 
Gram-positive bacteria and the existence of lyso (N-acyl-S-monoacylglyceryl), N-acetyl and peptidyl 
forms of mature lipoproteins116. In addition to conventional di-acylated lipoproteins, S. aureus 
displays tri-acylated lipoproteins that feature a lipoprotein lipase resistant N-acyl modification174. 
Tri-acylated forms of a conserved lipoprotein, SitC, were found in four S. aureus strains as well as a 
strain of Staphylococcus epidermidis. The current available evidence points towards the tri-acylated 
form being the major lipoprotein modification in S. aureus174. Further to this, lyso and N-acylated 
lipoproteins have been identified by MS analysis as being produced by a number of low G-C Gram-
positive bacteria. 
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Figure 7: Non-canonical lipidation in Gram-positive bacteria
116
. (A) The apo or diacyl- form of a lipoprotein; this is 
traditionally considered to be the mature form of a Gram-positive lipoproteins. (B) The triacyl- form. In Gram-negative and 
some high G-C content bacteria Lnt homologues exist which catalyse this PTM. In S. aureus and other Gram-positive 
bacteria for which this form of lipoprotein has been observed the Lnt has no homology to that of E. coli and remains 
unidentified. (C) The lyso (N-acyl-S-monoacylglyeryl) form. There are two putative mechanisms for the production of this 
PTM, either O-deacylation to remove one of the fatty acids from the glyceryl group (orange), or transfer of a fatty acid to 
the N-terminal amine by a transacylase (red). The enzymes that catalyse both potential reactions remain unidentified. (D) 
The N-acetyl form. This step is catalysed by an unusual, unidentified, Lnt that adds an acetyl group from an unknown 
substrate to the N-terminal amine of a diacyl-lipoprotein. 
The lyso form was found to be particularly prevalent among gut microbes, including E. faecalis, 
B. cereus and Lactobacillus bulgaricus175. The N-acetyl form of lipoprotein modification was found in 
three Bacillus species, including B. subtilis; in the majority of cases these non-canonical modifications 
were observed for at least three lipoproteins175. Lipoproteins that feature the lyso lipid modifications 
are capable of activating the host immune response via TLR2 at a similar level to the tri-acyl form of 
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the lipoprotein, indicating that these forms have physiological relevance. Although the enzymes that 
catalyse these lipid modifications have not been identified, the possibility that they are an 
experimental artefact is further reduced by the discovery that diacyl lipoproteins accumulate under 
certain environmental conditions in S. aureus. Stationary growth phase or acidic pH favour diacyl-
lipoproteins while logarithmic growth phase or neutral pH favours the synthesis of the non-canonical 
triacyl form. Protein synthesis was required for the accumulation of either form, indicating that this 
change occurs post-translationally and was not due to remodelling of the lipid moieties130. The 
discovery of novel lipid modifications and environment mediated changes in lipidation state 
indicates that lipidation in Gram-positive bacteria is more complex and potentially more dynamic 
than has previously been thought. 
1.2.3 Functions of Lipoproteins 
The functions of a large number of bacterial lipoproteins remain unknown, due in part to a lack of 
broadly applicable methods for their identification and study. However, the functions of individual 
lipoproteins have been studied in diverse species or inferred on the basis of homology, revealing 
several conserved functional groups176. Lipoproteins have been implicated in antibiotic resistance; 
the first Gram-positive lipoprotein biochemically identified was an extracellular penicillinase from 
Bacillus licheniformis176-177. Lipoprotein forms of secreted β-lactamases are commonly found in 
Gram-positive bacteria, including S. aureus178, and may represent an intermediate stage in the 
extracellular secretion of the enzyme179. 
ATP-Binding Cassette (ABC) transport system solute binding proteins are numerically the most 
abundant Gram-positive lipoproteins114. ABC transporters are conserved across all forms of life; 
however, only bacteria and archaea encode ABC-type importers. These are dependent on their 
solute-binding proteins for high affinity substrate binding and delivery to the associated permease 
and are vital for selectivity and directionality of the ABC-type solute transporters180. The ami operon 
from S. pneumoniae was first identified as containing lipidated solute-binding proteins and these 
proteins were shown to be essential for the uptake of oligopeptides181. ABC-type transporter solute-
binding lipoproteins have since been studied in several species and classified into at least 9 sub-
families, reflecting their diverse range of substrates114. The known substrates of ABC-type 
transporter solute-binding proteins include sugars, oligopeptides, divalent cations, anions 
(phosphates or sulphates), single amino acids, alkanes and nucleosides114, 176. The primary role of 
ABC-type transporters is nutrient acquisition, however, the substrates imported can also be 
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important signalling molecules, such as  quorum sensing peptides, and regulate processes including 
competence181 and sporulation182. 
Sporulation and germination in B. subtilis involves a number of known and putative lipoproteins176. 
In particular, SpoIIIJ has a membrane localisation and features a consensus lipobox; SpoIIIJ is 
required for the expression of late stage sporulation genes, including σG activity183. It is believed that 
SpoIIIJ functions as part of the communication pathway between the prespore and the mother 
cell183-184. Germination deficient mutants in B. subtilis have also been mapped to putative or known 
lipoproteins, which are believed to be located at the spore surface; these include GerBC, GerAC, 
GerD and GerM176. The gerA and gerB loci encode three proteins (GerAA to GerAC, for example), the 
latter of which is a putative lipoprotein, and are involved in sensing different germination signals185. 
Supporting the role of lipoproteins in the sporulation/ germination cycle, Lgt is essential for 
germination in a number of Bacillus species142, 186. 
Lipoproteins are also known to function in the post-translational processing of exported proteins, 
including membrane insertion and peptidyl-prolyl isomerisation. The membrane insertase, YidC is a 
transmembrane protein in E. coli187, but several Gram-positive members of the YidC family are 
putative lipoproteins114. There are numerous lipoproteins in Gram-positive bacteria with peptidyl-
prolyl isomerase function; these extracellular chaperones include PrsA, which is essential in 
B. subtilis188, and FkbA of Streptomyces anulatus189. These lipoproteins are presumed to be localised 
adjacent to the Sec translocon and to act as chaperones for exported proteins that emerge unfolded 
from Sec. These proteins therefore potentially play an important role in the folding of virulence 
factors of Gram-positive pathogens; for example the peptidyl-prolyl isomerase SlrA of S. pneumoniae 
is required for efficient adhesion in vitro and colonisation in vivo190. 
Approximately one third of total Braun’s lipoprotein in E. coli is found lipidated and linked to the 
peptidoglycan, while the remaining free form is only lipidated, the murein form is proposed to play a 
structural role anchoring the outer membrane to the cell wall191. Interestingly, the transpeptidases 
that catalyse this reaction belong to the ErfK family192, a subset of which are predicted to be 
lipoproteins in other bacteria, including M. tuberculosis  and S. coelicolor114. Almost all Gram-positive 
bacteria feature a sortase enzyme which recognises exported proteins that feature a C-terminal 
sorting signal composed of an LPXTG motif, a hydrophobic region and a C-terminal charged tail. 
Sortases recognise this sorting signal and catalyse cleavage of the protein between the threonine 
and the glycine of the LPXTG motif and transpeptidation to attach the protein to the 
peptidoglycan193. All sortase substrates feature an N-terminal signal peptide which is required for 
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export, but does not affect cell wall anchoring. Sortase substrates with Type II signal peptides have 
not been observed; however, a synthetic fusion of the N-terminus of a S. aureus lipoprotein to the C-
terminus of a sortase substrate, protein A, was found to be both lipid modified and anchored to the 
cell wall194. 
1.2.4 Methods to Study Bacterial Lipoproteins 
1.2.4.1 Traditional Methods 
In the past three main methods have been used to study bacterial lipoproteins; the metabolic 
labelling of lipoproteins with radiolabelled fatty acids, the interference or inhibition of lipoprotein 
processing, and the detection of a conserved lipobox motif by bioinformatic methods176. The use of 
radioactive metabolites, including [2-3H] glycerol, [3H] palmitate and [36S] cysteine, has been applied 
to the study of bacterial lipidation from the infancy of the field. Labelling with radioactive 
metabolites has been used to demonstrate the existence of the PTM125-126, 132, the activity of Lgt134, 136 
and to study the lipidation state of individual proteins, frequently in combination with 
overexpression188b. The use of radiolabelled fatty acids remains a common technique for 
demonstrating lipidation144, despite its hazardous nature, low sensitivity and the long exposure 
times required. 
Disruption of the lipoprotein processing pathway, either by inhibition of Lsps with globomycin154 or, 
in Gram-positive bacteria, the deletion of lgt has also been employed to identify bacterial 
lipoproteins. The inactivation of lgt causes an increase in shedding of pre-prolipoproteins into the 
media (discussed in section 1.2.2.2) and this has been capitalised on for the broader identification of 
lipoproteins by proteomic analysis129. Additionally, the pre-prolipoproteins found in lgt mutants 
migrate differently to apolipoproteins when subjected to PAGE. Separation by 2D gel 
electrophoresis, followed by proteomic analysis has enabled the broader scale identification of 
Gram-positive lipoproteins124, 159. These techniques, however, lack broader applicability as they can 
only be applied to genetically tractable strains. 
Bioinformatic methods, based on recognition of the conserved lipobox motif, have become the 
standard method for the identification of putative lipoproteins176, 195. However, bioinformatic 
methods do not provide biochemical verification of the PTM and fail to identify proteins that 
undergo non-canonical lipidation. As discussed above, all three methods have serious drawbacks and 
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consequently there has been an interest in the development of alternative methods to profile 
bacterial lipidation. 
1.2.4.2 Emerging Methods 
Emerging methods for the identification of bacterial lipoproteins, and surface exposed proteins, 
have focussed on the use of proteomic technologies to broadly study the exoproteome of Gram-
positive bacteria. Initially, this work focussed on analysis of proteins identified from the growth 
medium of B. subtilis mutants lacking extracellular proteases, implicating the extracellular proteases 
HtrA and HrtB in the “shaving” of lipoproteins and their release into the media196. This method was 
then extended to lgt and lsp mutants of S. pneumoniae; the bacterial surface proteins were 
subjected to “shaving” using trypsin immobilised on beads and the peptides released analysed by 
LC-MS/MS. Comparison between the mutant strains and the wild type, in conjunction with non-
specific biotinylation of the surface proteome and precipitation of shed proteins, enabled the 
identification of 95 % of the predicted S. pneumoniae lipoproteome197. Comparison between the 
wild type and lgt mutants provided evidence of canonical lipidation for many of these proteins. 
Finally, metabolic chemical tagging has been applied for the broad scale identification of E. coli 
lipoproteins; this technique has the additional advantage of providing verification of the PTM. 
Metabolic chemical tagging, discussed in detail in section 1.3, is conceptually similar to the use of 
radiolabelled fatty acids in that growing bacteria are treated with a fatty acid analogue, which is 
taken up and metabolically incorporated into the lipid modification. However, the fatty acid 
analogues used feature an unobtrusive chemical tag which allows the attachment by bioorthogonal 
ligation chemistry (section 1.3.2) of either a fluorophore for visualisation, or biotin for affinity 
purification and identification by LC-MS/MS analysis198. Application of this method to E. coli using an 
alkyne tagged analogue of palmitic acid enabled the identification of 87 lipoproteins and the 
detection of a non-canonical modification of YjgF, which does not feature a lipobox199. Metabolic 
tagging approaches are post genomic and are anticipated to display cross-species portability, 
enabling proteomic profiling of the lipoproteomes of diverse bacterial species. 
1.3 Metabolic Chemical Tagging 
1.3.1 Metabolic Chemical Tagging 
Isotopic labelling has a long history of use to track the fate of metabolites, to visualise PTMs, to 
elucidate biosynthetic mechanisms and to label proteins for proteomic or structural analysis. The 
41 
advent of highly selective bioorthogonal ligation chemistries (section 1.3.2) has largely replaced the 
use of radioisotope labelled metabolites to study PTM due to the ease of use, rapid and sensitive 
detection and relative safety of these techniques. The use of bioorthogonal ligations between 
chemically tagged substrate analogues and complementary reporter groups has greatly expanded 
metabolic tagging, enabling the attachment of diverse functionality including fluorophores and 
affinity labels. This allows visualisation of the PTM or the enrichment of the proteins of interest and 
identification by LC-MS/MS, referred to as chemical proteomics (section 1.3.3)200. 
1.3.1.1 Studying PTMs by Metabolic Tagging 
The rapid expansion of genome sequencing has provided a wealth of information and revolutionised 
understanding of biological systems, however, genome sequences alone do not fully explain the 
complexity of higher organisms. For example, the genome of the model Gram-positive bacterium 
B. subtilis features 4,100 protein coding genes201, the single celled eukaryote Caenorhabditis elegans 
features 19,000 genes202 while the human genome contains around 26,588 protein coding genes203. 
The increase in biological complexity between the nematode C. elegans and Homo sapiens does not 
correlate with this small increase in coding sequences and results from gene products performing 
more than one function, which can be due to alternative splicing, leading to different protein 
products. However, it has become apparent that the function of many proteins is regulated by PTMs. 
The proteomes of all forms of life can be elaborated with an array of PTMs, which can be either 
permanent or dynamic, and modulate protein stability, function, activity and localisation204. In 
eukaryotes, epigenetic modifications are also partly mediated and encoded by PTMs, for example 
histone acetylation and methylation, representing an additional level of heritable genomic 
complexity205. 
Exploring PTM using proteomic methods has proved challenging, due to the difficulties identifying 
modified peptides and high background derived from the unmodified fraction of the proteome. 
Identifying post-translationally modified proteins therefore often requires enrichment of the 
modified proteins or peptides200. Metabolic tagging facilitates the introduction of an affinity label to 
the modified proteins of interest, typically via a bioorthogonal ligation (section 1.3.2), a concept that 
has become central to the use of metabolic tagging for chemical proteomics applications. The 
introduction of the initial chemical tag is typically tailored to the PTM of interest, ideally using the 
in situ or in vivo cellular machinery to incorporate a synthetic substrate analogue featuring a 
biologically imperceptible tag (e.g. an alkyne or azide)200, 204. However, the tagged substrate 
analogue can also be incorporated in vitro using purified enzymes or chemoselective reactions206. 
42 
The tag remains functionally silent until a complementary reporter group, or capture reagent, is 
ligated to the substrate analogue enabling visualisation, enrichment and identification of the 
modified proteins200. The metabolic tagging strategy for investigating PTMs is summarised in Figure 
8. Although the tag groups typically used are considered bioorthogonal they are not of insignificant 
size and can affect recognition and metabolism of the substrate analogue; metabolic tagging is 
therefore better suited to the study of larger PTMs, such as lipidation (section 1.3.1.2), where the 
addition of the tag group is less likely to perturb the system. 
The key advantage of using metabolic tagging and chemical proteomics to study PTMs is that the 
technology is post-genomic and, as such, displays high cross species portability200. Additionally, these 
techniques have been applied to both cells in culture and for in vivo studies207 and the introduction 
of fluorescent labels enables imaging of the PTM in live cells208. This method presents significant 
advantages over traditional radiolabelling approaches to visualise PTMs with fluorescent imaging 
being both quicker and more sensitive, while the introduction of an affinity label enables enrichment 
of the modified proteins200. The site of modification can frequently be determined by proteomic 
analysis due to the characteristic mass shift resulting from the tag or affinity label; this is facilitated 
by the use of chemical or enzymatically cleavable capture reagents204, 209. Finally, metabolic tagging 
offers greater selectivity and efficiency of enrichment when compared to the use of antibody or 
affinity matrix based methodologies200. Although tagged substrate analogues have generally been 
found to be well tolerated by cells and whole organisms the disadvantages associated with this 
method include toxicity, unwanted reactivity, probe metabolism and potential off target labelling 
effects200, 204. 
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Figure 8: An overview of the use of metabolic tagging to study PTM. (A) A tagged analogue of the PTM of interest is fed to 
live cells. (B) The probe is incorporated into modified proteins at the side of the PTM. (C) Bioorthogonal ligation chemistry 
enables the attachment of a reporter group. (D) Visualisation or enrichment and identification of the target protein by 
LC-MS/MS is possible. 
Metabolic chemical tagging was first applied to study glycoproteins by the Bertozzi group210; their 
approach involved treating cultured cells with azide- or alkyne-tagged monosaccharides which were 
incorporated into glycosylated proteins. The chemical tags were then elaborated as described above, 
enabling visualisation and enrichment. Glycoslation is a highly complex and heterogeneous PTM and 
a number of glycoside analogues have been reported, enabling the selective enrichment of subsets 
of glycosylated proteins that bear the tagged glycoside211. This technique has been expanded for 
application to diverse species212, in vivo imaging208a and broad scale profiling of O-GlucNAc modified 
proteins213. Metabolic chemical tagging has since been applied to a host of PTMs including 
AMPylation214, acetylation215, SUMOylation216 and ubiquitination217, ADP-ribosylation218 and the D-
amino acids found in bacterial peptdioglycan219. Metabolic tagging has, however, found its most 
significant use in the study of post-translationally lipidated proteins, discussed in section 1.3.1.2. 
1.3.1.2 Application to Lipidation 
Lipid modifications are typically large and hydrophobic, presenting challenges for protein isolation 
and separation and making them difficult to detect by mass spectrometry, despite recent advances 
in this field220. However, these properties make lipid PTMs particularly well suited for study by 
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metabolic chemical tagging. The relatively large size of the PTM facilitates the introduction of a small 
biorthogonal tag, which is unlikely to perturb lipid metabolism or the function of the modified 
protein. Introduction of a fluorescent dye allows sensitive detection, while the ligation of an affinity 
handle for enrichment facilitates identification of the site of modification, presenting considerable 
advantages over of conventional proteomic methods198. Post- or co-translational protein lipidation is 
found in all forms of life and lipidation in bacteria has been addressed in section 1.2199, however, 
sophisticated and diverse lipid modifications are found in eukaryotes and archaea. These 
modifications can be static or dynamic and regulate localisation and membrane associated signalling 
systems; dysregulation of lipidation is frequently implicated in disease and consequently 
considerable effort has gone into profiling eukaryotic lipoproteins198. 
Lipid probes have been developed to target a number of distinct PTMs, with some chemotypes being 
applied to study diverse lipid modifications, summarised in Figure 9. Simple fatty acid based probes, 
which typically feature a terminal alkyne or azide tag, have been applied to several acylation 
PTMs221, including N-, S- and O-acylation as well as to more elaborate modifications including S-
diacylglyceryl modification199 and glycosylphosphatidylinositol (GPI) anchors222. The best 
characterised form of acylation is N-myristoylation, the permanent, co-translational, attachment of a 
C14 fatty acid to the N-terminal glycine of substrate proteins. This is catalysed by 
N-myristoyltransferase (NMT)198, 223. Both azide- and alkyne-tagged myristic acid analogues have 
been used to investigate myristoylation, with alkyne-tagged analogues giving lower background 
labelling (Figure 9 A)221. These probes have been applied to study N-myristoylation in vitro206 and 
in vivo; application to apoptotic human cells provided evidence for post-translational myristoylation 
following proteolysis to reveal a new N-terminal glycine residues224. Metabolic tagging,  in 
combination with selective NMT inhibitors, has also been applied to study myristoylation in the 
parasites Plasmodium falciparum222 and Leishmania donovani225. These studies have greatly 
expanded the number of known NMT substrates and enabled identification of many of these 
proteins at their endogenous levels for the first time. 
While shorter chain length probes (12 to 14 carbons) are selectively incorporated into myristoylated 
proteins, longer chain lengths are incorporated into S-acylated proteins223. S-acylation is a dynamic 
modification which occurs through the formation of a thioester bond at cysteine side chains, 
catalysed by Protein Acyltransferases (PATs) and removed by Acyl-Protein Thioesterases (APTs)198, 
226. The major, and best studied, modification is the attachment of the C16 saturated lipid palmitic 
acid, however, other chain lengths are known and the precise modification is rarely studied. 
S-acylation has previously been investigated by chemical methods which require capping of free 
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cysteines, before hydrolysing the base labile thioester linkages to reveal the acylated cysteine which 
is ligated to thiol-reactive biotinylated capture reagents227 or resins228. This approach is limited by a 
high false positive rate and, due to loss of the modification during analysis, it is impossible to identify 
the site or type of PTM. Metabolic tagging with an alkyne-tagged palmitic acid analogue (Figure 9 B) 
has therefore become the preferred method for studying S-palmitoylation198, 229. Metabolic tagging 
has been applied in a pulse-chase approach to quantify the dynamics of protein palmitoylation230 
and for in situ imaging of palmitoylated proteins231. Fatty acid acylations have been reported at 
residues other than cysteine, including lysine side chains232 and O-palmitoleoylation (C16, mono-
unsaturated) of Wnt proteins is known to be required for Wnt signalling198. Finally, lysine acetylation 
has also been studied by metabolic tagging (Figure 9 C)215b; this requires the use of short alkyne-
tagged acetate analogues or engineered lysine acetyl transferases (KATs)233 but has enabled the 
identification the site of acetylation for a number of known acetylated proteins215a. 
S-prenylation is the attachment of either farnesyl (C15) or genanylgeranyl (C20) isoprenoids to a 
cysteine side chain, typically found in a conserved CAAX motif at the C-terminus of the protein198, 200. 
Prenylation plays a critical role in cellular trafficking, membrane association and signalling and is 
catalysed by either Farnesyl Transferase (FTase) or Gernaylgeranyl Transferase (GGTase-1); a second 
geranylgeranyl transferase exists (Rab GGTase or GGTase-2) which attaches 1 or 2 geranylgeranyl 
groups to cysteine rich sequences at the C-terminus of Rab proteins. Prenylation is conserved in 
eukaryotes, with substrates including Ras, Rho and Rab family GTPases. Additionally, some bacterial 
effector proteins are substrates for prenylation by the host machinery111. Prenylation has been 
studied by in vitro metabolic tagging using recombinant Rab GGTase and an azide tagged 
geranylgeranyl diphosphate analogue234. This method has the advantages of allowing prenylation to 
be investigated in systems which are currently inaccessible to metabolic tagging, including mouse 
models and primary tissue samples234-235. However, detection is limited to the subset of proteins that 
are not already prenylated and consequently the in vivo prenylation state must be inferred. This 
method is therefore restricted to systems where a considerable pool of non-prenylated proteins 
exists; this is frequently achieved by inhibition of the mevalonate pathway using statins, which is 
likely to perturb the system under study198. Metabolic tagging of live cells has been reported, using 
alkyne-tagged isoprenoids (Figure 9 D) which are phosphorylated by a rescue pathway distinct from 
the isoprenoid biosynthetic pathway and incorporated into S-prenylated proteins by FTase or 
GGTases236. As with in vitro profiling, in situ metabolic tagging can use statin treatment to deplete 
endogenous isoprenoids and so drive probe incorporation; the effects of this have been investigated 
by quantitative mass spectrometry using isotope labelled farnesyl analogues236a. 
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Finally, O-cholesterylation is currently known to occur only at the C-terminus of the hedgehog family 
of secreted proteins; this PTM is best studied in the context of sonic hedgehog198. Hedgehog proteins 
undergo post-translational autocleavage of their C-terminal domain, followed by auto-
O-cholesterylation at the C-terminal acid. Both azide-237 and alkyne-tagged238 cholesterol analogues 
have been utilised to investigate this PTM (Figure 9 E), however, over expression of sonic hedgehog 
is typically required for efficient detection. Despite this, optimised alkyne-tagged cholesterol probes 
have been used to detect cholesterylated sonic hedgehog in developing zebrafish embryos238. These 
probes were expected to facilitate the identification of novel cholesterylated proteins and the lack of 
other reported substrates indicates that this PTM may be unique to hedgehog proteins.  
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Figure 9: Structures of probes reported for the investigation of lipid modifications by metabolic chemical tagging; protein 
residues are coloured blue, PTMs in black and alkyne tags in red. (A) Fatty acid probes to target N-myristoylation. (B) Fatty 
acid probes to target S-palmitoylation, lysine N-acylation, Wnt O-acylation and other more complex PTMs. (C) Probes for 
lysine acetylation. (D) Isoprenoid probes to target farnesylation and geranylgeranylation. (E) Cholesterol probes to target 
O-cholesterylation of sonic hedgehog protein. 
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1.3.2 Bioorthogonal Ligation Chemistry 
The use of minimal tag groups is attractive when designing probes for PTMs, as the direct 
attachment of a bulky label is likely to have a negative impact on the selectivity, cell permeability 
and incorporation efficiency of a substrate analogue. However, in order to specifically visualise and 
enrich proteins bearing the PTM of interest the chemistry used to connect the tagged substrate 
analogue and the capture reagent must be chemoselective, within the background of a complex cell 
lysate. A number of appropriate reactions, referred to as bioorthogonal, have been identified and 
optimised for use in chemical proteomic experiments239; a subset of these are referred to as “click” 
reactions. 
For a reaction to be considered bioorthogonal it must have a high thermodynamic driving force, 
making it fast and chemoselective, especially so with respect to the chemical groups found in 
biological systems. The reaction must proceed under mild, aqueous conditions, be compatible with 
living systems and highly efficient240. In addition to these attributes, to be considered a “click” 
reaction it must also enable a wide variety of functional partners to be coupled, be stereospecific, 
generate non-toxic by products and require simple reaction conditions241. Bioorthogonal reactions 
have been employed for use in metabolic tagging204, ABPP242 and to label proteins containing non-
natural amino acids243; the most commonly employed reactions are discussed below. 
1.3.2.1 Azide-Alkyne Cycloadditions 
The [3+2] cycloaddition between an alkyne and an azide is the prototypical “click” reaction, originally 
described by Huisgen240. Although the uncatalysed reaction is relatively slow and lacks 
stereospecificity, the copper I catalysed azide-alkyne cycloaddition (CuAAC) has a dramatically 
improved reaction rate and yields a single regioisomer, the 1,4 disubstituted triazole (Figure 10 A)244. 
A copper I catalyst is unsuitable for direct use in biological contexts as it requires an amine base and 
acetonitrile as a co-solvent and lacks efficiency, with the formation of undesired side products being 
observed. However, generating copper I in situ by the reduction of copper II results in a high 
yielding, aqueous compatible, bioorthogonal reaction244b. This requires three components in 
addition to the azide and complementary alkyne; copper II (typically in the form of CuSO4), a 
reducing agent to convert this to copper I and a ligand to stabilise the copper I catalyst during the 
reaction. Considerable effort has gone into optimisation of the reducing agents and ligands to 
ensure a high yielding, selective, reaction. In particular it has been found that the use of alkyne-
tagged probes and azide-tagged capture reagents limits background labelling245 and that hydrophilic 
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ligands increase both the rate and selectivity of the reaction246. CuAAC has developed into a widely 
used, highly robust reaction, occurring under ambient conditions, across a pH range from 4 to 12 
and in many solvents, including water. It is ideal for applications in metabolic tagging and chemical 
proteomics240, 247. Finally, this reaction forms an aromatic triazole; conjugating this to a larger 
aromatic system has enabled the development of fluorogenic capture reagents, which have greatly 
facilitated live cell imaging219a, 248. 
Although CuAAC is widely applied in vitro and has been used for imaging fixed cells the toxic copper 
catalyst limits its uses in vivo249. To circumvent this, a strain promoted azide-alkyne cycloadditon 
(SPAAC) has been developed which does not require a copper catalyst (Figure 10 B)250. This utilises a 
highly strained cyclooctene ring which, due to a bond angle of 163⁰ at the alkyne, has 18 kcal mol-1 
of ring strain. The release of this ring strain on reaction with an azide provides an entropic driving 
force for the reaction, which occurs readily under physiological conditions250. This process has been 
used for live cell imaging both of PTMs and in genetically encoded cyclooctene containing non-
natural amino acids251 and fluorogenic cyclooctenes have been reported252. However, CuAAC is both 
faster and more selective than SPAAC246a and the large cyclooctene group is likely to perturb 
biological systems if included in a substrate analogue to study PTM; SPAAC is therefore limited to 
systems where the probe features an azide tag. 
50 
 
Figure 10: (A) The mechanism of the copper I catalysed azide-alkyne cycloaddition (CuAAC). Initially, a copper acetylide 
forms, the azide associated with the catalyst and the reaction takes place in a stepwise annealing process via a 6-
membered copper containing intermediate to generate the 1,4-disubstituted triazole. R
1
 and R
2
 can be any group, typically 
a probe protein conjugate and the capture reagent, respectively. (B) The mechanism for the strain promoted azide-alkyne 
cycloaddition (SPAAC); the reaction is a typical 1,3-dipolar [3+2] cycloaddition. 
1.3.2.2 Other Bioorthogonal Reactions 
Although CuAAC and SPAAC are widely used, several alternative bioorthogonal ligation chemistries 
exist239-240, which have either been used in place of azide-alkyne cycloaddition reactions or in 
combination with them to enable dual labelling of the same protein237. The Staudinger ligation is one 
of the earliest reported bioorthogonal reactions and has found widespread use in chemical 
proteomics and metabolic tagging253. The Staudinger ligation is catalyst free and was developed from 
the Staudinger reaction between a phosphine and an azide254. By altering the structure of the triaryl 
phosphine to include an electrophilic trap, the aza-ylide intermediate rearranges to form a stable 
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amide, linking the azide-tagged probe to the phosphine containing capture reagent (Figure 11 A)253. 
A traceless Staudinger ligation has also been developed which connects the phosphine to the 
electrophile by a cleavable linker; on ligation this releases the phosphine oxide leaving a simple 
amide as bond linking the probe and capture reagent253a. However, the Staudinger ligation is limited 
by the instability of the phosphine to oxidation, which can result in increased background labelling 
and requires storage of the capture reagents under inert atmosphere255.   
 
Figure 11: (A) The mechanism of the “traceless” Staudinger ligation; the ester acts as an electrophilic trap and the 
intramolecular reaction takes place faster than the competing intermolecular hydrolysis. R
1
 and R
2
 can be any group, 
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typically a probe protein conjugate and the capture reagent, respectively. (B) The reverse electron demand Diels-Alder 
reaction between a strained alkene and a tetrazine; loss of nitrogen gas provides a strong entropic driving force. 
Several other reactions have been reported for use in bioorthogonal ligations, including aldol 
condensations256, the condensation of a ketone and a hydroxylamine to form an oxime and metal 
catalysed cross-metathesis and cross couplings239. However, the majority of these reactions require 
non-physiological conditions or toxic catalysts and lack the selectivity or efficiency to be considered 
truly bioorthogonal. The exception to this is the Diels-Alder reaction, which has recently found 
increasing use in chemical proteomic applications. The Diels-Alder is a [4+2] cycloaddition between 
an electron poor alkene (dienophile) and an electron rich diene and is selective, bioorthogonal and 
can proceed efficiently under aqueous conditions240-241. This reaction has been employed for 
bioorthogonal conjugations but is limited by the nature of the dieneophile; electron deficient 
alkenes act as Michael acceptors, leading to non-specific labelling of reactive cysteines, and 
preventing its application in vivo257. Reverse electron demand Diels-Alder reactions, which substitute 
a tetrazine for an electron deficient diene (Figure 11 B), have developed this into a truly 
bioorthogonal reaction and enabled in vivo258 use and live cell imaging259. Further refinements 
include the use of strained cyclic alkenes (dieneophiles), which in an analogous manner to that 
discussed for SPAAC (section 1.3.2.1), greatly increase the rate of reaction239. Finally, replacement of 
an alkene dienophile with an isonitrile also improves reaction efficiency260. 
1.3.3 Proteomic Analysis 
Proteomics is the characterisation, frequently in a quantitative manner, of the protein complement 
to the genome of a biological sample261. To study the proteome in depth rapid, parallel, analysis is 
required; in the past the techniques used have included protein microarrays, large scale yeast two-
hybrid screens and high throughput protein production and crystallisation262. These methods have a 
number of limitations and all fail to reflect conditions in vivo; consequently mass spectrometry (MS) 
based proteomics has become the principle method for the analysis of the protein components of 
biological systems261. 
1.3.3.1 Mass Spectrometry Based Proteomics 
The most useful output of metabolic chemical tagging experiments is the enrichment and 
identification of the modified proteins; this is typically performed using MS based proteomics. MS is 
now central to most proteomic studies, for peptide and protein identification the use of tandem 
mass spectrometry (MS/MS) is particularly important263. Here, following mass analysis (MS1) peptide 
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ions are selected (typically the top 10 to 20 most intense ions) and fragmented, before being 
subjected to a second round of mass analysis (MS2). As peptides primarily fragment at the amide 
bonds the sequence of the peptide can therefore be determined; this is typically performed by 
comparison to in silico predicted fragmentation patterns261. 
Two major strategies exist for proteomic analysis; “top-down” proteomics and “bottom-up” (or 
shotgun) proteomics. The former method refers to the MS/MS analysis of intact proteins, which are 
separated by HPLC and analysed by MS263. Despite recent advances264, the complexity of samples is 
often limited to a single protein or simple mix of proteins; complex samples are separated by SDS-
PAGE or 2D gel electrophoresis, bands or spots cut and the isolated proteins of interest analysed in 
individual MS runs. The primary advantage of this method is that the whole protein of interest is 
analysed, ensuring that the characterisation of the protein is as complete as possible, including 
information on domain-domain and protein-protein interactions and the identification of any 
PTMs265. However, proteome coverage is extremely, this method is limited to low molecular weight 
proteins, biased towards proteins with certain characteristics and requires mass spectrometers with 
high resolution and sensitivity265. A combination of “top-down” and “bottom-up” approaches has 
been employed for the detailed analysis of protein PTM266. 
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Figure 12: (A) “Top-down” and (B) “bottom-up” mass spectrometry based proteomics. 
In contrast, “bottom-up” proteomics is an unbiased approach in which the entire sample is digested, 
usually enzymatically with trypsin, into short peptides which can be fractionated prior to further 
separation and identification by LC-MS/MS analysis. The key advantages of this technique are the 
simple and fast experimental design; additionally it lacks the bias inherent in the “top-down” 
approach and in theory all proteins for which peptides are detected can be identified263. In practise, 
however, the dynamic range of the instrument used can seriously limit this and the sequence 
coverage for low abundance proteins can be very low. Despite this, advances in instrumentation and 
combinations of on- and off-line fractionation prior to MS/MS analysis have enabled extremely high 
proteome coverage using “bottom-up” methods267. “Bottom-up” proteomics has facilitated the 
identification of the sites of PTM, as digestion into peptides enables the modified amino acid to be 
assigned unambiguously by MS/MS268. Additionally, the application of “bottom-up” proteomics to 
the identification of PTM proteins enriched from metabolically tagged samples has become 
routine229.  
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1.3.3.2 Quantitative Proteomics 
The development of quantitative proteomics has become important for the production of 
statistically robust datasets, especially when considerable sample processing is performed before 
LC-MS/MS analysis. Quantitative proteomics has also enabled an accurate comparison between 
samples, allowing dynamic biological process to be visualised at a protein level265. Quantitative 
techniques can be grouped into three main areas; label free quantification (LFQ), metabolic labelling 
and chemical labelling. LFQ is widely used as sample preparation is extremely simple. LFQ can either 
be performed at a chromatographic level, by aligning the LC traces based on peptide mass 
fingerprinting and quantifying changes in peak area or intensity, or by spectral counting of identified 
proteins269. However, LFQ methods require careful sample processing and standardisation, and do 
not control for variations in performance of the LC-MS/MS system between runs. 
Metabolic and chemical labelling methods modify proteins or peptides such that samples from 
different experimental conditions can be combined and analysed in the same LC-MS/MS run, 
controlling for variations in instrument performance. Metabolic labelling techniques grow the 
organism of interest in the presence of isotopically heavy metabolites, such as 15N or isotope 
labelled amino acids, which are incorporated into proteins. Light and heavy isotope labelled samples 
are mixed prior to LC-MS/MS analysis and the relative abundance quantified by comparing MS1 
intensity for the heavy and light peptides. Initial studies used 15N labelling270, but the most common 
approach utilises heavy isotope labelled essential amino acids (Stable Isotope Labelling by Amino 
acids in Cell culture, SILAC)271, discussed in detail in Chapter 5.3.1.1. Chemical labelling techniques 
are more diverse and quantification can either be performed at the MS1 or MS2 level265. Isobaric 
tags, including iTRAQ272 and TMT273, are amine reactive tags used to label peptides. The isobaric 
reagents have the same precursor mass but on fragmentation in the MS2 generate a distinct pattern 
of isotope encoded reporter ions, the relative abundance of which is used for quantification. The 
iTRAQ reagents enable the simultaneous quantification of up to 8 samples in a single LC-MS/MS 
run265. Dimethyl labelling relies on a reductive amination between the N-terminal amine of digested 
peptides and isotope labelled formaldehyde and borohydride reducing agents274; quantification is 
then performed in the MS1. Although dimethyl labelling only allows a limited number of samples to 
be compared simultaneously, the low cost of reagents and efficient quantification have made 
dimethyl labelling, discussed in detail in Chapter 5.4.1.1, a popular choice for relative 
quantification265. Finally, absolute quantification (AQUA) of proteins by LC-MS/MS is also possible by 
spiking a stable isotope labelled synthetic peptide derived from the protein of interest into the 
sample to be analysed275. 
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1.4 Aims and Objectives 
The aim of this thesis is to investigate S-diacylglyeryl modification of lipoproteins in the nosocomial 
pathogen C. difficile, using metabolic tagging and chemical proteomic techniques. The lipoproteome 
of C. difficile is anticipated to play an important role during infection and individual lipoproteins have 
been shown to function in sporulation and adhesion, processes vital for transmission and 
colonisation of this pathogen. Despite this, the C. difficile lipoproteome has not been subjected to 
systematic study and the lipoprotein biogenesis machinery is uncharacterised. Metabolic tagging has 
been applied to study lipidation in many other systems, including Gram-negative bacteria, but has 
not been applied to a Gram-positive species or a bacterial pathogen. The objectives of this study 
were therefore: 
 To synthesise chemical probes for metabolic tagging of bacterial lipoproteins and to develop 
a general approach to target lipoproteins in C. difficile. 
 To use these techniques, in combination with genetic manipulation, to investigate 
lipoprotein biogenesis in C. difficile. 
 To identify and validate the lipoproteome of clinically relevant C. difficile strains.  
 To study the role of the lipoproteome in virulence, persistence and transmission of this 
important pathogen.
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Chapter 2: Bioinformatics Analysis of the Clostridium 
difficile Lipoproteome 
2.1 Lipoprotein Prediction Methodology 
To inform this investigation into the C. difficile lipoproteome it was considered important to 
generate a list of predicted lipoproteins. This would provide insight into the number of lipoprotein 
identifications expected in proteomic experiments and provide a database to cross reference 
proteomic hits against. Additionally, the protein identifiers could be used to extract information on 
the anticipated functions of the C. difficile lipoproteome. A number of bioinformatics tools for the 
identification of bacterial lipoproteins exist, using pattern matching techniques or Hidden Markov 
Models; these methods have been compared by Rahman and co-workers276. They recommend an 
approach based on the employment of ScanProsite277 (available at 
http://prosite.expasy.org/scanprosite/) as a pattern matching tool to generate an initial list of 
proteins that feature a Type II signal peptide. These can then be further analysed with a number of 
online tools to confirm the presence of a lipobox (as shown in Figure 13, typically 
L-3-[A/S/T]-2-[G/A]-1-C+1), as well as to eliminate false positives that have a Type I signal peptide or 
multiple transmembrane helices. 
For the bacterial strains discussed in this chapter lists of potential lipoproteins were generated using 
sequence patterns that define a Type II signal peptide sequence and lipobox; these are the Prosite 
pattern PS51257 and the optimised Gram-positive pattern reported by Rahman et al276 referred to as 
G+LPPv2. G+LPPv2 was created based on a comparison of the signal peptide sequences of 90 
experimentally verified Gram-positive lipoproteins, while PS51257 is derived from experimentally 
verified Gram-negative and Mycobacterial lipoproteins and considerably more relaxed in the -2 
and -3 positions. PS5127 typically returns a greater number of hits, with a corresponding increase in 
false positives, although true positives may be missed by G+LPPv2. In this study the complete 
proteomes of three C. difficile strains and Bacillus subtilis strain 168 were searched with both 
PS51257 and G+LPPv2 using ScanProsite. This approach was chosen to minimise the number of false 
negatives and maximise the list of predicted proteins for further analysis; although PS51257 typically 
returns a larger number of hits it was observed that some proteins were predicted to be lipidated by 
G+LIPPv2 but not PS51257. The Prosite patterns used for the initial search are shown in Figure 13 
and compared to the canonical lipobox motif.  
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Figure 13: The Prosite pattern PS51257 and the refined pattern G+LPPV2, written in Prosite syntax; ambiguities are 
indicated by square brackets containing allowed amino acids, or curly brackets containing forbidden amino acids. Elements 
are separated by “-“ and the number of repeats of each element given by numerals in parenthesis following the element. < 
indicates the N-terminus. For PS51257 the +1 cysteine must also appear between residues 15 and 35. The canonical lipobox 
sequence is shown for comparison. 
To eliminate false positives the PS51257 and G+LPPV2 hits were further analysed using the online 
tools LipoP (http://www.cbs.dtu.dk/services/LipoP/)278, SignalP 
(http://www.cbs.dtu.dk/services/SignalP/)279 and Phobius (http://phobius.sbc.su.se/)280. LipoP 
identifies Type II signal peptide sequences, including the lipobox and was the most specific 
predictive tool studied by Rahman and co-workers. SignalP identifies Type I signal peptides and was 
used to confirm that all the hit proteins featured a well-defined signal peptide sequence. Phobius is 
a combined transmembrane topology and signal peptide predictor and was used to confirm the 
presence of a signal peptide, while also identifying false positives that feature multiple 
transmembrane regions; proteins that were predicted to have a single transmembrane region were 
not excluded on the basis that this could correspond to the hydrophobic region of a mispredicted 
signal peptide.  
The datasets produced by PS5127 and G+LPPv2 were then combined and duplicates removed in 
Microsoft Excel. Proteins that were not predicted to be lipoproteins by LipoP, instead being 
predicted as either featuring a Type I signal peptide, transmembrane domains, or as being cytosolic 
were immediately discarded. Hits that were predicted to be a lipoprotein by LipoP but for which 
SignalP and Phobius both predicted either a cytosolic or transmembrane location were also 
removed. Of the remaining proteins those that were predicted by LipoP to feature a Type II signal 
peptide and were predicted to have a signal peptide by both SignalP and Phobius were recorded as 
“Probable Lipoproteins”. Proteins for which LipoP predicted a Type II signal peptide sequence but 
which one of either SignalP or Phobius did not predict a signal peptide sequence for were recorded 
as “Possible Lipoproteins”. A summary of this workflow is given in Figure 14. The proteins which 
were predicted to be lipidated by this method were then manually compared by their annotated 
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function, protein name and Uniprot Gene Ontology (GO) annotation, all of which were extracted 
from Uniprot.  
 
Figure 14: The bioinformatic workflow employed in this study to predict the lipoproteome of Gram-positive bacteria. 
2.1 Bioinformatic Analysis 
2.1.1 Clostridium difficile 630. 
C. difficile 630 and its erythromycin sensitive derivative, 630 Δerm, are the most commonly used 
laboratory strains due to the availability of a complete genome sequence and the early development 
of tools for genetic manipulation in these strains. For these reasons, the majority of the following 
experiments were to be performed in these strains and the method described in Chapter 2.1 was 
therefore applied to C. difficile 630 (ribotype 012). This method generated a total of 68 predicted 
lipoproteins, composed of 61 probable lipoproteins and a further 7 possible lipoproteins, as shown 
in Figure 15. Many of these were expected to be lipidated on the basis of homology to 
experimentally verified lipoproteins. This includes the chaperone PrsA, which is known to be 
lipidated in B. subtilis188b, and the ABC- type transporter solute binding proteins181 identified, which 
play an important role in nutrient uptake. Many of these proteins are only annotated as putative 
lipoproteins. 
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Figure 15: A breakdown of the predicted lipoproteins in C. difficile 630 by (A) prediction strength (Probable or Possible) and 
by annotated function, for all Predicted lipoproteins (B). 
A list of probable and possible lipoproteins is given in Table 1, briefly a large number of the predicted 
lipoproteins are ABC-transport solute-binding proteins (28, 41%) and a similarly large number (23, 
34%) are of uncharacterised function or putative existence. However a number of enzymes were 
also identified, including a metallopeptidase, a polysaccharide deacetylase and 4 nucelotidases or 
phophodiesterases. Additionally two cell wall binding proteins, Cwp22 and Cwp27, were predicted to 
be lipidated, as was the sporulation specific protein SpoIIIAG. This indicates that the lipoproteome of 
C. difficile 630 may play numerous roles beyond nutrient uptake and may also be important for cell 
wall remodelling, protein export and sporulation. 
Table 1: The numbers and functions of the predicted lipoproteins in C. difficile 630, divided into Probable and Possible 
lipoproteins. 
Functional Class Number Percentage 
Probable Lipoproteins 
ABC Transport System Solute Binding Proteins 26 38.8% 
Putative & Uncharacterised Proteins 21 31.3% 
Metallopeptidase 1 1.5% 
Transmembrane Transport 1 1.5% 
Polysaccharide Deacetylase 1 1.5% 
Nucleotidase/ Phosphodiesterase 4 6.0% 
PrsA-like Chaperones 2 2.9% 
Thioredoxin 1 1.5% 
Ribosome Recycling Factors 1 1.5% 
Signalling Proteins 1 1.5% 
Cell Wall Binding 2 2.9% 
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Functional Class Number Percentage 
Possible Lipoproteins 
ABC Transport System Solute Binding Proteins 2 2.9% 
Putative & Uncharacterised Proteins 2 2.9% 
Transmembrane Transport 2 1.5% 
Signalling Proteins 1 1.5% 
Sporulation Specific 1 1.5% 
 
2.1.2 Clostridium difficile R20291. 
This analysis was also performed for the “hypervirulent” strain C. difficile R20291; R20291 is a 
ribotype 027 strain and was of interest as it has been associated with a number of epidemic 
outbreaks. R20291 features 234 additional genes when compared to strain 630, as well as a 
truncation in the toxin regulatory tcdC gene resulting in de-repression of the Toxins, TcdA and TcdB, 
leading to more severe infection. Additionally R20291 has acquired resistance to fluoroquinolone 
antibiotics, complicating treatment281. A genome sequence is available for C. difficile R20291, making 
it amenable to proteomic analysis, and recent advances in genetic manipulation98 have enabled the 
construction of deletion mutants in this strain. Using the method described above, 53 probable and 
9 possible lipoproteins were identified, the numbers are comparable to C. difficile 630 with 5% more 
of the predicted lipoproteins being possible rather than probable; the total number is slightly 
reduced with 62 lipoproteins predicted, relative to 68 for C. difficile 630; this is represented in Figure 
16. 
 
Figure 16: A breakdown of the predicted lipoproteins in C. difficile R20291 by (A) prediction strength (Probable or Possible) 
and (B) by annotated function, for all Predicted lipoproteins. 
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These are of broadly similar annotated function to those identified in C. difficile 630, implying a 
degree of conservation in the function of the lipoproteome across C. difficile strains. A similar 
proportion to strain 630 are ABC-transport solute-binding proteins (27, 43%), however, there are 
considerably more uncharacterised or putative proteins (28, 45%) and correspondingly fewer 
proteins with an annotated function. For several of the other predicted lipoproteins there is a close 
homolog in strain 630. These include a phosphodiesterase, a polysaccharide deacetylase, a 
thioredoxin and the sporulation specific protein SpoIIIAG, which was predicted to be a possible 
lipoprotein in both strains. A breakdown of the functions of the predicted lipoproteins for R20291 is 
shown in Table 2. The extracellular chaperones PrsA and PrsA2 (CDR20291_3337 and 
CDR20291_1406, respectively) were missing from this list; this was unexpected as PrsA has been 
experimentally determined to be a lipoprotein in the model Gram-positive B. subtilis188b and will be 
discussed further in section 2.2. 
Table 2: The numbers and functions of the predicted lipoproteins in C. difficile R20291, divided into Probable and Possible 
lipoproteins. 
Functional Class Number Percentage 
Probable Lipoproteins 
ABC Transport System Solute Binding Proteins 25 40.3% 
Putative & Uncharacterised Proteins 23 37.1% 
Polysaccharide Deacetylase 1 1.6% 
Nucleotidase/ Phosphodiesterase 1 1.6% 
Thioredoxin 1 1.6% 
Cell Surface Protein 2 3.2% 
Possible Lipoproteins 
ABC transporter, substrate-binding lipoprotein 2 3.2% 
Putative & Uncharacterised Proteins 5 8.1% 
Metallo Beta-Lactamase Superfamily 1 1.6% 
Sporulation Specific 1 1.6% 
 
2.1.3 Clostridium difficile M120. 
The final C. difficile strain to which this analysis was applied was strain M120, a ribotype 078 strain 
which is evolutionarily divergent from 630 and R20291. M120 is capable of infecting animals, with 
outbreaks in pigs being frequent, but also infects humans and as such could provide an 
environmental reservoir for the bacterium. Interestingly, M120 human isolates have been found to 
contain a 100 kbp insert (Tn6164) which encodes over 90 proteins derived from phage, transposons 
and plasmids and includes several potential antibiotic resistance genes282. This insert has not been 
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found in any of the animal isolates of M120 studied to date. Bioinformatic analysis of strain M120 
was anticipated to provide an insight into how well conserved the C. difficile lipoproteome is across 
more distantly related strains, including those capable of infecting both animals and humans. 
Although the genome sequence of a human isolate of M120 including the Tn6164 insert is available 
from the Sanger Institute, a complete proteome has not been uploaded to Uniprot; a proteome file  
for strain M120, in FASTA format, was therefore generated our by extracting all coding regions using 
the genome viewer Artemis (http://www.sanger.ac.uk/resources/software/artemis/)283. A total of 64 
predicted lipoproteins were identified from the analysis of this proteome, of which 59 were 
probable lipoproteins as 5 possible lipoproteins. The total number is comparable to C. difficile 630 
and R20291, but the predictions show a closer confidence distribution to 630 with less than 10% of 
the hit proteins being possible lipoproteins as shown in Figure 17 A. 
 
Figure 17: A breakdown of the predicted lipoproteins in C. difficile M120 by (A) prediction strength (Probable or Possible) 
and (B) by annotated function, for all Predicted lipoproteins. 
The annotated functions of the predicted lipoproteome for C. difficile M120 were similar to those for 
C. difficile 630 and R20291; almost 44% were annotated as ABC-Transport Solute-Binding proteins 
and a further 34% were of putative or uncharacterised function, a description which here includes 6 
Conserved Hypothetical proteins for which homologues exist in other C. difficile strains. Several 
proteins for which predicted lipoproteins with similar functions were found in 630 and R20291 were 
also predicted to be lipidated in M120; these included several nucelotidases or phosphodiesterases, 
a polysaccharide deacetylase, a thioredoxin and the sporulation specific protein SpoIIIAG, which was 
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predicted to be a possible lipoprotein in all strains. Additionally, a number of predicted lipoprotein 
functions were conserved between 630 and M120, including ribosome recycling factors and 
signalling proteins. As in R20291, the extracellular chaperone PrsA was not predicted to be a 
lipoprotein, our attempts to rationalise this will be discussed below. A breakdown of the functions of 
the predicted lipoproteins for C. difficile M120 is shown in Table 3. 
Table 3: The numbers and functions of the predicted lipoproteins in C. difficile M120, divided into Probable and Possible 
lipoproteins. 
Functional Class Number Percentage 
Probable Lipoproteins 
ABC Transport System Solute Binding Proteins 28 43.8% 
Putative & Uncharacterised Proteins 22 34.4% 
Polysaccharide Deacetylase 1 1.6% 
Nucleotidase/ Phosphodiesterase 3 4.7% 
TPR-Superfamily Domain Containing 1 1.6% 
Thioredoxin 1 1.6% 
Ribosome Recycling Factors 1 1.6% 
Signalling Proteins 1 1.6% 
Cell Surface Protein 1 1.6% 
Possible Lipoproteins 
ABC transporter, substrate-binding lipoprotein 2 3.1% 
Putative & Uncharacterised Proteins 2 3.1% 
Sporulation Specific 1 1.6% 
 
2.1.4 Bacillus subtillis Strain 168. 
For all three C. difficile strains analysed it was found that 35 to 45% of all predicted lipoproteins were 
either putative or of uncharacterised function (GO). To further investigate the roles of lipoproteins in 
Gram-positive bacteria and find potential roles for these putative proteins, many of which are 
conserved between C. difficile strains, we chose to apply our bioinformatic method to the model 
Gram-positive bacterium, B. subtilis strain 168. The expectation was that, for B. subtilis 168, there 
would be far fewer uncharacterised proteins and that the functions of B. subtilis lipoproteins that 
were not represented in C. difficile could provide a qualitative insight into the conservation of 
function of Gram-positive lipoproteomes. B. subtilis 168 had many more predicted lipoproteins than 
the C. difficile strains analysed (94) but similar proportions were probable or possible lipoproteins 
(84% and 16%, respectively) to the C. difficile strains (Figure 18). 
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Figure 18: A breakdown of the predicted lipoproteome of Bacillus subtilis 168 by prediction strength (Probable or Possible 
lipoprotein) (A) and by annotated function for all predicted lipoproteins (B). 
As the predicted lipoproteome was larger it was unsurprising that there were more proteins with 
annotated function, however, the proportion of all predicted lipoproteins of putative or 
uncharacterised function was similar to the C. difficile strains analysed, at 32%. A similar proportion 
of the predicted lipoproteome were annotated as ABC-type transporter solute-binding proteins 
(40%). Additionally a number of other lipoproteins have annotated functions that are conserved with 
C. difficile; specifically the chaperone PrsA (conserved with 630) and a polysaccharide deacetylase 
(conserved across all strains). PrsA was expected to be predicted as a lipoprotein on the basis of its 
previous experimental validation188b and the failure to predict lipidation of PrsA in C. difficile R20291 
and M120 required further investigation (Chapter 2.2). B. subtilis 168 has a number of sporulation or 
germination associated lipoproteins (9), while the only sporulation associated C. difficile lipoprotein 
predicted for the strains analysed was SpoIIIAG. Given the importance of sporulation for C. difficile 
transmission and persistence it is probable that some of the uncharacterised Clostridial lipoproteins 
have a homologous role to the sporulation and germination associated Bacillus lipoproteins. A full 
breakdown of the predicted lipoproteome of B. Subtilis 168, by Probable and Possible prediction 
strength, is given in Table 4. 
Table 4: The numbers and functions of the predicted lipoproteins in B. subtilis 168, divided into Probable and Possible 
lipoproteins. 
Functional Class Number Percentage 
Probable lipoproteins 
ABC Transport System Solute Binding Proteins 37 39.4% 
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Functional Class Number Percentage 
Putative & Uncharacterised Proteins 23 24.5% 
Endonuclease 2 2.1% 
Polysaccharide Deacetylase 1 1.1% 
Phage Derived 1 1.1% 
PrsA Chaperone 1 1.1% 
L-Aspariginase 1 1.1% 
Cytochrome 1 1.1% 
Sporulation/ Germination 6 6.4% 
Membrane Bound 1 1.1% 
Carboxypeptidase 2 2.1% 
Penicillin Binding Protien 1 1.1% 
Superoxide Dismutase 1 1.1% 
Galactanase 1 1.1% 
Possible Lipoproteins 
ABC Transport System Solute Binding Proteins 1 1.1% 
Putative & Uncharacterised Proteins 7 7.4% 
Transcriptional Activator 1 1.1% 
Cytochrome 1 1.1% 
Sporulation/ Germination 3 3.2% 
SCO1 Protein 1 1.1% 
Pal Related Protein 1 1.1% 
 
2.2 Discussion and Further Analysis. 
The bioinformatic predictions described in this chapter revealed that the predicted lipoproteome 
corresponds to approximately 1.8% of the proteome for all three C. difficile strains studied; for 
comparison approximately 2.2% of the B. subtilis strain 168 proteome was predicted to be lipidated. 
This is possibly the result of the search patterns used being optimised against a panel of 
experimentally verified lipoproteins, many of which were from Bacillus. Consequently the Prosite 
patterns may not be as efficient at predicting Clostridial lipidation and there may be more 
lipoproteins than predicted. Alternatively there may be proportionally fewer lipoproteins in 
C. difficile than B. subtilis; having only analysed 3 Clostridial strains and B. subtilis 168 it is difficult to 
comment on whether this difference is significant. For the three C. difficile strains analysed using the 
method described in Chapter 2.1 the predicted lipoproteome was of similar absolute size, with 
60 to 70 predicted lipoproteins of which less than 15% were possible lipoproteins; the remainder 
were more confidently predicted as probable lipoproteins (Figure 19 A). There was no significant 
difference in the number or proportion of each confidence prediction for the three strains analysed.  
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As 25 to 45% of the predicted lipoproteome of all strains analysed was of putative or 
uncharacterised function it is difficult to comment on the precise conservation of lipoproteome 
function. However, it does appear that the size of the Clostridial lipoproteome and its annotated 
functions are largely conserved. The proportion of the lipoproteome annotated as ABC-Transport 
Solute-Binding proteins was very similar, being between 40 and 45% for all strains analysed, and 
nutrient uptake is clearly one of the main roles of the Gram-positive lipoproteome. ABC-transport 
solute-binding proteins main function is in the ATP-dependant uptake of nutrients, however, they 
have also been shown to play other roles including adhesion to host cells, often by binding to a 
surface carbohydrate or glycoprotein284. Additionally, there were a number of other protein 
functions that appeared to be conserved; a full comparison is shown in Figure 19 B. These conserved 
functions include a number of nucleotidases and phosphodiesterases, a thioredoxin and a 
polysaccharide deacetylase; the latter function is also conserved with a B. subtilis 168 protein YxkH. 
Finally, SpoIIIAG was predicted to be a lipoprotein for all three C. difficile strains studied; SpoIIIAG is 
a late stage sporulation protein under the control of σE. It was not predicted to be a lipoprotein for 
B. subtilis 168, but a number of other sporulation and germination specific proteins, including SpoIIIJ 
(BSU41040), were predicted to be such.  
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Figure 19: A) The numbers of predicted lipoproteins for C. difficile 630, R20291 and M120 B) A comparison between the 
functions of the predicted lipoproteomes of C. difficile strains 630, R20291 and M120. 
An alignment of these polysaccharide deacetylases reveals that the C. difficile proteins 
(CD630_27190, CDR20291_2608 and M120_RT078_27421) are highly homologous, with the 630 and 
R20291 proteins being 99.7% identical and the 630 and R20291 proteins being 92.0% and 91.7% 
identical to that of M120 respectively. Additionally, B. subtilis YxkH is homologous to these, with 
17.5% identity to the 630 and R20291 proteins and 17.2% identity to that of M12. Deaceltyation of 
the peptidoglycan is important for lysozyme resistance and it is likely that this is a conserved Gram-
positive lipoprotein. An alignment of the predicted polysaccharide deacetlyase lipoproteins for the C. 
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difficile strains is shown in Figure 20; B. subtilis strain 168 YxkH is not shown in order to illustrate the 
extremely high level of conservation between the C. difficile strains analysed. 
 
Figure 20: Alignment of the polysaccharide deacetylases from 630, R20291 and M120; identical residues are highlighted 
with a grey background and similar residues with a red background (charged) or a blue background (hydrophobic).The 
consensus predicted lipobox is highlighted in yellow. Alignments generated in Geneious (ClustalW) and annotated using 
Chroma.  
Analysis of the B. subtilis 168 lipoproteome was intended to provide an insight into the possible roles 
of the uncharacterised lipoproteins predicted for C. difficile. However, it was found that 25% of the 
predicted B. subtilis 168 lipoproteome was of putative or uncharacterised function; this likely 
reflects the lack of detailed study of Gram-positive lipoproteins. Despite this, some clues were 
gained to the possible functions of the uncharacterised Clostridial lipoproteins; for example only 
SpoIIIAG was identified as a potential sporulation associated lipoprotein for C. difficile but several 
predicted lipoproteins were annotated as sporulation or germination specific for B. subtilis 168. It is 
therefore possible that C. difficile has other sporulation and germination associated lipoproteins 
which are not currently annotated as such. Although this comparison has proved useful it has not 
>CD630_27190       MFRKVLHYLTLLSISIFFIVGCSNSQNNQNENQNKETQLQEDKEKIDSGKDTSNVIVSDG 
>CDR20291_2608     MFRKVLHYLTLLSISIFFIVGCSNSQNNQNENQNKETQLQEDKEKIDGGKDTSNVIVSDG 
>M120_RT078_27421  MFRKVLYSLTLLSISIIFLVGCSNSQNKQNANENKEIQSQEDTKKIDSSKDTSNVIVSDG 
Consensus          MFRKVLh.LTLLSISIhFhVGCSNSQN.QN.N.NKEhQ.QED.cKID..KDTSNVIVSDG 
 
 
>CD630_27190       TDKPSKATTNNDNNKLDVSSLDNTTLDWFYIPNNKHKTPEVNTDIEFKFSDYDALYNGPT 
>CDR20291_2608     TDKPSKATTNNDNNKLDVSSLDNTTLDWFYIPNNKHKTPEVNTDIEFKFSDYDALYNGPT 
>M120_RT078_27421  IDKPSKNATNNDNNKLDVSSLDNTALDWFYIPNNKHKTPEVNTDIGFKFSDYDAIYNGPT 
Consensus          hDKPSK.hTNNDNNKLDVSSLDNThLDWFYIPNNKHKTPEVNTDI.FKFSDYDAhYNGPT 
 
 
>CD630_27190       KDGQKTLYLTFDEGYENGYTTKILDTLKQNQVKAVFFVTAPYIKENKDLVKRMVSEGHIV 
>CDR20291_2608     KDGQKTLYLTFDEGYENGYTTKILDTLKQNQVKAVFFVTAPYIKENKDLVKRMVSEGHIV 
>M120_RT078_27421  KDGQKTLYLTFDEGYENGYTTKILDTLKQNQVKAVFFVTYPYIKENKDLVKRMVSEGHIV 
Consensus          KDGQKTLYLTFDEGYENGYTTKILDTLKQNQVKAVFFVThPYIKENKDLVKRMVSEGHIV 
 
 
>CD630_27190       GNHSKTHPSMPTKTSNLKNFNDELYDVEKLYKDVTGKDMVKFFRPPMGKYSEKSLAMTKN 
>CDR20291_2608     GNHSKTHPSMPTKTSNLKNFNDELYDVEKLYKDVTGKDMVKFFRPPMGKYSEKSLAMTKN 
>M120_RT078_27421  GNHSKTHPSMPTKTSNLKNFNDELYDVEKLYKDVTGKNMVKFFRPPMGKYSEKSLAMTKN 
Consensus          GNHSKTHPSMPTKTSNLKNFNDELYDVEKLYKDVTGK.MVKFFRPPMGKYSEKSLAMTKN 
 
 
>CD630_27190       LGYKTVFWSFAYRDWDTDKQPSHEEATQKIMDNLHDGSILLLHAVSKTSTEILNDFISNA 
>CDR20291_2608     LGYKTVFWSFAYRDWDTDKQPSHEEATQKIMDNLHDGSILLLHAVSKTSTEILNDFISNA 
>M120_RT078_27421  LRYKTVFWSFAYRDWDTKKQPPHEEATQKIMANLHDGSILLLHAVSKTSTEILNDFITNA 
Consensus          L.YKTVFWSFAYRDWDTcKQP.HEEATQKIM.NLHDGSILLLHAVSKTSTEILNDFI.NA 
 
 
>CD630_27190       RKLGYEFELLEY 
>CDR20291_2608     RKLGYEFELLEY 
>M120_RT078_27421  RKLGYEFELLEY 
Consensus          RKLGYEFELLEY 
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provided sequence based insight into the functions of the C. difficile lipoproteome, as we have relied 
on a comparison of the Gene Ontology (GO) annotations for these strains, where available. Further 
bioinformatic tools will be used to investigate the function of uncharacterised lipoproteins that are 
identified in later proteomic experiments; for example analysis of conserved domains using the Pfam 
database285. However, from this initial investigation it appears that conservation of function of the 
lipoproteome is likely across C. difficile strains, including more distantly related ribotypes.  
Our inability to predict the lipidation of PrsA and PrsA2 for the C. difficile strains M120 and R20291 
warranted further investigation as B. subtilis PrsA is an experimentally verified lipoprotein. We are 
unable to explain the failure to predict lipidation of either PrsA or PrsA2 (M120_RT078_34491 and 
M120_078_15501 respectively) in M120, as these proteins are almost completely homologous to 
those of 630 (CD630_35000 and CD630_15570) having 98.8% and 98.7% identity respectively. In 
particular the signal peptide sequence for both proteins is completely conserved between the two 
strains, as shown in Figure 21 and Figure 22; it is therefore almost certain that M120_RT078_34491 
and M120_RT078_15501 encode lipoproteins. The failure of this predictive methodology to identify 
these may be a due to the omission of coding sequences from the proteome file constructed in this 
study. 
For C. difficile R20291 the inability of this bioinformatic methodology to predict the lipidation of PrsA 
and PrsA2 could be readily rationalised by aligning these proteins with their homologues in 
C. difficile 630 and M120 as shown in Figure 21 and Figure 22. This revealed that, while PrsA and 
PrsA2 show high sequence identity between the 630 and R20291 (100.0% and 99.7%, respectively), 
it is clear that both PrsA and PrsA2 in R20291 feature an N-terminal truncation in the annotated 
protein sequence. This has removed the initial 10 and 8 N-terminal residues respectively, including 
the entire charged region of the signal peptide sequence (MKK for PrsA and MNKK for PrsA2 in both 
C. difficile 630 and M120). This accounts for the failure of this approach to predict these as 
lipoproteins as both patterns used in ScanProsite in our method require an N-terminal charged tail.  
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Figure 21: An alignment of PrsA from C. difficile 630, R20291 and M120; identical residues are highlighted with a grey 
background, similar residues are highlighted with a red background (charged) or a blue background (hydrophobic); the 
predicted consensus lipobox is highlighted with a yellow background. Alignments generated in Geneious (ClustalW) and 
annotated using Chroma. 
>630 PrsA (CD630_35000)        MKKVITLVIAMILVVSVTACSSSKGETVATVEGTKISSDEFKKTIALYKDSMEQTYGKDI 
>R20291 PrsA (CDR20291_3337)   ----------MILVVSVTACSSSKGETVATVEGTKISSDEFKKTIALYKDSMEQTYGKDI 
>M120 PrsA (M120_RT078_34491)  MKKVITLVIAMILVVSVTACNSSKGETVATVEGTKISSDEFKKTIALYKDSMEQTYGKDI 
Consensus                      ..........MILVVSVTAC.SSKGETVATVEGTKISSDEFKKTIALYKDSMEQTYGKDI 
 
 
>630 PrsA (CD630_22630)        WDKEVEKGVKYKDKFKDLILDQLITTEVIYSQAKKDNLLPKKEDVEKSFKELKDAMGKDE 
>R20291 PrsA (CDR20291_3337)   WDKEVEKGVKYKDKFKDLILDQLITTEVIYSQAKKDNLLPKKEDVEKSFKELKDAMGKDE 
>M120 PrsA (M120_RT078_34491)  WDKEVEKGVKYKDKFKDLILDQLITTEVIYSQAKKDNLLPKKEDVEKSFKELKDAMGKDE 
Consensus                      WDKEVEKGVKYKDKFKDLILDQLITTEVIYSQAKKDNLLPKKEDVEKSFKELKDAMGKDE 
 
 
>630 PrsA (CD630_22630)        KYKEQLKKLGIDDEFLRDQQEKDLAMQNYQSNFAKKTKISDEEMKKYYDTHKDEFKKDEV 
>R20291 PrsA (CDR20291_3337)   KYKEQLKKLGIDDEFLRDQQEKDLAMQNYQSNFAKKTKISDEEMKKYYDTHKDEFKKDEV 
>M120 PrsA (M120_RT078_34491)  KYKEQLKKLGIDDEFLRDQQEKDLAMQNYQSNFTKKTKISDEEMKKYYDTHKDEFKKDEV 
Consensus                      KYKEQLKKLGIDDEFLRDQQEKDLAMQNYQSNFhKKTKISDEEMKKYYDTHKDEFKKDEV 
 
 
>630 PrsA (CD630_22630)        EASHILLKTVDDNNKPLSDKEKAEAKKKAEEALKEVKSGEDFAKVAKKYSQDTSASDGGK 
>R20291 PrsA (CDR20291_3337)   EASHILLKTVDDNNKPLSDKEKAEAKKKAEEALKEVKSGEDFAKVAKKYSQDTSASDGGK 
>M120 PrsA (M120_RT078_34491)  EASHILLKTVDDNNKPLSAKEKAEAKKKAEEALKEVKSGEDFAKVAKKYSQDASASDGGK 
Consensus                      EASHILLKTVDDNNKPLS.KEKAEAKKKAEEALKEVKSGEDFAKVAKKYSQDhSASDGGK 
 
 
>630 PrsA (CD630_22630)        LGFFSRGQMVAEFEDAAFSMKKGEVSDLVETQYGYHIIKVTDRINEQTSFEDAKETIKDQ 
>R20291 PrsA (CDR20291_3337)   LGFFSRGQMVAEFEDAAFSMKKGEVSDLVETQYGYHIIKVTDRINEQTSFEDAKETIKDQ 
>M120 PrsA (M120_RT078_34491)  LGFFSRGQMVAEFEDAAFSMKKGEVSDLVETQYGYHIIKVTDRINEQTSFEDAKETIKDQ 
Consensus                      LGFFSRGQMVAEFEDAAFSMKKGEVSDLVETQYGYHIIKVTDRINEQTSFEDAKETIKDQ 
 
 
>630 PrsA (CD630_22630)        LLKNKYQEQIEKLTKEAKVEKDEKVINKITI 
>R20291 PrsA (CDR20291_3337)   LLKNKYQEQIEKLTKEAKVEKDEKVINKITI 
>M120 PrsA (M120_RT078_34491)  LLKNKYQEQIEKLTKEAKVEKDEKVINKITI 
Consensus                      LLKNKYQEQIEKLTKEAKVEKDEKVINKITI 
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Figure 22: An alignment of PrsA2 from C. difficile 630, R20291 and M120; identical residues are highlighted with a grey 
background; conserved residues are highlighted with a red background (charged) or a blue background (hydrophobic); the 
predicted consensus lipobox is highlighted with a yellow background. Alignments generated in Geneious (ClustalW) and 
annotated using Chroma. 
Analysis of the upstream nucleotide sequence for genes CDR20291_3337 (PrsA) and 
CDR20291_1406 (PrsA2) indicates that this apparent N-terminal truncation may simply be due to a 
misassigned start site. A conserved methionine residue within the hydrophobic region of the Type II 
signal peptide has been assigned as the f-Met for both R20291 proteins, however, it is possible 
(Figure 23), that a leucine or valine encoded in the region upstream of the predicted start site is the 
first amino acid. Sequence alignment with the N-terminal signal peptide sequence, up to the +1 
cysteine, with PrsA and PrsA2 from C. difficile 630 indicate that it is likely this leucine which is the 
first amino acid of both PrsA proteins in C. difficile R20291; it is encoded by TTG which is a common 
alternative start codon in C. difficile. This alternative is further supported by the presence of 
ribosome binding site-like elements upstream of these potential translational start sites (data not 
shown). As the predicted lipobox is completely conserved for PrsA and PrsA2 between strain 630, 
R20291 and M120 the possibility exists that these proteins have a complete signal peptide and are 
Lgt substrates in strain R20291.  This serves to highlight the importance of biochemical validation, 
rather than relying solely on a bioinformatic predication, of the post-translational modification of a 
>630 PrsA2 (CD630_15570)       MNKKLYIGMVGILSLMMVGCNKSLAKVNDVEITKEQYKKTKAVLSATNNYINGQSLDELE 
>R20291 PrsA2 (CDR20291_1406)  --------MVGILSLMMVGCNKSLAKVNDVEITKEQYKKTKAVLSATNNYINGQSLDELE 
>M120 PrsA2 (M120_078_15501)   MNKKLYIGMVGILSLMMVGCNKSLAKVNDVEITKEQYKKTKAVLSATNNYINGQSLDELE 
Consensus                      ........MVGILSLMMVGCNKSLAKVNDVEITKEQYKKTKAVLSATNNYINGQSLDELE 
 
 
>630 PrsA2 (CD630_15570)       KTLDKKGRNKLENVIISFMVDNELLYQEAKDKGLTPSKSEVDSKYQELEDKMNLNTSYKE 
>R20291 PrsA2 (CDR20291_1406)  KTLDKKGRNKLENVIISFMVDNELLYQEAKDKGLTPSKSEVDSKYQELEDKMNLNTSYKE 
>M120 PrsA2 (M120_078_15501)   KTLDKKGRNKLENVIISFMVDNELLYQEAKDKGLTPSKSEVDSKYQELEDKMNLNTSYKE 
Consensus                      KTLDKKGRNKLENVIISFMVDNELLYQEAKDKGLTPSKSEVDSKYQELEDKMNLNTSYKE 
 
 
>630 PrsA2 (CD630_15570)       KMDKAGVDKDYLKQEISRDLAIDKNKKAFEDRINISDNDMEAYYTSHKKDFNVEEVSASQ 
>R20291 PrsA2 (CDR20291_1406)  KMDKAGVDKEYLKQEISRDLAIDKNKKAFEDRINISDNDMEAYYTSHKKDFNVEEVSASQ 
>M120 PrsA2 (M120_078_15501)   KMDKAGVDKEYLKQEISRDLAIDKNKKAFEDRINISDNDMEAYYTSHKKDFNVEEISASQ 
Consensus                      KMDKAGVDKcYLKQEISRDLAIDKNKKAFEDRINISDNDMEAYYTSHKKDFNVEEhSASQ 
 
 
>630 PrsA2 (CD630_15570)       ILISTLDKNKKEVSKDKKEALKKKADNILTKIKNGESFESLAKKYSDDKATGKNGGQLGY 
>R20291 PrsA2 (CDR20291_1406)  ILISTLDKNKKEVSKDKKEALKKKADNILTKIKNGESFESLAKKYSDDKATGKNGGQLGY 
>M120 PrsA2 (M120_078_15501)   ILISTLDKNKKEVSKDKKEALKKKADNILTKIKNGESFESLAKKYSDDKATGKNGGQLGY 
Consensus                      ILISTLDKNKKEVSKDKKEALKKKADNILTKIKNGESFESLAKKYSDDKATGKNGGQLGY 
 
 
>630 PrsA2 (CD630_15570)       FTKDDKNAEFTKEVFKLKKNEVSNVFETSYGYHIVKVTDKRERQKSFNECQSLIRESILN 
>R20291 PrsA2 (CDR20291_1406)  FTKDDKNAEFTKEVFKLKKNEVSNVFETSYGYHIVKVTDKRERQKSFNECQSLIRESILN 
>M120 PrsA2 (M120_078_15501)   FSKDDKNAEFTKEVFKLKKNEVSKVFETSYGYHIVKVTDKRERQKSFNECQSLIRESILN 
Consensus                      F.KDDKNAEFTKEVFKLKKNEVS.VFETSYGYHIVKVTDKRERQKSFNECQSLIRESILN 
 
 
>630 PrsA2 (CD630_15570)       EKYIEHIKKLNEDAKIDR 
>R20291 PrsA2 (CDR20291_1406)  EKYIEHIKKLNEDAKIDR 
>M120 PrsA2 (M120_078_15501)   EKYIEHIKKLNEDAKIDR 
Consensus                      EKYIEHIKKLNEDAKIDR 
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protein. Additionally, automated tools for the annotation of newly sequenced genomes are likely to 
perpetuate errors such as this, until biochemical validation of PTM is taken into account by 
improvements and updates to the software in use.   
 
Figure 23: Alignment of the N-terminal sequences, up to the lipobox +1 cysteine, of PrsA and PrsA2 from C. difficile 630 and 
R2029. This includes a translation of the upstream 39 and 33 nucleotides for R20291 PrsA and PrsA2 respectively. Predicted 
translational start sites are indicated by . Identical residues are highlighted with a black background; alignment 
generated in Geneious (ClustalW) and annotated using Chroma. 
The main goal of this initial bioinformatic study was to create a list of predicted lipoproteins to 
compare the result of later proteomic experiments to; this would enable an assessment the signal to 
background ratio of these experiments, while the presence of a predicted lipobox would also 
provide an additional confirmation of lipidation by Lgt. This study was therefore informative, 
especially for the comparatively well annotated genome of C. difficile 630, in which the majority of 
metabolic tagging experiments were to be performed. This has also served to highlight the 
limitations to a purely bioinformatic approach, which has become the principal method for 
identification of not only Gram-positive lipoproteins but all coding sequences, and demonstrated the 
need for biochemical verification of lipidation. In the following chapters we will discuss the 
development and optimisation of a metabolic chemical tagging approach for the broad scale 
profiling of the C. difficile lipoproteome. 
>630_PrsA_N-Terminus     ---MKKVITLVIAMILVVSVTAC 
>R20291_PrsA_N-Terminus  VLNLKKVITLVIAMILVVSVTAC 
Consensus                ...hKKVITLVIAMILVVSVTAC 
 
>630_PrsA2_N-Terminus     ---MNKKLYIGMVGILSLMMVGC 
>R20291_PrsA2_N-Terminus  VGILNKKLYIGMVGILSLMMVGC 
Consensus                 ...hNKKLYIGMVGILSLMMVGC 
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Chapter 3: Development and Optimisation of Tagging by 
Substrate for Clostridium difficile 
3.1 Introduction and Preliminary Experiments 
3.1.1 Introduction 
This chapter covers the initial application of lipid analogues to investigate the Clostridium difficile 
lipoproteome, following bioinformatic investigation and prediction of the C. difficile lipoproteome 
described in Chapter 2, which has illustrated the advantages and limitations of a purely in silico 
approach. The biochemical verification of lipidation for these predicted proteins would be greatly 
facilitated by a broad scale approach such as metabolic chemical tagging and the development and 
optimisation of the method for C. difficile is described in this chapter. The aims of this work were; to 
demonstrate the incorporation of available lipid analogues into C. difficile lipoproteins and that their 
elaboration by click chemistry is efficient and selective; to identify the optimal probe chain length, 
concentration and feeding time; and finally to optimise affinity enrichment of the labelled proteins 
as a prerequisite for proteomic analysis. This included an investigation of probe incorporation into C. 
difficile lipoteichoic acid (LTA). 
3.1.2 Application of Existing Tools to Clostridium difficile 
To target a Post Translational Modification (PTM) in a metabolic tagging approach the probe must be 
a close substrate mimic, with the tag group as biologically imperceptible as possible. This is vital to 
ensure that the proportion of the proteome which is post-translationally labelled with the probe is 
representative of the proportion which has the natural PTM. Additionally, it must have selective and 
specific reactivity, such that it is unreactive in the cellular environment yet able to react rapidly and 
efficiently with an opposing chemical group on a capture reagent to enable visualisation or affinity 
enrichment. A subset of reactions, referred to as “click chemistry”, fulfil these criteria in that the 
reacting groups are small and unobtrusive and the reactions rapid and bio-orthogonal; these 
reactions are discussed in detail in Chapter 1.3.2. Azide and alkyne tagged lipid analogues have 
previously been developed in the Tate group206 and the bio-orthogonal ligation reaction, a copper 
catalysed azide-alkyne cycloaddition (CuAAC), optimised. Therefore these reagents and 
methodologies were to be applied in an initial investigation of the C. difficile lipoproteome. 
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Figure 24: A) The azide (blue) tagged lipid analogues previously synthesised in the Tate group. B) The alkyne (red) tagged 
lipid analogues previously synthesised in the Tate group. C) The natural lipids myristic and palmitic acid; AzC12, AzC13 and 
YnC12 are myristic acid analogues. AzC15, YnC15 and YnC16 are palmitic acid analogues. 
A number of azide- and alkyne-tagged fatty acid analogues, shown in Figure 24, had previously been 
synthesised by Professor Edward Tate and Doctors William Heal, Megan Wright, and Emmanuelle 
Thinon (Imperial College London). These were of a range of chain lengths, including myristic or 
palmitic acid analogues, and had been demonstrated to be specifically incorporated into post-
translationally myristoylated222, 224 and palmitoylated230 proteins in living cells. Complementary 
trifunctional capture reagents had been designed and synthesised by Dr Megan Wright; these 
featured either an azide or an alkyne group, a TAMRA fluorophore for in-gel fluorescence analysis 
and biotin as an affinity handle for enrichment of the labelled proteins. The capture reagents could 
be quickly and efficiently produced by Solid Phase Peptide Synthesis (SPPS) and were to be routinely 
used for elaboration of labelled proteins in C. difficile. The capture reagents used throughout this 
study, Alkyne-TAMRA-Biotin (YnTB) and Azido-TAMRA-Biotin (AzTB) are shown in Figure 25. 
Myristic Acid Palmytic Acid 
A B 
C 
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Figure 25: The trifunctional Capture Reagents used in this study, YnTB (A) and AzTB (B). The fluorophore TAMRA is shown in 
purple, biotin in grey and the click handle in either red (alkyne) or blue (azide). 
The tagged lipoproteins were to be captured with AzTB or YnTB by CuAAC ligation; as discussed in 
Chapter 1.3.2.1 this reaction is catalysed by copper I and requires a ligand to stabilise the copper and 
promote the reaction. Although this reaction has never been applied to metabolically tagged 
C. difficile lysates, the reaction conditions for labelling of metabolically tagged mammalian lysates 
were optimised by Dr Megan Wright (Imperial College London)206, 222, 224; briefly the capture reagent, 
copper II, TCEP to reduce the copper and the ligand, TBTA, were combined and the click reaction 
mixture added to the protein sample to give the final concentrations of each reagent shown in 
Figure 26. The click reaction was performed at room temperature for 1 hour on lysates at a protein 
concentration of 1 mg mL-1 before being quenched with 100 mM EDTA to chelate the copper. The 
protein was precipitated to remove the excess reagents and re-suspended prior to in-gel analysis or 
enrichment; this is described in detail in Chapter 9.2.3. 
A 
B 
AzTB 
YnTB 
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Figure 26: A) The optimised CuAAC ligation reaction for an azide or alkyne tagged protein and the complementary capture 
reagent. B) The reducing agent tris(2-carboxyethyl)phosphine(TECP). C) The ligand used to stabilise copper I, Tris[(1-benzyl-
1H-1,2,3-triazol-4-yl)methyl]amine (TBTA). 
The workflow employed was initially based on that developed for mammalian samples; the 
optimisation of the feeding conditions, including probe concentration and feeding time are 
described in section 3.2. The probes were fed to exponentially growing cultures of C. difficile in 
DMSO, with the final concentration of DMSO in the media fixed at 1% (v/v). Following metabolic 
incorporation of the probes into membrane phospholipids, by a mechanism that has not been 
studied in C. difficile, and their covalent attachment to lipoproteins by pre-prolipoprotein 
diacylglyceryl trasferase (Lgt, Chapter 1.2.2.2) the bacteria were lysed, fractionated and the CuAAC 
ligation reaction performed on 100 µL of protein at a concentration 1 mg mL-1. The protein was 
methanol/ chloroform precipitated and resuspended in 2% SDS, 10 mM EDTA in PBS to the desired 
concentration; samples were mixed with an equal volume of 2x sample loading buffer prior to in-gel 
fluorescence analysis or pulled down on neutravidin beads. This workflow is shown schematically in 
Figure 27. 
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Figure 27: An outline of the metabolic tagging workflow for the labelling of C. difficile lipoproteins with an alkyne-tagged 
lipid analogue and capture with AzTB. Following CuAAC proteins can be separated by SDS-PAGE and labelled proteins 
directly visualised by in-gel fluorescence analysis. Alternatively, samples can be incubated with Neutravidin coated beads 
and the biotin-avidin interaction exploited to allow enrichment (pull down) of post-translationally labelled proteins. Proteins 
can be eluted from the beads by boiling in sample loading buffer and visualised by in-gel fluorescence. 
3.1.3 Proof of Concept Experiments 
There has been no previous report of the use of lipid analogues for metabolic labelling in C. difficile, 
nor in any other Gram-positive bacteria, despite their widespread use in mammalian systems. The 
only reported use of a metabolic tagging approach to study lipidation in a bacterial system was in 
the model Gram-negative Escherichia coli K12, by Rangan and co-workers199. They utilised 20 µM of 
YnC15, synthesised by an alternative route as part of their study, for labelling of the E. coli 
lipoproteome; this probe is typically used at 25 µM in HeLa cells286. YnC12 has also been reported to 
give optimal labelling at 20 µM in human cell lines224. For incorporation into bacteria lipoproteins the 
probes must first be taken up by the bacteria and converted into membrane phospholipids, which 
enables their use as substrates by the enzyme Lgt to modify the +1 cysteine thiol within the lipobox 
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by the addition of a diacyl-glycerol motif. As there is a lack of information regarding the selectivity 
and substrate preferences for any of these steps in Clostridia all the readily available probes were 
tested at a concentration of 25 µM in the reference strain C. difficile 630. Following lysis, 
fractionation into soluble and insoluble sub-proteomes and elaboration by CuAAC ligation, the 
labelling efficiency after 18 hours growth (overnight) was assessed by in-gel fluorescence analysis 
(Figure 28). 
 
Figure 28: In-gel fluorescence analysis of the labelling profile for C. difficile 630, treating with 25 µM of the alkyne (left) and 
azide (right) tagged probes shown in Figure 24. C. difficile cultures were treated for 18 hours before lysis and fractionation 
into soluble (S) and insoluble (I) sub-proteomes. Palmitic acid (P.A.) was included as a negative control. Coomassie staining 
(total protein, bottom) is shown as a loading control. 
No background fluorescence was observed for the palmitic acid treated control, indicating that in all 
cases the in-gel fluorescence pattern was due to the specific attachment of the capture reagent. All 
three alkyne-tagged probes tested gave efficient labelling of proteins in the insoluble fraction, with 
low background; membrane associated proteins, including lipoproteins, are expected to be enriched 
in the insoluble sub-proteome. All three fatty acid analogues gave an almost identical labelling 
pattern, as shown in Figure 28, right. The in-gel fluorescence pattern seen for the soluble proteome 
was very similar to that for the insoluble, but at reduced intensity for the majority of the labelled 
proteins. As bacterial lipoproteins are membrane associated this result was expected; as there are 
no fluorescent bands unique to the soluble fraction this probably results from inefficient 
fractionation and carryover of putative lipoproteins into the soluble fraction and does not reflect 
their cellular location. To maximise the recovery of labelled proteins the C. difficile lysates were 
fractionated, unless otherwise indicated, in all the remaining experiments described in this study 
and the insoluble proteome used for further analysis. This result demonstrates that simple alkyne-
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tagged fatty acid analogues are taken up by C. difficile 630 and incorporated into lipoproteins in 
culture. 
In contrast, the azide-tagged probes were found to strongly label the soluble proteome in an 
abundance based manner, irrespective of chain length. The insoluble proteome was not significantly 
labelled by the shorter chain length azido probes; AzC12, 13 and 15 gave increased labelling of the 
insoluble sub-proteome but considerable smearing at lower molecular weight was observed.  For the 
samples treated with the longer chain length azide-tagged probes the in-gel fluorescence labelling 
pattern showed similarities to that observed for all alkyne tagged probes (Figure 28, left), indicating 
that these probes are incorporated into the same proteins. All azide-tagged probes showed 
considerable non-specific labelling; this may be due to instability of the azide group under the 
conditions required for the growth of C. difficile. Alkyl azides do not decompose to nitrenes at 37 °C 
(180 to 200 °C is required)287 but reduce readily under hydrogen atmosphere288. The anaerobic gas 
required for C. difficile growth contains 10% hydrogen and it is possible that azide probes are not 
compatible with these conditions. Despite previous reports of the successful use of azide-tagged 
probes for metabolic tagging in cell culture206 these probes lacked the required selectivity and 
specificity for use in C. difficile and were not investigated further. 
The alkyne tagged probes tested showed considerable promise; they were stable under C. difficile 
culture conditions, yet could be metabolically incorporated into proteins which were predominantly 
found in the membrane associated insoluble fraction. These putative lipoproteins could 
subsequently be visualised by in-gel fluorescence following the bioorthogonal attachment of AzTB by 
CuAAC with low background. Consequentially alkyne-tagged lipid analogues were selected for 
further evaluation and optimisation of the feeding conditions. 
3.2 Probe Synthesis, Selection & Optimisation 
3.2.1 Alkyne-Tagged Probe Synthesis 
It was not possible to infer the effect of chain length on uptake and metabolism of the azide probes 
by C. difficile as the reduced labelling of the insoluble sub-proteome may be a result of cross 
reactivity and instability of the azide group. To investigate the effect of chain length on the 
selectivity and specificity of incorporation into lipoproteins a series of alkyne-tagged fatty acid 
analogues were synthesised to complement those already tested (Figure 24B). The method reported 
by the Tate group224-225, 289 was adapted for the synthesis of C11, C12 and C13 fatty acid substrate 
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analogues, referred to in this study as YnC9, 10 and 11 respectively; the synthetic scheme employed 
is given in Figure 29. 
 
Figure 29: The synthetic route to alkyne tagged fatty acid analogues employed in this study. Activation of the bromine to 
the corresponding iodide (A) enabled nucleophilic substitution with TMS-acetylene; the product (B) was contaminated with 
residual iodide which was carried through the synthesis and converted to the corresponding amine (step 4), enabling 
purification of the fatty acid analogue (C). 
Briefly, the Finkelstein reaction was used to activate an alkyl bromide of desired chain length to the 
corresponding iodide, using sodium iodide in acetone. Trimethylsilylacetylene was deprotonated 
with n-butyl lithium and the iodide added at -78 ⁰C, the resulting nucleophilic substitution gave the 
TMS-protected alkyne tagged substrate analogue, contaminated with residual iodide (A, Figure 29). 
As it was difficult to separate these by column chromatography the TMS group was deprotected 
under basic conditions (K2CO3, methanol) and the residual iodide converted to the secondary amine 
by refluxing with ethanolamine in DMSO, since the desired product was stable under these 
conditions224. The secondary amine could then be readily separated from the desired product by 
flash column chromatography under acidic conditions. Yields over the four steps were 19%, 25% and 
14% for YnC9, 10 and 11 respectively. Yields for the individual steps and the quantity of residual 
iodo-compound, measured by 1H NMR, are given in Table 5. Due to the lack of commercially 
available starting materials the compounds of intermediate chain length between those synthesised 
and YnC15 (YnC13 and YnC14) could not be quickly accessed. As the lipid analogues synthesised 
cover a physiologically relevant range of chain lengths, the incorporation of these synthetically 
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accessible probes was tested first; in the event that incorporation of these probes was poor other 
chain lengths could have been synthesised and investigated. 
Table 5: Yields for the synthesis of YnC9, YnC10 and YnC11; steps 1 to 4 and compounds A, B and C correspond to the 
products shown in Figure 29. 
Compound Step 1 Step 2 Step 3 Step 4 
YnC9 (n=7) 95% 50% B, 16% A 63% C, 18% A 62% 
YnC10 (n=8) 88% 58% B, 13% A 61% C, 14% A 79% 
YnC11 (n=9) 81% 41% B, 2% A 93% C, ≤1% A 54% 
 
3.2.2 Probe Selection 
To investigate the effect of chain length on probe uptake and metabolism C. difficile 630 Δerm was 
grown overnight in the presence of 25 µM YnC9, 10, 11, 12, 15 or 16. The efficiency of probe uptake, 
metabolism and incorporation by Lgt into putative lipoproteins was assessed by in-gel fluorescence 
analysis following CuAAC ligation with AzTB. Selective labelling of a number of proteins in the 
insoluble fraction was observed, with a similar labelling pattern for all probes. As shown in Figure 
30 A, YnC9 was only incorporated into C. difficile lipoproteins at a low level while the labelling 
intensity increased with chain length for YnC10, 11 and 12. While the longer chain lipid analogues 
(YnC12, 15 and 16) showed comparable labelling efficiency at 25 μM, YnC12 (Figure 30 C) gave 
efficient labelling for 630 Δerm and was readily available in the Tate group; therefore YnC12 was 
selected as the probe of choice for all further experiments. 
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Figure 30: A) A comparison of the labelling efficiency for the alkyne tagged probes used in this study, treating C. difficile 
630 Δerm with 25 µM of each probe overnight in TY media. The efficiency of incorporation shows chain length dependence 
with YnC12 to YnC16 giving the most efficient labelling. Coomassie staining (total protein, bottom) is shown as a loading 
control.  B) YnC12 concentration series for C. difficile 630 Δerm; 10 and 25 µM YnC12 show comparable labelling, while 
there is a decrease in labelling efficiency above 25 µM. Coomassie staining (total protein, bottom) is shown as a loading 
control. C) The natural lipid myristic acid and the alkyne tagged analogue YnC12. The alkyne tag is highlighted in red. 
The optimal labelling concentration for YnC12 was identified; C. difficile 630 Δerm was treated with 
0 to 100 µM YnC12 overnight (Figure 30 B) and the efficiency of metabolic labelling assessed by 
CuAAC and in-gel fluorescence. The labelling was found to initially increase with concentration, up to 
10 µM YnC12, which showed a comparable labelling intensity to 25 µM YnC12. Above this 
concentration the effectiveness of metabolic labelling decreased, possibly due to poor probe 
solubility or the formation of micelles at higher concentrations, despite the presence of 1% DMSO 
(vehicle) in the media. Based on this result 10 and 25 µM YnC12 were selected as the optimal 
feeding concentrations, with 10 µM YnC12 being used for competition experiments and 25 µM 
YnC12 for general profiling experiments. 
3.2.3 Probe Specificity and Feeding Time Optimisation 
The specificity of YnC12 incorporation into lipoproteins was qualitatively investigated by labelling in 
the presence of the natural lipid, myristic acid (Figure 30 C); a reduction in in-gel fluorescence 
labelling was anticipated for genuine lipoproteins. Initially a pulse of myristic acid was used; after 
A B 
Probe/ 25 µM: 
Chain Length: 
In-gel fluorescence 
Coomassie 
In-gel fluorescence 
Coomassie 
[YnC12]/ µM: 
C 
YnC12 
Myristic Acid 
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overnight growth of 630 Δerm in the presence of 10 µM YnC12, the culture was split and the aliquots 
treated with 400 µM myristic acid for 0 to 120 minutes. Following lysis, fractionation and ligation to 
AzTB by CuAAC, as described in Chapter 3.1.2, the effect of the myristic acid pulse on labelling was 
assessed by in-gel fluorescence. No difference in the labelling pattern for any pulse time was 
observed (Figure 31 A), indicating that lipoprotein modification is not dynamic at stationary phase. It 
is likely only lipoprotein synthesis and degradation affects probe incorporation, indicating that 
modification take place immediately post-translationally. This result was anticipated as the majority 
of lipoprotein expression and lipidation occurs during exponential growth, when the bacteria are 
rapidly dividing, and it is probable that there is limited turnover of lipoproteins at stationary growth 
phase in C. difficile. 
To further investigate the dynamics of lipoprotein expression in C. difficile an exponentially growing 
culture of 630 Δerm (at an OD600
 of 0.03) was treated with 25 µM YnC12  and samples were taken at 
15 minutes, 30 minutes, 60 minutes and then every hour for a further 5 hours until the culture had 
reached stationary phase. As expected the intensity of the metabolic labelling pattern initially 
increased with time, corresponding to an increase in cell density (Figure 31 B). After 240 minutes the 
culture had reached stationary phase, however, metabolic tagging saturated 120 minutes after the 
addition of YnC12 (late exponential phase). 
       
Figure 31: A) A pulse of 400 µM myristic acid was added to a stationary phase culture of C. difficile 630 Δerm for the times 
shown; the lack of change in the labelling pattern indicates a slow turnover of the lipoproteome. Coomassie staining (total 
protein, bottom) is shown as a loading control. B) Labelling time course for C. difficile 630 Δerm, treated with 25 µM YnC12. 
Metabolic incorporation is saturated after 120 minutes. Coomassie staining (total protein, bottom) is shown as a loading 
control. 
Probe incorporation requires the bacteria to take up and metabolise the probe into membrane 
phospholipids before use as a substrate by Lgt. As pre-prolipoproteins in C. difficile can only be 
lipidated by Lgt following export in an unfolded form, via the Sec secretory system, YnC12 
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Time/ Minutes-1: 
+/- 400 µM Myristic Acid: 
B 
Time/ Minutes-1: 
In-gel fluorescence 
Coomassie 
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incorporation is presumed to be possible only for newly synthesised proteins. These results 
therefore indicate that the lipoproteome is rapidly expressed, exported and lipidated, during 
exponential growth and that the turnover of the lipoproteome at stationary phase is low. There does 
not appear to be any changes to the lipoproteome with growth phase, as the pattern given by 
overnight labelling is not qualitatively different from that given by 6 hours exposure to YnC12; this is 
the longest practical labelling time for the experiment to fit into a single day, if the probe is added 
during early exponential phase (OD600 ≈0.03). Additionally there are no noticeable changes to the 
lipoproteome over exponential phase labelling that could not be explained by increased probe 
incorporation. 
Based on these results a competition experiment was designed to determine the specificity of YnC12 
as an Lgt substrate analogue. C. difficile 630 Δerm was sub-cultured in the presence of a range of 
concentrations of the natural lipid, myristic acid, and treated with 10 µM YnC12 during early 
exponential phase (OD600 ≈0.03); the bacteria were therefore simultaneously exposed to the probe 
and the natural lipid which were expected to compete as substrates. 
 
Figure 32: A) Competition between 10 µM YnC12 and up to 400 µM myristic acid, with the bacteria (630 Δerm) exposed to 
the probe over 18 hours (overnight). Coomassie staining (total protein, bottom) is shown as a loading control. B) 
Competition between 10 µM YnC12 and up to 100 µM myristic acid, with the bacteria (630 Δerm) exposed to the probe over 
8 hours. Coomassie staining (total protein, bottom) is shown as a loading control. 
The competition was assessed after 8 hours growth, or overnight labelling; up to a 40 fold excess of 
myristic acid was required for effective competition over the latter timescale while a 10 fold excess 
was sufficient for the shorter competition experiment. As anticipated, a reduction in metabolic 
labelling was seen with an increasing concentration of myristic acid in both experiments (Figure 32 A 
and B), consistent with the hypothesis that the probe was being specifically incorporated into 
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lipoproteins in the place of myristic acid. However, there are multiple metabolic steps at which 
competition can occur; these include uptake of the fatty acid, activation and conversion into 
membrane phospholipids, and use as an Lgt substrate. It is most likely that competition occurs at the 
lipid uptake stage, as the rate of fatty acid uptake is unlikely to change and uptake of the probe as a 
fraction of the total lipids will therefore decrease when an excess of myristic acid is added.    
3.3 Incorporation of YnC12 into Lipoteichoic Acid 
3.3.1 Lipoteichoic Acid in Clostridium difficile 
Some of the most intensely labelled bands visualised by in-gel fluorescence were in the 15 to 17 kDa 
region; these bands were frequently smeared (Figure 30 B) and Coomassie staining demonstrated 
that they did not correspond to an abundant protein, as shown in Figure 33. The intensity of 
lipoprotein labelling by YnC12 was expected to correlate with protein abundance and the possibility 
that these bands were the result of YnC12 incorporation into lipoteichoic acid (LTA) was considered.  
 
Figure 33: Extremely intense bands were observed at an apparent molecular weight of 15 to 17 kDa; these were due to the 
specific incorporation of YnC12 into an unidentified biomolecule. Coomassie staining showed an absence of an abundant 
protein at the corresponding MW, indicating that these bands do not correspond to a lipoprotein and may be lipoteichoic 
acids. Coomassie staining (total protein, bottom) is shown as a loading control. 
LTA is defined as an alditolphosphate-containing polymer that is anchored to membrane by a 
diacylglyceryl lipid anchor in Gram-positive bacteria290; this is the same class of lipid anchor 
employed to anchor bacterial lipoproteins to the membrane. There are five LTA types, of which type 
I (found in Bacillus subtilis, Staphylococcus aureus and other Firmicutes) and type IV (found in 
Streptococcus species, including S. pneumonia) are the best studied. LTAs are frequently modified, 
including by phosphocholination, D-alanylation and glucosylation, which induce changes in charge 
[Myristic Acid]/ µM: 
+/- 10 µM YnC12 : 
In-gel fluorescence 
Coomassie 
 Smeared fluorescent bands at 15 to 17 kDa. 
 No abundant proteins in the corresponding region. 
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and conformation of the LTA. LTAs exact role is unknown but they have been proposed to be 
involved in cell wall anchoring. Furthermore they are important for bacterial growth and are also 
believed play roles in cell membrane homeostasis and virulence. 
C. difficile has an unusual type V LTA, the structure of which has been determined by Reid and 
co-workers291; to date, this LTA structure is only known to be shared with Peptostreptococcus 
anaerobius292. In contrast to the polyglycerolphosphate chain of type I LTA, type V LTA features a α-
D-GlcNAc(1–3)-α-D-GlcNAc glycosyl-phosphate repeat unit linked through C-6’ - C-6” phosphodiester 
bridges, the second GlcNAc residue of which is further decorated with D-glyceric acid. The polymer is 
linked to a β-1-6-linked triglucosyl-diacyl glycerol glycolipid, featuring C14, C16, or C18 saturated or 
mono-unsaturated fatty acids, which anchor the polymer to the membrane. YnC12 (C14) could 
therefore be incorporated into the lipid anchor in place of the natural lipid. The structure of 
C. difficile’s LTA is shown in Figure 34. The LTA of C. difficile is conserved between strains and 
glycoconjugates of LTA have been investigated as potential vaccine candidates293. Recently a total 
synthesis of C. difficile LTA was published, fully synthetic LTA is anticipated to enable large scale 
vaccine synthesis, should this strategy prove successful294. 
 
Figure 34: The structure of the type V LTA found in C. difficile. The repeat unit is enclosed by square brackets and D-glyceric 
acid is shown in blue. The LTA polymer is anchored to the membrane by a triglucosyl DAG-lipid anchor; the 
diacylglyceryl lipid is shown in red. The number of repeat units (x) in C. difficile LTA is unknown; the 
diacylglyceryl anchor is esterified with either C14, C16, or C18, saturated or mono-unsaturated fatty acids 
(n =12 to 16). 
3.3.2 YnC12 is Incorporated into Lipoteichoic Acid 
To investigate whether the low MW smearing observed by in-gel fluorescence, as described in 
Section 3.3.1, was due to the incorporation of YnC12 into the lipid anchor of LTA the resistance of 
α-D-GlcNAc(1–3)-α-D-
GlcNAc Repeat Unit 
β-1-6-Linked Triglucosyl Diacyl 
Glycerol Membrane anchor 
x 
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these bands to proteolytic digest was assessed. Treatment with Pronase, a cocktail of highly active 
proteases, was expected to digest all labelled lipoproteins while LTA would be unaffected. Initially a 
10-fold dilution series of Pronase was used, between 0.4 and 400,000 ng mL-1, to digest 100 µg of 
C. difficile 630 Δerm insoluble sub-proteome, labelled with AzTB via CuAAC, (at a protein 
concentration of 1 mg mL-1), digesting at 37 °C for 1 hour. Protein digestion was seen at a Pronase 
concentration of 4 µg mL-1, with complete digestion at 400 µg mL-1, as assessed by SDS-PAGE and 
Coomassie staining (Figure 35 B).  In-gel fluorescence analysis (Figure 35 A) revealed that the higher 
MW bands disappear in parallel with proteome digestion, indicating these are due to YnC12 
incorporation into lipoproteins. However, the 15-17 kDa smear was not susceptible to digestion by 
Pronase at the highest concentrations used and therefore does not correspond to a protein. These 
bands are not due to a naturally fluorescent molecule, or due to an excess of the fluorophore, as 
treatment with 25 µM myristic acid (Figure 35 C, Myr) did not result in any fluorescent labelling on 
CuAAC with AzTB. 
 
Figure 35: Pronase digestion of the insoluble proteome of C. difficile 630 Δerm. A) In-gel fluorescence analysis reveals that 
the 15-17 kDa fluorescent smear is unaffected by Pronase at the highest concentrations used, while the higher MW bands 
corresponding to lipoproteins are completely digested. B) Coomassie staining reveals complete digestion of the protein by 
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Pronase at 400 µg mL
-1
, demonstrating that the low MW smear is not a protein. C) The fluorescent smear is due to the 
incorporation of YnC12 into a Pronase resistant biomolecule as no fluorescence is seen on treatment with myristic acid 
(Myr). Coomassie staining (total protein, right) is shown as a loading control. D) The insertionally inactivated lgt mutant, 
630 Δerm lgt::erm, is lipidation deficient but still displays the characteristic smear at 15 to 17 kDa, providing further 
evidence that this is LTA, rather than a lipoprotein. Coomassie staining (total protein, right) is shown as a loading control. 
Additional evidence that this smear is LTA came from YnC12 labelling of an insertionally inactivated 
pre-prolipoprotein diacylglyceryl trasferase (Lgt) mutant strain of C. difficile 630 Δerm, 630 Δerm 
lgt::erm. Lgt catalyses the covalent attachment of a membrane phospholipid substrate to the 
conserved lipobox cysteine, forming a thioether linkage; the Lgt mutant 630 Δerm lgt::erm is 
lipidation deficient. Analysis of this strain will be discussed in detail in Chapter 4.3; however, it was 
observed that while fluorescent labelling corresponding to lipoproteins was absent, labelling of the 
lower MW smear was unaffected by inactivation of lgt (Figure 35 D) indicating that it does not result 
from the labelling of a canonical lipoprotein. Additionally, resistance to Pronase digestion (Figure 35) 
indicated they are unlikely to be a protein lipidated by a non-canonical pathway. Consequently these 
fluorescent bands are likely to be YnC12-tagged LTA. 
To demonstrate this unambiguously, we utilised an antibody specific for C. difficile 630 LTA, a 
generous gift from Susan Logan, National Research Council - Institute for Biological Sciences, 
Ottowa, Canada. As shown in Figure 36, a single band was seen in the western blot at the same MW 
as the smear visualised by in-gel fluorescence. It was unaffected by Pronase treatment and identical 
for 630 Δerm and 630 Δerm lgt::erm, demonstrating that this was the result of YnC12 incorporation 
into the lipid anchor of C. difficile’s LTA. The smeared pattern is due to YnC12 incorporation into 
LTAs of different numbers of repeat units; this indicates a relatively heterogeneous population of 
LTA lengths in C. difficile.  
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400 µg mL
-1
 Pronase: 
90 
Figure 36: An anti-LTA western blot demonstrates that the smeared fluorescent bands at 15 to 17 kDa are the result of 
YnC12 incorporation into the diacyl glycerol lipid anchor of LTA (). YnC12 labelling of LTA is not affected by inactivation of 
lgt (C. difficile 630 Δerm lgt::erm) and the LTAs are resistant to Pronase treatment, which digests lipoproteins. Coomassie 
staining (total protein, centre) is shown as a loading control. 
3.3.3 Depletion of Lipoteichoic Acid from Samples 
In-gel fluorescence analysis revealed that YnC12 labelled LTA is highly abundant, relative to the 
labelled lipoproteins, in the insoluble sub-proteome of C. difficile 630. It was therefore unsurprising 
when initial attempts to enrich the YnC12 labelled proteins by pull down onto neutravidin 
Dynabeads (at 100 µL of beads per mg of protein) gave poor results, with almost no detectable 
enrichment of lipoproteins and only a limited amount of LTAs eluted from the beads after boiling in 
1x sample loading buffer (Figure 37). The majority of labelled proteins and LTA remained in the 
supernatant and did not bind to the beads; the amount of LTA found in a typically prepared samples 
will therefore completely block pull down of the YnC12 labelled proteins.   
 
Figure 37: Attempts to enrich the lipoproteins (indicated) onto Neutravidin Dynabeads (Elutant, E), failed due to the large 
amount of labelled LTA () in the samples, which blocks pull down; the supernatant (S) is qualitatively identical to the pre-
pull down sample (-). No enrichment was expected for the myristic acid fed sample which was included as a negative 
control. Coomassie staining (total protein, bottom) is shown as a loading control.    
Efficient pull down is a prerequisite for proteomic analysis of the lipoproteome, therefore methods 
for the removal or depletion of the LTAs from samples were investigated. Initial attempts included 
the use of a molecular weight cut-off centrifugal filter to separate the higher MW lipoproteins from 
the LTA, salting out the highly charged LTA by ammonium sulphate precipitation or the use of 
boronic acid resin which reacts with the syn-hydroxyl groups on glucose residues at pH 9; all these 
methods proved unsuccessful. 
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It was discovered that, although precipitation with an organic solvent after CuAAC to isolate the 
proteins also precipitates labelled LTA, methanol/ chloroform precipitation prior to CuAAC ligation 
effectively removed the LTA from the sample, confirmed by both in-gel fluorescence and anti-LTA 
Western blot, Figure 38 A. Presumably prior to attachment of AzTB the LTA is hydrophilic enough to 
remain in solution in the aqueous/ methanol supernatant during precipitation. A range of protein 
precipitation methods using organic solvent were then tested to investigate whether this was a 
general property of pre-precipitation with an organic solvent, and to identify the most effective pre-
precipitation method (Figure 38 B). It was found that a methanol overnight and acetone pre-
precipitations did not deplete the LTA but chloroform/ methanol pre-precipitation resulted in a 
5-fold reduction in LTA, as assessed by in-gel fluorescence and quantification using ImageJ 
(http://imagej.nih.gov/ij/)295. A second sequential chloroform/ methanol precipitation improved this, 
leading to an almost 34-fold reduction in levels of labelled LTA (Figure 38 C). A single chloroform/ 
methanol pre-precipitation followed by washing the protein pellets with methanol resulted in loss of 
sample, observed by both in-gel fluorescence and coomassie staining. Double chloroform/ methanol 
pre-precipitation method gave the greatest reduction in LTA, without affecting protein recovery, and 
was therefore used to optimise the affinity enrichment of the labelled lipoproteins. 
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Figure 38: A) Chloroform methanol pre-precipitation effectively reduces the quantity of LTA in samples for both C. difficile 
630 Δerm and 630 Δerm lgt::erm, without affecting the protein concentration, as assessed by in-gel fluorescence and anti-
LTA western blot. Coomassie staining (total protein, middle) is shown as a loading control. B) A range of pre-precipitation 
conditions were trialled for C. difficile 630 Δerm; methanol/ chloroform was the only method that effectively removed the 
LTA with sequential precipitations giving increased depletion of the LTA. Coomassie staining (total protein, bottom) is 
shown as a loading control.  C) Quantification of the reduction in fluorescent signal on depletion of LTA performed using 
ImageJ, pixel numbers are indicated on the gel. Coomassie staining (total protein, bottom) is shown as a loading control. 
Two sequential methanol/ chloroform precipitations lead to an approximately a 34-fold reduction in LTA. 
3.4 Optimisation of Affinity Enrichment 
3.4.1 Optimisation of Avidin Bead Concentration 
The affinity enrichment strategy employed utilises a biotin moiety on the capture reagent, 
capitalising on the high strength of the biotin – (strept)avidin interaction, which is comparable to 
covalent bonding296 (Ka= 10
15
 M-1). This allows highly efficient purification of labelled proteins using 
streptavidin or neutravidin beads, following attachment of biotin by CuAAC ligation. Neutravidin is a 
deglycosylated form of streptavidin, which has comparable affinity to biotin as the glycans are not 
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required for this interaction, but displays reduced non-specific protein binding297. A drawback to the 
use of the biotin – avidin interaction is that, due to its high strength, elution of labelled proteins 
from the beads is difficult; in this study boiling at 95 °C for 10 minutes, in SDS-PAGE sample loading 
buffer, was typically used. To accurately assess the pull down efficiency it was necessary to compare 
an aliquot of the sample before pull down to both the elutant from the beads and the supernatant, 
which would contain any residual fluorescence resulting from labelled proteins that were not pulled 
down. 
The effect of pre-precipitation on pull down efficiency was assessed using 100 µL of streptavidin 
Dynabeads (Life Technologies) per mg of protein; these magnetic beads allow rapid and simple 
washing and were therefore used for optimisation of affinity enrichment. As anticipated, pre-
precipitation dramatically improved pull down efficiency, however at this bead concentration a 
similar quantity of labelled protein could be pulled down on a second exposure to streptavidin 
beads. A considerable amount of labelled protein also remained in the supernatant (Figure 39 A), 
even after double methanol/ chloroform pre-precipitation and two pull downs. The ability to pull 
down further labelled protein upon a second exposure to streptavidin beads indicates that 
increasing the quantity of beads used for the pull down would further improve the efficiency. 
Consequently the optimal amount of streptavidin beads for efficient affinity enrichment was 
investigated; total pull down increased with increasing volume of streptavidin Dynabeads, as shown 
in Figure 39 B. However, even at the highest amount tested, 300 µL per mg of protein, complete pull 
down of the labelled proteins was not achieved. 
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Figure 39: A) Pre-precipitation improves pull down efficiency; with two chloroform/ methanol pre-precipitation providing a 
greater improvement, but it remains incomplete. This is due to an excess of labelled lipoproteins in the sample, which can 
be pulled down on a second exposure to the beads (2) but also remain in the supernatant after the second pull down (S). 
Coomassie staining (total protein, bottom) is shown as a loading control. B) The efficiency of pull down improves with 
increasing quantities of streptavidin Dynabeads, up to 300 µL mg
-1
 of protein, as assessed by comparison between the pre-
pull down sample (-), the labelled lipoproteins eluted from the beads (E) and the supernatant (S). Coomassie staining (total 
protein, bottom) is shown as a loading control. 
3.4.2 Re-suspension Buffer Optimisation 
It was possible that the incomplete pull down was not simply due to a high abundance of labelled 
lipoproteins, and residual LTA, in the insoluble fraction, but also a result of protein aggregation after 
repeated precipitations. As demonstrated for LTA, the addition of the capture reagent makes bio-
molecules considerably more hydrophobic and therefore harder to re-suspend and solubilise 
following precipitation. Following all chloroform/ methanol precipitations described above the 
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protein pellet was air dried to remove excess methanol and re-suspended to 10 mg mL-1 in 2 % SDS/ 
PBS, then diluted to 1 mg mL-1 with PBS, 0.2 % SDS; after CuAAC the 2 % SDS solution was 
supplemented with 10 mM EDTA. To reduce the potential for aggregation, the effect on pull down 
efficiency of the addition of 10 mM DTT and 3 % of the non-ionic detergent IGEPAL-CA-630 to the re-
suspension buffer, in addition to SDS and EDTA as described above, was tested. DTT is commonly 
used as a reducing agent to break disulphide bonds within proteins and would also reduce those that 
have formed between aggregated proteins. The addition of a second, non-ionic, detergent was 
anticipated to also aid the solubilisation of hydrophobic membrane proteins which would be 
enriched in the insoluble sub-proteome used (section 3.2.2). IGEPAL-CA-630 is an NP-40 analogue, 
the addition of which has been reported to facilitate the re-suspension of lipidated, insoluble 
proteins prior to affinity purification234. DTT and IGEPAL-CA-630 were both found to improve the pull 
down efficiency when added individually to the re-suspension buffer. When used in combination the 
pull down was almost complete (Figure 40 A). Using this optimised re-suspension buffer (2 % SDS, 
3 % IGEPAL-CA-630, 10 mM DTT and EDTA) the efficiency of pull down onto neutravidin agarose 
beads was investigated; these beads typically give a lower background than streptavidin Dynabeads 
and will be used for proteomic applications.  
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Figure 40: A) Re-suspension buffer screening; the efficiency of affinity enrichment is improved by the addition of both DTT 
and the detergent IGEPAL-CA-630 (final concentrations after dilution of the protein to 1 mg mL
-1
 shown). The addition of 
both DTT and IGEPAL-CA-630 to the resuspension buffer enables almost complete enrichment as assessed by comparison 
between the pre-pull down samples (-), the proteins eluted from the beads (E) and the supernatant removed from the bead 
after pull down (S).  Coomassie staining (total protein, bottom) is shown as a loading control. B) Neutravidin agarose beads 
perform comparably to streptavidin dynabeads (Figure 39 B) with 300 µL of beads per mg of protein required for efficient 
affinity enrichment, enrichment as assessed by comparison between the pre-pull down samples (-), the proteins eluted from 
the beads (E) and the supernatant (S).  Coomassie staining (total protein, bottom) is shown as a loading control. 
The pull down efficiency on neutravidin agarose resin (Figure 40 B) was similar to that for the 
streptavidin Dynabeads, with 300 µL of bead solution per mg of protein required for efficient 
enrichment. Having determined that these beads perform comparably using the optimised 
conditions, streptavidin Dynabeads were used for affinity enrichment for all further in-gel 
fluorescence analysis, while neutravidin agarose was used for all proteomic experiments. Following 
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efficient enrichment, the YnC12 labelled proteins correspond to a relatively small fraction of the 
insoluble sub-proteome and cannot be detected by Coomassie staining. 
3.4.3 Optimised Workflow 
This section has described the development of an optimised workflow for affinity enrichment of 
YnC12 tagged lipoproteins in C. difficile, to enable proteomic analysis of the lipoproteome. All 
further analysis of the C. difficile lipoproteome described in this thesis was performed using this 
method. After feeding exponentially growing C. difficile cultures with YnC12, typically at 10 or 25 µM 
for 6 hours, the bacteria were lysed and fractionated. The insoluble sub-proteome, which contains 
the majority of the lipoproteins, was standardised to a protein concentration of 1 mg mL-1 and 
chloroform/ methanol pre-precipitated twice to deplete the LTA prior to affinity enrichment, if 
required. The samples were then subjected to CuAAC ligation with AzTB, chloroform/ methanol 
precipitated to remove the excess capture reagent and re-suspended in 2 % SDS, 3 % IGEPAL-CA-
630, 10 mM DTT and EDTA to 10 mg mL-1 and diluted to 1 mg mL-1 with PBS. The labelled 
lipoproteins could then be enriched with avidin coated beads at a concentration of 300 µL per mg of 
protein, or further diluted with sample loading buffer for gel based analysis. Enriched proteins were 
either eluted from the avidin beads by boiling in sample loading buffer, or subjected to on-bead 
tryptic digest and proteomic analysis, as described in Chapter 9.2.4. 
3.5 Discussion 
The work described in this chapter has focussed on a proof of concept for the use of metabolic 
tagging to profile lipoproteins in C. difficile, the investigation of YnC12 as a substrate analogue and 
the dynamics and selectivity of YnC12 incorporation. The incorporation of YnC12 into LTA has been 
demonstrated and a method to deplete the LTAs from samples developed, leading to optimisation of 
the conditions for affinity enrichment of YnC12 labelled proteins. The work desccribed in this 
chapter has been restricted to gel-based analysis but has laid the foundations for proteomic analysis 
of the C. difficile lipoproteome, to be discussed in later chapters.  
An initial series of proof-of-concept experiments were performed utilising previously synthesised 
azide- and alkyne-tagged fatty acid analogues (Section 3.1.3). Azide-tagged substrate analogues 
were found not to be compatible with C. difficile growth conditions, but alkyne-tagged analogues 
were suitable for use in a metabolic chemical tagging approach, in combination with the capture 
reagent AzTB. A series of alkyne-tagged lipid analogues were synthesised (Section 3.2) and YnC12 
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found to give efficient labelling in C. difficile 630 Δerm. This probe was selected for further 
experiments and the optimal feeding time and probe concentration identified. 
Probe incorporation, and therefore the majority of lipoprotein biosynthesis, was observed to occur 
predominantly during exponential growth phase, saturating at late exponential phase. It was found 
that turnover of the lipoproteome at stationary growth phase in C. difficile is limited, consistent with 
the majority of lipoprotein expression and lipidation occurring during exponential growth (Section 
3.2.3). The specificity of YnC12 for uptake and metabolism by C. difficile 630 Δerm was demonstrated 
by the reduction in metabolic tagging observed on competition with an excess of the natural lipid 
(Section 3.2.3). Competition overnight required increased concentrations of myristic acid indicating 
that some turnover of these putative lipoproteins occurs over longer timescales. 
C. difficile has an unusual type V LTA, discussed in Section 3.3.1; incorporation of YnC12 into the lipid 
anchor of C. difficile’s LTA was demonstrated by a combination of proteolytic digestion of the 
proteins and western blotting with an anti-type V LTA antibody (Section 3.3.2). Probe incorporation 
into C. difficile LTA provides a simple in-gel visualisation method and may have future applications in 
the investigation of LTA biosynthesis in C. difficile and other Gram-positive bacteria. However, LTA 
was highly abundant in the insoluble fraction of C. difficile lysates and blocked affinity enrichment of 
the labelled proteins by saturating the streptavidin beads. A pre-precipitation method to deplete the 
LTAs from C. difficile samples was developed resulting in an up to a 34-fold reduction in LTA, 
measured by in-gel fluorescence (Section 3.3.3). 
Despite depletion of LTA from the samples affinity enrichment was not sufficiently efficient for 
quantitative proteomic analysis. The amount of beads required and the re-suspension buffer used 
after CuAAC were optimised, resulting in almost complete pull down of the labelled proteins. 
Coomassie staining of the gels to visualise the total protein loading revealed that the labelling 
pattern does not correspond to abundant proteins. 
In this chapter in-gel fluorescence analysis was utilised to rapidly investigate the feasibility of a 
metabolic tagging approach to profile the C. difficile lipoproteome, to select a substrate analogue 
from a panel of alkyne-tagged fatty acids and to develop an optimised workflow for affinity 
enrichment of labelled proteins (Section 3.4.3). The methods developed in this chapter will be 
applied in the remainder of this thesis to profile the C. difficile lipoproteome both qualitatively by in-
gel fluorescence and by proteomic analysis. 
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Chapter 4: Lipoprotein Biogenesis in Clostridium difficile 
4.1 Introduction 
In the preceding chapter, the development and use of alkyne tagged lipid analogues to label the 
lipoproteome of Clostridium difficile was described. The subsequent application of these probes to 
investigate lipoprotein biogenesis in C. difficile is discussed in this chapter. The primary aim of this 
work was to investigate the effect of inactivation of the prolipoprotein diacylglyceryl transferase (lgt) 
and lipoprotein signal peptidase (lspA) genes in C. difficile 630 Δerm on lipoprotein biogenesis, using 
the optimised labelling methodology. C. difficile, in contrast to the majority of Gram-positives, 
contains two lspA genes. The activity of this second gene (lspA2) was to be investigated and any 
substrate selectivity between LspA and LspA2 studied. Finally the phenotypes, including protein 
shedding, toxin production and sporulation efficiency, of these mutants were to be investigated. 
Throughout this chapter the effect of mutation or inhibition on lipoprotein biogenesis in C. difficile 
was studied qualitatively, by in-gel fluorescence. 
4.2 Lipoprotein Biogenesis in Gram-Positive Bacteria 
4.2.1 Lipoprotein Biogenesis in Gram-Positive Bacteria and C. difficile 
4.2.1.1 Lipoprotein Biogenesis 
Bacterial lipoprotein biogenesis, in both Gram-positive and Gram-negative bacteria is discussed in 
detail in Chapter 1.2.2 (Figure 41); in both cases bacterial lipoproteins are initially translated as a 
pre-prolipoprotein. This features an N-terminal Type II signal peptide sequence which targets the 
protein for export via the General Secretory (Sec) pathway and remains embedded in the membrane 
following export. A lipobox motif, at the C-terminal end of the signal peptide sequence, is recognised 
by the enzyme prolipoprotein diacylglyceryl transferase (Lgt); Lgt catalyses the covalent attachment 
of a membrane phospholipid substrate125 to the conserved +1 cysteine side chain forming a 
thioether linkage126.  
Following lipid modification the signal peptide is then cleaved by a Type II signal peptidase, also 
referred to as lipoprotein signal peptidase (Lsp), a transmembrane aspartate protease152a 127, 153. The 
signal peptide is recycled and the mature lipoprotein remains anchored to the membrane via the 
lipid modified cysteine, which is the new N-terminal residue. This pathway generally occurs 
sequentially however, there is evidence that Lsp can cleave unmodified pre-prolipoproteins129. 
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Figure 41: Lipoprotein biogenesis in Gram-positive bacteria; the pre-prolipoprotein (A) features an N-terminal Type II signal 
peptide sequence, containing a lipobox. The enzyme prolipoprotein diacyl-glycerol transferase (Lgt) catalyses the addition 
of a diacyl-glycerol fatty acid to the invariant lipobox cysteine side chain (B). The signal peptide is then cleaved within the 
lipobox, leaving the conserved cysteine as the N-terminal residue. The mature lipoprotein (C) remains anchored to the 
membrane via the lipid modification. Further modifications (N-terminal acylation) can occur in Gram-negative and high G-C 
content Gram-positive bacteria. 
4.2.1.2 Inactivation of lgt and lsp in Gram-Positive Bacteria  
The entire lipoprotein biogenesis pathway is essential in Gram-negative bacteria, but has been 
studied using antisense RNA knock down approaches128. Deletion of enzymes in the lipoprotein 
biogenesis pathway is lethal due to retention of essential outer membrane lipoproteins at the inner 
membrane by uncleaved signal peptide on depletion of Lgt and Lsp114 or by avoidance of the 
lipoprotein localisation (Lol) pathway on depletion of Lnt128. However, Lgt and Lsp are dispensable in 
Gram-positive bacteria. A number of Gram-positive lipoproteins have been shown to be essential, 
including the chaperone PrsA, however, mutants defective in lipoprotein biogenesis enzymes remain 
viable, possibly because pre-prolipoproteins and proliproteins remain anchored to the membrane 
and retain functionality. Additionally, an accumulation of unprocessed lipoproteins at the membrane 
is avoided due to cleavage by scavenging peptidases, including Type I signal peptidases and 
metallopeptidases, referred to as “shaving”114. 
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Deletion mutants of lgt and lsp have been created in a number of Gram-positive bacteria, including 
Streptococcus pneumonia (Δlgt141 and Δlsp149b), Bacillus anthracis (Δlgt142), S. suis (Δlsp149a), Listeria 
monocytogenes (Δlgt129 and Δlsp154), Mycobacterium tuberculosis (Δlsp155) and  B. subtilis (ΔlspA127). 
Complete inactivation of the lipoprotein biogenesis machinery in a single study has been reported in 
S. peumoniae197, S. coelicolor158 and S. scabies159. The phenotypes of mutants deficient in lipoprotein 
biogenesis vary between species; inactivation of lgt does not typically affect growth in vivo but can 
be important for virulence in vivo and has also been shown to be important for sporulation in 
Bacillus species142, 186b. Inactivation of lsp also leads to varied phenotypes, even within a genus, as 
inactivation of S. suis lsp has no effect on virulence149a but S. pneumonia lsp is required for full 
virulence in a mouse model of infection149b. This highlights the different roles the lipoproteome can 
play in virulence and indicates that the effect of inactivation lgt and lsp largely depends on 
lipoprotein function. 
4.2.2 Lipoprotein Biogenesis in C. difficile 
In addition to the general Secretory (Sec) apparatus, comprised of the membrane channel SecYEG 
and an ATPase (SecA1, CD630_01430), C. difficile has a parallel Sec system, characterised by the 
presence of an additional ATPase, SecA2 (CD630_27920). In M. smegmatis lipoproteins have been 
demonstrated to be dependent on SecA2 for export122, however the primary role of SecA2 in C. 
difficile has been shown to be export of the S-Layer proteins and CwpV58. Consequently, it is 
probable that the majority of lipoproteins are exported via SecA1. Although lipoproteins have been 
demonstrated to be translocated via the twin arginine protein transport (TAT) pathway in other 
organisms298 C. difficile does not possess any alternative export pathways to Sec. 
C. difficile Lgt (CD630_26590), as shown in Figure 42, is homologous to the corresponding proteins 
from B. subtiltis 168 and Escherichia coli K12; with 45.0 % identity between C. difficile and B. subtilis 
Lgt and 23.5 % identity between C. difficile and E. coli Lgt. The relationship between primary 
sequence and activity of Lgt has been investigated for E. coli SD9, by comparing wild type to 
temperature sensitive mutants and the Lgt from Staphylococcus aureus. The longest invariant region 
between the Lgt sequences studied was H103GGLIH108 (H90GGLIH95 in C. difficile) and this region was 
proposed to be important for the structure-function relationship of this enzyme family137. Site 
directed mutagenesis has demonstrated that histidine-103 (H90 in C. difficile) in the conserved region 
and tyrosine-235 (Y196 in C. difficile) are essential for Lgt activity in E. coli
138. This tyrosine and the 
HGGLIH region are conserved between the three Lgt enzymes studied. Based on this and previously 
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obtained in-gel fluorescence labelling of putative lipoproteins (Chapter 3.1.3), it is probable that 
CD630_26590 encodes an active Lgt. 
 
Figure 42: Alignment of Lgt from C. difficile 630, B. subtilis strain 168 and E. coli K12 reveals a high degree of similarity; 
alignment generated using Geneious (ClustalW) and annotated using CHROMA. Identical residues are highlighted with a 
black background while similar residues are highlighted with a red (charged) or blue (hydrophobic) background. The 
proposed phospholipid binding sequence H90GGLIG95 (relative to C. difficile Lgt) is conserved in all three sequences 
(highlighted in yellow in the consensus sequence), as is the essential tyrosine Y196 (C. difficile) which is also highlighted 
yellow in the consensus.  
C. difficile 630 encodes two lsp genes, referred to as lspA and lspA2 (CD630_25970 and 
CD630_19030, respectively). The presence of two lsp genes is relatively unusual, as discussed in 
Chapter 1.2.2.3; although other bacteria have been reported to encode more than one lsp gene they 
are not always active. In L. monocytogenes the second putative lsp does not compensate for 
inactivation of the primary lsp114 and while the Gram-negative Myxococcus xanthus DK1622 encodes 
four lsp genes (lspA1 to lspA4), two of these are involved in resistance to and regulation of the M. 
xanthus produced antibiotic TA156. Therefore, the identification of a second putative lspA gene in C. 
difficile does not guarantee the existence of two functionally redundant LspAs as it may perform an 
alternate function, or be inactive. 
LspA proteins have four transmembrane spanning domains152a and consequently have a large 
number of hydrophobic regions, which are conserved between both LspA homologues from 
C. difficile 630 and LspA from B. subtiltis 168 and E. coli K12, as shown in Figure 43 (highlighted blue). 
>Lgt C. difficile 630  ----------MDRVAFTLFGIDIMWYGILMACGMILGTLIAIKEAKR--VGIKEDDVLNI 
>Lgt B. subtilis 168   ---MNEAIEPLNPIAFQLGPLAVHWYGIIIGLGALLGLWIAMRESEK--RGLQKDTFIDL 
>Lgt E. coli K12       MTSSYLHFPEFDPVIFSIGPVALHWYGLMYLVGFIFAMWLATRRANRPGSGWTKNEVENL 
Consensus              ..........h..hhF.hh.h.hhWYGhhhhhGhhhhhhhAhcc..c...Gh.c..h..h 
 
 
>Lgt C. difficile 630  AIIAIPVGLICARIYYVVFN-WSYYAQNMSQIFNFRGGGLAIHGGLIGGILAGYIYTKIK 
>Lgt B. subtilis 168   VLFAIPIAIICARIYYVAFE-WDYYAAHPGEIIKIWKGGIAIHGGLIGAILTGYVFSRVK 
>Lgt E. coli K12       LYAGFLGVFLGGRIGYVLFYNFPQFMADPLYLFRVWDGGMSFHGGLIGVIVVMIIFARRT 
Consensus              hhhhh.hhhhhhRIhYVhF..h..hh.....hh.h..GGh.hHGGLIGhIhhhhhh.c.. 
 
 
>Lgt C. difficile 630  NINFLKMADTVILGMPLAQAIGRWGNFINGEAHG-------------GATN--------L 
>Lgt B. subtilis 168   NLSFWKLADIAAPSILLGQAIGRWGNFMNQEAHG-------------EAVSRAFLENLHL 
>Lgt E. coli K12       KRSFFQVSDFIAPLIPFGLGAGRLGNFINGELWGRVDPNFPFAMLFPGSRTEDILLLQTN 
Consensus              ...Fh.h.Dhhh..h.hh.hhGRhGNFhN.EhhG.......................... 
 
 
>Lgt C. difficile 630  PWGIM----VDGVKVHPTFLYESIWD-FGIFIVLLLFRKNKKYEGQVIVTYITLYSIGRF 
>Lgt B. subtilis 168   PEFIINQMYINGQYYHPTFLYESLWS-FVGVIVLLLLRRANLRRGEMFLIYIIWYSIGRY 
>Lgt E. coli K12       PQWQSIFDTYGVLPRHPSQLYELLLEGVVLFIILNLYIRKPRPMGAVSGLFLIGYGAFRI 
Consensus              P.h......h.h...HP..LYE.hh..hhhhIhL.Lh.c.....G.h.hhhhhhY.hhRh 
 
 
>Lgt C. difficile 630  FIEGLRTDSLMLG-----PLRMAQVISLIGVIGGIIAHVYLSKK--NKNNISEE 
>Lgt B. subtilis 168   FIEGMRTDSLMLTD----SLRIAQVISIVLIVLAVAAIIFRRVKGYSKERYAE- 
>Lgt E. coli K12       IVEFFRQPDAQFTGAWVQYISMGQILSIPMIVAGVIMMVWAYRR--SPQQHVS- 
Consensus              hhEhhR...h.hh......h.hhQhhSh.hhhhhhhhhhh...c......h... 
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These proteins are homologous, with C. difficile LspA having 36.2 % identity with B. subtilis LspA and 
28.4 % identity with E. coli LspA. In contrast C. difficile LspA2 has only 19.1 % identity with B. subtilis 
LspA and 16.4 % identity with E. coli LspA; C. difficile LspA and LspA2 share 18.4 % identity. 
Type II signal peptidases (Lsps) are aspartate proteases; the residues required for activity of 
B. subtilis LspA have been identified by site directed mutagenesis as Asn-99, Asp-102, Asn-126, Ala-
128, and Asp-129 where D102 and D129 are the catalytically active aspartates. The remaining three 
residues are required for active site geometry, or the specific recognition of lipid-modified 
prelipoproteins153. All five residues are conserved between B. subtilis, E. coli and C. difficile LspA 
(Figure 43, highlighted yellow), however Asn-99, Asn-126 and Ala-128 are not conserved in C. difficile 
LspA2. The catalytic aspartate dyad is conserved between all four sequences, leaving the activity of 
LspA2 uncertain; if Asn-99, Asn-126 and Ala-128 are involved in substrate recognition it is possible 
that LspA2 is active but has different substrate specificity to LspA. Alternatively, if these residues 
play a role in active site geometry LspA2 may not be an active Type II signal peptidase. 
 
Figure 43: Alignment of LspA and LspA2 from C. difficile 630 with LspA B. subtilis strain 168 and E. coli K12 reveals four 
distinct transmembrane regions (hydrophobic; highlighted blue). Identical residues are highlighted with a black background 
while similar residues are highlighted with a red (charged) or blue (hydrophobic) background. The five conserved catalytic 
resides are highlighted yellow in the consensus sequence and in the specific sequences if not conserved; the catalytic 
aspartate residues are conserved across all four sequences. The four hydrophobic, transmembrane domains are underlined. 
Alignment generated using Geneious (ClustalW) and annotated using CHROMA. 
There is no obvious Lnt homologue in C. difficile; this is not unexpected as Lnt is typically only found 
in Gram-negative and high G-C content Gram-positive bacteria. Although there is evidence that 
>LspA C. difficile 630   ----------MLYILIIILLIGLDQLSKIWVLNNLVDVSTIPIINNVFHLTYVENRGAAF 
>LspA2 C. difficile 630  MQGGVNIRQVKSFVFPVISLIFLDQISKVLIG-LFLMDFEIDIIGKFLRFNPVQNTNLSY 
>LspA B. subtilis 168    ----------MLYYMIALLIIAADQLTKWLVVKNMELGQSIPIIDQVFYITSHRNTGAAW 
>LspA E. coli K12        -MSQSICSTGLRWLWLVVVVLIIDLGSKYLILQNFALGDTVPLFP-SLNLHYARNYGAAF 
Consensus                ............hhh.hh.hhhhD.h.Khhhh..h.....h.hh...h.h..h.N..h.h 
  
 
>LspA C. difficile 630   G-----LLQN----NQWIFIIVALLATVFGLYYLN--TRKVHIFGRLGIILIISGALGNL 
>LspA2 C. difficile 630  GGNFIGILSN--LWVLVLFNILVILVIISGYAFYKSKNEQTSYSVKVIMSCGLAGTICSL 
>LspA B. subtilis 168    G-----ILAG----QMWFFYLITTAVIIGIVYYIQRYTKGQRLLG-VALGLMLGGAIGNF 
>LspA E. coli K12        S-----FLADSGGWQRWFFAGIAIGISVILAVMMYR-SKATQKLNNIAYALIIGGALGNL 
Consensus                ......hL........hhF.hhhhhh.h.hhhhh....c.......hhh.hhh.Ghhh.h 
 
 
>LspA C. difficile 630   IDRVRLGFVVDYFDFRII-WEY-VFNIADVFVVVGTVFLCIYVLFFESKSR--------- 
>LspA2 C. difficile 630  IDKLFWGGSLDFLQIPSF----FIFDLKDCYLTVAEIIFVVIGILHNREISMKEYIYFCY 
>LspA B. subtilis 168    IDRAVRQEVVDFIHVIIVNYNYPIFNIADSSLCVGVMLLFIQMLLDSGKKKKEQ------ 
>LspA E. coli K12        FDRLWHGFVVDMIDFYVGDWHFATFNLADTAICVGAALIVLEGFLPSRAKKQ-------- 
Consensus                hDch.....hDhh.h..h.....hF.h.D..hhVh.hhhhh.hhh............... 
 
 
>LspA C. difficile 630   ----- 
>LspA2 C. difficile 630  RQFKR 
>LspA B. subtilis 168    ----- 
>LspA E. coli K12        ----- 
Consensus                ..... 
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transacylases and deacylases can further remodel the lipid anchor post-translationally in Firmicutes, 
the phylum to which C. difficile belongs130, further modification of lipoproteins in C. difficile was not 
investigated. 
It has been demonstrated in S. uberis that, in the absence of full processing of prolipoproteins by 
Lsp, a membrane associated metalloprotease (Eep) is capable of cleaving lipoproteins162. C. difficile 
630 features an Eep homologue, encoded by CD630_21290, which is 30.7 % identical to the S. uberis 
Eep. However, Eep was not investigated further as it is not part of the prolipoprotein processing 
pathway and instead is proposed to play a role in the maintenance of secretion pathways on 
disruption of lipoprotein processing. While a role for the Eep homologue (CD630_21290) or other 
unidentified proteins in lipoprotein biogenesis in C. difficile cannot be ruled out, this study has 
focused on the core lipoprotein biogenesis pathway; Lgt, LspA and LspA2.  
4.3 Dissecting the Lipidation pathway in C. difficile 
4.3.1 Genetic Inactivation of Lipoprotein Biogenesis 
4.3.1.1 Construction of Deletion Mutants and Complements 
C. difficile 630 Δerm lgt, lspA, and lspA2 were inactivated by the insertion of an erythromycin 
resistance cassette in the antisense orientation by Doctor Andrea Kovacs-Simon and Doctor Stephen 
Michell at the University of Exeter299, utilising the ClosTron insertional mutagenesis system92a. The 
inactivated mutants, referred to as lgt::erm, lspA::erm and lspA2::erm respectively, were 
complemented in trans with plasmids derived from pMTL960, containing the corresponding gene 
under the control of a constitutive promoter, pcwp258. The corresponding gene was amplified from 
C. difficile 630 Δerm genomic DNA, using the primers detailed in Appendix A, which added a 5’ SacI 
and a 3’ BamHI restriction digest site to the product (Figure 44 A and  C). The PCR products and 
vector backbone were doubly digested with BamHI and SacI, ligated and transformed into E. coli NEB 
5α. Transformants were selected for by chloramphenicol resistance. The plasmids were confirmed 
by restriction digest (Figure 44 B and D) and sequenced before conjugation into the corresponding C. 
difficile mutant strain from E. coli CA434’s. Transconjugants were selected for growth on media 
containing thiamphenicol and cycloserine as described in Chapter 9.1.2.11. The exception to this was 
the plasmid for complementation of lspA2::erm, pMCD003, which was cloned under the supervision 
of Andrea Kovacs-Simon, University of Exeter, and conjugated into C. difficile lspA2::erm as part of 
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this study. The complemented strains produced are referred to as 630 Δerm lgt::erm +pTMC002, 
630 Δerm  lspA::erm +pTMC001 and 630 Δerm  lspA2::erm +pMCD003. 
 
Figure 44: Cloning of plasmids for the constitutive expression of lgt and lspA. A)  Amplification of lgt () with primers 
NF2204 and NF2205 to add 5’ SacI and 3’ BamHI restriction digest sites. B) Restriction digest of 4 unique transformants of 
pTMC002 (constitutive expression of Lgt); the vector backbone is based on pRPF144 (constitutive expression under the 
control of pcwp2, ); a digest of pRPF144 is included as a control, the original insert, gusA is indicated by . The lgt insert 
is indicated with , colony number 1 was selected for sequencing and transformation of C. difficile. C)  Amplification of lspA 
() with primers NF2182 and NF2183 to add 5’ SacI and 3’ BamHI restriction digest sites. D) Restriction digest of pTMC002 
(constitutive expression of LspA) for 3 unique transformants; the vector backbone is based on pRPF144 (constitutive 
expression under the control of pcwp2, ); a digest of pRPF144 is included as a control, the original insert, gusA is indicated 
by . The lspA insert is indicated with , colony number 1 was selected for sequencing and transformation of C. difficile. 
4.3.1.2 Qualitative Profiling of Lipoprotein Biogenesis 
The effect of inactivation of lgt, lspA and lspA2 on lipoprotein biogenesis and processing was 
assessed by treating the mutants and complements with 25 µM YnC12 during early exponential 
phase and allowing growth for a further 5 hours, to early stationary phase. Following lysis, 
fractionation and CuAAC ligation to AzTB, changes to lipidation and prolipoprotein cleavage were 
visualised by in-gel fluorescence analysis. The labelled lipoproteome of the parental strain, C. difficile 
630 Δerm, showed no qualitative difference in the presence of thiamphenciol (630 Δerm +pMTL960, 
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vector control) however, the labelling pattern for the mutant strains showed a number of changes, 
as shown in Figure 45Figure 45. 
 
Figure 45: The effect of insertional inactivation of lgt, lspA and lspA2 on prolipoprotein processing in C. difficile 630 Δerm 
was assessed by treating the parental strain and the insertionally inactivated mutants, lgt::erm, lspA::erm and lspA2::erm, 
with 25 µM YnC12. Inactivation of lgt results in a loss of tagging indicating the lgt is essential for lipidation in C. difficile. 
Inactivation of LspA resulted in the shift of a number of fluorescent bands to a higher MW (); this is proposed to be due to 
the retention of the signal peptide. Inactivation of lspA2 resulted in no obvious changes to lipoprotein processing, but a 
general reduction in fluorescence intensity was observed. In all cases complementation restored the wild type labelling 
pattern. Coomassie staining (total protein, bottom) is shown as a loading control.  
As anticipated there was an almost complete loss of fluorescent labelling for lgt::erm, revealing the 
vital role of Lgt in catalysing lipidation in C. difficile. Indeed, based on this in-gel fluoresecence 
output, it appears that in the absence of Lgt C. difficile is essentially lipidation deficient. Inactivation 
of lgt had no effect on the incorporation of YnC12 into lipoteichoic acid (LTA), as discussed in 
Chapter 3.3. Complementation by constitutive expression of the lgt gene (lgt::erm +pTMC002) 
restored the wild type phenotype, with no qualitative difference observed between 
lgt::erm +pTMC002 and the control strains 630 Δerm and 630 Δerm +pMTL960. Inactivation of lgt 
revealed that the vast majority of lipoproteins in C. difficile are lipidated by the canonical pathway, 
as labelling is lost on inactivation of lgt. However, as Lnt would only be expected to modify 
lipoproteins after lipidation by Lgt and cleavage by either Lsp, the loss of labelling observed for 
lgt::erm does not rule out the existence of an Lnt homologue. 
The in-gel fluorescence labelling pattern for lspA::erm showed a number of bands shift to a higher 
apparent molecular weight (MW), as indicated in Figure 45. This is proposed to be due to retention 
of the signal peptide for a number of lipoproteins, which are substrates of LspA. Complementation 
by constitutive expression of the lspA gene (lspA::erm + pTMC001) partially restored the wild type 
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labelling pattern. In contrast, inactivation of LspA2 (lspA2::erm) resulted in a general reduction in 
fluorescence labelling intensity, but no fluorescent bands shifted to a higher apparent MW. From 
this result it is apparent that LspA has a number of unique substrates, for which the signal peptide is 
not cleaved in the absence of LspA (lspA::erm) and, as all prolipoproteins appeared to be correctly 
processed in the absence of LspA2 (lspA2::erm), LspA may be capable of processing the majority of 
lipoproteins. LspA2 may not be actively involved in lipoprotein biosynthesis, as inactivation of lspA2 
does not result in any obvious defects in prolipoprotein processing, however the possibility remains 
that LspA2 is active but does not have any unique substrates. From these qualitative results no 
explanation for the general reduction in fluorescence observed in lspA2::erm could be suggested. It 
remains possible that only partial complementation of the lspA mutant could be achieved due to 
spatial or temporal regulation of LspA and LspA2 expression ar activity, which is lost on constitutive 
expression. 
Although lgt::erm showed a dramatic loss of lipidation some residual, low intensity, fluorescent 
bands could still be observed. These bands could be affinity enriched and eluted from the beads 
(Figure 46 A, ), indicating covalent attachment of biotin and the fluorophore resulting from 
specific incorporation of the probe into a low expression level protein, rather than background 
fluorescence. This hypothesis was supported by competition between 10 µM YnC12 and up to a 40-
fold excess of myristic acid overnight, as described for 630 Δerm in Chapter 3.2.3, revealing that 
tagging of these bands could be competed out (Figure 46 B). However, as the intensity of these 
bands was low the possibility remains that they are not the product of an alternative lipidation 
mechanism, but instead the result of auto-lipidation of the lipobox cysteine thiol. This “auto-
lipidation” could occur at a low level in the absence of Lgt as the lipobox cysteine is expected to be in 
close proximity to the diacylglyceryl head group of membrane phospholipids, which are the natural 
substrate. Proteomic analysis of these potential lipoproteins, affinity enriched from lgt::erm, is 
required to discover whether these bands are predicted lipoproteins or the product of an alternative 
lipidation mechanism. Despite this, the majority of lipidation occurs in an Lgt dependent manner as 
inactivation of lgt results in a loss of labelling for almost all fluorescent bands. 
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Figure 46: A) Affinity enrichment of lipoproteins from 630 Δerm and 630 Δerm lgt::erm, and the complement (pTMC002); 
the vector control (630 Δerm +pMTL960) is included to control for any potential effect of thiamphenicol on the 
lipoproteome. Two fold more protein equivalent is loaded in the Elutant lanes (E) relative to the pre-pull down (-) and 
supernatant (S) lanes. Low intensity fluorescent bands, which can be affinity enriched, were still observed in the lgt mutant 
(). Coomassie staining (total protein, bottom) is shown as a loading control. B) The labelling of these low intensity bands 
in lgt::erm can be competed out with an excess of myristic acid, indicating that they are the product of specific 
incorporation of YnC12 into proteins. As this occurs in the absence of Lgt this process presumably occurs by a non-canonical 
pathway. Coomassie staining (total protein, bottom) is shown as a loading control. 
4.3.2 Chemical Inhibition of Lipoprotein Biogenesis 
4.3.2.1 Chemical Genetics 
To further investigate the activity of LspA2 and whether it plays a role in prolipoprotein processing, 
the construction of a ΔlspA/ΔlspA2 doubly inactivated mutant was desirable. However, this was not 
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considered practical as the creation of multiple knock out mutants has only been described once 
using the ClosTron mutagenesis system97 and has historically proved extremely challenging in C. 
difficile. Since this work was performed, considerable advances in C. difficile genetics have been 
made, as discussed in Chapter 1.1.598. During this study, a chemical genetic approach was adopted 
to further unravel the potential activity, selectivity and any functional redundancy of LspA and LspA2 
in C. difficile. 
Chemical genetics is defined as the study of gene-product function in a cellular context, using an 
exogenous ligand, which is frequently a small molecule300. A traditional reverse genetics approach, in 
which the gene of interest is deleted and the resulting phenotype observed, was employed to 
investigate the roles of the products of lgt, lspA and lspA2 in lipoprotein biogenesis (section 4.3.1). 
The corresponding reverse chemical genetics approach was utilised to study LspA and LspA2. 
Reverse chemical genetics is the use of a small molecule partner to inhibit or otherwise perturb the 
function of the protein of interest and the resulting phenotype is then observed301. There are many 
advantages to chemical genetic approaches; compound application is conditional and reversible and 
the application of small molecules is rapid, allowing kinetic studies to be performed and dose-
response data to easily be produced. The primary disadvantage of a chemical genetic approach is 
that it cannot be applied universally as a selective small molecule ligand is required for the protein of 
interest. Chemical genetic tools have been applied to study a range of systems, including the 20S 
proteasome, signalling via cyclin dependent kinases and the cytoskeleton302. 
Chemical genetic approaches require that two conditions are met: a selective small molecule must 
be identified and a biological screening assay is required to characterise the interaction between the 
small molecule and its target protein. Metabolic tagging with YnC12 (Section 4.3.1.2) provides a 
suitable biological assay to assess the cleavage of prolipoproteins, as demonstrated by the genetic 
inactivation of lspA. Additionally, a specific inhibitor of Type II signal peptidases, globomycin, is 
readily available, making a chemical genetic approach suitable to further investigate LspA and LspA2.  
4.3.2.2 Globomycin 
Globomycin is a cyclic peptide antibiotic and a specific inhibitor of E. coli Lsp, produced by 
Streptomyces halstedii, S. neohygroscopicus, S. hagronensis and Streptoverticillium cinnamoneum. 
Globomycin was discovered to have specific antibiotic activity against Gram-negative bacteria by 
Inukai and co-workers in 1978303 and was isolated in bulk from cultures of S. halstedii304, which 
facilitated characterisation of its activity and determination of its structure. Globomycin is a cyclic 
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lipo-peptide which features a number of unusual amino acids and modifications. The linear 
sequence of globomycin is 3-hydroxy-2-methylnonaic acid – N-methyl leucine – allo-isoleucine – 
serine – allo-threionie – glycine – OH. This is cyclised by the formation of an ester bond between the 
hydroxyl on the N-terminal 3-hydroxy-2-methylnonaic acid and the glycine carboxylate as shown in 
Figure 47 A305. A total synthesis of globomycin and subsequent X-ray crystallography confirmed this 
absolute configuration in 2000306. The total synthesis of globomycin has since been reported by 
numerous routes307 and the structure activity relationship investigated308; recently a solid phase 
synthesis of Globomycin has been reported309. Globomycin was discovered to exert its antibiotic 
effect by inhibition of Lsp in E. coli, resulting in a lethal accumulation of prolipoprotein in the cell 
envelope310. Globomycin inhibition was used to demonstrate that cleavage of Type II signal peptides 
occurs after lipidation in E. coli, and that inhibition of Lsp prevents trafficking of lipoproteins to the 
outer membrane311. Globomycin is a reversible and non-competitive Lsp inhibitor; the chemical 
structure suggests a binding mode in which the 2-methylnonaic acid chain mimics an acyl chain of 
diacylglyceryl modified prolipoproteins. 
From its first use to dissect the lipidation pathway in E. coli globomycin has had a long history of use 
as a tool compound to study Type II signal peptidases, in both Gram-negative and Gram-positive 
bacteria. Over expression of Lsps from other Gram-positive and Gram-negative species in E. coli 
desensitises E. coli to globomycin inhibition and this method has been used to demonstrate activity 
of Type II signal peptidases from Gram-positives including S. suis149a, S. pneumoniae149b and 
L. monocytogenes154, and Gram-negatives including R. typhi149c and M. xanthus156. Globomycin 
represents the ideal small molecule for use in a chemical genetic approach to investigate LspA and 
LspA2 in C. difficile. 
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Figure 47: A) The structure of Globomycin B) Growth curves for C. difficile 630 Δerm and the Lsp mutants lspA::erm and 
lspA2::erm in the presence (+, solid lines) and absence (-, dashed lines) of Globomycin at 100 µg mL
-1
. Globomycin (+) or 
DMSO vehicle only (-) was added at an OD600 of approximately 0.05 (inoculation) and growth followed for 9 hours. Only a 
slight growth defect was observed in the presence of Globomycin at this concentration. Due to the limited supply of 
Globomycin only a single biological replicate could be performed. 
Before use of globomycin to investigate prolipoprotein cleavage by LspA and LspA2 in C. difficile, a 
growth curve was performed to confirm that globomycin did not cause a significant growth defect, 
which might lead to a change in the YnC12 labelling pattern. As shown in Figure 47 B, all three 
strains showed a slight reduction in growth rate in the presence of 100 µg mL-1 globomycin. 
However, this effect was not pronounced with all cultures reaching similar final OD600 values. C. 
difficile 630 Δerm and lspA2::erm showed similar growth, while lspA::erm showed a lower growth 
rate than the other two strains, both in the presence and absence of globomycin. As there was no 
significant effect on growth, the impact of globomycin on prolipoprotein processing at 100 µg mL-1 
was investigated. 
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4.3.2.3 Globomycin Inhibition of Prolipoprotein Processing 
The effect on lipoprotein processing was investigated by metabolic tagging; overnight cultures of 
C. difficile 630 Δerm, lspA::erm and lspA2::erm were sub-cultured to an OD600 of 0.05 and 
immediately treated with globomycin to 100 µg mL-1, or DMSO vehicle only. Upon reaching an 
OD600 of approximately 0.30, 25 µM YnC12 was added and the cultures were allowed to grow to 
stationary phase over a total of 9 hours. Due to the limited quantities of globomycin available 
cultures were grown on approximately a quarter of the scale of those previously described and, 
in order to release sufficient protein for CuAAC ligation, whole C. difficile lysates were prepared 
by enzymatic lysis and the membranes solubilised by the addition of SDS to 1 %, without 
fractionation. The YnC12 tagged lipoproteins where then ligated to AzTB and visualised by in-gel 
fluorescence. 
 
Figure 48: Globomycin treatment of the parental strain 630 Δerm on and the lsp mutants, lspA::erm and lspA2::erm. 
Samples were treated with either DMSO (vehicle only, -) or 100 µg mL
-1
 globomycin (+) and the effect on prolipoprotein 
processing assessed by CuAAC ligation on whole cell lysates using SDS-PAGE and in-gel fluorescence analysis. 630 Δerm 
showed an lspA::erm-like phenotype on treatment while lspA2::erm showed a global migration of labelled lipoproteins to a 
higher apparent MW; indicated by  for both strains. Coomassie staining (total protein, bottom) is shown as a loading 
control. 
Globomycin treatment of 630 Δerm resulted in the shift of a number of fluorescent bands to a higher 
MW, indicative of retention of the signal peptide, resulting from inhibition of an Lsp. The in-gel 
fluorescence pattern for 630 Δerm on globomycin treatment was remarkably similar to that for 
untreated lspA::erm; while lspA::erm, which possesses only LspA2, showed no real changes on 
treatment with Globomycin, as shown in Figure 48. This indicates that Globomycin is unable to 
inhibit LspA2 at the concentration used and instead predominantly inhibits LspA in 630 Δerm, 
resulting in an lspA::erm-like phenotype. This differential inhibition of LspA and LspA2 can be readily 
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rationalised by a comparison of the primary sequence of C. difficile LspA and LspA2 to E. coli LspA, as 
discussed in Section 4.2.2. 
Although this phenotype is also consistant with LspA2 being inactive, lspA2::erm, which only 
expresses LspA, showed dramatic changes in apparent MW of the tagged lipoproteome on 
globomycin treatment. A global retention of signal peptides, and corresponding migration of tagged 
lipoproteins to a higher MW was observed (Figure 48). This suggests that genetic inactivation of 
lspA2, combined with Chemical Genetic inhibition of LspA, leads to a doubly inactivated phenotype 
indicating that LspA2 is active and processes prolipoproteins in C. difficile. 
4.4 Phenotypes of C. difficile Lipoprotein Biogenesis Mutants 
The impact of insertional inactivation of the lipoprotein biogenesis pathway on the physiology of 
C. difficile was of interest as it could provide further information on the functions of the C. difficile 
lipoproteome. Independent studies by Doctor Andrea Kovacs-Simon at the University of Exeter 
(personal communication) had found there was no significant growth defect, changes to cell shape 
or colony morphology on inactivation of lgt, lspA or lspA2. Despite this, a number of other 
phenotypes remained to be investigated including potential effects on toxin production and 
sporulation, which are discussed in this section. 
4.4.1 Protein Shedding 
Increased shedding of lipoproteins into the media on the inactivation or deletion of lgt has been 
reported and this effect utilised to identify lipoproteins, following their precipitation from the 
culture supernatant and MS/MS analysis129, 197. To investigate whether this was true for C. difficile, 
overnight cultures of 630 Δerm, lgt::erm, lspA::erm and lspA2::erm in BHIS broth were pelleted and 
the supernatant isolated. Proteins shed into the culture supernatants were TCA precipitated and the 
s-Layer proteins (SLPs) extracted from the bacterial pellet for comparison. The SLPs are non-
covalently anchored to the cell wall and can be readily released from the cell using chaotropic agents 
such as guanidinium or urea; the S-Layer was extracted using the low pH glycine method as 
described in Chapter 9.1.4.1312. Both the S-Layer extracts and culture supernatants were 
standardised by bacterial cell density (OD600) and compared by SDS-PAGE and Coomassie staining.  
As shown in Figure 49 A, the S-Layer extracts for all four strains were largely similar.  Cwp84, Cwp2, 
Cwp66 and the High (HMW) and Low (LMW) Molecular Weight S-Layer proteins (decreasing order by 
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molecular weight),  were expressed at similar levels between the four strains. However, lspA::erm 
and lspA2::erm expressed considerably more FliC, as indicated by the red arrow in Figure 49 A. It has 
previously been demonstated that this band is FliC by Western blotting313. An increase in flagella 
display is likely and it is probable that these strains are more motile; a hypothesis as to why this may 
be is discussed in section 4.5 and Chapter 8.3.2.1. 
 
Figure 49: A) The effect of insertional inactivation of lgt, lspA and lspA2 on the S-Layer and protein shedding into the culture 
supernatants. No discernible effect was seen on the S-Layer; Cwp84, Cwp2, Cwp66 and the HMW and LMW SLPs (in 
decreasing order by molecular weight) were expressed at a similar level. There was, however, an increase in FliC level () 
for lspA::erm and lspA2::erm. There was an increase in protein shedding into the media by all three mutant strains with 
lgt::erm showing the largest increase. The samples were standardised by bacterial cell density; the S-Layer extracts were 
loaded to 20 OD600 equivalents and the culture supernatants to 30 OD600 equivalents. B) Shedding of Cwp66 and LMW SLP 
into the media assessed by western blotting; increased levels of Cwp66 and the LMW SLP were shed into the media by all 
three mutant strains relative to the parental strain 630 Δerm, indicating a slight defect in S-Layer integrity. The samples 
were standardised by bacterial cell density to 30 OD600 equivalents. 
As anticipated, an increased shedding of proteins into the culture supernatant was seen for all three 
mutants, with the most pronounced effect for lgt::erm (Figure 49 A). Many of these proteins do not 
correspond to a SLP or CWP and are possibly prolipoproteins, released either as intact proteins by 
“shedding” or “shaving” following cleavage by a Type I signal peptidase or Eep (Chapter 1.2.2.3). 
However, several bands were at a similar MW to the SLPs and CWPs and potential loss of the S-Layer 
was assessed by western blotting using anti-LMW SLP and anti-Cwp66 antibodies. It was found that 
the integrity of the S-Layer is slightly perturbed on partial loss of lipoprotein processing; no 
detectable Cwp66 was shed into the media by 630 Δerm but all three mutants shed Cwp66 into the 
media at detectable levels, where degradation occurred (Figure 49 B, top). The level of Cwp66 shed 
corresponded to the total amount of protein in the culture supernatants (Figure 49 A, Coomassie), 
with lgt::erm shedding more Cwp66 than lspA::erm or lspA2::erm. Additionally, although the LMW 
SLP could be detected in the supernatant for the parental strain, more LMW SLP was shed into the 
media by all three mutants. The LMW SLP was shed at similar levels by lspA::erm or lspA2::erm, with 
Coomassie 
Anti-Cwp66 Blot 
Anti-LMW SLP Blot 
A B 
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slightly higher levels shed by lgt::erm (Figure 49 B, bottom). Shedding of the S-Layer on inactivation 
of members of the lipoprotein biogenesis pathway was unexpected but may be due to misprocessing 
of the extracellular chaperones PrsA and PrsA2, which are known to be lipidated in B. subtilis188a. The 
S-Layer is exported at an extremely high rate during exponential growth and reduced activity of PrsA 
and PrsA2, due to disruption of the lipidation pathway, could lead to an accumulation of misfolded 
protein in the S-Layer which is subsequently shed into the media. 
4.4.2 Toxin Production 
The production of the large Clostridial Toxins (LCTs), Toxin A and Toxin B (TcdA and TcdB), by the 
lipoprotein biogenesis pathway mutant strains was also of interest. The level of secreted TcdA and 
TcdB was measured using a commercial quantitative Enzyme Linked Immunosorbant Assay (ELISA) 
(Tgc Biomics). Overnight cultures, in biological triplicate, of 630 Δerm, lgt::erm, lspA::erm and 
lspA2::erm in TY broth were pelleted by centrifugation and the concentration of TcdA and TcdB in 
the culture supernatant measured by ELISA, following the manufacturer’s instructions. The data 
were standardised relative to the positive controls (TcdA and TcdB) at 80 ng mL-1 and by bacterial 
cell density (Figure 50). Buffer only wells were included as a negative control and the background 
level was approximately 2 % of the signal observed for 630 Δerm for TcdA and 8 % of that for TcdB 
(data not shown, as this cannot be standardised by OD600). This experiment was also performed for 
the complemented strains, but the presence of thiamphenicol led to an overproduction of TcdA and 
TcdB by all strains, including the vector control 630 Δerm +pMTL960 (data not shown). 
No significant difference in levels of secreted TcdA or TcdB by the Lgt mutant, lgt::erm, relative to 
the parental strain 630 Δerm was observed. However both Lsp mutants, lspA::erm and lspA2::erm, 
showed an increased secretion of both TcdA and TcdB relative to the parental strain (Figure 50). For 
all strains, including 630 Δerm, more TcdA was secreted than TcdB; a 4-fold increase in secreted 
TcdA was seen for lspA::erm (p= 0.11) and a 2.5-fold increase was seen for lspA2::erm (p= 0.03), 
relative to 630 Δerm. TcdB was secreted at a lower level, but a 2.5-fold increase relative to 630 Δerm 
was observed for lspA::erm (p= 0.01) and a 2.6-fold increase was observed for lspA2::erm (p= 0.17). 
This increase in toxin secretion by both Lsp mutants is possibly part of a general stress response due 
to the accumulation of prolipoprotein signal peptides in the membrane. Further experiments are 
required to assess the intracellular TcdA and TcdB concentration in the lipoprotein biogenesis 
mutants. Alternatively, incomplete processing of the lipoproteome may lead to disruption of sensing 
or signalling pathways, resulting in a specific increase in toxin production and secretion. This will be 
discussed further in section 4.5 and Chapters 8.3.2.2. 
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Figure 50: The concentration of secreted toxin for strains 630 Δerm, lgt::erm, lspA::erm and lspA2::erm, standardised by 
bacterial cell desnity (OD600), as determined by a quantitative ELISA for Toxin A and Toxin B. The data shown are the 
average of three biological repeats; error bars represent the standard deviation; lspA::erm and lspA2::erm show an 
increased secretion of both TcA and TcdB into the media.*, p ≤0.05, **, p ≤0.01. 
4.4.3 Sporulation Assay 
Mutations in B. subtilis lgt (also known as yvoC) have been demonstrated to cause a germination 
defect186b; lgt is also required for full spore germination in B. anthracis142. While this work was being 
performed Dembek et al reported the use of a mariner-based transposon library, coupled with 
transposon-directed insertion site sequencing, to identify essential genes and those required for 
efficient sporulation in C. difficile R20291102. They reported 798 genes which show a significant 
reduction in insertion containing mutants on sporulation, which included lgt (CDR20291_2547) and 
lspA (CDR20291_2484) as well as two ABC-type transporter solute-binding lipoproteins (potD, 
CDR20291_0883 and CDR20291_1487) and the putative lipoprotein CDR20291_0950 which shares 
99 % sequence identity with CD630_11190 a putative lipoprotein of unknown function. This 
implicates lipoprotein processing and the C. difficile lipoproteome in efficient sporulation. Finally, a 
number of predicted and known lipoproteins in B. subtilis are sporulation or germination associated 
and a sporulation specific protein, SpoIIIAG, was predicted to be lipidated in C. difficile as part of this 
study (Chapter 2.1.1). Spores are the main infectious agent involved C. difficile transmission and are 
resistant to heat treatment, desiccation, and environmental insult; spores are therefore difficult to 
effectively remove from the environment, contributing to C. difficile recurrence and persistence. 
Consequently the identification of any pathway or gene that is required for efficient sporulation is of 
great interest. 
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The effect of inactivation of the members of the lipoprotein biogenesis pathway on C. difficile 
sporulation and germination was assessed; lgt::erm, lspA::erm, lspA2::erm were compared to the 
parental strain 630 Δerm and the sporulation deficient mutant spo0A::erm51, which was included as 
a control.  Assays for the evaluation of C. difficile sporulation efficiency were recently reviewed by 
Burns and Minton314 which informed the experimental design used in this study, described in detail 
in Chapter 9.1.3.2. Briefly, a subculture of the C. difficile strains in BHIS broth was inoculated to an 
OD600 of approximately 0.10 from an overnight culture and allowed to grow up to an OD600 of 
approximately 0.60. Two sequential subcultures were performed to limit the carryover of any 
spores. The second sub-culture was then diluted to an OD600 of 0.10 and the culture grown overnight 
to stationary phase, at which the first time point was taken. Sporulation efficiency was measured on 
agar plates containing 0.1% of the germinant taurocholate, by comparison between the total 
number of colony forming units (CFU) and the CFUs for heat treated samples (80 °C, 45 minutes), 
after 24 hours growth. While spores would survive heat treatment, this was expected to kill all 
vegetative cells, allowing differentiation between CFUs arising from vegetative C. difficile and 
germinating spores. Samples were taken every 24 hours over 120 hours (5 days); the complements 
were not included in this experiment as thiamphenicol was not expected to be stable at 37 °C over 
this time scale. 
As shown in Figure 51, the total CFUs were comparable at 0 hours, confirming that each C. difficile 
strain was inoculated to the same bacterial cell density. The total CFUs (Figure 51, solid lines) 
remained at an order of 107 CFU mL-1 throughout the experiment and all strains were within error of 
each other; these values include both vegetative C. difficile cells and germinated spores. Heat 
resistant CFUs, which correspond to bacterial cells that have sporulated and successfully 
germinated, could be counted for 630 Δerm after 48 hours. In contrast, all three lipoprotein 
biogenesis mutants showed a considerable delay in the formation of heat resistant spores with 
lgt::erm and lspA::erm forming between 101 and 102 CFU at 120 hours; no heat resistant CFUs could 
be counted for lspA2::erm or the negative control spo0A::erm (Figure 51, dashed lines). This is a 
striking phenotype; as inactivation of lgt, lspA or lspA2 resulted in a dramatic reduction in the 
formation of heat resistant CFUs, complete lipoprotein processing is clearly required for either 
efficient sporulation or germination in C. difficile. 
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Figure 51: Sporulation dynamics for the lipoprotein biogenesis pathway mutants; the asporogenous mutant spo0A::erm was 
incuded as a negative control. Values are the average for technical triplicates of biological duplicates (6 values); the error 
bars are the standard deviation. Total colony forming units (CFU) per mL of culture (solid lines) were consistent across the 
experiment while heat resistant CFUs (spores, dashed lines) could be counted for 630 Δerm after 48 hours. In contrast, all 
three lipoprotein biogenesis mutants showed a considerable delay in the formation of heat resistant spores and reduced 
CFUs per mL of culture. Values of zero were artificially set to 1 to allow plotting on a log10 scale. 
The sporulation efficiency assay revealed that complete lipoprotein processing is required for the 
formation of heat resistant CFUs. However, to give a countable colony a C. difficile cell must 
sporulate, the endospore survive heat treatment and finally the spore must germinate.  To confirm 
whether this phenotype was due to a sporulation defect or a failure to germinate, the experiment 
was monitored by phase-contrast microscopy throughout the time course. As anticipated, 
characteristic phase bright spores were observed for 630 Δerm after 48 hours (Figure 52). However, 
no spores could be seen at any time point for lgt::erm, lspA::erm, lspA2::erm or spo0A::erm. 
Elongated cells were seen for lspA::erm, lspA2::erm and spo0A::erm after 24 hours and an 
accumulation of cell debris was observed after 72 hours. Elongated cells were only observed for 
lgt::erm after 96 hours and reduced amounts of cell debris were observed, compared to the lsp 
mutants. As no spores could be seen by phase-contrast microscopy for any of the lipoprotein 
biogenesis pathway mutants, complete processing of the lipoproteome is required for efficient 
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sporulation in C. difficile. The eventual formation of heat resistant CFUs by lgt::erm and lspA::erm 
indicates that spores formed by the lipoprotein biogenesis mutants are capable of survival and 
germination. 
 
Figure 52: Phase-contrast microscopy indicated that the dramatic reduction in CFUs for C. difficile lgt::erm, lspA::erm and 
lspA2::erm is the result of a sporulation deficiency not due to effects on germination. Phase bright spores could be observed 
for 630 Δerm, the parental strain, after 48 hours, indicated by . However, no spores were observed for any of the mutant 
strains. Complete processing of the lipoproteome is therefore required for efficient sporulation in C. difficile, implicating 
lipoproteins in sporulation. The scale bar (10 µm) is shown in the bottom right panel. 
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4.5 Discussion 
In this chapter, lipoprotein biogenesis in C. difficile 630 Δerm was investigated using a combination 
of genetic inactivation and metabolic tagging to visualise the effect of insertional inactivation of 
members of the lipoprotein biogenesis pathway on proplipoprotien processing. The activity and 
specificity of C. difficile LspA and LspA2 were further investigated by chemical genetic inhibition with 
globomycin. Finally, phenotypic analysis of these mutants has implicated the lipoproteome in 
regulation of toxin production and demonstrated that complete lipoprotein biogenesis is required 
for efficient sporulation. The experiments described in this chapter have been restricted to an in-gel 
fluorescence output but, while proteomic analysis is expected to provide further information, this 
has provided an important insight into lipidation in C. difficile. 
The lipoprotein biogenesis pathway in C. difficile 630 is composed of one lgt gene (CD630_26590) 
and two lsp genes, lspA and lspA2 (CD630_25970 and CD630_19030 respectively). The ClosTron 
mutagenesis system was used by Andrea Kovaks-Simon (University of Exeter) to create insertionally 
inactivated mutants in all three genes, in a 630 Δerm background. These mutants were 
complemented in trans under the control of a constitutive promoter, pcwp2 (section 4.3.1.1). 
Metabolic tagging with YnC12 allowed the effect of inactivation on prolipoprotein processing in 
C. difficile to be visualised by SDS-PAGE and in-gel fluorescence, following CuAAC ligation to AzTB. An 
almost complete loss of fluorescent labelling of lipoproteins was observed on inactivation of lgt, 
demonstrating the key role of Lgt in catalysing lipdiation in C. difficile. Despite this, some low 
intensity fluorescent bands could be observed for lgt::erm; these could be affinity enriched and 
competed out with an excess of myristic acid, indicating that they are potentially the result of 
lipidation by a non-canonical mechanism (Figure 46). 
In-gel analysis of lspA::erm and lspA2::erm revealed that LspA has a number of unique substrates, 
visualised by the shift of in-gel fluorescent bands to a higher apparent MW; however, no band shifts 
were observed for lspA2::erm. The activity of LspA2 was confirmed by a chemical genetic approach 
using the Lsp inhibitor globomycin; although inhibition of LspA2 could not be detected at the 
concentration used, LspA was inhibited by globomycin at 100 µg mL-1. The doubly inhibited system 
(lspA2::erm + globomycin) showed a global retention of signal peptides and a corresponding 
migration of labelled proteins at a higher apparent MW, (Figure 48). This phenotype differed from 
that of either singly inactivated mutant, demonstrating that, although only LspA is required to 
process the majority of lipoproteins, LspA2 is active and processes prolipoproteins in C. difficile. This 
represents the first use of globomycin in combination with metabolic chemical tagging in a chemical 
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genetic approach; additionally this is the first time metabolic tagging has been used to visualise 
global changes to a bacterial lipoproteome on inactivation of lgt and lsp. 
The proposed pathway for lipoprotein biogenesis in C. difficile 630 Δerm is shown in Figure 53; the 
Type II signal peptide of C. difficile pre-prolipoproteins targets them for secretion, primarily via 
SecA1. The pre-prolipoproteins then fold, anchored to the outside of the cell membrane by the 
signal peptide. The lipobox motif is recognised by Lgt which catalyses the addition of a diacylglyceryl 
fatty acid to the lipobox cysteine side chain forming a thio ether bond, using a membrane 
phospholipid as the substrate. The possibility of an alternative lipidation mechanism exists, as 
discussed in section 4.3.1.2, however, further work is required to prove this unambiguously. 
Following lipidation the signal peptide is cleaved by either LspA or LspA2. LspA appears to be capable 
of processing the majority of lipoproteins and has several unique substrates; LspA is also sensitive to 
inhibition by globomycin at 100 µg mL-1. LspA2 is not capable of processing all lipoproteins, 
indicating a degree of substrate specificity, but is resistant to globomycin at 100 µg mL-1; this 
difference in sensitivity to Globomycin is readily rationalised by comparison to Lsp of E. coli, as 
described in section 4.2.2. 
 
Figure 53: The proposed lipoprotein biogenesis pathway in C. difficile; pre-prolipoproteins are secreted by the Sec system 
and fold on the exterior of the cell, anchored by their signal peptide. The lipbox motif is then recognised by Lgt which 
catalyses the addition of a membrane phospholipid to the lipobox cysteine thiol, although alternative or auto lipidation 
mechanisms may also occur. The signal peptide (red) is then cleaved from the prolipoprotein by either LspA or LspA2; LspA 
has some unique substrates, but is more sensitive to inhibition by Globomycin. This leaves the mature lipoprotein anchored 
to the membrane by the signal peptide sequence.   
The lipoprotein biogenesis mutants displayed a number of interesting phenotypes, including 
increased shedding of proteins, including CWPs and SLPs, into the media when compared to the 
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parental strain (section 4.4.1). lspA::erm and lspA2::erm  also secreted 2- to 4-fold more of the 
toxins, TcdA and TcdB, relative to the parental strain, although whether this is a general stress 
response or the result of aberrant signalling on incomplete prolipoprotein processing is uncertain 
(section 4.4.2). S-Layer extracts of the lsp mutants showed that they produced an increased amount 
of FliC, relative to 630 Δerm and lgt::erm. FliC is the major falgellin; fliC mutants are incapable of 
assembling flagella filaments and consequently are non-motile313. FliC expression has been 
demonstrated to be linked to toxin production, with inactivation of fliC resulting in significantly 
increased levels of TcdA and TcdB49. As a significant proportion of the C. difficile 630 lipoproteome 
are ABC-type transport solute-binding proteins (41%), as discussed in Chapter 2.1.1, the 
lipoproteome plays an important role in nutrient uptake. It is possible that, on inactivation of lspA or 
lspA2, nutrient uptake is limited and flagella display and toxin production are up-regulated in 
response to the perceived nutrient deficiency, potentially via CodY47a and CcpA48 which are known to 
control of toxin production in C. difficile. 
Finally, it was found that the lipoprotein biogenesis mutants all displayed a severe sporulation defect 
(section 4.4.3); complete processing of the lipoproteome is required for efficient sporulation in 
C. difficile. The loss of sporulation for lspA2::erm was especially surprising as LspA appears to be 
capable of processing the majority of lipoproteins. It is unlikely that the sporulation defect observed 
for all three mutant strain is the result of a deficiency in nutrient uptake as this would be expected 
to lead to an increase in sporulation. Additionally, the increase in FliC, TcdA and TcdB production 
was not observed for lgt::erm, which displayed a sporulation defect. This result indicates that 
lipoproteins play a vital role in transmission and persistence of C. difficile and are likely to have a 
number of sporulation associated functions.  
In this chapter metabolic tagging and in-gel fluorescence was used, in combination with genetic 
inactivation and chemical inhibition, to investigate lipoprotein biogenesis in C. difficile. This has 
provided an insight into the processing of prolipoproteins in C. difficile. However, the selectivity 
between LspA and LspA2 requires further investigation. Proteomic analysis is required to determine 
whether the labelled bands correspond to predicted lipoproteins and to confirm that the changes to 
the lipoprotein band patterns on inactivation of lspA and lspA2 are due to retention of Type II signal 
peptides, rather than changes in lipoprotein expression. Additionally a molecular explanation for 
many of the phenotypes observed could be provided by quantitative proteomic analysis of these 
strains. The following chapters will focus on initial proteomic analysis of the C. difficile lipoproteome, 
the development and optimisation of quantitative techniques and the use of these methods to 
create a comprehensive profile of the lipoproteome. 
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Chapter 5: Development of Proteomic Methods and 
Quantitative Proteomics for C. difficile 
5.1 Introduction 
Having described the development and optimisation of conditions for metabolic tagging with YnC12 
and for the affinity enrichment of C. difficile 630 lipoproteins (Chapter 3.2), this methodology was 
applied to qualitatively study the effects of inactivation of lgt, lspA and lspA2 on lipoprotein 
biogenesis (Chapter 4:). In this chapter, the application of these methods to create a preliminary 
profile of the C. difficile 630 Δerm lipoproteome is described, as is the development of a quantitative 
proteomic strategy for C. difficile. The aims of this work were; to utilise the optimised labelling and 
affinity enrichment methodology to pull down and identify C. difficile lipoproteins and to develop 
quantitative proteomics for C. difficile. To this end, both Stable Isotope Labelling with Amino acids in 
Cell culture (SILAC) and dimethyl labelling approaches were investigated. A proof-of-principle 
experiment, and comparison to label free quantification, using the latter method is also described. 
5.2 Label Free Proteomic Analysis 
Having demonstrated that metabolically tagged proteins could be efficiently enriched (Chapter 3.4), 
an initial proteomic experiment using Label Free Quantification (LFQ) was performed to confirm that 
the pulled down proteins were predicted lipoproteins. To investigate this, an exponentially growing 
culture of C. difficile 630 Δerm was treated with YnC12 to 25 µM and compared to an identical 
culture of 630 Δerm, treated with 25 µM myristic acid, and to two cultures of the lipidation deficient 
mutant lgt::erm, treated with YnC12 or myristic acid at 25 µM, as negative controls. Following lysis 
and fractionation, CuAAC ligation to AzTB was performed and the labelled proteins were pulled 
down onto streptavidin agarose beads. The enriched proteins were eluted from an aliquot of these 
beads and compared to the supernatant and the sample before pull down to check the enrichment 
efficiency (Figure 54). The beads were stored under a minimal volume of 50 mM 
tetraethylammonium bicarbonate solution (TEAB) and subjected to on-bead reduction, alkylation 
and tryptic digest prior to LC-MS/MS analysis by Doctor Andrew Bottrill (PNACL, University of 
Leicester). This experiment was performed in biological duplicate; the results are discussed in the 
following sections (5.2.1 and 5.2.2). 
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Figure 54: An initial LFQ proteomic experiment to demonstrate that the enriched proteins are predicted lipoproteins. 
C. difficile 630 Δerm and lgt::erm were treated with YnC12 or myristic acid (25 µM) in biological duplicate and the efficiency 
of pull down assessed by comparison between the elutant (E), supernatant after pull down (S) and a pre-pull down aliquot 
of the sample (-). The affinity enriched proteins were sent for proteomic identification by Dr Andrew Bottrill at the PNACL 
facility, University of Leicester. Coomassie staining (total protein, bottom) is shown as a loading control. 
5.2.1 Comparison between YnC12 and Myristic Acid 
A total of 158 proteins were identified in this experiment, in either the YnC12 or myrsitic acid fed 
C. difficile 630 Δerm samples for at least one biological replicate. A comparison of the average LFQ 
intensities between the YnC12 and myristic acid fed samples (Figure 55 A) revealed that the 
predicted lipoproteins were highly enriched and found at high intensity in the YnC12 tagged samples 
but at a low or zero intensity in the myristic acid treated samples. In contrast, proteins that were not 
expected to be lipidated showed similar intensities in both the YnC12 and myristic acid treated 
samples, indicative of non-specific pull down. To discriminate between genuinely enriched proteins 
and background proteins the Enrichment Factor (EF) was calculated for each protein by dividing the 
intensity for the YnC12 tagged sample by that for the myristic acid treated sample. Proteins with a 
greater than 5-fold enrichment were selected as enriched; this is an arbitrary cut off - 119 proteins 
had an EF ≥5. 
As shown in Figure 55 B, the majority of proteins which showed an EF ≥5 were not predicted to be 
lipidated with only 41 (35 %) being predicted lipoproteins; this corresponds to 60 % of the predicted 
lipoproteome (41 of a potential 68). The remaining proteins were largely predicted by LipoP278 to 
have a cytosolic location, with only 2 % being transmembrane proteins and 3 % having a Type I signal 
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peptide. The predicted lipoproteins were all highly enriched with an EF of 25 or greater however, 
many non-predicted proteins also had an EF ≥25. The majority of these non-predicted proteins are 
unlikely to be lipidated, either by Lgt or a non-canonical method. Instead their high EF results from 
identification, typically at low intensity, in only the YnC12 sample or fractional enrichment in the 
YnC12 sample but at low intensity in both YnC12 and myristic acid treated samples. These proteins 
are possibly being pulled down in association with specifically enriched proteins in the YnC12 tagged 
samples, or bind non-specifically to an enriched protein or LTA, at a greater level than they bind non-
specifically to the beads. 
The functions of the predicted lipoproteins identified are shown in Figure 55 C; the majority were 
ABC-type transport system solute-binding proteins (21, 51 %) or of putative or uncharacterised 
function (14, 33 %). Other predicted lipoproteins identified included a polysaccharide deacetylase 
(CD630_27190), a Thioredoxin (CD630_15070) and the extracellular chaperone PrsA (CD630_35000). 
Additionally a nucelotidase and a phosphodiesterase were identified (CD630_01990 and 
CD630_06890 respectively) and a metallopeptidase (CD630_16220) which contains a YpeB domain. 
The germination protein YpeB is required for spore cortex hydrolysis during germination in Bacillus 
subtilis and other Bacillus species315; consequently CD630_16220 may also be involved in 
germination of C. difficile spores. The identification of the latter lipoprotein is of interest in light of 
the lack of heat resistant CFUs observed for the mutants in the lipoprotein biogenesis pathway, but 
does not fully explain the lack of spores observed by microscopy, as discussed in Chapter 4.4.3. 
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Figure 55: A) The distribution of all proteins identified for YnC12 and myristic acid treated C. difficile 630 Δerm. Predicted 
lipoproteins are shown in red while all other proteins are shown in blue; the enrichment factor cut off (EF =5) is indicated by 
a line. Lipoproteins are generally highly enriched (EF >5) with a high intensity in the YnC12 samples and a low intensity in 
the myristic acid samples. Non lipoproteins are more variable and of lower intensity but show similar enrichment between 
the two samples.B) A breakdown of all proteins with EF ≥5 by predicted cellular location; the majority are not predicted to 
be lipidated however 41 lipoproteins were identified. C) A breakdown of all lipoproteins with EF ≥5 by predicted function, 
with the majority being either ABC-Transport Solute-Binding-Proteins or putative and uncharacterised proteins. The data 
was analysed using Scaffold 3 and graphs plotted using Microsoft Excel. 
5.2.2 Comparison between 630 Δerm and lgt::erm 
A second comparison was performed between the YnC12 treated C. difficile 630 Δerm and lgt::erm 
samples. A total of 223 proteins were identified in at least one of the YnC12 tagged samples in this 
experiment. The average intensities for these proteins were compared and, as anticipated, predicted 
lipoproteins were found to have higher intensities in the 630 Δerm samples than in lgt::erm (Figure 
56 A).  Similarly to the comparison between YnC12 and myristic acid treated 630 Δerm, proteins that 
were not expected to be lipidated showed similar intensities in both sets of samples, or a slightly 
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higher intensity in the lgt::erm samples (Figure 56 A). As previously, to discriminate between 
enriched proteins and the background, proteins with an EF of greater than 5 were selected for 
further analysis; 55 proteins had an EF ≥5. 
Fewer proteins had an EF ≥5 in this experiment, relative to the comparison between YnC12 and 
myristic acid treated samples (section 5.2.1). However, a similar number of lipoproteins were 
enriched (42, 82 %); this corresponds to 62 % of the predicted lipoproteome. Correspondingly the 
number of background proteins with EF ≥5 was reduced, as shown in Figure 56 B. The total number 
of proteins identified with an EF ≤5 was higher, indicating that there is a similar non-specific pull 
down of background proteins when comparing YnC12 treated 630 Δerm and lgt::erm. This raises the 
possibility that the background proteins are binding to YnC12 tagged and affinity enriched residual 
LTA, rather than to the beads. Predicted lipoproteins were the clear majority of enriched proteins 
(EF ≥5), while the remaining proteins were predicted to have either a cytosolic location (9, 17 %) or a 
Type I signal peptide (1, 2 %). As for the previous experiment these proteins pass the EF ≥5 cut off 
due to either identification in only the 630 Δerm samples, or low intensity identification in both 
samples (Figure 56 A). 
The high enrichment of lipoproteins in 630 Δerm over lgt::erm indicates that they are lipidated in an 
Lgt dependant manner, confirming for many lipoproteins the bioinformatic prediction of lipidation 
discussed in Chapter 2.1.1. Additionally there is a strong correlation in the predicted lipoproteins 
enriched between YnC12 and myristic acid treated 630 Δerm and YnC12 treated 630 Δerm and 
lgt::erm. The functions of the predicted lipoproteins identified are given in Figure 56 C; the only 
difference being the absence of one ABC-type transport solute-binding protein, which had an EF ≥5 
in the previous experiment, and an additional uncharacterised protein which passed the enrichment 
cut off. A full list of all predicted lipoproteins identified in these initial experiments is given in 
Appendix C. 
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Figure 56: A) The distribution of all proteins identified for YnC12 treated C. difficile 630 Δerm and YnC12 treated lgt::erm. 
Predicted lipoproteins are shown in red while all other proteins are shown in blue; the enrichment factor cut off (EF =5) is 
indicated by a line. Lipoproteins are generally highly enriched (EF >5) with a high intensity in the 630 Δerm samples and a 
low intensity in the lgt::erm samples, which indicates lipidation in an Lgt specific manner. Non lipoproteins are more 
variable and of lower intensity but show similar enrichment between the two samples. B) A breakdown of all proteins with 
EF ≥5 by predicted cellular location; the majority are predicted to be lipidated (42, 81 %). C) A breakdown of all lipoproteins 
with EF ≥5 by predicted function; this is similar to the comparison between YnC12 and myrisitc acid fed 630 Δerm (section 
5.2.1 and Figure 55) with the majority being either ABC-Transport Solute-Binding-Proteins or putative and uncharacterised 
proteins. The data was analysed using Scaffold 3 and graphs plotted using Microsoft Excel. 
Finally, a comparison between the YnC12 and myristic acid treated lgt::erm samples was performed; 
184 proteins were identified in at least one sample. Only 9 lipoproteins were identified in both the 
YnC12 and myristic acid treated samples; all were of a low intensity (Figure 57, shown in red). The 
other proteins were largely predicted to have a cytosolic location and were found at a similar 
intensity in the YnC12 and myristic acid treated samples, indicating that they are non-specifically 
enriched in lgt::erm. These proteins were, however, found at slightly higher intensity in the YnC12 
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labelled samples, supporting the theory that they are enriched by non-specific binding to labelled 
LTA. 
 
Figure 57: The distribution of all proteins identified for YnC12 and myristic acid fed lgt::erm. Predicted lipoproteins are 
shown in red while all other proteins are shown in blue; the enrichment factor cut off (EF =5) is indicated by a line. 
Lipoproteins were only found at a low intensity in either sample. Non lipoproteins are show similar enrichment between the 
two samples, with fractionally higher intensity in the YnC12 sample. The data was analysed using Scaffold 3 and graphs 
plotted using Microsoft Excel. 
This result demonstrates that the YnC12 probe is being specifically incorporated into lipoproteins 
(and LTA, as discussed in Chapter 3.3.2) in C. difficile and that the tagging, labelling and enrichment 
protocol optimised using in-gel fluorescence analysis has enabled proteomic identification of the 
lipoproteome. This represents the first biochemical validation of lipidation for all lipoproteins 
identified and for many is the first verification of their existence. Additionally, these preliminary LFQ 
experiments have validated both the natural lipid, myristic acid, and the lipidation deficient mutant, 
lgt::erm, as negative controls. Although more non-specifically enriched proteins were identified in 
the lgt::erm samples (181 versus 116), fewer of these had an EF ≥5 and consequently the enriched 
background was lower for this comparison that that between YnC12 and myristic acid. This is 
probably related to the pull down of LTA in the YnC12 tagged lgt::erm samples, to which proteins will 
bind non-specifically in the 630 Δerm sample but which will not be pulled down in myristic acid 
treated samples. 
A final observation from these experiments is that a direct LFQ comparison between YnC12 and 
myristic acid and an arbitrary EF cut-off is not the best method for assigning significance to the 
enrichment observed. Small fold changes, or the absence in myristic acid samples, of low intensity 
proteins between the samples led to a number of background proteins being classed as enriched. 
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Additionally EF does not discriminate between these background proteins and low abundance 
lipoproteins that are only found at low intensity, despite being enriched. A statistical method which 
takes into account the variance between samples when assigning significance would improve the 
signal to background ratio; the variance would be expected to be small for a specifically enriched 
lipoprotein but larger for background proteins. This in turn would give higher confidence data sets 
and allow the identification of non-predicted lipoproteins and proteins that are potentially lipidated 
by a non-canonical pathway. Although this is possible using LFQ, due to the large number of 
processing steps involved in this workflow (as described in Chapter 3.4.3) and therefore the 
potential for sample handling errors to be introduced, it was expected that a label based method for 
relative quantification would facilitate this. 
5.3 Attempts to Develop SILAC for C. difficile 
5.3.1 Stable Isotope Labelling by Amino Acids in Cell Culture (SILAC) 
5.3.1.1 Background to SILAC 
Stable Isotope Labelling by Amino acids in cell Culture (SILAC) is a label based proteomic 
quantification method that utilises non-radioactive, stable isotope labelled amino acids. These are 
chemically identical to the natural amino acid and, when cells are grown in the media in which an 
essential amino acid has been replaced by its stable isotopically “heavy” variant, will be metabolised 
and incorporated into newly synthesised proteins in cell culture. After approximately five 
doublings271a complete incorporation (≥97 %) was observed for mammalian cell lines and this has 
been used for relative quantification by proteomic mass spectrometry. On proteolytic digest, 
peptides that contain the isotopically labelled amino acid display a mass shift in the MS1, 
corresponding to the difference in MW between the labelled and the natural amino acid. This 
distinguishes the two forms of the peptide and allows the abundance of peptides from the same 
protein, but from different samples, to be quantified relative to each other by calculating the H/L 
intensity ratio.  The relative difference in abundance for a protein is then calculated as the median 
ratio of all quantified peptides and changes in expression or enrichment level between two samples 
can be assessed271b; this is represented schematically in Figure 58. The relative abundance is 
calculated according to the formula shown below: 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 𝐴: 𝐵 = (𝐻 𝐿⁄ ) 𝑅𝑎𝑡𝑖𝑜 =
𝐻𝑒𝑎𝑣𝑦 (𝑆𝑡𝑎𝑡𝑒 𝐴)
𝐿𝑖𝑔ℎ𝑡 (𝑆𝑡𝑎𝑡𝑒 𝐵)
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The advantages of SILAC include firstly, the use of metabolic labelling; heavy amino acids are stable 
in cell culture and incorporated into proteins as they are synthesised so there is no need for 
chemical labelling steps. Secondly, the quantitative tags are amino acids – these are incorporated in 
a sequence specific manner, allowing the mass difference between two states to be specified 
directly. Thirdly, the extent of incorporation of isotope labelled amino acids is virtually 100 % and 
consequently there are no differences in labelling efficiency between samples, which is a problem 
associated with chemical labelling. Fourthly, combining samples directly after lysis, standardised by 
protein concentration, ensures that any further processing steps, including tryptic digest, do not 
introduce error into the experiment. Finally, several peptides from a single protein are typically 
quantified, leading to highly robust quantification. 
 
Figure 58: A general workflow for a SILAC experiment; in this case triplex SILAC using light, medium and heavy lysine and 
arginine (K0 & R0, K4 & R6 and K8 and R10). Samples are grown in SILAC media and one or more state perturbed to study a 
system of interest. After lysis the samples are combined 1:1:1 based on protein concentration and all further processing, 
including LC-MS/MS analysis are performed on the combined sample. The isotopically labelled peptides are chemically 
identical and will elute in the same fraction; the mass differences are quantified in the MS1 and relative changes in peptide 
and protein abundance are quantified by calculating the ratio of intensities for the heavy and light samples (H/L).  
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SILAC was originally developed for mammalian cells, which cannot synthesise a number of essential 
amino acids, using deuterated (D3) leucine
271a.  Leucine was selected as this is the most abundant 
amino acid; however it only labelled approximately half of the tryptic peptides derived from the 
mouse C2C12 myoblast proteome. The labelling efficiency of SILAC was improved by the use of 
lysine316 and arginine271b; typically 12C6
14N2 lysine (K0) and 
12C6
14N4 arginine (R0) as light amino acids 
and 13C6
15N2 (K8) lysine and 
13C6
15N4 (R10) arginine as heavy amino acids. Trypsin cleaves proteins 
directly after these positively charged residues and consequently every peptide except that derived 
from the C-terminus of the protein can be quantified using this combination. SILAC has been 
reported to be compatible with many Chemical Proteomic techniques, including metabolic tagging 
and Activity Based Protein Profiling (ABPP)230, and is advantageous as the large number of sample 
processing steps required by these workflows are controlled for by mixing the samples directly after 
lysis. 
Beyond cell culture, SILAC has been applied to a number of other organisms including yeast317, 
Drosophila318 and even mice319. Of relevance to this study is the application of SILAC to B. subtilis, in 
this case to a lysine auxotroph320. This required growth in minimal media, supplemented with either 
light (K0) or heavy (K8) lysine; following inoculation from a single colony after seven generations full 
theoretical incorporation of heavy lysine was observed. Proteolytic digest was performed using Lys-C 
which specifically cleaves after lysine residues; in this way every peptide except the C-terminus could 
be quantified. Arginine was not used due to high arginine – proline interconversion by B. subtilis; this 
is a common limitation of SILAC in bacterial species, as well as some human cell lines, including 
HeLa271b. The use of SILAC has been compared to 14N/ 15N labelling in B. subtilis and, although the 
results were very similar, it was found that 14N/ 15N labelling gave more reproducible quantification 
and significantly more peptides could be quantified per protein270.  
Multiplexed SILAC has also been reported, with the addition of intermediate stable isotope labelled 
lysine and arginine (4,4-5,5 D4 lysine (K4) and 
13C6
14N4 arginine (R6)) enabling a triplex approach,  as 
represented in Figure 58271b. SILAC has recently been extended enable quantification of, 
theoretically, unlimited numbers of samples in what is referred to spike-in SILAC321.  This 
methodology uses a heavy SILAC labelled cell line as a reference proteome, which is added at the 
same concentration to the proteomes under investigation, after cell lysis but before any sample 
processing. The labelling procedure is therefore completely decoupled from the experiment. Spike-in 
SILAC is compatible with affinity enrichment methods, including cation exchange for phosphosite 
identification322. The changes in peptide, and protein, abundance are then quantified as the ratio of 
 133 
H/L ratios between the different samples of interest; this approach is summarised in Figure 59. The 
formula for calculating relative abundance is shown below. 
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𝑅𝑎𝑡𝑖𝑜 1 =
𝐻𝑒𝑎𝑣𝑦 (𝑆𝐼𝐿𝐴𝐶 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑)
𝐿𝑖𝑔ℎ𝑡 (𝑆𝑡𝑎𝑡𝑒 𝐴)
 
𝑅𝑎𝑡𝑖𝑜 2 =
𝐻𝑒𝑎𝑣𝑦 (𝑆𝐼𝐿𝐴𝐶 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑)
𝐿𝑖𝑔ℎ𝑡 (𝑆𝑡𝑎𝑡𝑒 𝐵)
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 =  
𝑅𝑎𝑡𝑖𝑜 1
𝑅𝑎𝑡𝑖𝑜 2
=
𝐿𝑖𝑔ℎ𝑡 (𝑆𝑡𝑎𝑡𝑒 𝐵)
𝐿𝑖𝑔ℎ𝑡 (𝑆𝑡𝑎𝑡𝑒 𝐴)
 
Spike-in SILAC places no restrictions on experimental design, as the light cultures can be grown in 
normal media, and the number of samples that can be compared is theoretically unlimited. Spike-in 
SILAC also allows comparison between different sets of experiments that use the same heavy 
standard and dramatically reduces the cost of the experiment; especially so when the spike-in 
standard is expensive to produce, for example a model organism such as a SILAC mouse. Despite this 
there are a number of disadvantages to the spike-in approach; the most serious of these is the risk of 
propagating errors. As the relative abundance is calculated from a ratio of ratios the error is 
calculated as the square root of the sum of the individual (H/L) errors, increasing quantification 
variation. The samples to be compared are also measured separately in a spike-in approach; not only 
does this increase the measuring time when compared to traditional SILAC but, if the proteome 
coverage is low the overlap between runs will also be low, reducing the number of quantifiable 
proteins. Finally, the selection of an appropriate standard is important; the SILAC proteome should 
be similar to the proteomes under investigation to provide counterparts to the proteins expressed in 
the samples. However, this similarity does not have to be very high and the spike-in standard does 
not need to represent the biological conditions or processes being investigated and instead simply 
provides a list of peptides to quantify against. 
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Figure 59: A schematic representation of the spike-in SILAC approach. Non-labelled (light) cultures are treated under the 
desired experimental conditions and, after lysis, the proteomes are combined 1:1 with a separately prepare heavy SILAC 
standard (the spike-in).And additional sample processing can be performed and the samples are measured in separate 
MS/MS runs. The ratio of H/L ratios is used to calculate the relative abundance as discussed in Section 5.3.1.1. 
5.3.1.2 Rationale and Initial Development 
SILAC was considered the most appropriate method for relative quantification of the lipoproteome 
in C. difficile. The primary reason for initially selecting a metabolic labelling (SILAC) approach over 
the chemical labelling methods discussed in Chapter 1.3.3.2 is the large number of sample 
processing steps, including multiple precipitations, required for efficient affinity enrichment. As 
discussed in section 5.3.1.1, combining the samples directly after lysis means that any sample loss 
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occurs equally in both the heavy and light labelled samples and therefore the relative quantification 
is not affected. The practicality of creating SILAC C. difficile was also considered; a major 
requirement is growth in the absence of light amino acids. This prevents the use of rich media or 
supplementation with undefined amino acid mixtures (e.g. casamino acids) which will lead to a 
mixture of light and heavy amino acids in the labelled population, reducing the accuracy of 
quantification. Defined media have been reported for the growth of C. difficile, enabling the 
complete replacement of an amino acid with a heavy labelled version. A defined media, CDCDM, was 
originally reported by Seddon and co-workers323. However, this requires the addition of an 
undefined supplement such as proteose peptone or casamino acids to support good growth and 
therefore was not suitable for SILAC labelling. A complete defined medium, CDMM, has been 
reported by Karasawa and co-workers324; the components of CDMM are given in Table 7, 
Chapter 9.1.1. CDMM has been used in independent studies to investigate the effect of amino acid 
starvation on toxin production in C. difficile325. 
The second requirement was the selection of a suitable SILAC amino acid. Ideally this should be 
essential for survival of C. difficile in culture, to ensure that the heavy version is the only source of 
the amino acid, and present in as many peptides as possible to facilitate quantification. It has 
recently been reported that C. difficile is an autotroph and is capable of subsisting on only CO2 and 
H2 gas, which are converted via formate to acetate through the Wood-Ljungdahl pathway
326. Despite 
this, a number of amino acids have been reported as essential for growth when C. difficile is cultured 
in CDMM, including cysteine, leucine, isoleucine, proline, tryptophan and valine324. Although these 
are presumably not essential for C. difficile survival they are none the less required for detectable 
growth over a 20 to 22 hour time period and as such may be suitable for SILAC labelling, in an 
analogous manner the use of 13C6
15N4 arginine in human cell lines
271b. 
To maximise the number of tryptic peptides that can be quantified, lysine and arginine are the most 
commonly used SILAC amino acids. However, neither amino acid is required for C. difficile growth in 
CDMM. This limited the potential SILAC amino acid to either isoleucine or leucine, for which heavy 
isotope labelled versions are commercially available (both as 13C6 or 
13C6
15N1 enriched). As shown in 
Figure 60, isoleucine is the most abundant amino acid encoded in the C. difficile 630 proteome, at 
9.9 % of all residues. Leucine is also highly abundant (9.1 %) however, 10 times the amount of 
leucine than isoleucine is required to support growth of C. difficile in CDMM324. This is because 
C. difficile has an extremely active leucine fermentation pathway, converting L-leucine to ammonia, 
carbon dioxide, 3-methylbutanoate and 4-methyl penatnoate327. Leucine was therefore considered 
inappropriate as a SILAC amino acid in C. difficile, both due to the cost associated with the larger 
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quantities of heavy leucine required and the likelihood of fermentation of the heavy leucine and 
incorporation of the heavy atoms into other metabolites and amino acids, complicating analysis. 
Isoleucine, in contrast, is essential for growth in CDMM, likely to be present in a large number of 
tryptic peptides and less likely to be fermented. Additionally, isoleucine has been used as a SILAC 
amino acid in other organisms, notably Plasmodium falciparum328. 
 
Figure 60: The abundance of amino acids in C. difficile 630, as a percentage of all residues in the complete proteome. Amino 
acids are grouped into essential, growth enhancing and non-essential amino acids, as identified by Karasawa and co-
owrkers
324
. 
Prior to SILAC labelling with 13C6
15N1 isoleucine, changes in protein expression and lipoproteome 
composition were investigated. Cultures of C. difficile 630 Δerm were inoculated to an OD600 of 0.05 
from an overnight culture in TY media; there was an approximately 3 % (v/v) carryover of rich media 
into the CDMM. The cultures were grown for approximately 5 hours in TY (the rich media typically 
used for labelling), or CDMM, in the presence of either 25 µM YnC12 or myristic acid. Following lysis 
and fractionation changes to the proteome were assessed by comparing both the soluble and 
insoluble fractions by SDS-PAGE, standardising by approximate bacterial cell density. Coomassie 
staining was used to visualise the total protein, as shown in Figure 61 A. There was a reduction in 
total protein concentration in both fractions for cultures grown in CDMM, but there were relatively 
few obvious changes in the soluble proteome. In contrast, the insoluble proteome displayed a 
number of clear changes in protein expression. These may simply be more readily discerned due to 
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the reduced complexity of the insoluble sub-proteome, or may be related to changes in expression 
of nutritional uptake pathways between growth in rich media containing complex sugars and 
peptides and CDMM which contains glucose and single amino acids only. 
 
Figure 61: A) Changes to the proteome of C. difficile 630 Δerm on growth in CDMM when compared to TY media; 630 Δerm 
was grown for approximately 5 hours in the presence of 25 µM of either YnC12 or the natural lipid, myristic acid. Following 
lysis and fractionation changes to the global proteome were assessed by SDS-PAGE, standardising to 20 OD Units. There is a 
reduction in total protein expression in CDMM and some clear changed to protein expression in the insoluble sub-proteome. 
B) In-gel fluorescence analysis of changes to the lipoproteome of 630 Δerm when grown in CDMM and TY media. Although 
there are a number of changes to lipoprotein expression level there are no qualitatively unique bands to either sample. 
Coomassie staining (total protein, bottom) is shown as a loading control. 
As the ultimate goal was to use SILAC C. difficile to quantify affinity enriched lipoproteins; any 
changes to the lipoproteome of C. difficle 630 Δerm between TY media and CDMM were 
investigated. Following treatment with 25 µM YnC12 or myristic acid the bacteria were lysed, 
fractionated and the protein concentration for the insoluble fraction standardised to 1 mg mL-1; 
AzTB was attached by CuAAC ligation and the lipoproteome visualised by in-gel fluorescence (Figure 
61 B). As anticipated from the large changes in protein expression observed for the insoluble 
proteome (Figure 61 A), there were a number of changes in lipoprotein expression. Despite this, 
there did not appear to be any bands that were unique to one media over the other. As a spike-in 
approach was envisaged, the sample provides reference peptides only and, provided the protein of 
interest is present, it is inconsequential if the lipoproteomes are not identical322. 
5.3.1.3 SILAC in C. difficile 630 Δerm 
The percentage incorporation of 13C6
15N1 isoleucine (I7), which has been described as an essential 
componend of CDMM, into the C. difficile 630 Δerm proteome was then investigated. Direct 
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inoculation of CDMM with C. difficile from solid media gave extremely irreproducible and variable 
growth and therefore was not considered reliable enough for preparation of SILAC samples. Instead, 
an initial overnight culture was performed in TY media and this used to inoculate CDMM to an OD600 
of 0.05, typically resulting in a 2 to 3 % (v/v) carryover of TY media. To dilute out the natural isotope 
abundance isoleucine (light, I0) carried over the CDMM cultures were passaged twice more (using I0 
or I7 CDMM as indicated); the first subculture was allowed to grow for approximately 8 hours and 
then subcultured in light or heavy CDMM to an OD600 of 0.005. This typically resulted in a 0.4 % (v/v) 
carryover of the first passage, which represents 0.012 % TY carryover, and the second passage was 
allowed to grow overnight (approximately 16 hours) to stationary phase. A third passage was then 
set up diluting to an OD600 of 0.05 which typically corresponded to a 5 % (v/v) carryover of the 
second passage, or 0.00006 % TY (v/v); it was assumed that this level would be low enough to permit 
efficient incorporation of heavy isoleucine. The third passage was allowed to grow for approximately 
8 hours and it was during this period that YnC12 treatment was performed, if desired, when the 
culture reached an OD600 of 0.30. 
 To determine the percentage incorporation of I7 the light and heavy cultures of C. difficile 630 Δerm 
were lysed and fractionated. A sample of soluble and insoluble fractions from the heavy culture 
were reduced, alkylated and digested with trypsin. Additionally, a 1:1 mixture of heavy and light 
samples was prepared, for both the soluble and insoluble sub-proteomes. The mixture was reduced, 
alkylated and digested with trypsin. After digestion the peptides were purified on StageTips329 and 
analysed by LC-MS/MS on a Q-Exactive orbitrap in the Department of Chemisty, Imperial College 
London, as part of this study. The data was processed using MaxQuant330 and the percentage 
incorporation was calculated at a peptide level, as recommended by the Mann group, using the 
equation below:  
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐼𝑛𝑐𝑜𝑝𝑜𝑟𝑎𝑡𝑖𝑜𝑛 (%) =  1 −
1
𝑅𝑎𝑡𝑖𝑜 (𝐻 𝐿⁄ )
 
In the heavy only soluble fraction 1070 unique, C. difficile derived, peptides were quantified; these 
all contained at least one isoleucine residue. The percentage incorporation was calculated for each 
peptide as described above and the average incorporation was found to be 67 %, with a standard 
deviation of 237 %. Only 173 peptides were quantified in the insoluble fraction however, a 
percentage incorporation of 86 % was found, with a standard deviation of 73 %. These values may 
not, however, reflect the true extent of incorporation as peptides that only contained 13C6
15N1 
isoleucine would not be quantified. Therefore, the 1:1 mixture of heavy and light peptides was 
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subjected to the same analysis; as anticipated considerably more peptides were quantified for the 
1:1 samples, with 2136 peptides in the insoluble fraction and 3161 in the soluble being quantified. 
However, as shown in Figure 62, the median log2 H/L ratios were below 0, with a median H/L ratio of 
0.49 for the soluble sub-proteome and 0.34 for the insoluble fraction. 
SILAC labelling with 13C6
15N1 isoleucine in C. difficile 630 Δerm was initially tested, as isoleucine has 
previously been described as an essential amino acid. However, the overall incorporation rate was 
low (≥95 % is typically required for SILAC) and the deviation in percentage incorporation extremely 
high, indicating that C. difficile is synthesising light isoleucine from other components of the CDMM 
media.  Although this was not unexpected in light of C. difficile’s reported autotrophy326, it was 
hoped that isoleucine was an essential component of the CDMM due to a strong preference for 
import of this amino acid. However, it appears that C. difficile 630 Δerm may prefer to synthesise 
isoleucine rather than take it up from the media. It has been reported that C. difficile prefers to 
import short peptides rather than single amino acids323, which may play a role in this selectivity. The 
creation of mutant of C. difficile 630 Δerm that is auxotrophic for isoleucine was anticipated to 
improve the I7 incorporation rate and reduce associated errors in quantification. Attempts to create 
such a mutant are described in the following section (5.3.2).  
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Figure 62: A) The log2 (Ratio H/L) for peptides quantified in the soluble fraction for a 1:1 mixture of heavy and light labelled 
lysates. If incorporation was 100 % efficient the histogram would be tightly centred at 0 (H/L =1); a broad distribution was 
observed with a median value of -1.03 (H/L =0.49). B) The log2 (Ratio H/L) for peptides quantified in the soluble fraction for 
a 1:1 mixture of heavy and light labelled lysates. If incorporation was 100 % efficient the histogram would be tightly centred 
at 0 (H/L =1); a broad distribution was observed with a median value of -1.56 (H/L =0.34). Histograms were created using 
Perseus; minimum and maximum axis values were set automatically; the y-axis maximum corresponds to 218 peptides. 
Peptides were binned every 0.12 units (x-axis). 
5.3.2 Deletion of ilvD 
5.3.2.1 Selection and Deletion of ilvD 
There has been a lack of research into the synthesis of branched chain amino acids by C. difficile, 
which complicated efforts to identify a suitable point at which to inactivate the isoleucine 
biosynthesis pathway. However, the predicted biosynthesis pathway for isoleucine, leucine and 
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valine was available for C. difficile 630 from the Kyoto Encyclopedia of Genes and Genomes 
(KEGG)331; this pathway is represented in Figure 63. The enzymes that catalyse the final steps in the 
isoleucine biosynthesis pathway remain unidentified however, in B. subtilis this is catalysed by a 
transaminase for which functional redundancy exists. The preceding step, the conversion of (R)-2,3-
dihydroxy-3-methylpenanoate to (S)-3-methyl-2-oxopenanoate, is catalysed by a dihydroxy-acid 
dehydratase, IlvD (EC 4.2.1.9). This enzyme was initially identified in Escherichia coli as being 
required for the biosynthesis of isoleucine and valine and it was noted that it requires ferrous iron 
for activity332; IlvD is an iron-sulphur protein and also catalyses the analogous reaction in valine 
biosynthesis. In C. difficile it is encoded by ilvD, CD630_20140. This enzyme represents a bottleneck 
in the predicted biosynthesis pathways of both L-isoleucine and L-valine, as BLAST analysis found 
only a single copy of ilvD in the C. difficile 630 genome and it is sufficiently close to the final step in 
the biosynthesis pathway to avoid perturbing the cellular concentrations of other metabolites. 
 
Figure 63: The isoleucine, valine and leucine biosynthesis pathway in C. difficile 630; adapted from the Kyoto Encyclopaedia 
of Genes and Genomes (KEGG). Enzymes are indicated by EC number (boxed), green boxes indicate known genes, white 
boxes inferred or unidentified genes, circles correspond to metabolites. The ilv pathway is annotated; tdcB is an ilvA 
homologue as identified by BLAST comparison to B. subtilis ilvA (data not shown). 
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Inactivation of ilvD was originally reported to give rise to isoleucine and valine auxotrophy in E. coli 
K12, with ilvD mutants requiring excess isoleucine and either valine or leucine for growth333. 
Deletion mutants in ivlD have been shown to be isoleucine auxotrophs in a number of other species, 
including the Gram-negative Caulobacter cresecentus334 and an isoleucine/ valine auxotroph in the 
model Gram-positive B. subtilis335. The isoleucine/ valine/ leucine biosynthesis pathway appears to 
be largely conserved across many bacterial species and therefore it was anticipated the inactivation 
of ilvD would create an isoleucine auxotroph in C. difficile. 
To delete ilvD the recently developed codA mediated allele exchange system was employed98, as 
described in Chapter 1.1.5.2. As a heavy labelled SILAC strain would be predominantly used to 
quantify proteome changes in mutants made in a 630 Δerm background92a, deletion of ilvD was to be 
performed in this strain. This system relies on recombination between regions of homology on a 
plasmid, derived from pMTL-SCSC7215, and the chromosome. Therefore, primers were designed to 
amplify homologous regions 1.2 kbp upstream and downstream of ilvD; long homologous regions 
have been reported to improve the efficiency of the rare second recombination and facilitate the 
use of allele coupled exchange deletion methods in C. difficile100. The homologous arms were to be 
assembled into pMTL-SC7215 using the Gibson assembly system and were cloned using primers, 
described in Table 15, that overlapped with pMTL-SC7215 and with each other such that ilvD was 
deleted between bases 9 and 1,558 (Figure 63 A and B). This covered the majority of the protein 
product, including the active site metal binding cysteines 118 and 190. Bases 1,559 to 1,656 were 
not deleted in order to minimise polar effects on CD360_20131 which is only 125 bp upstream. The 
resulting plasmid, pTMC003, was transformed into E. coli and conjugated into C. difficile 630 Δerm.  
This plasmid contains a defective origin of replication, making it segregationally unstable; it is 
therefore referred to as pseudo-suicide98. This allows selection of clones where the plasmid has 
integrated into the chromosome (referred to as single cross over integrants) based on colony size. In 
the presence of thiamphenicol, resistance to which is encoded on the plasmid backbone, cells which 
have integrated the plasmid form bigger colonies as growth is no longer limited by replication and 
segregation of the plasmid. Candidate single cross over integrants were re-streaked to purity and 
confirmed by colony PCR using primer pairs to generate a product that overlapped the chromosome 
and plasmid, for both possible insertion orientations. 
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Figure 64: A) Cloning of the homologous arms to delete ilvD; the primers were designed such that the left arm overlaps with 
pMTL-SC7215 at the 5’ end and the right homologous arm at the 3’ end; the right homologous arm overlaps with the left at 
the 5’ end and pMTL- SC7215 at the 3’ end. B) Assembly of pTMC003, the plasmid for deletion of ilvD, confirmed by PCR 
using plasmid specific primers. The product of the correct size, 2,619 bp, is indicated by . C) PCR screening of 5FC 
resistant, thiamphenicol sensitive colonies using chromosome specific primers that bind outside the homologous arms. 
Deletion mutants of ilvD are indicated by  and wild type revertants by . 
Following selection, pure single cross over integrants were grown in the absence of selection to 
allow plasmid loss to occur, following a rare second recombination event in which the plasmid is 
excised from the chromosome. Double cross over clones were then isolated by growth on minimal 
agar containing 5-fluorocytosine (5FC); the presence of cytosine deaminase (EC 3.5.4.1, codA) on the 
plasmid backbone enables the conversion of the innocuous 5FC to 5-fluorouracil, which is highly 
toxic. C difficile lacks an endogenous codA; therefore colonies which are able to grow on 
5FC-containing media are potential double cross over recombinants. 5FC resistant colonies were 
screened for thiamphenicol resistance to exclude clones that had acquired a mutation in codA. 5FC 
resistant, thiamphenicol sensitive isolates, which were either double cross over recombinants or 
wild type revertants, were screened by PCR and deletion mutants of ilvD, C. difficile 630 Δerm ΔilvD, 
isolated (Figure 64 C). The identity of clones 3, 16 and 18 was confirmed by sequencing.  
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5.3.2.2 C. difficile 630 Δerm ΔilvD Does Not Require Isoleucine  
Before attempting SILAC labelling of C. difficile 630 Δerm ΔilvD, the effect of isoleucine on growth 
was investigated, both in liquid media and on agar. Following an initial overnight culture in TY media, 
the cultures were diluted to an OD600 of approximately 0.1 in either TY or CDMM with and without 
isoleucine. The cultures were performed in biological triplicate and growth monitored (OD600) over 
10 hours. As shown in Figure 65, C. difficile 630 Δerm ΔilvD (#18) grew identically to the parental 
strain, 630 Δerm, in rich media (TY) and in complete CDMM, although considerably worse growth 
was observed in CDMM than TY. In CDMM prepared without isoleucine (-Ile) the growth of 630 
Δerm ΔilvD was within error of that for the parental strain and, although growth for both strains was 
slow and levelled off after approximately 8 hours, it was comparable to that observed for complete 
CDMM. As this residual growth could conceivably result from growth until exhaustion of any 
isoleucine carried over from the initial culture in rich media (TY), growth on solid media in the 
presence or absence of isoleucine was investigated.   
 
Figure 65: Growth in rich media (TY, short dashed lines) and CDMM with (complete, long dashed lines) or without (-Ile, solid 
lines) isoleucine. Growth is reduced in CDMM relative to TY but there is no significant difference in growth rate or final 
OD600 between the strains in either the presence or absence of isoleucine and growth between these two conditions remains 
similar. Values are the average of three biological replicates and error bars correspond to the standard deviation. 
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All three sequenced colonies of C. difficile 630 Δerm ΔilvD (#3, #16 and #18) were then compared to 
630 Δerm on solid media, composed of CDMM, with or without isoleucine (Figure 66 A and B, 
respectively), supplemented with 1 % agar. The strains were patch plated on quartered plates, with 
or without isoleucine, in biological triplicate and growth assessed after 24 hours. All three mutants 
grew comparably to 630 Δerm, indicating that either isoleucine is present in the agar or that 630 
Δerm ΔilvD is not an isoleucine auxotroph. 
 
Figure 66: Patch plating of 630 Δerm and 630 Δerm ΔilvD #3, #16 and #18 to assess whether isoleucine is required for 
growth. A) Growth on plates composed of complete CDMM, supplemented with 1 % agar. B) Growth on plates composed of 
CDMM prepared without isoleucine, supplemented with 1 % agar. Growth is identical between all four strains on both 
plates; this experiment was performed in biological triplicate and representative images are shown.  
5.3.2.3 SILAC in C. difficile 630 Δerm ΔilvD  
In both experiments described in section 5.3.2.2 potential external sources of isoleucine exist, 
whether as carry over from the initial culture in rich media or as a component of the agar. 
630 Δerm ΔilvD may therefore be SILAC capable, following additional passages to deplete any 
residual light isoleucine. Additionally, it was possible that, even if 630 Δerm ΔilvD is not an isoleucine 
auxotroph the deletion of ilvD may reduce the rate at which isoleucine can be synthesised to a level 
that makes SILAC practical. Therefore 630 Δerm ΔilvD was cultured as described in section 5.3.1.3, in 
CDMM with either heavy (I7) or light (I0) isoleucine. Samples were taken after two and three 
passages in SILAC amino acid containing CDMM and the incorporation efficiency assessed as 
described above for both heavy cultures only and a 1:1 mixture of heavy and light cultures. 
For the heavy only samples, after two passages 1141 unique C. difficile derived peptides that 
contained at least one isoleucine residue were quantified in the soluble proteome. The percentage 
incorporation was calculated for each peptide as described in section 5.3.1.3 and the average 
incorporation was found to be 41 %, with a standard deviation of 706 %. This was improved by the 
addition of a third passage in heavy CDMM; 1167 peptides that contained at least one isoleucine 
residue were quantified in the soluble proteome. The percentage incorporation was calculated to be 
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48 % with a standard deviation of 665 %; surprisingly this was considerably lower incorporation 
efficiency than that observed for SILAC labelled C. difficile 630 Δerm, with a greater error. However, 
as discussed previously, these values may not reflect the true extent of incorporation as peptides 
that only contained I7 would not be quantified. 
Considerably more peptides were quantified for the 1:1 samples, with 3614 isoleucine containing 
peptides from the soluble fraction after 2 passages and 3679 peptides after 3 passages in CDMM. 
However, the median H/L ratios (converted to log2) were considerably below zero, with a median 
H/L of -0.90 after two passages and -1.09 after three passages, as shown in Figure 67. These 
correspond to H/L ratios of 0.54 and 0.47, respectively. These are no closer to the expected value of 
H/L= 1 than that observed for 630 Δerm, indicating that C. difficile 630 Δerm ΔilvD, when grown for 
either two or three passages in heavy CDMM, gave a comparable percentage incorporation than the 
parental strain (section 5.3.1.3). 
These experiments have demonstrated that SILAC labelling, in either the parental strain 630 Δerm or 
the ilvD deletion mutant 630 Δerm ΔilvD is not practical. For accurate quantification an incorporation 
efficiency of ≥95 % is required, with as low a standard deviation as possible271a, which was not 
achieved. The percentage incorporation remained low for 630 Δerm ΔilvD, with an extremely high 
standard deviation. It is difficult to hypothesise why this may be; however, possibilities include the 
existence of an alternative and unidentified isoleucine biosynthesis pathway. Additionally, possible 
alternative routes for the uptake or production of (S)-3-methyl-2-oxopenanoate, the product of IlvD, 
may exist. Finally, it has been observed that C. difficile uptakes and metabolises short peptides in 
preference to single amino acids and growth is enhanced by the addition of peptide mixtures to 
minimal media323. It is possible that the low incorporation observed for 630 Δerm and 
630 Δerm ΔilvD results from preferential uptake of residual light isoleucine containing peptides 
carried over from the initial culture, or derived from lysed C. difficile cells. Regardless, it was not 
considered practical to continue with attempts to develop SILAC for C. difficile and alternative label 
based methods for quantification were investigated.  
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Figure 67: A) The log2 (Ratio H/L) for peptides quantified in the soluble fraction for a 1:1 mixture of heavy and light labelled 
lysates of C. difficile 630 Δerm ΔilvD, grown for two passages in heavy CDMM. If incorporation was 100 % efficient the 
histogram would be tightly centred at 0 (H/L =1); a broad distribution was observed with a median value of -0.90 
(H/L =0.54). B) The log2 (Ratio H/L) for peptides quantified in the soluble fraction for a 1:1 mixture of heavy and light 
labelled lysates of C. difficile 630 Δerm ΔilvD, grown for three passages in heavy CDMM. If incorporation was 100 % efficient 
the histogram would be tightly centred at 0 (H/L =1); a broad distribution was observed with a median value of -1.09 
(H/L =0.47). Histograms were created using Perseus; minimum and maximum axis values were set automatically; the y-axis 
maximum corresponds to 238 peptides. Peptides were binned every 0.33 units (x-axis). 
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5.4 Dimethyl Labelling 
5.4.1 Development of Dimethyl Labelling 
5.4.1.1 Dimethyl Labelling 
Dimethyl labelling is a chemical labelling method for quantitative proteomics, originally reported by 
Hsu and co-workers274a. Samples are digested with a protease such as trypsin and the peptides 
labelled with isotopically distinct dimethyl labels. This occurs via reductive amination of the peptides 
N-terminus and lysine ε-amines, with stable isotope labelled formaldehyde and sodium 
cyanoborohydride, or sodium cyanoborodeuteride. This labelling approach utilises the following 
combinations of reagents which are referred to as heavy, medium and light dimethyl labels: 13CD2O 
and NaBD3CN (heavy), 
12CD2O and NaBH3CN (medium) or 
12CH2O and NaBH3CN (light). This results in 
a mass shift of +36, +32 and +28 Da per amine, respectively; there is a 4 Da mass difference between 
them when proteolysis occurs after an arginine residue and an 8 Da shift if cleavage occurs after a 
lysine residue allowing the three states to be readily distinguished in the MS1. These reagent 
combinations can be used to analyse three samples in a single MS run, a “triplex” approach, or 
alternatively the light and medium conditions can be used to analyse two samples in a “duplex” 
approach. Using dimethyl labelling all peptides can be quantified, with the exception of rare 
instances where the N-terminal residue is proline, in which case only monomethylation is possible. 
This is an advantage over other chemical labelling approaches such as ITRAQ, where only cysteine 
containing peptides can be quantified, and would be expected to lead to more accurate 
quantification. 
Other advantages of dimethyl labelling include the fast reaction time, low cost of reagents, when 
compared to both SILAC and ITRAQ, the increased stability of dimethyl labelling reagents over ITRAQ 
reagents and its broad applicability.  Dimethyl labelling is potentially applicable to any sample, 
including tissue samples, with no restriction to the choice of protease and has previously been 
employed both in combination with affinity pull down336 and to study a spo0A mutant of C. difficile 
630 Δerm337. Dimethyl labelling can be performed on large scales, in-solution, on column or on 
StageTips, and automation has been reported274b. Several studies have reported the use of dimethyl 
labelling on a range of primary cells and tissue samples, in combination  with fractionation, as 
highlighted by Boersema and co-workers274b. 
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There are however, some disadvantages to the dimethyl labelling approach. Notably, dimethyl 
labelling is performed in one of the final steps in a proteomic workflow, following all sample 
processing and directly prior to LC-MS/MS analysis. Consequently, any variation introduced during 
sample preparation will introduce an error in quantification. Dimethyl labelling has been rigorously 
compared to SILAC338 and was found to be considerably less accurate when the SILAC labelled 
samples are combined early in the workflow. Additionally, lower peptide signal intensity was 
observed and reduced numbers of peptides and proteins were identified using dimethyl labelling, 
when compared to SILAC. Finally, dimethyl labelling is usually only applied for the simultaneous 
analysis of three samples, although since this work was conducted “5-plex” dimethyl labelling has 
been reported339. Dimethyl labelling is therefore lower throughput than ITRAQ, which allows up to 
eight samples to be analysed simultaneously272, and spike-in SILAC which theoretically allows an 
unlimited number of samples to be compared321. 
The low cost and broad applicability of dimethyl labelling make it a practical alternative to SILAC for 
quantitative proteomics in C. difficile. It should be possible to apply dimethyl labelling quantification 
to a range of C. difficile mutants and, unlike SILAC, to strains other than 630 and its erythromycin 
sensitive derivative 630 Δerm. Although dimethyl labelling limits quantification to the simultaneous 
analysis of three samples, considerate experimental design would allow a number of conditions and 
strains to be investigated. 
5.4.1.1 Application of Dimethyl Labelling to C. difficile 
Both in-solution and on StageTip dimethyl labelling protocols have been described274b, 336; the latter 
method was reported for use with Activity Based Protein Profiling and affinity enrichment. 
Therefore, on StageTip dimethyl labelling would be compatible with the metabolic tagging and 
affinity enrichment method described in Chapter 3.4.3, while the in-solution protocol could be 
utilised for global proteome analysis. Prior to performing dimethyl labelling based quantification 
experiments in C. difficile the efficiency of the in-solution labelling reaction in our hands was 
assessed. 
A single culture of C. difficile 630 Δerm, in TY media, was fractionated into soluble and insoluble sub-
proteomes and 25 µg of each fraction digested, StageTip desalted, dried, resuspended in 
tetraethylammonium bicarbonate (TEAB) and subjected to dimethyl labelling using light reagents 
only, following the protocol described by Boersema and co-workers274b. The labelled peptides were 
StageTip desalted and analysed by LC-MS/MS analysis on a Q-Exactive orbitrap. The data was 
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processed using MaxQuant, with dimethyl and monomethyl modification of the peptides N-terminus 
and lysine side chain set as variable modifications using Andromeda340.  
A total of 12,108 peptides were identified; 11,793 peptides had a dimethyl labelled N-terminal 
amine, 211 had a singly methylated N-terminal amine and 104 were not modified, as shown in 
Figure 66 A. This corresponds to the N-terminal amine being dimethyl labelled for 97 % of all 
identified peptides. A total of 9,360 lysine containing peptides were identified; when processing the 
data up to two missed cleavages were permitted and consequently there could be a maximum of 
three lysines per identified peptide. The variable dimethyl and monomethyl modification state, on 
up to three lysine residues, was therefore investigated. As shown in Figure 68 B, a total of 9,264 
peptides were found that have complete lysine modification (99 %), of which 7,524 contained a 
single dimethyl modified lysine, 1622 contained two dimethylated lysines (one missed cleavage) and 
118 have two missed cleavages (3 modified lysines). There were a total of 95 peptides (1 %) with at 
least one unmodified or partially modified lysine, including up to two missed cleavages. As almost 
complete labelling of both N-terminal amines and lysine ε-amines was achieved, the use of dimethyl 
labelling is unlikely to result in a significant reduction in identification due to partial or incomplete 
peptide modification.  
 
Figure 68: A) Variable modification of N-terminal amines by dimethyl labelling; the majority of peptides (97 %) have a fully 
labelled N-terminus. B) Variable modification of lysine side chain amines by dimethyl labelling; the majority of peptides 
(99 %) have fully labelled lysine ε-amines, allowing for up to two missed cleavages. Labelling is almost complete for both 
N-termini and lysine residues and consequently it is expected the dimethyl labelling will enable efficient quantification. The 
data was processed using MaxQuant and analysed using the statistical package Perseus, charts were plotted in Microsoft 
Excel. 
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5.4.2 Proof of Principle Study: YnC12 versus Myristic Acid 
5.4.2.1 Dimethyl Labelling 
Having demonstrated that the in-solution dimethyl labelling reaction works efficiently, the on 
StageTip method336 was adapted to the metabolic tagging methodology described in Chapter 3:. A 
comparison between YnC12 and myristic acid was used as a proof of principle experiment, with a 
technical replicate of each sample left unlabelled to compare LFQ to dimethyl labelling. Cultures of 
C. difficile 630 Δerm, during early exponential phase, were treated with 25 µM of YnC12 or myristic 
acid and allowed to grow for a further 5 hours. The bacteria were lysed, fractionated and the tagged 
lipoproteins ligated to AzTB by CuAAC. The labelled lipoproteome was affinity enriched using 
NeutrAvidin beads and the pull down efficiency assessed by comparison between an aliquot of the 
sample pre-pull down, the elutant from an aliquot of the beads and the supernatant from the beads 
(Figure 69). The samples were reduced, alkylated and digested on-bead, and the peptides either 
StageTip desalted for LFQ analysis or subjected to on-StageTip duplex dimethyl labelling and 
desalting. This experiment was performed in biological triplicate.   
 
Figure 69: YnC12 and myristic acid tagging, for comparison between dimethyl labelling and label free quantification. The 
efficiency of pull-down was confirmed by comparison between the pre-pull down sample (-), enriched proteins, eluted from 
the beads by boiling in sample loading buffer (E) and the supernatant (S). This experiment was performed in biological 
triplicate; the gel for a representative replicate is shown here. Coomassie staining (total protein, bottom) is shown as a 
loading control. 
The RAW files for the dimethyl labelled samples were processed using MaxQuant and statistical 
analysis performed using Perseus. The data was filtered to remove contaminant proteins and to 
restrict the data set to proteins that were quantified in all three biological repeats. Plotting 
histograms, binning proteins by log2 (Ratio H/L), revealed that the protein distribution was 
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reproducible across the three repeats (Figure 70). The median log2 (Ratio H/L) was 2.9, 3.3 and 3.3 
for repeats 1, 2 and 3 respectively. As anticipated the histograms were centred at log2 (Ratio H/L) 
values greater than zero as the YnC12 treated samples were labelled with the heavier dimethyl 
labelling conditions. The distribution of non-predicted proteins is also centred at a log2 (Ratio H/L) 
greater than zero (Figure 70, shown in blue), indicating that they are binding to specifically enriched 
proteins or LTA at a greater rate than non-specific binding occurs to the beads only. This was also 
observed in the LFQ experiments performed to directly compare YnC12 and myristic acid treatment 
(sections 5.2.1 and 5.4.2.1). Despite this, predicted lipoproteins (Figure 70, shown in red) have a 
higher than average log2 (Ratio H/L), indicating enrichment. 
 
Figure 70: Distribution of all protein quantified by dimethyl labelling in all three biological replicates, by log2 (Ratio H/L); 
predicted lipoproteins are shown in red and all other proteins in blue. There is a good agreement between all three 
biological replicates (repeats 1, 2 and 3; A, B, and C respectively), with the median log2 (Ratio H/L) being 2.9, 3.3 and 3.3 
respectively). The data was processed using MaxQuant and analysed using the statistical package Perseus; histograms were 
plotted in Perseus. Maximum and minimum axis values were created automatically; the y-axis maximum corresponds to 20 
proteins, which were binned every approximately 0.25 log2 (Ratio H/L) units (x-axis). 
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In total, 101 proteins were quantified in all three samples, of which 36 (36 %) were predicted to be 
lipoproteins, the remaining 65 (64 %) were non-specifically enriched proteins; a breakdown of all 
quantified proteins by function is given in Figure 71 B. To investigate whether the above median 
log2 (Ratio H/L) observed for the predicted lipoproteins was significant a single sample T-test was 
performed. The value to test against was set as zero, which corresponds to no change in enrichment 
between the YnC12 and myristic acid treated samples; the significance cut-off was set to p= 0.01. It 
was found that the majority of proteins, 75 in total, were significantly different from zero (Figure 
71 A); this may be due to non-specific pull down of other proteins with specifically enriched 
lipoproteins or LTA. A breakdown of the T-test significant proteins by function is given in Figure 71 C. 
 
Figure 71: A) A scatter plot of all quantified proteins, comparing the average log2 (Ratio H/L) to the significance 
(-log10 T-test P Value). Although predicted lipoproteins (shown in red) have a higher log2 (Ratio H/L) distribution than the 
other proteins (blue) many other proteins are also significant. B) A breakdown of all proteins quantified in all three 
biological repeats by function; emphasis is placed on predicted lipoproteins. C) A breakdown of T-test significant proteins 
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repeats by function; emphasis is placed on predicted lipoproteins. The data was processed using MaxQuant and analysed 
using the statistical package Perseus, charts were plotted in Microsoft Excel. 
28 out of 36 predicted lipoproteins quantified were T-test significant. The majority of predicted 
lipoproteins, quantified in all three repeats, were ABC-type transport system solute-binding proteins 
(19) or of putative and uncharacterised function (13), of which 15 and 11 respectively where T-test 
significant (p ≤0.01). Other predicted lipoproteins quantified were similar to those identified in the 
LFQ experiment described in section 5.2, including the polysaccharide deacetylase (CD630_27190), a 
thioredoxin (CD630_15070), a nucelotidase (CD630_01990) and the extracellular chaperone PrsA 
(CD630_35000). Of these only PrsA and the polysaccharide deacetylase were t-test significant, while 
non-predicted proteins, which were believed to be non-specifically enriched, remained the majority 
(63 %) of the T-test significant proteins. 
Improvements in experimental design are required to enable lipoproteins to be distinguished from 
the background proteins and to facilitate the identification of non-predicted lipoproteins. Despite 
this, dimethyl labelling works reproducibly, as shown in Figure 70. Dimethyl labelling also facilitates 
significance testing, controls for sample variation resulting from manipulation of the peptide 
mixtures after combining and for the run on the mass spectrometer, as well as reducing sample 
processing time. The results of a technical replicate of this experiment analysed using label free 
quantification and a comparison to dimethyl labelling are discussed in the following section. 
5.4.2.1 Label Free Quantification 
For label free analysis the YnC12 and myristic acid treated samples were analysed in separate 
nano-LC-MS/MS runs and the data processed using the LFQ intensity setting in MaxQuant. The data 
set was then analysed in Perseus and restricted to proteins that were quantified in all three 
biological repeats for either the YnC12 or myristic acid fed samples. A total of 340 proteins were 
identified using this method, almost three times as many as in the dimethyl labelling experiment. 
However, the requirement for valid quantification values is considerably more relaxed in this 
analysis. Most of the identified proteins in the YnC12 tagged samples were not found in the myristic 
acid treated samples. Therefore, restricting the data set to proteins that were quantified in both 
YnC12 and myristic acid samples for each biological repeat (as was performed for dimethyl labelling) 
would have resulted in a considerable reduction in the number of quantified proteins.  Additionally, 
as lots of background proteins have zero intensity in the myristic acid treated samples it is extremely 
difficult to discriminate between background and hit proteins; a comparison between the average 
LFQ intensity for the YnC12 and myristic acid treated samples is shown in Figure 72 A. This is likely an 
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artefact due to binding of other proteins to specifically pulled down, YnC12 tagged, proteins or LTA 
at a greater rate than non-specific binding occurs to the beads only, as discussed in section 5.4.2.1. 
Statistical analysis was impractical for this experiment as for many proteins identified in the YnC12 
samples there was no corresponding value for the myristic acid samples. For this reason, performing 
a two sample T-test between YnC12 treated samples and the myristic acid treated samples resulted 
in very few proteins being assigned significance (p≤ 0.01). Consequently, the enrichment factor (EF) 
was calculated instead, as described in section 5.2; a breakdown of proteins with an EF≥ 5 is shown 
in Figure 72 B.  
 The vast majority of proteins with an EF≥ 5 were not predicted to be lipidated (237, 83 %); as shown 
in Figure 72 A (blue). As these background proteins frequently have zero intensity in the myristic acid 
treated samples it is impossible to discriminate between these and genuine hits on the basis of 
enrichment factor. It is clear that, despite the higher quantification rate, there is a much higher 
background (83 % to 64 %) when compared to dimethyl labelling. A total of 49 lipoproteins (17 %) 
had an EF≥ 5; this is a larger number than for dimethyl labelling but may contain a number of false 
positives. Additionally, while 55 predicted lipoproteins (of any EF) were identified by LFQ analysis, a 
total of 51 lipoproteins were identified by dimethyl labelling, although only 36 of these were 
quantified (section 5.4.2.1 and Appendix C). In all cases this was due to a failure to identify peptides 
corresponding to the lipoprotein in the myristic acid treated (light) samples, which likely results from 
a lack of enrichment of these proteins in the myristic acid treated samples. This was expected as, in 
the absence of an alkyne tag, these proteins should not be specifically enriched and any proteins for 
which a H/L ratio could be calculated were quantified against the background binding to the beads. 
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Figure 72: A) The distribution of all proteins identified for YnC12 and myristic acid fed C. difficile 630 Δerm. Predicted 
lipoproteins are shown in red while all other proteins are shown in blue; the enrichment factor cut off (EF =5) is indicated by 
a line. Lipoproteins are generally highly enriched (EF >5) with a high intensity in the YnC12 treated samples and a low 
intensity in the myristic acid treated samples. Non lipoproteins are more variable and of lower intensity but the majority 
have an EF≥ 5. B) A breakdown of all proteins with EF ≥5 by predicted function; the majority are not predicted to be 
lipidated however 49 lipoproteins were identified; emphasis is placed on the function of predicted lipoproteins. The data 
was processed using MaxQuant and analysed using the statistical package Perseus, charts were plotted in Microsoft Excel. 
5.5 Discussion 
In this chapter an initial proteomic profile of the lipoproteome of C. difficile 630 Δerm was 
performed, using a label free approach. Based on the results of these experiments label based 
quantitative proteomic methods were investigated. These approaches included an attempt to 
develop SILAC for C. difficile; the efficiency of uptake and incorporation of 13C6
15N1 isoleucine by C. 
difficile 630 Δerm was investigated and an attempt made to create an isoleucine auxotrophic strain, 
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C. difficile Δerm ΔilvD. As this strain proved not to be SILAC capable an alternative label based 
quantification approach, dimethyl labelling, was applied. The dimethyl labelling reaction efficiency 
was investigated and a proof of principle study conducted, comparing YnC12 treated to myristic acid 
treated C. difficile Δerm, using both dimethyl label and label free approaches. 
The profiles of the C. difficile Δerm lipoproteome created using LFQ proteomic analysis (sections 5.2 
and 5.4.2.1) demonstrated that the lipoproteins labelled with YnC12 could be efficiently enriched 
and identified. However, it was observed that the background proteins appeared to bind more 
strongly to specifically enriched proteins, or LTA, than to the beads. Many of these background 
proteins were highly enriched in the YnC12 fed 630 Δerm samples; only 35 % and 17 % of proteins 
identified in these experiments with an EF≥ 5 were predicted lipoproteins. A comparison between 
YnC12 treated 630 Δerm and lgt::erm gave considerably lower background, with 82 % of proteins 
with EF≥ 5 being predicted lipoproteins. This raises the possibility that the background proteins are 
binding to enriched residual LTA, which is present in both YnC12 treated strains, rather than to 
lipoproteins. 
A total of 42 predicted lipoproteins were identified with an EF≥ 5 in these initial two LFQ 
experiments (section 5.2) while 49 predicted lipoproteins had an EF≥ 5 in the latter LFQ experiment 
(section 5.4.2.1); this proteomic analysis provided a biochemical verification of lipidation for the 
majority of these proteins and validated use of the natural lipid myristic acid and the lipidation 
deficient mutant lgt::erm as negative controls. However, initial label free experiments also revealed 
areas where the experimental design could be optimised. The use of a quantitative proteomic 
strategy was anticipated to produce higher quality data sets and enable a more sensitive 
discrimination between genuinely enriched proteins and the background. Label based methods for 
quantitative proteomics typically involve mixing two or more samples and consequently the 
complexity of the sample to be analysed is increased; this can result in a failure to identify low 
abundance proteins. A label based method may reduce the identification rate but this was not 
expected to be problematic as the affinity enriched samples are relatively simple. 
An attempt was made to develop SILAC271a for C. difficile 630 Δerm, using I7 as the heavy amino acid. 
The incorporation efficiency for 630 Δerm was investigated using a defined media, CDMM324, and 
found to be 67 % with a high error; typically an incorporation rate of ≥95 % is required for SILAC 
experiments. Therefore a dehydroxy acid dehydratase (ilvD) knockout was created using the CodA 
system98 (section 5.3.2.1); IlvD catalyses the penultimate step in the biosynthesis pathway for 
isoleucine and valine and it was anticipated that 630 Δerm ΔilvD would be an isoleucine auxotroph, 
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enabling efficient SILAC labelling. However, it was observed that 630 Δerm ΔilvD was capable of 
growth in the absence of isoleucine, both in liquid media and on solid agar (section 5.3.2.2). SILAC 
labelling of 630 Δerm ΔilvD revealed that the incorporation rate remained low, with an extremely 
high standard deviation (section 5.3.2.3). Despite the unsuitability of this strain for use in SILAC 
based quantitative proteomics this result was none the less interesting from a metabolic 
perspective; it is possible that there is an alternative, unknown, biogenesis pathway for isoleucine in 
C. difficile. Alternatively, a preference for the uptake and metabolism of short peptides over single 
amino acids by C. difficile has been observed323 and it is possible that short peptides carried over 
when the culture is inoculated or released by lysis of C. difficile cells are taken up in preference to 
13C6
15N1 isoleucine, leading to a reduction of the incorporation efficiency.  
As an alternative label based quantitative proteomic approach dimethyl labelling was utilised 
(section 5.4.1); this presented several advantages over SILAC labelling as the reagents were stable 
and inexpensive, and the method applicable to any sample274b. As expected, It was found that the 
dimethyl labelling reaction was highly efficient when applied to C. difficile (section 5.4.1.1), with 
97 % of peptides having a fully labelled N-terminus and 99 % of lysine containing peptides having a 
fully modified ε-amine. As a proof of principle study, dimethyl labelling was used to quantify the 
difference in enriched proteins between YnC12 and myristic acid treated C. difficile 630 Δerm, in 
comparison to LFQ analysis. This demonstrated the applicability of the on-StageTip dimethyl 
labelling336 approach to the workflow used. This method allowed quantification of predicted 
lipoproteins and enabled statistical testing, however, as this was a direct comparison between the 
probe and the natural lipid, for which no enrichment was expected, specifically enriched proteins 
were quantified against the background. Consequently significance was poor and 15 lipoproteins 
were identified, but not quantified, due to low abundance in the myristic acid treated samples. 
In this chapter proteomic analysis of the C. difficile 630 Δerm lipoproteome has been developed, and 
the use of SILAC and dimethyl labelling for quantification investigated. This has validated the use of 
the lipidation deficient mutant, lgt::erm, as a negative control and provided biochemical verification 
of lipidation for a number of lipoproteins. However, due to the high background further 
investigation is required to demonstrate this unambiguously. Quantitative proteomic analysis using 
dimethyl labelling and competition between myristic acid and YnC12 (Chapter 3.2.3) coupled with 
statistical testing, is required to create a high confidence profile of the C. difficile lipoproteome. This 
would be expected to increase the quantification and identification rate, as quantification will being 
performed against a reduced level of specifically enriched proteins, rather than the background. 
Additionally, differentiation between proteins that are non-specifically enriched by binding to 
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lipoproteins or LTA and genuinely enriched lipoproteins would be possible. The following chapter 
will describe the application of this method to profile the lipoproteome of C. difficile 630 Δerm and 
R20291 and to investigate any non-predicted proteins that are potentially lipidated. 
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Chapter 6: Quantitative Proteomic Profiling of the 
Clostridium difficile Lipoproteome 
6.1 Introduction 
In the previous chapter, label free proteomic analysis was used to demonstrate that the proteins 
tagged with YnC12, and enriched as described in Chapter 3.4.3, are predicted lipoproteins. The 
development of quantitative proteomic techniques for C. difficile was described, including the 
optimisation and application of dimethyl labelling. The use of this chemical labelling strategy, in 
combination with a metabolic chemical tagging approach, to investigate the C. difficile lipoproteome 
is described in this chapter. The primary aim of the research described here was to quantify the 
competition between YnC12 and myristic acid to generate a statistically significant profile of the 
lipoproteome of the reference strain C. difficile 630 Δerm and a hypervirulent strain, R20291. 
Additionally, any non-predicted proteins that were statistically likely to be lipoproteins were to be 
further investigated and their lipidation verified. 
6.2 Profiling the C. difficile Lipoproteome by Competition 
As discussed in Chapter 5.2, a direct proteomic comparison between YnC12 and myristic acid treated 
samples resulted in a high enrichment of background proteins, likely due to non-specific binding to 
YnC12-tagged LTA, which is not enriched in myristic acid fed samples. Therefore, competition 
between the natural lipid analogue of YnC12, in conjunction with dimethyl labelling, was to be used 
to create a comprehensive profile of the C. difficile 630 Δerm lipoproteome. Quantification of the 
reduction in enrichment anticipated for genuine lipoproteins would allow their elucidation over non-
specifically enriched proteins, the relative abundance of which was not expected to change, and 
facilitate the identification of non-predicted lipoproteins. Additionally, relative quantification against 
reduced levels of specifically enriched proteins was anticipated to lead to a higher identification rate 
than quantification against background binding, as all genuine lipoproteins would be present in all 
samples, albeit at a reduced level on competition. 
6.2.1 Profiling the C. difficile 630 Lipoproteome 
Three biological replicates of C. difficile 630 Δerm, in TY broth, were inoculated from overnight 
cultures to an OD600 of approximately 0.05 and immediately treated with 0 µM, 50 µM or 100 µM 
myristic acid. During early exponential growth (OD600 ≈0.3) the subcultures were treated with 10 µM 
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YnC12 and allowed to grow to stationary phase over seven and a half hours. Following lysis and 
fractionation CuAAC ligation of the YnC12 tagged lipoproteome to AzTB was performed. The labelled 
lipoproteins were pulled down onto neutravidin beads and the enrichment efficiency assessed by 
comparison between an aliquot of the samples before pull down and the supernatant from the 
beads via SDS-PAGE and in-gel fluorescence analysis. This step also served to ensure that the protein 
concentration was equal across all samples to be compared (Figure 73). The beads were stringently 
washed to remove all non-specifically bound proteins and the enriched proteins subjected to on-
bead reduction, alkylation and tryptic digest. The peptides were then dimethyl labelled on 
StageTips336, with the 0 µM myristic acid treated samples being labelled with the light reagents, the 
50 µM samples with the medium and the 100 µM samples with the heavy reagents;  the labelled 
peptides were combined 1:1:1 prior to LC-MS/MS analysis on a Q-Exactive Orbitrap at Imperial 
College London. 
 
Figure 73: The efficiency of affinity enrichment of the C. difficile 630 Δerm lipoproteome was assessed by an in-gel 
fluorescence comparison between an aliquot of the samples before pull down (-) and the supernatant (S). The cultures were 
treated with 10 µM YnC12, in competition with 0, 50 or 100 µM myristic acid; this experiment was performed in biological 
triplicate. Coomassie staining (total protein, bottom) is shown as a loading control. 
The data were processed using MaxQuant330; a total of 187 proteins were quantified across all the 
three biological repeats, with both M/L and H/L ratios, of these 48 were predicted to be lipoproteins 
(Figure 74 A). To distinguish between lipoproteins and background proteins for which the 
enrichment was reduced on competition with myristic acid a multiple sample ANOVA was performed 
using the statistical package Perseus330, testing between the 50 µM and 100 µM values (M/L and H/L 
Ratio respectively) and a series of values artificially added for the 0 µM myristic acid samples, which 
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were 1 by default (L/L). A p value significance cut-off of p =0.01 was used and the variance, S0, was 
set to zero (default).  A total of 56 proteins showed a significant (p ≤0.01) reduction in enrichment 
on competition with an excess of myristic acid, as shown in Figure 74 B. Of these hits 46 (82 %) were 
predicted to be lipoproteins, as described in Chapter 2.1.1. 
 
Figure 74: A) Average (mean) relative enrichment for the proteins which were quantified in all three biological repeats, with 
values found for both the M/L and H/L samples. Predicted lipoproteins are shown in red; other proteins are coloured in grey. 
A total of 187 proteins were quantified of which 48 were predicted lipoproteins. B) All proteins which showed an ANOVA 
significant (p ≤0.01) reduction in enrichment on competition with an excess of myristic acid. Predicted lipoproteins are 
shown in red (46), other significant proteins in blue (10). RAW data was processed using MaxQuant and analysis and 
statistical testing performed in Perseus; graphs were plotted using Microsoft Excel. In both A and B the 0 µM value 
corresponds to log2 (Average Ratio L/L) =0, the 50 µM value corresponds to log2 (Average Ratio M/L) and the 100 µM value 
to log2 (Average Ratio H/L). 
Of the predicted lipoproteins which showed a significant reduction in enrichment on competition 
with a 5- and 10-fold excess of myristic acid, the majority were either ABC-type transporter solute-
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binding proteins (20), which play an important role in nutrient uptake and are known to be lipidated 
in other species181, and uncharacterised proteins (4) or putative lipoproteins (14) of unknown 
function. The function of significant lipoproteins was further investigated by retrieving their gene 
ontology (GO) annotations from Uniprot and searching the pfam database285 for conserved domains 
and motifs; the functions of the predicted lipoproteins identified are given in Figure 76 A and Table 
21. 
A number of conserved ABC-type transporter solute-binding proteins were identified, including the 
oligopeptide transporters OppA and AppA, the ribose binding protein RbsB, the alkane sulfonate 
binder SsuA, the spermidine/ putrescine solute binding protein PotD and molybdenum-specific 
solute binding protein ModA. Other ABC-type transporter solute-binding proteins identified were 
annotated as binders of iron, sugars, oligopeptides, amino acids and nitrates. Finally, enrichment of 
CD360_08730, annotated as a sugar-family solute binding protein, was significantly out competed by 
an excess of myristic acid. CD630_08730 has also been shown to function as a surface exposed 
adhesin341; recombinant CD630_08730 binds directly to Caco-2 cells, while an insertionally 
inactivated mutant, 630 Δerm 08730::erm, is unable to adhere to Caco-2 cells299.  As shown in Figure 
75, deletion of CD630_08730 did not lead to an obvious change to the in-gel fluorescence pattern, 
indicating a relatively low expression level. However, overexpression of CD630_08730 by the 
complemented strain, under the control of the cwp2 promoter58, resulted in the appearance of a 
more intense band at the expected MW of 36.1 kDa (both strains provided by Dr Andrea Kovacs-
Simon, University of Exeter). This provides direct evidence for the lipidation of CD630_08730 and 
demonstrates that lipoproteins can play an important role in C. difficile colonisation. ABC-type 
transporter solute binding proteins have been shown to act as adhesins in other species342 and the 
possibility that other C. difficile lipoproteins annotated as having this function are also involved in 
adhesion cannot be excluded. 
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Figure 75: The YnC12/ AzTB labelling pattern for C. difficile 630 Δerm, CD630_08730::erm and the complement 
CD630_08730::erm +pMTL-KAS2, expressing CD630_08730 under the control of pcwp2. Exponentially growing cultures 
were treated with 25 µM YnC12 and, following lysis, fractionation and CuAAC ligation to AzTB, the labelling pattern was 
visualised by SDS-PAGE and in-gel fluorescence analysis; CD630_08730 is indicated by . Coomassie staining (total protein, 
bottom) is shown as a loading control. 
The extracellular chaperones PrsA (CD630_35000) and PrsA2 (CD630_15570) were also significantly 
reduced on competition with myristic acid. Bacillus subtilis PrsA is a known lipoprotein and PrsA is 
essential in a number of bacterial species188. PrsA-like proteins have peptidylprolyl isomerise 
function and form part of the Sec secretion system, where they play an important role in the 
extracellular folding of exported proteins. This competition experiment has demonstrated the 
lipidation of PrsA and PrsA2 in C. difficile, which is of particular interest as C. difficile has an 
additional secondary Sec system (SecA2) and a second PrsA may be required for association with this 
accessory Sec system. Secretion via SecA2 has been shown to function as the major export pathway 
for the S-Layer Proteins (SLPs) and both Sec systems are essential in C. difficile 63058. It is probable 
that one, or both, of C. difficile PrsAs play an essential role in the export and folding of the SLPs. The 
major component of the S-layer, SlpA, is strongly transcribed throughout growth65b and it has been 
estimated that up to 400 molecules per cell per second are exported during exponential growth69b; 
these lipoproteins are therefore likely to be essential in C. difficile. 
C. difficile has highly deacetlyated peptidoglycan, with up to 93 % of glucosamine units being 
deactleyated343; lysozyme recognises acetylated peptidocglycan and thus this deacetlyation is 
important for resistance during infection344. A polysaccharide deacetylase (CD630_27190) also 
displayed a significant reduction in enrichment on competition; it is likely that CD630_27190 helps 
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In-gel fluorescence 
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Strain: 
Plasmid: 
25 µM Lipid Analogue: 
 166 
maintain the intrinsically high deacetlyation of the C. difficile cell wall and consequently may play a 
key role in infection. Additionally, the enrichment of two lipoproteins involved in the degradation of 
nucleotide phosphates was significantly reduced. These were a putative nucleotide 
phosphodiesterase (CD630_06890) and a nucleotidase (CD630_01990). Their likely role is in the 
degradation of nucleotide phosphates prior to import however, pfam analysis revealed that the 
former lipoprotein also contains a PGA_cap domain345. PGA_cap containing proteins are involved in 
poly-γ-glutamate capsule biosynthesis; poly-γ-glutamate is a virulence factor and may protect 
bacteria from high salt concentrations. Finally, a thioredoxin (CD630_15070) was also identified as 
being significantly reduced on competition; this protein is conserved across a number of C. difficile 
strains and is involved in cellular redox homeostasis. 
A further two predicted lipoproteins were identified which showed a reduction in enrichment on 
competition with myristic acid but did not make the significance cut-off; SsuA2 (CD630_29890) and 
MetQ (CD630_14910). Both are ABC-type transporter solute-binding proteins and had 0.01≥ p ≤0.05 
(p= 0.018 and p= 0.023 respectively). It is likely that these are genuine lipoproteins and the lack of 
highly significant competition may result from variation in either expression or turnover rate, 
resulting in a higher variability in H/L and M/L ratios between the biological repeats. 
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Figure 76: A) A breakdown of all proteins which showed a significant reduction in enrichment on competition with a 5- and 
10-fold excess of myristic acid (p ≤0.01), by predicted function. An emphasis is placed on predicted lipoproteins; the majority 
are either ABC-type transporter solute-binding proteins (19) or putative (14) and uncharacterised proteins (4). B) A 
breakdown of the non-predicted hits that showed a significant reduction in enrichment on competition, by predicted cellular 
location (lipoP, SignalP and Phobius). C) A breakdown of the non-predicted proteins that showed a significant reduction in 
enrichment on competition, by annotated function. The data was analysed using MaxQuant and significance testing 
performed using Perseus; annotations were extracted from Uniprot, LipoP, SignalP and Phobius and charts were plotted 
using Microsoft Excel. 
Several proteins that were not predicted to be lipidated in the bioinformatic studies also showed a 
significant reduction in enrichment on competition with 50 and 100 µM myristic acid. There were 10 
of these, corresponding to 18 % of the significant proteins. This represents a considerable 
improvement over the direct comparisons between YnC12 and myristic acid, described in 
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Chapter 5.4.2, where 63 % of the proteins that passed the significance cut-off (p ≤0.01, 1-sample T-
test) were not predicted to be lipidated. 
This reduced the list of non-predicted hits to a number where the reason for their reduced 
enrichment could be rationalised and the possibility that they represented non-predicted or non-
canonical lipoproteins considered. The non-predicted hits were subjected to the bioinformatic 
verification applied to the ProSite hits in Chapter 2.1, and analysed with LipoP278, SignalP279 and 
Phobius280 to determine their predicted cellular location. 
 Of these non-predicted hits, 4 were predicted to have multiple transmembrane domains (Phobius), 
and one has one transmembrane domain; these were considered unlikely to be lipidated as there 
are no previous reports of bacterial transmembrane lipoproteins. It is possible that these proteins 
show compete-able enrichment as they are being pulled down in close association with a 
lipoprotein. The significant reduction in enrichment of a calcium transporting ABC-transporter 
ATPase (CD630_16370) which, as part of an ABC-type transport system would be expected to have a 
high affinity protein-protein interaction with a solute binding lipoprotein, reinforces this hypothesis. 
A further two of these proteins, CD630_14680 and CD630_19670 were predicted to have no 
transmembrane domains (Phobius) or a signal peptide (SignalP and LipoP) and are most likely 
cytosolic contaminants.  
A further two proteins were predicted to have a Type I signal peptide; these were RnfG 
(CD630_11390) and CD630_18710. RnfG is a member of the Rnf electron transport family and is 
known to be exported346, but there is no evidence for lipidation of RnfG; additionally, RnfG does not 
contain any cysteine residues. CD630_18710 has a predicted signal peptide and closer inspection 
revealed the presence of a potential poorly conserved lipobox, shown in Figure 77 (middle), which 
was not identified as such by the bioinformatic analysis. 
Finally, one of these 10 proteins, CD630_19300, was predicted to have a lipobox, which perfectly 
matched the consensus (Figure 77, bottom). CD603_19300 was not identified as a lipoprotein in the 
preliminary bioinformatic study due to the length of its signal peptide sequence. Both ProSite277 
motifs used require the charged region to be no longer than 13 amino acids from the N-terminus; 
the charged region of the signal peptide of CD630_19300 features multiple lysine residues and ends 
15 amino acids after the N-terminus. Further investigation of the lipidation state of these proteins is 
discussed in section 6.3. 
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Figure 77: The potential lipobox of CD630_1870 (middle) and CD630_19200 (bottom) is shown in comparison to the 
consensus sequence (top), highlighted in red. The -1 glycine and conserved +1 cysteine are present for CD630_18710, but 
the -2 and -3 positions (A21V) are non-consensus. CD630_19300 has a consensus lipobox. 
In comparison to the bioinformatic study, 46 of a potential 68 predicted lipoproteins were identified 
as being significantly out-competed by the natural lipid (p ≤0.01). This corresponds to 68 % of the 
predicted lipoproteome, representing an excellent level of coverage as not all of the predicted 
lipoproteins were expected to be expressed under the experimental conditions used. It is also 
possible that some of the predicted lipoproteins are false positives and not Lgt substrates. For 
example Cwp22 and Cwp27 were predicted to be lipoproteins, however, they were not identified in 
these experiments and are unlikely to be lipidated. The use of competition led to a dramatic 
improvement in the significant identification of lipoproteins over a direct comparison between 
YnC12 and myristic acid, as described in Chapter 5.4.2, for which 36 predicted lipoproteins were 
significantly enriched (p ≤0.01), corresponding to 53 % of the predicted lipoproteome. Additionally, 
the number of non-predicted proteins that were identified as significant (p ≤0.01) was much reduced 
by the use of competition, from 63 % to 18 %.  Despite this, the number of predicted lipoproteins 
identified was reduced when compared to the LFQ analysis (Chapter 5.4.2.1), for which 49 predicted 
lipoproteins had an EF ≥5 (72 % coverage).  This may be due to the increased complexity of sample, 
on combining the light medium and heavy labelled peptides, leading to a failure to detect or quantify 
lower abundance lipoproteins by LC-MS/MS. Despite this, the statistical confidence is considerably 
higher for those lipoproteins identified by competition and dimethyl labelling. 
6.2.2 Investigating Strains of Representative Ribotypes 
C. difficile 630 Δerm is widely used as a laboratory strain due to the relative ease with which genetic 
manipulation can be performed92a. However, as lipoproteins potentially play an important role in 
colonisation and infection the YnC12 tagged lipoproteome of C. difficile 630 was compared to a 
range of clinically relevant strains of different of ribotypes; a list of strains used in this study is given 
in Appendix A. Cultures of C. difficile of different ribotypes, in TY media, were treated with YnC12 to 
25 µM during early exponential growth (OD600 ≈0.30) and allowed to grow to stationary phase. 
Following lysis and fractionation the YnC12 tagged lipoproteome was ligated to AzTB by CuAAC and 
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differences in the lipoprotein labelling pattern visualised by SDS-PAGE and in-gel fluorescence 
analysis.  In general, the labelling pattern was similar between the strains (Figure 78 A); only the 
evolutionary divergent strain M120 (ribotype 078) showed a strikingly different labelling pattern, 
indicating a lack of conservation of lipoprotein primary sequences. Despite this, bioinformatic 
analysis (Chapter 2.1.3) indicates that the M120 lipoproteome is predicted to perform similar 
functions to that of 630 and R20291. A complete proteome for M120 is not available from Uniprot, 
complicating a proteomic analysis of the lipoproteome of this strain.  
The ribotype 027 strain R20291 also displayed a subtly different profile to 630 (Figure 78 A) and 
further analysis of this strain was of interest due to its “hypervirulence”. Ribotype 027 strains have 
been associated with a number of epidemic outbreaks of C. difficile, feature 234 new genes when 
compared to strain 630 and have acquired resistance to fluoroquinolone antibiotics, in addition to a 
truncation in the toxin regulatory tcdC gene resulting in de-repression of TcdA and TcdB281. A 
complete proteome for C. difficile R20291 is available from Uniprot. The lipoproteome of R20291 
was investigated by bioinformatic analysis (Chapter 2.1.2) and found to have some differences to the 
predicted lipoproteome of 630, including the identification of a metallo β-lactamase that may be 
involved in antibiotic resistance. Finally, a number of known lipoproteins were not predicted to 
lipidated in R20291, possibly due to misannotated start codons, and therefore determining whether 
they are Lgt substrates is important.  
 
Figure 78: A) The lipoproteome for a number of C. difficile strains of representative ribotypes; exponentially growing 
cultures were treated with 25 µM YnC12 and the labelling pattern visualised by SDS-PAGE and in-gel fluorescence analysis 
following lysis and CuAAC ligation to AzTB. Coomassie staining (total protein, bottom) is shown as a loading control. B) 
Competition between 10 µM YnC12 and a 5- and 10-fold excess of myristic acid, for C. difficile 630 Δerm and R20291. 
Cultures grown in the presence of 0, 50 or 100 µM myristic acid were treated with 10 µM YnC12 at an OD600 of 
approximately 0.3 and allowed to grow to stationary phase. The effectiveness of competition for R20291 was assessed by 
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SDS-PAGE and in-gel fluorescence, following lysis and CuAAC ligation of AzTB to the YnC12-tagged lipoproteins. Coomassie 
staining (total protein, bottom) is shown as a loading control. 
Prior to performing proteomic analysis the effectiveness of competition between 10 µM YnC12 and 
a 5- and 10-fold excess of myristic acid, as described for 630 Δerm in section 6.2.1, was investigated 
for C. difficile R20921. Overnight cultures of 630 Δerm and R20291 were diluted to an OD600 of 0.05 
and immediately treated with 0, 50 or 100 µM myristic acid; during early exponential growth 
(OD600 ≈0.30) all cultures were treated with 10 µM YnC12 and allowed to grow to stationary phase. 
Following lysis, fractionation and click chemistry to ligate the capture reagent AzTB competition was 
assessed by SDS-PAGE and in-gel fluorescence analysis. As shown in Figure 78 B, competition was 
comparable between the two strains, although fluorescent bands of similar MW competed 
differently, indicating differences in expression level or protein turnover of members of the 
lipoproteome between the strains.   
6.2.3 Profiling the C. difficile R20291 Lipoproteome 
Having demonstrated that competition between YnC12 and a 5- or 10-fold excess of myristic acid 
gave the expected result in C. difficile R20291, the competition experiment described in section 6.2.1 
was applied to R20291 in biological triplicate, as described above (section 6.2.1). The efficiency of 
competition and affinity enrichment was assessed by SDS-PAGE and in-gel fluorescence analysis, 
comparing between an aliquot of the pre-pull down samples and the supernatant from the beads. 
Coomassie staining was used to ensure the protein concentration was standardised across all 
samples (Figure 79). Following enrichment of the AzTB labelled lipoproteome and on-bead 
reduction, alkylation and tryptic digest the peptides were dimethyl labelled on StageTips336; the 
0 µM myristic acid treated samples were labelled with the light reagents, the 50 µM treated samples 
with the medium reagents and the 100 µM treated samples with the heavy reagents. The dimethyl 
labelled peptides were combined 1:1:1 and analysed by LC-MS/MS as described above.  
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Figure 79: The efficiency of affinity enrichment of the C. difficile R20291 lipoproteome was assessed by an in-gel 
fluorescence comparison between an aliquot of the samples before pull down (-) and the supernatant (S). The cultures were 
treated with 10 µM YnC12, in competition with 0, 50 or 100 µM myristic acid; this experiment was performed in biological 
triplicate. Coomassie staining (total protein, bottom) is shown as a loading control. 
A total of 110 proteins were quantified, with both M/L and H/L values, across the three biological 
repeats. Of these, 37 proteins were predicted to be lipoproteins by bioinformatic analysis. This is 
represented in Figure 80 A; predicted lipoproteins are coloured in red.  To identify proteins which 
showed a significant reduction in enrichment on competition with 50 µM and 100 µM myristic acid a 
multiple ANOVA significance test was performed, as described in section 6.2.1; the cut-off was set to 
p≤ 0.01 and S0 was set to zero. A total of 61 proteins showed a significant difference in enrichment 
on competition with an excess of myristic acid (Figure 80 B). However, enrichment of one of these 
proteins increased with increasing myristic acid concentration. This protein was annotated as a 
pyruvate carboxylase, Pyc (CDR20291_0010); its increased enrichment could be readily rationalised 
as it endogenously biotinylated. Pyc was pulled down in competition with the biotin labelled 
lipoproteins; reduction in enrichment of the labelled lipoproteome therefore led to an increase in 
Pyc enrichment. 
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Figure 80: A) Average (mean) relative enrichment of the proteins which were quantified in all three biological repeats from 
R20291, with values found for both the M/L and H/L samples. Predicted lipoproteins are shown in red; other proteins are 
coloured in grey. A total of 110 proteins were quantified of which 37 were predicted lipoproteins. B) All proteins which 
showed an ANOVA significant (p ≤0.01) reduction in enrichment on competition with an excess of myristic acid. Predicted 
lipoproteins are shown in red (35), other significant proteins in blue (26). RAW data was processed using MaxQuant and 
analysis and statistical testing performed in Perseus; graphs were plotted using Microsoft Excel. In both A and B the 50 µM 
value corresponds to log2 (Average Ratio M/L) and the 100 µM value to log2 (Average Ratio H/L). 
Of the 60 significant hits which showed a reduction in enrichment, 35 (57 %) were predicted to be 
lipoproteins (Chapter 2.1.2); a breakdown of their functions is shown in Figure 81 A. There were 
predominantly ABC-type transporter solute binding proteins (17) and putative lipoproteins (15) of 
unknown function. Among the ABC-type transporter solute binding proteins were the oligopeptide 
transporter OppA (CDR20291_0785), the ribose binding protein RbsB (CDR20291_0303), the 
molybdenum-specific solute binding protein ModA (CDR20291_0798) and the D-methionine specific 
solute-binding protein MetQ (CDR20291_1341); homologues for all of these proteins were identified 
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in 630 Δerm (section 6.2.1). The other 13 ABC-type transporter solute binding proteins are 
annotated as binders of iron, sugars and amino acids. 
Other predicted lipoproteins which were enriched at a significantly reduced level on competition 
with a 5- and 10-fold excess of myristic acid included a polysaccharide deacetlyase, CDR20291_2608, 
which is a direct homologue of that identified in C. difficile 630 Δerm, having 99.7 % sequence 
identity. A Thioredoxin, CDR20291_1355, homologous to that of C. difficile 630 Δerm, with 96.4 % 
sequence identity, was also identified. Finally a nucleotide phosphodiesterase (CDR20291_0616) was 
found; this is a direct homologue (99.7 % sequence identity) of the lipoprotein 
withphosphodiesterase function identified in 630 Δerm, CD630_06890 (section 6.2.1). 
A further 25 proteins (41 %) were not predicted to be lipidated in the bioinformatic study, but 
displayed a significant reduction in enrichment on competition between YnC12 and an excess of 
myristic acid. 5 of these (8 %) were direct homologues of predicted lipoproteins in C. difficile 630, as 
discussed in Chapter 2.2. These included the extracellular chaperones PrsA and PrsA2 
(CDR20291_3337 and CDR20291_1406, respectively) and the ABC-type transporter solute-binding 
lipoproteins SsuA (CDR20291_1333), AppA (CDR20291_2560) and CDR20291_2835. In all cases these 
were not predicted to be lipidated as the start codon has been incorrectly assigned to a methionine 
codon either in the hydrophobic region of the signal peptide sequence or upstream of the 
transcriptional start site in 630. Inspection of the upstream region reveals alternative start sites that 
would give Type II signal peptides highly homologous to those for the corresponding proteins in 
C. difficile 630 Δerm; this is confirmed by the presence of ribosome binding site-like elements 
upstream of the alternative start codons and is discussed further in section 6.4. This result serves to 
demonstrate the limitations of solely using bioinformatic tools for the identification of lipoproteins 
in Gram-positive bacteria and confirms that the chaperones PrsA and PrsA2 are lipidated in both 
C. difficile strains. 
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Figure 81: A) A breakdown of all R20291 proteins which showed a significant reduction in enrichment on competition 
between 10 µM YnC12 and a 5- and 10- fold excess of myristic acid (p ≤0.01), by predicted function. An emphasis is placed 
on predicted lipoproteins (red) and non-predicted proteins (blue) that are likely to be lipidated; the majority are either ABC-
type transporter solute-binding proteins (17 and 3) or putative lipoproteins (15). B) A breakdown of the non-predicted 
proteins that showed a significant reduction in enrichment on competition, by predicted cellular location (lipoP, SignalP and 
Phobius). C) A breakdown of the non-predicted proteins that showed a significant reduction in enrichment on competition, 
by annotated function; those that are likely to be lipidated are shown in red. The data was analysed using MaxQuant, 
significance testing performed using Perseus; annotations were extracted from Uniprot, LipoP, SignalP and Phobius and 
charts were plotted using Microsoft Excel. 
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Of the remaining 20 non-predicted proteins (33 %) two have multiple transmembrane domains and 
therefore are unlikely to be lipidated; the remaining proteins are either endogenously biotinylated 
or assumed to be abundant background proteins. It is possible that these showed significantly 
compete-able enrichment as they are being pulled down via a protein-protein interaction with a 
lipoprotein, or via a non-specific interaction with the enriched proteins or LTA, rather than by 
binding non-specifically to the beads. The number of non-predicted proteins was higher for R20291 
than 630 Δerm, this possibly reflects the fact that the enrichment conditions were optimised for 
630 Δerm. A breakdown of the non-predicted hits by function is given in Figure 81 C.  Overall this 
result demonstrates that the lipoproteome is highly conserved, both at a sequence level and 
functionally, between these C. difficile strains. 
6.3 Identifying Novel Lipoproteins in 630 Δerm 
6.3.1 Potential Novel Lipoproteins 
Of the 10 non-predicted hits identified for C. difficile 630 Δerm two proteins, CD630_18710 and 
CD630_19300, feature an N-terminal signal peptide sequence, which contains a potential lipobox 
and therefore warranted further investigation. As discussed in section 6.2.1, CD630_19300 features 
a Type II signal peptide with a consensus lipobox, but an unusually long charged region at the N-
terminus. This prevented detection by the ProSite277 motifs used to create an initial list of predicted 
lipoproteins, which require the charged region to be 13 amino acids or less in length (Chapter 2.1). 
CD630_18710 has a well-defined signal peptide sequence but the potential lipobox is poorly 
conserved (Figure 77). Additionally, CD630_18710 was detected in further proteomic experiments 
which will be described in the following chapter. These include a comparison between the 
lipoproteome of 630 Δerm and lgt::erm, where it was enriched at a significantly higher level from the 
wild type than from the lgt mutant and an analysis of lipoproteins shed into the media by lgt::erm 
(Chapter 7.2), where CD630_18710 was shed at a significantly increased rate by lgt::erm; taken 
together these results indicate that CD630_18710 is an Lgt substrate. However, for both 
CD630_19300 and CD630_18710 verification of lipidation was required. 
Overexpression of CD630_18710 and CD630_19300 would be expected to demonstrate whether 
these proteins were genuine Lgt substrates as, on metabolic tagging with YnC12, a fluorescent band 
of increased intensity would be observed by in-gel fluorescence in a 630 Δerm background, but not 
in an lgt::erm background. The addition of a C-terminal His6 tag would allow confirmation of 
expression in both strains.  
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A third non-predicted protein showed a significant decrease in enrichment on competition with an 
excess of myristic acid for both C. difficile 630 Δerm and R20291; this was RnfG (CD630_11390 and 
CDR20291_0975). RnfG from C. difficile 630 features an N-terminal signal peptide but does not 
contain a potential lipobox, nor any cysteine residues. It is possible that RnfG is lipidated in a non-
canonical manner, for example at a serine residue, or that RnfG is being enriched through a high 
affinity protein-protein interaction with an unidentified lipoprotein. In the former case 
overexpression with a C-terminal His6 tag would allow this to be demonstrated, while if the latter is 
true it would be possible to use the His6-tagged RnfG construct to enrich RnfG in complex with its 
binding partners and identify its associated lipoprotein. 
6.3.2 Investigation by Constitutive Expression 
To investigate the lipidation state of CD630_18710, CD630_19300 and RnfG (CD630_11390) 
plasmids derived from pMTL960 were created, containing the corresponding gene under the control 
of a constitutive promoter, pcwp258, with a C-terminal His6 tag. The genes were amplified from C. 
difficile 630 Δerm genomic DNA, using the primers detailed in Appendix A, which added a 5’ SacI and 
a 3’ XhoI restriction digest site to the product (Figure 82 A). The PCR products were doubly digested 
with SacI and XhoI, ligated into a vector backbone that featured a His6 sequence at the 3’ end of the 
XhoI site (provided by Dr Alexandra Shaw, Imperial College London) and transformed into 
Escherichia coli NEB 5α. The plasmids, referred to as pTMC004, pTMC005 and pTMC006, are for the 
constitutive expression of CD630_18710-His6, RnfG-His6 and CD630_19300-His6, respectively. 
Transformants were selected for by chloramphenicol resistance, the plasmids purified and 
confirmed by PRC analysis, using plasmid specific primers to amplify across the insert (Figure 82 B). 
The plasmids were sequenced before conjugation into C. difficile 630 Δerm and lgt::erm from E. coli 
CA434. Transconjugants were selected for growth on media containing thiamphenicol and 
cycloserine. 
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Figure 82: A) Cloning of plasmids for the constitutive expression of CD630_18710, CD630_19300 and rnfG. A)  Amplification 
of CD630_18710, CD630_19300 and rnfG. B) PCR confirmation for 4 unique transformants of pTMC004 (CD630_18710-His6) 
and pTMC005 (rnfG-His6) and for 6 unique transformants of pTMC006 (CD630_19300-His6); the original insert for this 
plasmid (pHAS005) is indicated by . Colony number 2, 3 and 4 of pTMC004, pTMC005 and pTMC006 respectively, were 
confirmed by sequencing and transformed into C. difficile. 
The expression and potential lipidation of CD630_18710, RnfG and CD630_19300 was then 
investigated; overnight cultures of 630 Δerm +pTMC004, +pTMC005 and +pTMC006 (respectively) 
and lgt::erm +pTMC004, +pTMC005 and +pTMC006 were sub-cultured to an OD600 of 0.05 in TY 
media and allowed to grow to an OD600 of 0.30; 630 Δerm and lgt::erm +pMTL960, the empty vector, 
were included as a negative control. All the cultures were all treated with YnC12 to 25 µM and 
allowed to grow for a total of 7 hours. The cultures were harvested, lysed and fractionated using the 
C. difficile specific endolysin; the YnC12 tagged lipoproteins in the insoluble sub-proteome were 
ligated to AzTB by CuAAC, The tagged lipoproteome was visualised by SDS-PAGE and in-gel 
fluorescence analysis, expression was confirmed by Western blotting to detect the His6 tag. An in-gel 
fluorescence band appeared at increased intensity in the 630 Δerm +pTMC004 samples, 
demonstrating that CD630_18710 is a lipidated by Lgt; the appearance of a double band by in-gel 
fluorescence implies that overexpression of the construct is overwhelming the lipoprotein 
biogenesis machinery in C. difficile and the upper band may correspond to lipidated CD630_18710-
His6 for which the signal peptide has not been cleaved. Western blotting with an anti-His6 antibody 
confirmed expression of the CD630_18710-His6 construct at the correct MW, 44.6 kDa, by both 
630 Δerm + pTMC004 and at a reduced level by lgt::erm + pTMC004 (Figure 83 A). 
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No in-gel fluorescence bands were observed to have increased intensity for either 
630 Δerm +pTMC005 or pTMC006. Western blotting indicated that CD630_19300-His6 (pTMC006, 
expected MW of 43.2 kDa) was not expressed at a detectible level by either 630 Δerm or lgt::erm. 
Although the lack of lipidation of RnfG-His6 was not unexpected, the construct was approximately 
the same MW as the His-tagged endolysin added during lysis347 (Figure 83 A), at 20.6 kDa. It was 
therefore difficult to be certain whether RnfG was expressed and this was further investigated using 
freeze-thaw lysis58 (Chapter 9.1.4.3). The experiment described above was repeated for the RnfG-
His6 expressing strains; the CD630_18710-His6 expressing strains were included as a positive control 
and 630 Δerm and lgt::erm + pMTL960 as a negative control. Following freeze-thaw lysis and CuAAC 
ligation to AzTB the potential lipid modification and expression of RnfG-His6 was assessed by in-gel 
fluorescence analysis and Western blotting (Figure 83 B). It was found that RnfG-His6 was not 
expressed at a detectible level by either 630 Δerm or lgt::erm. 
 
Figure 83: A) The YnC12/AzTB labelling pattern for C. difficile 630 Δerm and lgt::erm, expressing CD630_18710-His6 
(pTMC004), RnfG-His6 (pTMC005) and CD630_19300-His6 (pTMC006); the empty vector (pMTL960) was included as a 
negative control. Exponentially growing cultures were treated with 25 µM YnC12 and the labelling pattern visualised by 
SDS-PAGE and in-gel fluorescence analysis following enzymatic lysis with the C. difficile specific endolysin and CuAAC 
ligation to AzTB. Coomassie staining of a technical replicate of the gel, run using the same samples, (total protein, middle) is 
shown as a loading control and expression was assessed by anti-His Western blotting (bottom). CD630_18710-His6 is 
indicated by  and the His-tagged endolysin by . B) The expression and lipidation of RnfG-His6 (pTMC005) by 630 Δerm 
and lgt::erm was investigated by metabolic tagging and SDS-PAGE and Western blotting, following freeze-thaw lysis; 
630 Δerm and lgt::erm + pTMC004 was included as a positive control and 630 Δerm and lgt::erm + pMTL960 as a negative 
control. The CD630_18710-His6 construct is indicated by . No expression of the RnfG-His6 construct could be detected by 
Western blotting (bottom). Coomassie staining of a technical replicate of the gel, run using the same samples, (total 
protein, middle) is shown as a loading control. 
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As CD630_19300 features a Type II signal peptide it is possible that, when overexpressed, 
CD630_19300-His6 is secreted and shed into the supernatant; this may simply be due to the 
recombinant protein being poorly tolerated at the membrane.  Additionally,   CD630_18710-His6 was 
found at a considerably lower level in the insoluble proteome of lgt::erm (Figure 83 A and B). To 
investigate whether these constructs are being shed into the media, overnight cultures of 630 Δerm 
and lgt::erm +pMTL960, +pTMC004 and +pTMC006 in BHIS media were harvested, subjected to 
freeze-thaw lysis and fractionated into the soluble and insoluble sub-proteomes. The protein shed or 
secreted into the media was recovered by TCA precipitation and 10 µg of each sample separated by 
SDS-PAGE; the expression and location of CD630_18710-His6 and CD630_19300-His6 was assessed by 
Western blotting, as shown in Figure 84.  
The CD630_18710-His6 construct was expressed by both 630 Δerm and lgt::erm at a detectible level 
when Western blots of the two strains were exposed separately; the expression level in an lgt::erm 
background lower than that for 630 Δerm and when exposed together it was hard to detect the 
construct in lgt::erm +pTMC004 (Figure 83). In the 630 Δerm +pTMC004 samples the construct was 
not detected in the soluble sub-proteome, as anticipated for a membrane associated lipoprotein. 
However, it was found to be predominantly shed into the media after overnight growth, indicating 
that CD630_18710-His6 is not well tolerated at the membrane when overexpressed. Interestingly, 
when expressed in an lgt::erm background, the construct was predominantly found in the insoluble 
sub-proteome and was of a higher MW than when expressed from 630 Δerm +pTMC004. This can be 
explained as retention of the signal peptide sequence on inactivation of lgt, indicating that the 
lipoproteins biogenesis pathway is largely stepwise in C. difficile and lipidation by Lgt is required for 
recognition and cleavage by LspA or LspA2. Expression of the CD630_19300-His6 construct, which 
had an expected MW of 43.2 kDa, could not be detected in the samples from either 630 Δerm or 
lgt::erm, in any fraction (Figure 84). 
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Figure 84: The expression and localisation of the constructs CD630_18710-His6 (pTMC004) and CD630_19300-His6 
(pTMC006) was investigated for C. difficile 630 Δerm and lgt::erm. Overnight cultures of the corresponding strains in BHIS 
media were lysed by freeze-thaw treatment and fractionated into insoluble (Insol.) and soluble (Sol.) sub-proteomes. 
Additionally, proteins shed or secreted into the media were TCA precipitated (Media). The localisation of the constructs was 
investigated by SDS-PAGE and Western blotting with an anti-His6 antibody (bottom); Coomassie staining (total protein, top) 
is included as a loading control. 
These experiments have demonstrated that CD630_18710 is lipidated in an Lgt dependant manner 
however, RnfG-His6 and CD630_19300-His6 were not expressed at a detectible level from the cwp2 
promoter. Despite this, the CD630_19300-His6 and the RnfG-His6 constructs may be expressed at a 
low level when under the control of pcwp2 and therefore cannot be detected simultaneously by 
Western blotting when compared to the well expressed CD630_18710-His6 construct. The use of a 
tetracycline inducible promoter, pTet, in the place of pcwp2, would allow the expression level to be 
tuned by varying the concentration of anhydrotetracyline (ATc), enabling imaging of all three 
constructs in the same blot.  
6.3.3 Investigation by Inducible Expression 
To allow the inducible expression of C-terminal His6-tagged CD630_18710, CD630_19300 and RnfG 
(CD630_11390), a plasmid derived from pMTL960, which featured a tetracycline inducible promoter 
(ptet) and a His6 sequence the 3’ end of the XhoI site, was doubly digested with SacI and XhoI. The 
digested PCR products described in section 6.3.2 were ligated into the vector backbone (provided by 
Edward Couchman, Imperial College London) and transformed into E. coli NEB 5α. Transformants 
were selected for by resistance to chloramphenicol and the plasmids were purified and confirmed by 
restriction digest with SacI and XhoI, as shown in Figure 85. The plasmids, referred to a pTMC007, 
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pTMC008 and pTMC009 (for the inducible expression of CD630_18710-His6, RnfG-His6 and 
CD630_19300-His6, respectively), were sequenced and conjugated into C. difficile 630 Δerm and 
lgt::erm from E. coli CA434’s. In addition the empty vector, pASF85 (donated by Dr Amanda Fivian-
Hughes, Imperial College London), was conjugated into C. difficile 630 Δerm and lgt::erm as a 
negative control. Transconjugants were selected for by resistance to thiamphenicol and cycloserine. 
 
Figure 85: 6 unique transformants of pTMC007 (CD630_18710-His6), pTMC008 (rnfG-His6) and pTMC009 (CD630_19300-
His6) were confirmed by SacI and XhoI restriction digest; an unidentified band is indicated by . Colony numbers 1, 4 and 4 
of pTMC007, pTMC008 and pTMC009 respectively, were confirmed by sequencing and transformed into C. difficile 
630 Δerm and lgt::erm. 
Inducible expression of these constructs was initially investigated as follows; overnight cultures of 
c. difficile 630 Δerm and lgt::erm +pASF85, +pTMC007, +pTMC008 and +pTMC009 were sub-cultured 
to an OD600 0f 0.05 and allowed to grow to an OD600 of approximately 0.30. All cultures were then 
treated with YnC12 to 25 µM and ATc to a final concentration of 100 ng mL-1. The cultures were 
allowed to grow to stationary phase, harvested, lysed using the freeze-thaw protocol and the 
insoluble sub-proteome ligated to AzTB. Expression and lipidation was visualised by SDS-PAGE, in-gel 
fluorescence and Western blotting. 
As shown in Figure 86 A, CD630_18710-His6 was highly over expressed, with a clear band visible by 
in-gel fluorescence and Coomassie staining in the 630 Δerm +pTMC007 sample. The appearance of a 
further band at high MW was also observable by in-gel fluorescence analysis; Western blotting 
revealed that, in addition to the band at the expected MW corresponding to CD630_18710-His6, this 
high MW band was also CD630_18710-His6 and probably corresponds to a trimer. The 
CD630_18710-His6 construct was also observed for the lgt::erm +pTMC007 samples, by both in-gel 
fluorescence, Coomassie staining and Western blotting. It is probable, however, that 
CD630_18710-His6 is not lipidated in the absence of Lgt and instead the bands visible by in-gel 
fluorescence reflect background fluorescence due to the large amount of protein being expressed. 
Expression of RnfG-His6 or CD630_19300-His6 was not detectible by Western blot analysis at 
100 ng mL-1 of ATc, when expressed in either a 630 Δerm or lgt::erm background. 
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It was possible that the expression of the latter two constructs occurs at an extremely low level at an 
ATc concentration of 100 ng mL-1, preventing detection in comparison to CD630_18710-His6. 
Therefore the experiment described above was repeated, inducing the expression of all three 
constructs, and pASF85, in both a 630 Δerm and lgt::erm background with different concentrations 
of ATc. Expression of the CD630_18710-His6 construct was induced with 50 ng mL
-1 of ATc, while 
expression of RnfG-His6 and CD630_19300-His6 was induced with 500 ng mL
-1 of ATc. Induction and 
treatment with 25 µM YnC12 was performed at an OD600 of 0.30 and, following freeze-thaw lysis, 
fractionation and CuAAC ligation to AzTB, expression and lipidation of the constructs was visualised 
by in-gel fluorescence and Western blot analysis (Figure 86 B). Expression of CD630_18710-His6 was 
reduced, as anticipated, however a clear band corresponding to the construct and its multimers was 
visible in the 630 Δerm +pTMC007 sample by in-gel fluorescence. Western blotting with an anti-His6 
antibody confirmed the expression of this construct in both a 630 Δerm and lgt::erm background. 
However, expression of neither RnfG-His6 nor CD630_19300-His6 was detected by Western blot 
when inducing with 500 ng mL-1 of ATc (Figure 86 B).  
Despite the lack of Western blot detection of CD630_19300-His6 a faint band was visible by in-gel 
fluorescence in the 630 Δerm +pTMC009 samples, which was not present in the 630 Δerm +pASF85 
samples, at the correct MW for CD630_19300-His6 (Figure 86 A and B). As in-gel fluorescence is 
typically more sensitive than chemiluminescent detection it is possible that CD630_19300-His6 is 
expressed and lipidated at an extremely low level when induced with 500 ng mL-1 ATc. 
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Figure 86: A) The YnC12/AzTB labelling pattern for C. difficile 630 Δerm and lgt::erm, with the expression of CD630_18710-
His6 (pTMC007), RnfG-His6 (pTMC008) and CD630_19300-His6 (pTMC009) induced with 100 ng mL
-1
 of ATc; the empty 
vector (pASF85) was included as a negative control. Exponentially growing cultures were treated with 25 µM YnC12 and 
100 ng mL-
1 
ATc and the labelling pattern visualised by SDS-PAGE and in-gel fluorescence analysis following freeze-thaw 
lysis and CuAAC ligation to AzTB. Coomassie staining of a technical replicate of the gel, run using the same samples (total 
protein, middle) is shown as a loading control and expression was assessed by anti-His6 Western blotting (bottom). 
CD630_18710-His6 and its multimers are indicated by . B) The expression of CD630_18710-His6 (pTMC007), RnfG-His6 
(pTMC008) and CD630_19300-His6 (pTMC009) and the empty vector (pASF85), in both a C. difficile 630 Δerm and lgt::erm 
background, was induced with the concentration of ATc shown at an OD600 of 0.30. On induction the cultures were treated 
with 25 µM YnC12 and the labelling pattern visualised by SDS-PAGE and in-gel fluorescence analysis following freeze-thaw 
lysis and CuAAC ligation to AzTB. Coomassie staining of a technical replicate of the gel, run using the same samples (total 
protein, middle) is shown as a loading control and expression was assessed by anti-His6 Western blotting (bottom). 
CD630_18710-His6 and its multimers are indicated by ; the potential CD630_19300-His6 band is indicated by . 
As increasing the concentration of ATc above 500 ng mL-1 is toxic to C. difficile a final attempt to 
detect expression of RnfG-His6 and CD630_19300-His6 was performed by exposing each construct 
separately on cut membrane slices. This would rule out the possibility that the dominant 
CD630_18710-His6 band was causing fainter bands, corresponding to RnfG-His6 or CD630_19300-
His6, to fail to be detected. As before the samples were separated by SDS-PAGE, analysed by in-gel 
fluorescence and an anti-His6 Western blot performed. The membrane was then cut into four and 
each construct exposed separately, as shown in Figure 87. No expression of the RnfG-His6 construct 
(pTMC008) could be detected in either a 630 Δerm or lgt::erm background by in-gel fluorescence, 
Coomassie staining or Western blotting. A band at the correct MW for the CD630_19300-His6 
construct was visible by in-gel fluorescence for the 630 Δerm + pTMC009 sample,  however 
expression of this construct could not be detected by Coomassie staining or Western blotting with 
an anti-His6 antibody. 
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Figure 87: The samples used in Figure 86 B (CD630_18710-His6 (pTMC007), RnfG-His6 (pTMC008) and CD630_19300-His6 
(pTMC009) and the empty vector (pASF85) induced with the concentration of ATc shown, in both a C. difficile 630 Δerm and 
lgt::erm background) were separated by SDS-PAGE and lipidation of the constructs was visualised by in-gel fluorescence 
analysis. Expression of the constructs was assessed by Western blotting; the membrane was cut into four as shown and 
each construct exposed separately (bottom). Coomassie staining (total protein, middle) is shown as a loading control. 
CD630_18710-His6 is indicated by ; the potential CD630_19300-His6 band is indicated by . 
The experiments described in this section have demonstrated unambiguously that, despite its non-
consensus lipobox, CD630_18710 is tagged with YnC12 in an Lgt dependant manner and therefore is 
a lipoprotein. In contrast, the lipidation status of CD630_19300 is less certain; the CD630_19300-His6 
construct could not be detected by Western blotting with an anti-His6 antibody when expressed 
from either a constitutive or inducible promoter. However, when expression of CD630_19300-His6 
was induced with 500 ng mL-1 ATc in a 630 Δerm background a faint band at the corresponding MW 
was visible by in-gel fluorescence, which was not present in the 630 Δerm +pASF85 control. This 
result does not demonstrate unambiguously that CD630_19300 is a lipoprotein. None the less, the 
reduced enrichment of CD630_19300 on competition between YnC12 and an excess of myristic acid 
(section 6.2.1), combined with the fact it has a consensus lipobox, make it likely that CD630_19300 is 
a lipoprotein. As no expression of the RnfG-His6 construct was detected, whether an inducible or 
constitutive promoter was used, for either 630 Δerm or lgt::erm, it is impossible to be certain 
whether RnfG is a lipidated. However, as RnfG does not have a lipobox and there is no evidence of 
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RnfG being lipidated in other species it is probable that RnfG is not a lipoprotein and instead is being 
enriched through a high affinity interaction with an unidentified lipoprotein.  
6.4 Discussion 
Boersema and co-workers reported dimethyl labelling to be an effective quantification method274b, 
which has since been expanded for use with chemical proteomic strategies336. Dimethyl labelling has 
previously been utilised in C. difficile, in conjunction with transcriptomics, to study the regulation of 
protein expression by Spo0A337. In the previous chapter (5.4.1.1) the development of dimethyl 
labelling, in combination with metabolic tagging with YnC12, to quantify the lipoproteome of 
C. difficile 630 Δerm was reported. In this chapter, the use of these techniques to quantify 
competition between YnC12 and the natural lipid, myristic acid, for C. difficile 630 Δerm and R20291 
has been described. A number of non-predicted hits were identified and for 630 Δerm the lipidation 
by Lgt of CD630_18710 was verified by overexpression. 
Competition between YnC12 and a 5- and 10-fold excess of myristic acid, in combination with 
quantitative proteomic analysis, was used to create a high confidence profile of the lipoproteome of 
the reference strain C. difficile 630 Δerm (section 6.2.1). In total 46 predicted lipoproteins showed a 
significant reduction in enrichment (p ≤0.01) on competition with the natural lipid, including the 
adhesin CD3630_08730341. The main role of the C. difficile lipoproteome appears to be solute 
binding in ATP dependant nutrient import, with 20 ABC-type transporter solute-binding proteins 
identified; however, a significant proportion of the predicted lipoproteins identified (18, 39 %) are of 
unknown function. Finally, of the 10 non-predicted hits two featured a potential lipobox; 
CD630_18710 and CD630_19300. Overexpression with a C-terminal His6 tag, in both 630 Δerm and 
lgt::erm backgrounds, (section 6.3) has demonstrated that CD630_18710 is lipidated in an Lgt 
dependant manner. It was not possible to unambiguously demonstrate lipidation of CD630_19300, 
as detectible expression could not be achieved from either a constitutive (section 6.3.2) or inducible 
(section 6.3.3) promoter. Despite this, CD630_19300 features a perfect consensus lipobox and it is 
probable that it is a lipoprotein. 
The lipoproteome of a panel of C. difficile strains of representative ribotypes was qualitatively 
profiled by in-gel fluorescence analysis (section 6.2.2); for the majority of strains tested the YnC12 
tagging pattern was similar however, some differences were observed for the evolutionarily distant 
strain M120 and for the hypervirulent strain R20291. Quantification of the reduction in enrichment 
observed on competition between 10 µM YnC12 and a 5- and 10-fold excess of myristic acid was also 
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performed for C. difficile R20291. Although the enrichment of non-predicted proteins was higher for 
R20291 than 630 Δerm, possibly reflecting the fact that the competition experiments were 
optimised for 630 Δerm, a total of 35 predicted lipoproteins were significantly (p ≤0.01) reduced in 
enrichment on competition with an excess of myristic acid (section 6.2.3). Of these, the majority 
were either ABC-type transporter solute binding proteins (17), or putative lipoproteins (15). 
Additionally, a polysaccharide deacetylase, a thioredoxin and a nucleotide phosphodiesterase which 
have high homology to those found for C. difficile 630 Δerm were identified; the lipoproteome of 
C. difficile R20291 therefore appears to perform highly similar functions to that of 630 Δerm. 
Of the 25 non-predicted hits that were identified by competition, 5 were direct homologues of 
lipoproteins identified for 630 Δerm (section 6.2.1). These included the extracellular chaperones 
PrsA and PrsA2 and the ABC-type transporter solute-binding proteins SsuA, AppA and 
CDR20291_2835. In all cases the transcriptional start site had been misassigned when the R20291 
genome was annotated; for PrsA and PrsA2 this is shown in Chapter 2.2, in the case of AppA a 
potential methionine codon upstream of the homologous start site has been misassigned as the 
start codon, disguising the signal peptide sequence and preventing bioinformatic detection (Figure 
88 A). The translational start site was also misassigned for R20291 SsuA, as shown in in Figure 88 B, 
with a methionine residue within the Type II signal peptide sequence being wrongly assigned as the 
start codon; the annotated N-terminus lacks a charged region and therefore was not recognised by 
the bioinformatic methods used. The identification of these proteins which, as their homologues in 
C. difficile 630 are lipoproteins, are likely genuine Lgt substrates highlights the importance of 
biochemical validation of lipidation, rather than relying on bioinformatics prediction which has 
become the primary method for the identification of Gram-positive lipoproteins. 
 
Figure 88: A) An alignment of the annotated signal peptide regions, up to the lipobox +1 cysteine, of AppA from C. difficile 
630 and R20291; a potential methionine residue upstream of the start site in the R20291 genome has been wrongly 
assigned as the translational start site, preventing detection the Type II signal peptide by the bioinformatics tools used in 
Chapter 2.1. B) Alignment of the N-terminal sequences, up to the lipobox +1 cysteine, of SsuA from C. difficile 630 and 
R20291, including a translation of the 33 nucleotides upstream of R20291 ssuA. The annotated translational start site for 
R20291 indicated by . In both alignments identical residues are highlighted with a black background and the lipobox 
indicated in the consensus sequence by a yellow background; both alignments were generated in Geneious (ClustalW) and 
annotated using Chroma. 
>AppA C. difficile 630      ------------MKFKKLASLILVSSLMLTFTAC 
>AppA C. difficile R20291   MLNIILWRFYKNMKFKKLASLILVSSLMLTFTAC 
Consensus/80%               ............MKFKKLASLILVSSLMLTFTAC 
A 
>SsuA C. difficile 630     MIKRNKKILAVMTSLIMVLVGTVGC 
>SsuA C. difficile R20291  MIKRNKKILAVMTSLIMVLVGTVGC 
Consensus/80%              MIKRNKKILAVMTSLIMVLVGTVGC 
 
 
  
 
B 
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In this chapter the use of quantitative proteomics, coupled with metabolic tagging with YnC12, to 
create a profile of the lipoproteome of C. difficile 630 Δerm and R20291 has been described. As this 
methodology has previously only been applied to E. coli199, this represents the first use of metabolic 
tagging to profile of the lipoproteome of a Gram-positive bacterium. This technology has clear 
advantages over previously reported methods; quantification of the reduction of enrichment on 
competition between YnC12 and myristic acid using dimethyl labelling provides both identification 
and verification of lipidation. Additionally, statistical testing generated a higher confidence profile of 
the lipoproteome. Furthermore, both 630 Δerm and R20291 are toxicogenic strains, with R20291 
being referred to as “hypervirulent” (section 6.2.2), making this the first use of metabolic tagging to 
profile the lipoproteome of a bacterial human pathogen. 
In addition to providing a useful resource for those studying the surface proteome of C. difficile, the 
results described in this chapter pave the way for the investigation of the role of the C. difficile 
lipoproteome in other biological processes, including sporulation. In the following chapter the use of 
metabolic tagging and quantitative proteomic analysis to profile the lipoprotemes of several mutant 
strains derived from C. difficile 630 Δerm, including the lipoprotein biogenesis mutants, will be 
described. 
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Chapter 7: Proteomic Profiling of Mutant Strains of 
Clostridium difficile  
7.1 Introduction 
In the preceding chapter, dimethyl labelling based quantitative proteomics, in conjunction with 
competition between an alkyne-tagged analogue of myristic acid and the natural lipid, was used to 
produce a comprehensive proteomic profile of the lipoproteome for C. difficile 630 Δerm and the 
“hypervirulent” strain R20291. In this chapter, the application of quantitative proteomics to a range 
of mutant strains of C. difficile is described. This research focussed on the use of dimethyl labelling to 
gain a quantitative insight into the effect of inactivation of lgt, lspA and lspA2 on the C. difficile 
lipoproteome and to quantify the proteins shed into the media by these strains, relative to the wild 
type. Additionally, the lipoproteome of mutant strains in which the transcriptional regulators spo0A 
and codY have been insertionally inactivated were studied, to investigate the role of lipoproteins in 
sporulation and starvation response respectively. 
7.2 Profiling the Lipoprotein Biogenesis Pathway Mutants 
The effect of genetic and chemical inactivation of lgt, lspA and lspA2 on lipoprotein biogenesis has 
been qualitatively investigated by metabolic tagging and in-gel fluorescence, as described in 
Chapter 4.3. This demonstrated that Lgt is required for lipidation in C. difficile 630 Δerm and 
provided evidence for the activity of both Lsps. Quantitative proteomic analysis of the lipoproteome 
of 630 Δerm lgt::erm in comparison to the parental strain would provide further validation that the 
lipoproteins identified by competition are Lgt substrates. Additionally, the identification of proteins 
that are lipidated independently of Lgt may be possible. The selectivity between LspA and LspA2 also 
requires further investigation; changes to in-gel fluorescent band patterns on inactivation of lspA 
and lspA2 are proposed to be due to retention of Type II signal peptides, rather than changes in 
lipoprotein expression, and quantitative proteomic analysis is required to demonstrate this. 
The lipoprotein biogenesis mutants were observed to shed proteins into the media at an increased 
rate quantification of this and identification of the shed proteins is of interest.  This would be 
expected to confirm whether they are lipoproteins and to provide further evidence for the increased 
toxin production by these strains. Finally, analysis of the global proteome of all three strains is 
required to confirm that the changes in in-gel fluorescence pattern reflect changes in lipidation state 
or cleavage of the signal peptide and are not related to changes in lipoprotein expression level. 
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7.2.1 Comparison between 630 Δerm and lgt::erm 
In-gel fluorescence analysis of the lgt mutant of C. difficile 630 Δerm, lgt::erm, revealed that it is 
lipidation deficient (Chapter 4.3.1.2) and it has been demonstrated to be an appropriate negative 
control by LFQ proteomic analysis (Chapter 5.2.2). Therefore, to validate the lipoproteins identified 
by competition between YnC12 and myristic acid and to quantify the effect of inactivation of lgt on 
lipidation in C. difficile, lgt::erm was compared to the parental strain using duplex dimethyl labelling. 
Overnight cultures of 630 Δerm and lgt::erm, in biological triplicate, were subcultured to an OD600 of 
0.05 in TY media and allowed to grow to early exponential phase. At an OD600 of approximately 0.30 
the cultures were treated with 25 µM YnC12 and allowed to grow to stationary phase, over a total of 
7 hours. The cells were lysed, fractionated and 200 µg of the insoluble sub-proteome ligated to AzTB 
by CuAAC. The labelled lipoproteome was affinity enriched on NeutrAvidin agarose beads and the 
efficiency of pull down assessed by comparison between an aliquot of the samples before pull down 
and the supernatant from the beads (Figure 89 A). The enriched lipoproteins were then subjected to 
on-bead reduction, alkylation and tryptic digest. The peptides were desalted and dimethyl labelled 
on StageTips336; the lgt::erm samples were labelled with light reagents and the 630 Δerm samples 
with the medium reagents. The samples were combined 1:1 and the differences in the enriched 
lipoproteome quantified by LC-MS/MS analysis. 
 
Figure 89: The efficiency of affinity enrichment of YnC12 tagged proteins from 630 Δerm and lgt::erm was assessed by an in-
gel fluorescence comparison between an aliquot of the samples before pull down (-) and the supernatant (S). The cultures 
were treated with 25 µM YnC12; this experiment was performed in biological triplicate. Coomassie staining (total protein, 
bottom) is shown as a loading control. 
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A total of 210 proteins were quantified in all 3 biological repeats, with predicted lipoproteins 
clustered at a high H/L ratio (Δerm/ lgt::erm), indicating that they are lipidated in 630 Δerm, but not 
in the lgt mutant (Figure 89 B). A total of 45 predicted lipoproteins were quantified in this 
experiment and 9 of the non-predicted hits from the competition experiment described in Chapter 
6.2.1 were also quantified. To assess the significance of the difference in enrichment observed 
between 630 Δerm and lgt::erm a one-sample T-test was performed, with the value to test against 
set to zero, corresponding to no change between the samples; the p-value cut off was set as p ≤0.05. 
 
Figure 90: A) A scatter plot of all quantified proteins for a comparison between 630 Δerm (M) and lgt::erm (L), plotting the 
average log2 (Ratio M/L) (Δerm/ lgt::erm) against the significance (-log10 T-test P Value); the significance cut-off was set to 
p= 0.05. The non-predicted lipoprotein CD630_18710 was significantly enriched from the 630 Δerm samples relative to 
lgt::erm and is indicated by . Predicted lipoproteins (shown in red) have a higher log2 (Ratio M/L) distribution than the 
other proteins (grey) and are significantly enriched in 630 Δerm over lgt::erm. The non-predicted hits (blue) are more varied. 
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B) A breakdown of all proteins that displayed a significant (T-test) difference in enrichment by function; emphasis is placed 
on predicted lipoproteins. The data was processed using MaxQuant and statistical analysis performed using Perseus, charts 
were plotted in Microsoft Excel. 
Of the 210 proteins quantified, 53 showed a significant change in enrichment between the 630 Δerm 
and lgt::erm samples (p ≤0.05); of these 10 had significantly increased enrichment in the lgt mutant 
with a log2 (Average Ratio M/L) less than zero. Of the remaining 43, which showed significantly 
increased enrichment in 630 Δerm over lgt::erm, 41 were predicted lipoproteins and one was the 
non-predicted lipoprotein, CD603_18710. All but one of the predicted lipoproteins that were 
significantly enriched in 630 Δerm when compared to lgt::erm, MetQ (CD630_14910), showed a 
significant reduction in enrichment on competition between YnC12 and an excess of myristic acid 
(Chapter 6.2.1); this further validates the use of myristic acid as a control. The annotated functions 
of all proteins that were enriched at a significantly differently level (p ≤0.05) between 630 Δerm and 
lgt::erm is given in Figure 90 B, with an emphasis on predicted lipoproteins. The background 
enrichment was reduced in this comparison, when compared to the competition experiment; 
although 12 non-predicted proteins showed a significant difference in enrichment only two of these 
displayed an increased enrichment in 630 Δerm over lgt::erm, of which CD630_18710 had been 
demonstrated to be a lipoprotein (Chapter 6.3).  
CD603_18710 was significantly enriched in 630 Δerm over lgt::erm (p≤0.05) and clustered with the 
predicted lipoproteins (Figure 90 A), providing further evidence that CD630_18710 is an Lgt 
substrate. The other lipobox containing non-predicted hit, CD630_19300, was identified but not 
quantified in all three repeats and therefore excluded from the analysis (data not shown). The only 
other protein that was enriched at an increased level from 630 Δerm relative to lgt::erm was 
CD630_08280, a putative oxidative stress glutamate synthase. The remaining 10 significant proteins 
all showed higher enrichment in the lgt mutant over Δerm and therefore are likely to be binding 
directly to the beads in a non-specific manner, which is reduced by the binding of YnC12 tagged 
lipoproteins in the 630 Δerm samples. None of these proteins are annotated as being biotinylated or 
binding biotin as a cofactor. This result provides further validation for the proteins identified by 
competition with myristic acid; their enrichment is reduced in in lgt::erm; therefore they are tagged 
by YnC12 in an Lgt dependent manner and are canonical lipoproteins. 
7.2.2 Comparison between 630 Δerm, lspA::erm and lspA2::erm 
In Chapter 4.3.1.2 a qualitative study of the Lsp mutants, lspA::erm and lspA2::erm, was performed 
using in-gel fluorescence as the output. A number of fluorescent bands appeared to have a higher 
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MW and it was inferred that this was due to retention of the Type II signal peptide on genetic or 
chemical inactivation of the Lsps. However, to confirm that this is the reason for the shifts in 
labelling pattern, rather than a perturbation in lipoprotein expression, a quantitative proteomic 
comparison between the lspA mutants and the parental strain, 630 Δerm was essential. Overnight 
cultures of C. difficile 630 Δerm, lspA::erm and lspA2::erm, in biological triplicate, were sub-cultured 
to an OD600 of 0.05 and treated with 25 µM YnC12 during early exponential phase, at an OD600 of 
approximately 0.30. The cultures were allowed to grow to stationary phase over a total of 7 hours 30 
minutes, lysed and fractionated. The insoluble sub-proteome (200 µg) was subjected to CuAAC 
ligation with AzTB and the labelled lipoproteome affinity enriched on NeutrAvidin agarose beads. 
The efficiency of pull down was assessed by comparison between an aliquot of the clicked sample 
before pull down and the supernatant from the beads (Figure 91). The enriched lipoproteins were 
then reduced, alkylated and digested with trypsin on-bead. The peptides desalted and dimethyl 
labelled on StageTips336. The 630 Δerm, lspA::erm, and lspA2::erm samples were labelled with the 
light, medium and heavy reagents, respectively. The samples were combined 1:1:1 and the 
differences in the enriched lipoproteomes quantified by LC-MS/MS analysis.  
 
Figure 91: The efficiency of affinity enrichment of YnC12 tagged proteins from 630 Δerm, lspA::erm and lspA2::erm was 
assessed by comparison between an aliquot of the samples before pull down (-) and the supernatant (S), visualised by 
SDS-PAGE and  in-gel fluorescence analysis. The cultures were treated with 25 µM YnC12; this experiment was performed in 
biological triplicate. Coomassie staining (total protein, bottom) is shown as a loading control. 
In total, 208 proteins were quantified with M/L and H/L values in all three samples (6 valid values); 
of these 46 were predicted lipoproteins and a further 9 were non-predicted hits identified by 
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competition, as shown in Figure 92 A. To investigate whether the differential enrichment of any of 
these proteins was significant, a one-sample T-test was performed for both the M/L and H/L values 
(lspA::erm and lspA2::erm, respectively); the p-value cut-off was set to p ≤0.01. Each Lsp sample set 
was tested individually against a value of zero, which represents no change between the mutant and 
the parental strain. 
As shown in Figure 92 B, relatively few of the predicted lipoproteins quantified showed a significant 
change in enrichment (p ≤0.01), allowing confidence that the changes in the in-gel fluorescence 
band pattern (Chapter 4.3.1.2) are due to retention of Type II signal peptides. Notably, only the ABC-
transport solute binding protein SsuA (CD630_14840) showed a significantly altered enrichment for 
lspA::erm, which showed the most obviously altered labelling pattern by in-gel fluorescence. The 
enrichment of SsuA was also significantly reduced for lspA2::erm and a further 5 proteins showed 
significant changes to enrichment level in lspA2::erm (Figure 92 B, green). However, in the majority 
of cases this was a less than 2 fold change and few corresponding band shifts were detected by in-
gel fluorescence. 
Finally, to assess whether there were any differences in enrichment between lspA::erm and 
lspA2::erm a two-sample T-test was performed; the p-value cut-off was set to p ≤0.01. Only three 
predicted lipoproteins showed a significant difference in enrichment between the two mutants, 
indicating that changes in lipoprotein expression level between these strains are limited. This 
supports the hypothesis that retention of the Type II signal peptide is the major cause of the altered 
labelling pattern observed by in-gel fluorescence. 
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Figure 92: A) The average (mean) relative enrichment for all proteins that were quantified the comparison between 
630 Δerm, lspA::erm and lspA2::erm, in all three biological repeats, with for both M/L and H/L values found. Predicted 
lipoproteins are shown in red and non-predicted hits in blue; other proteins are coloured in grey. A total of 208 proteins 
were quantified of which 46 were predicted lipoproteins and a futher 9 were non-predicted hits. B) The average (mean) 
relative enrichment for the predicted lipoproteins; predicted lipoproteins which were not significantly (one-sample T-test, 
p ≤0.01) different between the strains are shown in red. SsuA showed a significant reduction in enrichment for both 
lspA::erm and lspA2::erm, in comparison to Δerm (shown in dark blue). Five other proteins showed a significantly different 
enrichment for lspA2::erm, relative to 630 Δerm, shown in green. RAW data was processed using MaxQuant and analysis 
and statistical testing performed in Perseus; graphs were plotted using Microsoft Excel. In both A and B the lspA::erm value 
corresponds to log2 (Average Ratio M/L) and the lspA2::erm value to log2 (Average Ratio H/L); a 630 Δerm value (L/L, zero 
by default) was added for comparison but not used for significance testing. 
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7.2.3 Quantification of Proteins Shed into the Media 
Increased shedding of lipoproteins into the media on the inactivation or deletion of lgt has 
previously been reported158. This phenotype has been capitalised on to study lipoproteins in Listeria 
monocytogenes129 and Streptococcus pneumoniae197, following precipitation of the shed lipoproteins 
from culture supernatants and identification by MS/MS analysis. As discussed in Chapter 4.4.1, 
C. difficile lgt::erm, lspA::erm and lspA2::erm all display increased shedding of proteins, including 
SLPs, into the media. Therefore, a proteomic comparison of the shed and secreted proteins between 
630 Δerm and the lipoprotein biogenesis mutants was performed, to investigate whether the 
majority of these shed proteins were lipoproteins. Additionally, the increased secretion of TcdA and 
TcdB observed for lspA::erm and lspA2::erm could be confirmed by proteomic detection and 
quantififcation. To investigate this, cultures of 630 Δerm, lgt::erm, lspA::erm and lspA2::erm in BHIS 
broth were grown overnight to stationary phase, in biological triplicate. The bacteria were harvested 
by centrifugation and the supernatant isolated. Proteins shed into the culture supernatants were 
TCA precipitated and re-suspended to 400 OD600 equivalents. The increased shedding of protein into 
the media was visualised by SDS-PAGE and Coomassie staining, with the samples standardised either 
by bacterial cell density (OD600) or protein concentration (Figure 93). 
For proteomic analysis 25 µg of each sample was reduced, alkylated and digested with trypsin in-
solution. The peptides were desalted on StageTips, re-suspended in 100 mM TEAB, pH 7, and 
dimethyl labelled in solution following the method reported by Boersema and co-workers274b. The 
630 Δerm samples were dimethyl labelled with the light reagents, lgt::erm and lspA::erm with 
medium reagents and lspA2::erm with heavy reagents. Following in-solution dimethyl labelling, the 
630 Δerm and lgt::erm samples were mixed 1:1 and analysed as a duplex experiment and the same 
630 Δerm samples were mixed 1:1:1 with lspA::erm and lspA2::erm samples and analysed as a triplex 
experiment. The combined samples were desalted on StageTips prior to LC-MS/MS analysis. 
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Figure 93: A) Proteins shed or secreted into the media by the parental strain, 630 Δerm, and the lipoprotein biogenesis 
mutants, lgt::erm, lspA::erm and lspA2::erm, for three biological repeats, visualised by SDS-PAGE and Coomassie staining. 
Samples standardised by bacterial cell density (30 OD600 mL
-1
; 10 µL per lane). B) Proteins shed or secreted into the media 
by the parental strain and the lipoprotein biogenesis mutants, for three biological repeats; visualised by SDS-PAGE and 
Coomassie staining. Samples standardised by protein concentration to 1 mg mL
-1
; 10 µg per lane.  
A total of 164 proteins were quantified in all three biological repeats when comparing the 
supernatant proteome of lgt::erm to 630 Δerm, 28 of these were predicted lipoproteins; this is a 
considerably reduced rate of identification when compared to the use of YnC12 tagging to study 
lgt::erm (section 7.2.1), demonstrating superior detection of lipoproteins by metabolic tagging, 
compared to traditional techniques. As anticipated, based on the previously reported effects of lgt 
inactivation in other species, predicted lipoproteins were shed at an increased level by the lgt 
mutant over the parental strain (high H/L ratio), as shown in Figure 94 A. 
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Figure 94: A) A scatter plot of all quantified proteins shed or secreted into the media by 630 Δerm (L) and lgt::erm (H), 
comparing the average log2 (Ratio H/L) (corresponding to lgt::erm/ Δerm) to the significance (-log10 T-test P Value). The 
significance cut-off was set to p= 0.05. The non-predicted lipoprotein CD630_18710 was the only significantly enriched non-
predicted hit (blue). Predicted lipoproteins (shown in red) have a higher log2 (Ratio H/L) distribution than other proteins 
(grey) and are shed at a significantly higher level by lgt::erm when compared to 630 Δerm. B) A breakdown of all proteins 
that displayed a significant (T-test) difference in shedding or secretion by function; emphasis is placed on predicted 
lipoproteins. The data was processed using MaxQuant and statistical analysis performed using Perseus, charts were plotted 
in Microsoft Excel. 
The significance of these shed proteins was assessed by a one-sample T-test; the p-value cut-off was 
set to p ≤0.05. A total of 28 proteins were shed at a significantly different level; the majority of the 
predicted lipoproteins quantified were T-test significant (22) and all were shed at an increased level 
in the lgt mutant (high H/L ratio). Of the predicted lipoproteins shed at a significantly increased level 
by lgt::erm the majority (15) were ABC-type transport system solute-binding proteins or putative (5) 
and uncharacterised (1) lipoproteins. Additionally PrsA (CD630_35000) was shed at a significantly 
increased level by lgt::erm, when compared to the parental strain. A non-predicted hit from the 
competition experiment, CD630_18710, was also shed in significantly higher amounts by lgt::erm 
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than by 630 Δerm, providing further confirmation that the lipidation demonstrated in Chapter 6.2.1 
occurs in an Lgt dependant manner. The only other protein that was shed at a significantly increased 
level by lgt::erm, when compared to 630 Δerm was Cwp6 (CD630_27840), an 
N-acetylmuramoyl-L-alanine amidase annotated as a putative autolysin. Although Cwp6 does not 
contain a lipobox (lipoP) and therefore is unlikely to be lipidated, the increased shedding of the is 
protein by lgt::erm is not unexpected in light of the increased shedding of cell wall proteins 
discussed in Chapter 4.4.1.  
The remaining 4 proteins that were shed significantly differently between the two strains were all 
shed at an increased level by 630 Δerm, when compared to lgt::erm. These are the ribosomal protein 
RpsH (CD630_00850), a rubrerythrin Rbr (CD630_08250), a rubredoxin oxidoreductase Rbo 
(CD630_08270) and a putative oxidative stress glutamate synthase (CD630_08280). The increased 
secretion of the latter three, which may exist in an operon, is possibly due to an increased oxidative 
stress response by the 630 Δerm samples, which may be the result of exposure to the atmosphere 
during sample preparation for a prolonged period relative to the lgt::erm samples. The functions of 
all proteins that were significantly differently shed, or secreted, between the two strains are shown 
in Figure 94 B. 
When comparing the supernatant proteome of lspA::erm and lspA2::erm to 630 Δerm, 222 proteins 
were quantified with both M/L and H/L values, in all three biological repeats. Many fewer predicted 
lipoproteins were identified when comparing lspA::erm and lspA2::erm to the parental strain, with 
only 11 predicted lipoproteins being quantified. To investigate the significance of these shed 
proteins a one-sample T-test was performed; the p-value cut-off was set to p ≤0.05. A scatter plot of 
all quantified proteins shed or secreted into the media, distributed by the log2 (H/L) or (M/L) ratio 
and -log10 (T-test p Value) is shown in Figure 95 A for lspA::erm and Figure 95 B for lspA2::erm, both 
relative to 630 Δerm. 
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Figure 95: A) A scatter plot of all quantified proteins shed or secreted into the media by 630  Δerm (L) and LspA::erm (M), 
comparing the log2 (Average Ratio M/L) (corresponding to lspA::erm/ 630 Δerm) to the significance (-log10 T-test P Value). 
The significance cut-off was set to p= 0.05. Predicted lipoproteins are shown in red, non-predicted hits are shown in blue 
and other proteins are shown in grey. CD630_35280 is indicated by , CD630_00650 is indicated by  and TcdA is 
indicated by . B) A scatter plot of all quantified proteins shed or secreted into the media by 630  Δerm (L) and LspA2::erm 
(H), comparing the log2 (Average Ratio H/L) (corresponding to lspA2::erm/ Δerm) to the significance (-log10 T-test p Value). 
The significance cut-off was set to p= 0.05. Predicted lipoproteins are shown in red, non-predicted hits are shown in blue 
and other proteins are shown in grey. TcdA is indicated by  and CD630_00650 is indicated by . The data was processed 
using MaxQuant and statistical analysis performed using Perseus, charts were plotted in Microsoft Excel.
The majority of the predicted lipoproteins quantified for lspA::erm and lspA2::erm were shed at a 
lower level in the mutant strain than in 630 Δerm, however this was not significantly different to the 
wild type. No lipoproteins were shed at a significantly reduced level when comparing lspA::erm to 
the parental strain. However, CD630_35280, an ABC-type transporter solute-binding protein, was 
shed at a significantly increased level by the mutant strain, as indicated in Figure 95 A. When 
comparing lspA2::erm to 630 Δerm significantly higher amounts of the ABC-type transport system 
solute-binding proteins AppA (CD630_26720, p ≤0.05), CD630_23650 and CD630_21770 (both 
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p ≤0.005) were shed by the parental strain, raising the possibility that these proteins may be 
retained at the membrane by their signal peptide in the lspA2::erm mutant and represent unique 
substrates of LspA2. A non-predicted hit, RnfG (CD630_11390), was shed at a significantly higher 
level by 630 Δerm than by either lsp mutant. 
The proteins shed in increased amounts by the lspA and lspA2 mutants than in 630 Δerm included a 
number of oxidoreductases and electron transport proteins, as well as oxidative stress proteins and 
heat shock proteins, indicating that these strains are stressed. However, in common with the 
analysis of the lgt::erm culture supernatant, a rubrerythrin Rbr (CD630_08250), a rubredoxin 
oxidoreductase Rbo (CD630_08270) and a putative oxidative stress glutamate synthase 
(CD630_08280) were all shed in significantly reduced amounts by both lsp mutants, relative to 
630 Δerm. In both lspA::erm and lspA2::erm the amount of Toxin A (TcdA) secreted into the media by 
lspA::erm and lspA2::erm was significantly higher than that secreted by 630 Δerm (p ≤0.05), at 
approximately 2-fold and 2.4-fold respectively. This confirmed the increase in TcdA secretion 
observed by quantitative Toxin ELISA (Chapter 4.4.2). Finally, CD630_00650, a NADP-dependent 
deshydrogenase, was shed in significantly increased (p ≤0.005) amounts by both lspA::erm and 
lspA2::erm, at a 5.3-fold level in both cases, relative to the wild type. Additionally, ProC 
(CD630_32810) and PflD (CD630_32820), a pyrroline-5-carboxylate reductase and a pyruvate 
formate-lyase, were shed at a significantly increased (p ≤0.005) level by lspA::erm, with 6.4 and 10.3 
times the amount shed by 630 Δerm being shed into the media respectively. These proteins are 
encoded by adjacent genes and may be co-transcribed; there was no difference in the shedding of 
ProC or PflD when lspA2::erm was compared to the parental strain.  
7.2.4 Analysis of the Global Proteome of lgt::erm, lspA::erm and lspA2::erm 
Finally, to confirm that changes in the lipoprotome visualised and quantified for the lipoprotein 
biogenesis mutants (Chapter Chapter 4: and section 7.2) were due to changes in PTM, not 
expression level, the global proteomes of lgt::erm, lspA::erm and lspA2::erm were compared to the 
parental strain, 630 Δerm.  Additionally, this would allow investigation of changes to global protein 
expression and provide a biochemical insight into the phenotypes described in Chapter 4.4. 
Cultures of C. difficile 630 Δerm, lgt::erm, lspA::erm and lspA2::erm, in biological triplicate, were 
grown overnight in TY media. The cultures were harvested and the bacteria lysed, fractionated and 
the global proteome visualised by SDS-PAGE, shown in Figure 96. For all three biological repeats 
25 µg of both the soluble and insoluble sub-proteomes were reduced, alkylated and digested with 
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trypsin. The peptide mixtures were desalted and dimethyl labelled on StageTips; the 630 Δerm 
samples were labelled with the light reagents, the lgt::erm and lspA::erm samples were labelled with 
the medium reagents and the lspA2::erm samples were labelled with the heavy reagents. The 
dimethyl labelled peptides were combined 1:1 (630 Δerm and lgt::erm) and 1:1:1 (630 Δerm, 
lspA::erm and lspA2::erm); the same 630 Δerm sample was used for both combinations, enabling the 
ratios found for lgt::erm to be compared to those found for lspA::erm and lspA2::erm. 
 
Figure 96: The global proteome of C. difficile 630 Δerm and the lipoprotein biogenesis mutants, lgt::erm, lspA::erm and 
lspA2::erm, fractionated into the soluble (S) and insoluble (I) sub-proteomes, for three biological repeats. The proteins 
concentration was confirmed and changes to the global proteome visualised by SDS-PAGE and Coomassie staining. Samples 
were standardised by protein concentration to 1 mg mL
-1
; 10 µg per lane. 
When comparing lgt::erm to the parental strain, 630 Δerm, a total of 476 proteins were quantified in 
the insoluble sub-proteome and 432 proteins were quantified in the soluble sub-proteome; in both 
cases these proteins were quantified in all three biological repeats. A total of 673 unique proteins 
were quantified in either fraction, with 234 proteins being quantified in both fractions. In the 
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insoluble fraction 10 predicted lipoproteins and 7 non-predicted hits identified by competition were 
quantified. As shown in Figure 97 A, the predicted lipoproteins were all found in reduced amounts in 
the lgt::erm insoluble sub-proteome than in the parental strain. It is likely, however, that this does 
not reflect a difference in lipoprotein expression between the strains and instead is a result of the 
increased shedding of lipoproteins by lgt::erm, as demonstrated in section 7.2.3. The other proteins 
that were found at a very low M/L ratio were a rubrerythrin, CD630_08250, (26 fold decrease, 
p ≤0.01) and a putative oxidative stress glutamate synthetase, CD630_08280, (24 fold decrease, 
p ≤0.01). Two uncharacterised proteins, CD630_13460 and CD630_13470 showed significantly 
increased expression in the lgt mutant (11 and 29 fold, p ≤0.05). These proteins are adjacent to each 
other on the genome and pfam analysis reveals that they contain conserved bacterial domains of 
unknown function and transmembrane regions, but does not provide any insight into their function. 
The other proteins which passed the p ≤0.05 significance cut-off typically had a less than 2-fold 
average difference in expression between the strains. 
In the soluble (cytosolic) fraction 7 predicted lipoproteins were identified; the detection of 
lipoproteins in the soluble fraction is due to carry over from the insoluble sub-proteome on 
fractionation (Chapter 3.2.2). Two of these lipoproteins showed a significantly (p ≤0.05) different 
level between the two strains, with SsuA (CD630_14840) showing reduced expression and 
CD630_23650 showing increased expression. However, in both cases this was a small (less than 
2-fold) change. None of the non-predicted hits identified by competition were quantified in the 
soluble fraction.  
The expression of TcdA was significantly (p =0.02) decreased in the soluble proteome (Figure 97 B). 
This observation was surprising as the level of TcdA secreted into the media was not significantly 
different between 630 Δerm and lgt::erm when assessed by quantitative ELISA (Chapter 4.4.2). 
However, only a small (2-fold) reduction was observed by quantitative proteomic analysis. Cwp6 
(CD630_27840) was found to have highly significant increase in expression in the soluble fraction, 
with a 3.5-fold increase observed (p ≤0.005). Cwp6 is an S-layer protein with 
N-acetylmuramoyl-L-alanine amidase function and was also found to be shed at a significantly 
increase rate by lgt::erm (section 7.2.3). The expression and secretion of Cwp6 is increased on 
inactivation of lgt, suggesting it plays a compensatory role in cell wall processing due to the 
mislocalisation of cell wall remodelling lipoproteins. Additionally, the rubrerythrin, Rbr 
(CD630_08250), a rubredoxin, Rbo (CD630_08270) and a putative oxidative stress glutamate 
synthetase, CD630_08280, were all expressed in significantly reduced amounts (p ≤0.01), displaying 
a 12-, 6.6- and 10.6-fold reduction, respectively. The genes corresponding to these proteins are 
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adjacent on the genome and potentially form an operon; Rbo and Rbr were also down regulated the 
insoluble sub-proteome, indicating a reduction of expression on inactivation of lgt. An 
uncharacterised protein, CD630_13460, was found to be expressed at a significantly (p =0.03) 
increased level by lgt::erm relative to the wild type (9-fold increase). Finally, in light of the 
sporulation defect observed for lgt::erm it was interesting to observe a 2.2-fold reduction in 
expression of Spo0A, the master control proteins for sporulation51, by lgt::erm, when compared to 
630 Δerm. However, this was not statistically significant (p =0.09). 
 
Figure 97: A) A scatter plot of all quantified proteins found in the insoluble sub-proteome, comparing 630 Δerm (L) and 
lgt::erm (M). The log2 (Average Ratio M/L) (corresponding to lgt::erm/ Δerm) is plotted against the significance 
(-log10 T-test p Value). The significance cut-off was set to p= 0.05. Predicted lipoproteins are shown in red, non-predicted 
hits are shown in blue and other proteins are shown in grey. Rbr (CD630_08250) is indicated by , the oxidative stress 
glutamate synthetase CD630_08280 by  and CD630_13460 and CD630_13470 are indicated by  and , respectively. B) 
A scatter plot of all proteins quantified in the soluble sub-proteome, comparing 630 Δerm (L) and lgt::erm (M). The 
log2 (Average Ratio H/L) (corresponding to lgt::erm/ Δerm) is compared to the significance (-log10 T-test p Value). The 
significance cut-off was set to p= 0.05. Predicted lipoproteins are shown in red and other proteins are shown in grey; no 
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non-predicted hits were quantified in the soluble sub-proteome. Rbr (CD630_08250) is indicated by , the oxidative stress 
glutamate synthetase CD630_08280 by  and Rbo (CD630_08270) by ; TcdA is indicated by , Cwp6 is indicated by  
and Spo0A is indicated by . The data was processed using MaxQuant and statistical analysis performed using Perseus, 
charts were plotted in Microsoft Excel. 
A comparison between the soluble and insoluble sub-proteomes of lspA::erm and lspA2::erm to the 
parental strain, 630 Δerm, was also performed. A total of 643 proteins were quantified in all three 
biological repeats for the insoluble fraction and 369 proteins for the soluble fraction (6 valid values). 
A total of 748 unique proteins were quantified in either fraction, with 264 proteins being quantified 
in both sub-proteomes. 
In the insoluble sub-proteome 22 predicted lipoproteins and 6 non-predicted hits identified in 
Chapter 6.2.1 were quantified. In both the lspA and lspA2 mutants a general reduction in lipoprotein 
expression level was observed, as shown in Figure 98. Unlike the reduction in membrane associated 
lipoproteins found for lgt::erm, this is not due to shedding of lipoproteins into the media, as a 
reduction in shed lipoproteins was observed for lspA::erm and lspA2::erm (section 7.2.3). This result 
differs from the enrichment study described in section 7.2.2, where 46 lipoproteins were quantified, 
of which 41 were enriched at a significantly similar level between 630 Δerm and the mutant strains. 
However, the analysis of both proteins shed into the media (section 7.2.3) and the global proteome 
were performed using overnight cultures, while the labelling experiments (sections 7.2.1 and 7.2.2) 
were performed using cultures grown for 7 to 8 hours.  In the absence of LspA or LspA2, specific 
substrates of either Lsp will retain their signal peptides; an accumulation of signal peptides at the 
membrane is likely to be poorly tolerated over longer growth periods.  An increase in degradation 
and a reduction in stability of these lipoproteins would account for the apparent reduction in 
expression level observed after overnight growth. The in-gel fluorescence results (Chapter 4.X) 
revealed a general reduction in fluorescence for the lspA2 mutant, which supports this hypothesis. 
For these reasons the quantitative proteomic comparison between the enriched lipoproteomes of 
the lsp mutants and 630 Δerm more accurately reflects differences in lipoprotein expression 
between the strains and over shorter timescales there are unlikely to be large changes in lipoprotein 
abundance in the lsp mutants. 
In the majority of cases the reduction in lipoprotein level found in the insoluble sub-proteome was 
not significant (p ≥0.05). However, when comparing lspA::erm to 630 Δerm, 3 predicted lipoproteins 
had a significantly reduced expression and only one had a significantly increased expression; none of 
the predicted lipoproteins were found at a significantly different level in lspA2::erm. The three 
lipoproteins that were found at a significantly reduced level in lspA::erm were CD630_07500, FhuD 
(CD630_28780) and CD630_05450; the latter is an uncharacterised protein and the former two ABC-
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type transporter solute-binding proteins. The predicted lipoprotein that was found at a significantly 
increased level in lspA::erm over 630 Δerm was CD630_08760, an ABC-type transporter solute-
binding protein. None of the non-predicted hits quantified in this experiment were found to have a 
significantly altered expression level between the lsp mutants and the parental strain.  
Four proteins were found to be expressed in significantly higher amounts by lspA::erm than 
630 Δerm (Figure 98 A); these were a pyruvate formate-lyase, PlfD (CD630_32820), which was 
15-fold increased in expression (p =0.0007) and a pyrroline-5-carboxylate reductase, ProC 
(CD630_32810) which was 7.2-fold increased in expression (p =0.003); both of these were shed at 
significantly increased levels by lspA::erm (section 7.2.3). Additionally, two peptidases were 
expressed in an approximately 4-fold higher amount by lspA::erm, relative to the parental strain; 
CD630_26130 an M24 family peptidase (p =0.001) and CD630_23470, an Xaa-Pro dipeptidase 
(p =0.006). 
Finally, three proteins that were found to be shed in significantly increased amounts by 630 Δerm, 
when compared to the lipoprotein biogenesis mutants (section 7.2.3) and expressed at a higher level 
by lgt::erm (section 7.2.4) were also found to be expressed at a significantly higher level by 630 Δerm 
relative to lspA::erm and lspA2::erm. The rubrerythrin, Rbr (CD630_08250), and a putative oxidative 
stress glutamate synthase (CD630_08280) displayed significantly decreased expression by lspA::erm 
and lspA2::erm while the rubredoxin, Rbo (CD630_08270) was expressed in decreased amounts by 
lspA::erm only, relative to 630 Δerm, as shown in Figure 98. 
It was observed that the S-layer extracts of lspA::erm and lspA2::erm contained considerably more 
flagellin C (FliC) than that of the wild type, 630 Δerm (Chapter 4.4.1), which was confirmed by the 
quantitative proteomic comparison between these mutants and the parental strain, described in this 
chapter. In the soluble fraction, expression of FliC (CD630_02390) was significantly increased by 
2.5-fold by lspA::erm (p =0.03) and 3.7-fold by lspA2::erm (p =0.004). Additionally, analysis of the 
insoluble sub-proteomes of both strains, in comparison to 630 Δerm revealed that several other 
flagella proteins were expressed in significantly increased amounts by lspA::erm; these were FliW 
(CD630_02330) which was 2.3-fold increased (p =0.005), FlgE (CD630_02550) which was 1.9-fold 
increased (p =0.001), FliF (CD630_02480) which was 1.3-fold increased (p =0.02), FlhA (CD630_2630) 
which was 1.4-fold increased (p =0.03) and FliG (CD630_2490) which was 1.6-fold increased 
(p =0.03). Expression of FliG by lspA2::erm was also significantly increased by 1.4-fold (p =0.04), but 
no other flagella proteins were significant when comparing lspA2::erm to 630 Δerm.  
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Figure 98: A) A scatter plot of all proteins quantified in the insoluble sub-proteome, comparing 630 Δerm (L) and lspA::erm 
(M). The log2 (Average Ratio M/L) (corresponding to lspA::erm/ Δerm) is plotted against the significance 
(-log10 T-test p Value). The significance cut-off was set to p= 0.05. Predicted lipoproteins are shown in red and other proteins 
are shown in grey, non-predicted hits are shown in blue. CD630_08760 is indicated by , FhuD by , CD630_05450 by  
and CD630_7500 by ; Rbr (CD630_08250) is indicated by , Rbo (CD630_08270) by  and the oxidative stress 
glutamate synthetase CD630_08280 by . B) A scatter plot of all proteins quantified in the insoluble sub-proteome, 
comparing 630 Δerm (L) and lspA2::erm (H). The log2 (Average Ratio H/L) (corresponding to lspA2::erm/ Δerm) is compared 
to the significance (-log10 T-test p Value). The significance cut-off was set to p= 0.05. Predicted lipoproteins are shown in red 
and other proteins are shown in grey; no non-predicted hits were quantified in the soluble sub-proteome. Rbr 
(CD630_08250) is indicated by  and the oxidative stress glutamate synthetase CD630_08280 by . The data was 
processed using MaxQuant and statistical analysis performed using Perseus, charts were plotted in Microsoft Excel. 
A comparison between the soluble sub-proteome of lspA::erm or lspA2::erm and 630 Δerm was also 
performed; a total of 369 proteins were quantified in all three biological repeats, 7 predicted 
lipoproteins were quantified (Figure 99). These lipoproteins were of a variable distribution and result 
from carryover during fractionation. The significance of changes in expression level between the lsp 
mutants and the parental strain 630 Δerm was assessed using a one sample t-test for lspA::erm and 
lspA2::erm, the p-value cut-off was set to p ≤0.05. The level of TcdA in the cytosolic fraction, while 
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slightly increased, was not significantly different between lspA::erm and the parental strain however, 
lspA2::erm showed a 3 fold increase in TcdA level (p =0.02). A number of other proteins showed 
significantly altered expression between the wild-type and the mutant strains, including the stress 
response protein HtpG (Hsp90, CD630_02730) which showed significantly (p ≤0.005) increased 
expression by both lspA::erm and lspA2::erm, relative to 630 Δerm, although the fold change is small 
in both cases. This implies that the lsp mutants are stressed, possibly due to accumulation of Type II 
signal peptides in the cell membrane. 
 In parallel with the insoluble sub-proteome, the rubrerythrin, Rbr (CD630_08250), putative 
oxidative stress glutamate synthase (CD630_08280) and  rubredoxin, Rbo (CD630_08270) all 
displayed a significantly decrease in expression by lspA::erm and lspA2::erm, relative to the parental 
strain, 630 Δerm, as shown in Figure 99. 
Finally for both lsp mutants a significant reduction in the levels of Spo0A (CD630_12140) was 
observed, as indicated in Figure 99. As discussed in detail in Chapter 1.1.4, Spo0A is a transcriptional 
regulator that controls the initiation of sporulation; genetic inactivation of C.  difficile spo0A leads to 
sporulation deficiency51 and a reduction in persistence and transmission in vivo79. The observed 
reduction in Spo0A expression was particularly interesting in light of the sporulation defect observed 
for the lgt and lsp mutants. The reduction in Spo0A for lspA::erm and lspA2::erm was, on average 
across three biological repeats, 2.5 fold and 4.3 fold (p ≤0.05 and p ≤0.02, respectively). Incomplete 
prolipoprotein processing in C. difficile 630 therefore results in a decrease in Spo0A expression and 
this is the potential cause of the sporulation defect observed. 
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Figure 99: A) A scatter plot of all proteins quantified in the soluble sub-proteome, comparing 630 Δerm (L) and lspA::erm 
(M). The log2 (Average Ratio M/L) (corresponding to lspA::erm/ Δerm) is plotted against the significance 
(-log10 T-test P Value). The significance cut-off was set to p= 0.05. Predicted lipoproteins are shown in red and other proteins 
are shown in grey; no non-predicted hits were quantified in the soluble sub-proteome. Spo0A is indicated by , HtpG by  
and TcdA is indicated by ; Rbr (CD630_08250) is indicated by , Rbo (CD630_08270) by  and the oxidative stress 
glutamate synthetase CD630_08280 by . B) A scatter plot of all proteins quantified in the soluble sub-proteome, 
comparing 630 Δerm (L) and lspA2::erm (H). The log2 (Average Ratio H/L) (corresponding to lspA2::erm/ Δerm) is compared 
to the significance (-log10 T-test P Value). The significance cut-off was set to p= 0.05. Predicted lipoproteins are shown in red 
and other proteins are shown in grey; no non-predicted hits were quantified in the soluble sub-proteome. Spo0A is indicated 
by , HtpG by  and TcdA is indicated by ; Rbr (CD630_08250) is indicated by , Rbo (CD630_08270) by  and the 
oxidative stress glutamate synthetase CD630_08280 by . The data was processed using MaxQuant and statistical analysis 
performed using Perseus, charts were plotted in Microsoft Excel. 
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7.3 Profiling the Lipoproteome of Transcriptional Regulator 
Mutants 
7.3.1 C. difficile Δerm spo0A::erm 
7.3.1.1 Spo0A and Sporulation 
Spo0A is the master control protein that regulates the initiation of sporulation in spore forming 
bacteria80, including B. subtilis81 and the Clostridia. Spo0A is activated by phosphorylation in the 
early stages of sporulation in C. difficile and binds directly to the DNA upstream of a number of 
genes, activating early sporulation genes and repressing those required for stationary phase 
growth90b. An insertionally inactivated mutant of C. difficile spo0A has been produced and was found 
not only to be defective in sporulation51, but also to be unable to persist in mice or transmit between 
animals79. This suggests that sporulation is essential for infection, transmission and recurrence of C. 
difficile infection.  
C. difficile Spo0A has also been implicated in the regulation of other genes, including the toxins tcdA 
and tcdB. Spo0A has been reported to be involved in positive regulation of toxin production, with a 
spo0A mutant reported to produce TcdA at <10 % of the wild type level51. However, the role for 
Spo0A in TcdA regulation is by no means clear as other studies have found that TcdA is up regulated 
in the absence of Spo0A in C. difficile 630 Δerm79, 337. Direct DNA binding studies have shown that 
Spo0A binds to a 0A box upstream of tcdB, but not tcdA, and that the differences in toxin production 
between the spo0A mutant and parental strain are not significant107. A more recent study has shown 
Spo0A to be a negative regulator of both TcdA and TcdB in ribotype 027 strains, including R20291, 
but it was not found to regulate toxin production in 630 Δerm, a ribotype 012 strain 50.  
A number of predicted lipoproteins have been observed, either by transcriptomic or proteomic 
analysis, to be differentially expressed by spo0A mutants, including the stage III sporulation protein 
SpoIIIAG, the putative lipoproteins CD630_24820, CD630_13480, CD630_20520 and CD630_10800, 
the adhesin CD630_08730299 and the ABC-type transporter solute-binding proteins CD630_21740, 
CD630_21770, RbsB (CD630_03000), OppA (CD630_08500) and SsuA (CD630_ CD630_14840)337. 
Spo0A has been shown to bind in vitro to a 0A box, upstream of SsuA 107. For many of these Spo0A 
regulated predicted lipoproteins lipidation has been biochemically verified as part of this study. 
Finally, two ABC-type transporters which function as oligopeptide permeases, Opp and App, have 
been shown to be negative regulators of sporulation in C. difficile; both the opp and app operons 
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contain a lipoprotein, OppA and AppA, implicating the lipoproteome in the regulation of sporulation 
in C. difficile 348.   
A significant reduction in expression of Spo0A, relative to 630 Δerm, was observed for lspA::erm and 
lspA2::erm. Additionally, a reduction in Spo0A expression, which approached significance, was also 
seen for lgt::erm (section 7.2.4). This provides an insight into the sporulation deficiency observed for 
the lipoprotein biogenesis mutants of 630 Δerm and the reduced representation of insertional 
mutants in lgt and lspA reported by Dembek et al, following sporulation of a transposon library in 
R20291102. It is possible that lipoprotein mediated systems positively regulate Spo0A expression in C. 
difficile. In this case an analysis of the spo0A::erm lipoproteome would provide an insight into the 
effect of reduced Spo0A levels on the lipoproteome of lgt::erm, lspA::erm and lspA2::erm. However, 
a hypothesis for this  must exclude a deficiency in nutrient import as the loss of the oligopeptide 
transporters Opp or App leads to a hyper-sporulative phenotype348. As a general reduction in 
nutrient import would be anticipated to lead to an increase in sporulation, an alternative hypothesis 
is that lipoproteins play a role in the formation of spores and therefore may be under the control of 
Spo0A. On the basis of previously reported transcriptional and proteomic studies with C. difficile 
spo0A mutants, changes to the C. difficile lipoproteome on the inactivation of spo0A were 
anticipated. Identification of differentially expressed lipoproteins, using the metabolic tagging 
approach developed in this study, would provide a further insight into the role of lipoproteins in 
C. difficile sporulation. 
To investigate any changes to the C. difficile lipoproteome on inactivation of spo0A 630 Δerm was 
compared to the insertionally inactivated mutant, 630 Δerm spo0A::erm. Overnight cultures of the 
two strains were sub-cultured to an OD600 of 0.05 in duplicate and treated with either 25 µM YnC12 
or 25 µM myristic acid, at an OD600 of approximately 0.30. The cultures were allowed to grow to 
stationary phase over a total of seven and a half hours and the bacteria lysed and fractionated. The 
YnC12 tagged lipoproteins, found in the insoluble sub-proteome, were ligated to AzTB by CuAAC and 
changes in lipoprotein expression or modification visualised by SDS-PAGE and in-gel fluorescence 
analysis (Figure 100). A number of fluorescent bands corresponding to lipoproteins showed a change 
in intensity, while those corresponding to LTA appeared to be unaffected, indicating that expression 
of several lipoproteins may be controlled, either directly or indirectly, by Spo0A. 
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Figure 100: A comparison of the YnC12 tagged lipoproteome of 630 Δerm and the sporulation deficient mutant, spo0A::erm, 
as assessed by SDS-PAGE and in-gel fluorescence analysis. The cultures were treated with 25 µM YnC12 or 25 µM myristic 
acid; fluorescent bands that showed a noticeable change in intensity between spo0A::erm and the parental strain are 
indicated by . Coomassie staining (total protein, bottom) is shown as a loading control. 
7.3.1.2 Profiling the Lipoproteome of spo0A::erm 
To identify the lipoproteins showed different expression or modification levels in the spo0A mutant 
strain, and which therefore may have an important role in sporulation in C. difficile, a quantitative 
proteomic comparison between 630 Δerm and spo0A::erm was conducted. Overnight cultures of 
C. difficile 630 Δerm and spo0A::erm, in biological triplicate, were sub-cultured to an OD600 of 0.05. 
The 630 Δerm subculture was immediately treated with DMSO to 1 % (v/v) and one spo0A::erm 
subculture was treated with DMSO and a second with 50 µM myristic acid, for each biological 
repeat. All cultures were allowed to grow to early exponential phase (OD600 ≈0.30) before being 
treated with 10 µM YnC12. The cultures were allowed to grow to late exponential phase before 
being harvested, lysed and fractionated. The inclusion of a spo0A::erm sample, where the 10 µM 
Ync12 is in competition with a 5-fold excess of the natural lipid, ensured than any lipoproteins which 
were expressed in the spo0A mutant, but not detectable in the parental strain, could be quantified 
and their lipidation demonstrated. 
200 µg of the insoluble sub-proteome was pre-precipitated to deplete the LTAs and the YnC12 
tagged lipoproteins elaborated by CuAAC ligation with AzTB and affinity enriched on NeutrAvidin 
agarose beads. The pull down efficiency was assessed by comparison between an aliquot of the 
clicked sample before pull down and the supernatant from the beads, as shown in Figure 101. The 
enriched lipoproteins were then reduced, alkylated and digested with trypsin on-bead. The peptides 
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were desalted and dimethyl labelled on StageTips336; the 630 Δerm samples, the spo0A::erm samples 
in competition with 50 µM myrsitic acid and the spo0A::erm samples were labelled with the light, 
medium and heavy reagents, respectively. The samples were combined 1:1:1 and the differences in 
the enriched lipoproteome quantified by LC-MS/MS analysis.  
 
Figure 101: The affinity enrichment efficiency of YnC12 tagged proteins from 630 Δerm and spo0A::erm, either with (+) or 
without (-) competition with a 5-fold excess of myritic acid, was assessed by comparison between an aliquot of the samples 
before pull down (-) and the supernatant (S), visualised by SDS-PAGE and in-gel fluorescence analysis. Cultures were treated 
with 10 µM YnC12 and this experiment was performed in biological triplicate. Coomassie staining (total protein, bottom) is 
shown as a loading control. 
A total of 168 proteins were quantified in all three biological repeats for at least one comparison 
(H/L or M/H). Of these, 46 were predicted lipoproteins and a further 9 non-predicted hits identified 
in the competition experiment. When comparing the spo0A::erm to the parental strain, 630 Δerm, 
(Ratio H/L, Figure 102 A) a number of lipoproteins showed differential enrichment between the two 
strains. To assess whether this was significant a one-sample T-test was performed; the T-test value 
was zero, corresponding to no change, and the p-value cut off set to p ≤0.05. Four ABC-type 
transporter solute-binding proteins showed a significantly reduced enrichment in spo0A::erm 
relative to the parental strain. These were CD630_07500 and ModA (CD630_08690), which had 
p ≤0.05, and SsuA (CD630_14840) and OppA (CD630_08550) which were found to have a greater 
reduction in enrichment, both in log2 fold ratio and in significance (p ≤0.01). These proteins are 
annotated as solute-binding proteins in nutrient import; CD630_07500 and OppA bind to amino 
acids and oligopeptides respectively while SsuA imports alkane sulfonates and ModA binds to 
molybdenum. As the enrichment level of these proteins is significantly reduced in the absence of 
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Spo0A it is likely that expression of these proteins is positively regulated by Spo0A, either directly or 
indirectly.  
The ssuA gene has an upstream Spo0A binding sequence which has previously been verified in vitro 
and is therefore considered to be under direct positive regulation by Spo0A107. The genes encoding 
the other three ABC-type transporter solute-binding lipoproteins do not have a Spo0A box within 
200 bp of the start site and it is probable that they are indirectly regulated by Spo0A, possibly by 
sigma factors downstream in the Spo0A signalling cascade. However, it is possible that 
non-canonical 0A boxes exist to allow direct regulation of the corresponding genes337 as strong 
Spo0A dependant regulation of genes that lack a consensus 0A box has been observed for 
Clostridium acetobutylicum349. 
The differential enrichment of OppA between spo0A::erm and the wild type 630 Δerm is interesting 
as the opp and app operons, both of which encode oligopeptide specific ABC-type transporter 
complexes, have recently been shown to repress sporulation in C. difficile348. The inactivation of 
either operon results in the early expression of sporulation regulatory proteins and a 
hypersporulative phenotype in vivo, although only the loss of the app operon resulted in this 
phenotype in vitro. AppA (CD630_26720), the lipoprotein component of the app operon, displayed a 
1.6-fold increase in enrichment from spo0A::erm relative to the parental strain, however, this was 
not significant (p =0.18). It has been proposed that opp and app are important for nutrient sensing in 
the initiation of sporulation in C. difficile and that, on the inactivation of opp or app, sporulation is 
initiated due to low intracellular nutritional availability348. It is possible therefore that the ABC-type 
solute-binding proteins, including OppA, which showed reduced enrichment in spo0A::erm are 
positively regulated by Spo0A as a nutrient sensing feedback loop. In low nutrient conditions Spo0A 
is phosphorylated and becomes active; spo0A acts as a transcriptional activator resulting in up-
regulation of SsuA, OppA, ModA and CD630_07500. This increases the rate of nutrient import, 
providing a greater sensitivity to external nutrient levels and allows sporulation to be avoided if 
extracellular nutrition is available. 
Finally, two lipoproteins showed a significantly increased enrichment in the spo0A::erm mutant 
when compared to 630 Δerm (p ≤0.05). These were SsuA2 (CD630_29890) and CD630_19300, which 
was a non-predicted hit identified in by competition between YnC12 and an excess of myristic acid, 
but features a consensus lipobox motif (Chapter 6.2.1). Neither gene features an upstream 0A box 
however, the increase in SsuA2 can be rationalised as a compensatory effect due to the reduction in 
SsuA expression; ClustalΩ alignment reveals that SsuA and SsuA2 share 67 % sequence identity. 
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CD630_19300 is annotated as an uncharacterised protein; however, BLAST and pfam searching 
revealed it to be a metallo-β-lactamase which is conserved across 225 strains of C. difficile, including 
R20291 (CDR20291_1853). Additionally, there are homologues in a number of other pathogenic 
Clostridial species including C. botulinum, C. sordellii and C. tetani. While its exact role is unknown, 
the beta-lactamase domain is associated with hydrolase activity and competence; additionally, beta-
lactamases are important for the breakdown of antibiotics. This is a plausible role as C. difficile is 
highly antibiotic resistant. As there is no upstream 0A box, CD630_19300 appears to be indirectly 
down regulated by Spo0A, suggesting that it is expressed during vegetative growth and repressed 
during sporulation. Transcriptome analysis has previously demonstrated an approximate 2-fold 
increase transcription of CD630_19300 in the spo0A::erm mutant337, providing further evidence for 
Spo0A dependant regulation of this lipoprotein.   
 
Figure 102: A) A scatter plot of all quantified proteins for a comparison between 630 Δerm (L) and spo0A::erm (H), 
comparing the average log2 (Ratio H/L), corresponding to spo0A::erm/ 630 Δerm, to the significance (-log10 T-test p Value); 
the significance cut-off was set to p= 0.05. The highly significant hits (p ≤0.01) SsuA and OppA are indicated by  and  
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respectively. The non-predicted hit CD630_19300 is indicated by  and SsuA2 is indicated by . B) A scatter plot of all 
proteins quantified in the spo0A::erm samples, comparing the 10 µM YnC12 treated sample (H) to the sample with 10 µM 
YnC12 in competition with 50 µM myristic acid (M).  The average log2 (Ratio H/L) (corresponding to 50 µM/ 0 µM myristic 
acid) is plotted against the significance (-log10 T-test p Value); the significance cut-off was set to p= 0.05. The data was 
processed using MaxQuant and statistical analysis performed using Perseus, charts were plotted in Microsoft Excel. 
Despite allowing proteins that were quantified in all three biological repeats for either comparison 
the same proteins were quantified on competition in spo0A::erm as for the comparison between 
spo0A::erm and the parental strain, including all 46 predicted lipoproteins. This indicates that the 
changes to the lipoproteome on inactivation of spo0A are relatively subtle; there do not appear to 
be any lipoproteins that are completely repressed or activated by Spo0A. 
As anticipated, the predicted lipoproteins showed a reduction in enrichment when the YnC12 
labelling was competed against a 5-fold excess of the natural lipid; the significance of this was 
assessed using a one-sample T-test, with the p-value cut-off set as p ≤0.05; T-test value =0 (no 
change). Of the 46 predicted lipoproteins that were quantified in all three biological repeats 36 
showed a significant (p ≤0.05) reduction in enrichment, as did all 9 of the non-predicted hits 
identified. However, a high background was observed, with a further 64 other proteins also showing 
a significant reduction in enrichment in the competition samples (p ≤0.05). A more stringent P-value 
cut-off of p ≤0.01 reduced the number or proteins showing a significant reduction in enrichment to 
35, of which 19 were predicted lipoproteins and a further 5 non-predicted hits, including 
CD630_18710. 
7.3.1.3 Global Proteomic Analysis 
To confirm that the differential enrichment of the spo0A::erm lipoproteome, relative to 630 Δerm, 
was due to Spo0A related changes in expression level, the global proteome of spo0A::erm was 
compared to that of 630 Δerm. Cultures of both strains, in biological triplicate, were treated as 
described in section 7.3.1.2 and the lysates were fractionated into soluble and insoluble sub-
proteomes. 25 µg of each sub-proteome was reduced, alkylated, digested with trypsin in solution 
and de-salted on StageTips.  The de-salted peptides were resuspended in TEAB and dimethly labelled 
in solution according to the method reported by Boersema and co-workers274b. The soluble and 
insoluble sub-proteomes were compared separately by duplex dimethyl labelling; the 630 Δerm 
samples and the spo0A::erm samples were labelled with the light and medium reagents, 
respectively. Following dimethyl labelling the samples were de-salted on StageTips for a second time 
and the elutants combined 1:1.  
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A total of 746 proteins were quantified in the insoluble sub-proteome and 550 proteins were 
quantified in the soluble sub-proteome, in all three biological repeats; 349 proteins were quantified 
in both sub-proteomes and a total of 947 unique proteins were quantified. This is comparable to the 
number of proteins quantified in previous proteomic studies of spo0A::erm; Pettit and co-workers 
reported the identification of 1000 proteins in a similar comparison337. Following normalisation to 
the median, significance was assigned for the dataset produced using a one-sample T-test; p ≤0.01, 
T-test value =0 (no change between the strains). It proved possible to quantify even small changes in 
expression with high statistical significance with 38 proteins in the insoluble sub-proteome and 29 
proteins in the soluble sub-proteome having significantly different expression in spo0A::erm when 
compared to 630 Δerm, as shown in Figure 103 and Figure 104. 
 
Figure 103: A scatter plot of all proteins quantified in the insoluble sub-proteome, comparing 630 Δerm (L) to spo0A::erm 
(M), the average log2 (Ratio M/L) (spo0A::erm/ 630 Δerm) is plotted against the significance (-log10 T-test p Value); the 
significance cut-off was set to p = 0.01. The lipoproteins identified as being significantly reduced in the analysis of the 
lipoproteome (section 7.3.1.2) SsuA and OppA are indicated by  and  respectively. The data was processed using 
MaxQuant and statistical analysis performed using Perseus, charts were plotted in Microsoft Excel. 
 In the insoluble sub-proteome (Figure 103) both SsuA and OppA showed a highly significant 
(p ≤0.005) reduction expression by spo0A::erm relative to 630 Δerm, with SsuA levels showing a 
5-fold reduction and OppA a 2-fold reduction. This demonstrates that the reduction in enrichment of 
SsuA and OppA observed in section 7.3.1.2 is due to a reduction in expression level on inactivation of 
spo0A, as anticipated for SsuA which features a Spo0A binding site upstream of the gene107. The 
other two ABC-type transporter solute-binding proteins that were found to have a reduced 
enrichment in spo0A::erm relative to 630 Δerm were CD630_07500 and ModA (CD630_08690). 
ModA was not identified, possibly due to a low expression level; CD630_07500 was found to have a 
1.2-fold reduction in expression however, this was not significant (p =0.22). 
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Neither SsuA2 nor CD630_19300 were detected in this experiment, possibly reflecting a low 
expression level or the fact that samples were taken at a slightly earlier growth point. However, two 
other lipoproteins were found to be expressed at a significantly higher level in spo0A::erm when 
compared to the parental strain. These were CD630_27190, a polysaccharide deacetylase, which 
showed a 1.4-fold increase (p =0.01) and RbsB (CD630_03000), an ABC-type transporter solute-
binding protein, which showed a 1.8-fold increase in expression (p =0.01). Despite the failure to 
identify SsuA2, CD630_19300 or ModA, it is probable that the results of the enrichment experiment 
accurately reflect changes to the lipoproteome. The enriched samples are of reduced complexity, 
enabling the detection and quantification of lower abundance proteins, which may include these 
lipoproteins. 
Intriguingly, of the opp operon, composed of oppBCADF, only OppA, OppB and OppD were detected 
in this experiment; neither OppB nor OppD showed a significant change in expression level between 
the two strains. oppF is a pseudogene which contains an in frame stop codon and was not expected 
to be expressed. While the oppB and oppC genes overlap, there is a 112 bp gap between oppC and 
oppA which contains a potential promoter, identified using Softberry Bprom350. This raises the 
possibility that oppA may be transcribed monocistronically in a manner that is indirectly regulated by 
Spo0A, as well as being transcribed as part of the operon. Although expression of the complete 
operon was not detected, oppB encodes a permease, oppA an oligopeptide solute-binding 
lipoprotein and oppD an ATPase. Therefore all the components required for a functional ATP-
dependant oligopeptide transporter were detected in this experiment and it is possible that oppC is 
not expressed at a significant level. Further studies into transcription of the opp operon, including 
RT-PCR, would be required to investigate the expression and composition of this ABC-type 
transporter. 
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Figure 104: A) A scatter plot of all proteins quantified in the insoluble sub-proteome, comparing 630 Δerm (L) to spo0A::erm 
(M), the average log2 (Ratio M/L) (corresponding to spo0A::erm/ 630 Δerm) is plotted against the significance 
(-log10 T-test p Value); the significance cut-off was set to p = 0.01. B) A scatter plot of all proteins quantified in the soluble 
sub-proteome, comparing 630 Δerm (L) to spo0A::erm (M), the average log2 (Ratio M/L) (corresponding to spo0A::erm/ 
630 Δerm) is plotted against the significance (-log10 T-test p Value); the significance cut-off was set to p = 0.01. In both 
cases the data is highlighted in comparison to previously published transcriptome (+) and proteome (•) data comparing 
spo0A::erm to 630 Δerm, reported by Pettit and co-workers
337
; proteins that were significantly different in both 
transcriptome and proteome data are represented by . The data were processed using MaxQuant and statistical analysis 
performed using Perseus, charts were plotted in Microsoft Excel. 
The global proteome data, for both soluble and insoluble sub-proteomes, showed a good correlation 
with previously reported data comparing spo0A::erm to the parental strain, 630 Δerm (Figure 
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104)337; for this comparison a more relaxed cut-off of p ≤0.05 was used to assign significance. Three 
sporulation associated proteins were found to have reduced expression in the soluble sub-proteome 
of the spo0A mutant, including Spo0A (CD630_12140) which had an 11-fold reduction (p =0.02), 
SpoIIAB (CD630_07710) which had a 6-fold reduction (p =0.04) and SpoVG (CD630_35160), which 
approached significance with a 2.9-fold reduction (p =0.09).  In the insoluble fraction six sporulation 
associated proteins were quantified; these included Spo0A, Spo0J (CD630_36710), SpoIIAB, SpoIIE 
(CD630_34900), SpoVG and Spo0VS (CD630_19350); however of these only Spo0A approached 
significance with a 2.8-fold (p =0.06) reduction in protein level. Finally, none of the sporulation 
specific sigma factors88a downstream of Spo0A in the sporulation cascade were detected in this 
experiment however, this may reflect an extremely low expression level in the absence of spo0A.  
Transcripton of the two flagellar loci in C. difficile 630 Δerm, as well as the putative flagellar 
glycosylation locus351, have been reported to be up regulated on insertional inactivation of spo0A337. 
Pettit and co-workers were unable to detect this at a proteomic level, which was attributed to loss of 
flagellar from the bacterial cells during sample preparation; despite this hyper-flagellation of 
C. difficile spo0A::erm was observed by electron microscopy. In the experiment described here a 
significant increase in expression of several flagella proteins was detected by spo0A::erm, relative to 
the parental strain. In the insoluble sub-proteome flagellin C (FliC, CD630_02390) showed a 2.4-fold 
increase in expression level (p =0.03) and a flagellar motor switch protein, FliG (CD630_02490), 
showed a 2-fold increase in expression (p =0.003). Additionally, FlgE (CD630_02550), a falgellar hook 
protein, showed a 1.5-fold increase in expression in the spo0A mutant (p =0.007) and the flagellar 
M-ring protein FliF (CD630_02480) showed a 1.4-fold increase in expression (p =0.02). A number of 
other flagellar proteins were also quantified, including FliL (CD630_02580), FlhA (CD630_02630), 
MotA (CD630_02560), FliM (CD630_02700) and FliS1 (CD630_02350); all of these, with the 
exception of MotA, showed an increased expression level on inactivation of spo0A, although this was 
not significant.  
Finally, Pettit and co-workers reported the down regulation of butyrate biosynthesis in the spo0A 
mutant, at both a transcriptional, proteomic and phenotypic level, suggesting a role for Spo0A as a 
positive regulator of butyrate biosynthesis337. In this study, when comparing in the insoluble sub-
proteomes, the beta-glucoside transporter, BglF (CD630_31370), was down regulated 16-fold 
(p =0.001). Additionally, when comparing the soluble sub-proteome, the six enzymes involved in the 
conversion of acetyl-CoA to butyryl-CoA (Figure 105) were all found to be down regulated in the 
absence of spo0A; these enzymes are adjacent on the genome and exist in a putative operon337. 
ThlA1 (CD630_10590) showed a 5.7-fold reduction in expression (p =0.02) in spo0A::erm, relative to 
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630 Δerm, Hdb (CD630_10580) showed a 7.4-fold reduction (p =0.0002), Crt2 (CD630_10570) 
showed a 12.2-fold reduction in expression (p =0.001) and Bcd2 (CD630_10540) showed a 5.8-fold 
reduction (p =0.003). The other two members of this operon, EtfA (CD630_10560) and EtfB 
(CD630_10550), showed a 5.1- and 4.3-fold reduction in expression, respectively (p ≤0.006). This 
supports the claim that Spo0A controls butyrate production via activation of the bcd2 operon, likely 
by an indirect mechanism.  
 
Figure 105: The proposed biosynthesis pathway for the conversion of acetyl-CoA to butyryl-CoA in C. difficile 630
337
; all 6 
genes exist in a putative operon, which is indirectly activated by Spo0A. 
7.3.2 C. difficile Δerm codY::erm 
7.3.2.1 Background to CodY 
CodY is a transcriptional repressor found in low GC content Gram-positive bacteria which controls 
the adaptation of the bacteria to starvation, corresponding to stationary growth phase in culture 352. 
CodY exists as a dimer; each monomer binds a Branched Chain Amino Acid (BCAAs) such as leucine, 
isoleucine or valine. For example B. subtilis CodY binds to isoleucine and valine352 while C. difficile 
CodY has been shown to have an increased affinity for DNA in the presence of a mix of BCAAs47a. 
CodY detects intracellular nutritional levels by binding to BCAAs and in the bound form the CodY 
dimers bind to a consensus palindromic DNA sequence, referred to as a CodY box, via a C-terminal 
winged helix-turn-helix domain. The CodY binding motif from C. difficile 630 has been identified by 
enriching and sequencing regions of DNA that bind to purified CodY47b; the C. difficile CodY box is 
similar to the consensus, shown in Figure 106. 
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Figure 106: The C. difficile 630 CodY box, as determined by Dineen and co-workers
47b
 (top), compared to the consensus CodY 
box defined for B. subtilis
353
 and Lactococcus Lactis
354
 (bottom). Similar sequences are highlighted in red. W indicates a 
nucleotide that forms a weak base pair (A, T), Y indicates a pyrimidine (C, T) and R indicates a purine (A, G). 
Decreasing intracellular BCAA concentrations during starvation leads to dissociation of the BCAAs 
from the CodY dimer, which then releases the DNA, resulting in transcriptional de-repression of the 
direct targets of CodY352. These targets are typically involved in the adaption of the bacteria to 
starvation and include amino acid transporters, secreted proteases and, in many pathogenic 
bacteria, virulence factors. C. difficile CodY has been shown to bind to the tcdR promoter region and 
represses the expression of TcdR in the presence of high concentrations of BCAAs. This results in 
downstream repression of tcdA and tcdB, which have TcdR dependant promoters47a. On starvation, 
CodY repression of tcdR is released and the toxins are expressed. CodY also senses intracellular 
energy levels, by binding to GTP352, and this may control the expression of genes involved in 
morphological differentiation, for example sporulation or flagella expression. The DNA binding 
affinity of C. difficile CodY has been demonstrated to increase with GTP concentration47a however, 
not all CodY homologues bind GTP352. Across low GC Gram-positives CodY proteins have in common 
the ability to sense intracellular nutrition and energy levels and to repress genes whose products are 
not required when nutrients are in excess (typically a period of rapid bacterial growth), releasing this 
repression under starvation conditions. 
Transcriptome microarray analysis of an insertionally inactivated codY mutant of C. difficile 630 Δerm 
has shown that CodY regulates the expression of a number of genes, 146 of which are repressed by 
CodY and a further 19 of which are CodY activated47b. In addition to being a repressor of toxin 
production47, inactivation of CodY was also found to lead to a de-repression of genes involved in 
metabolism, including the biosynthesis of amino acids, glycogen synthesis, fatty acid biosynthesis, 
the transport of amino acids, oligopeptides and sugars, proteolysis, ATP synthesis and sporulation47b. 
This included a number of predicted lipoproteins, including OppA (CD630_08550), CD630_80730, 
CD630_08760, CD630_1476 and CD630_04400. Additionally, CodY boxes have been identified 
upstream of a further two predicted lipoproteins, CD630_17740 and CD630_2029047b, implying 
direct CodY dependant regulation of these lipoproteins. The tools developed to tag and enrich the 
C. difficile lipoproteome would enable a proteomic investigation of CodY control of lipoprotein 
expression in C. difficile. In addition to this, the changes in the lipoproteome labelling pattern 
C. difficile CodY box: TTYWRAATWTTCWRAATWTTY 
Consensus CodY box: AATTTTCWGAAAATTY 
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observed on growth in minimal media, as discussed in Chapter 5.3.1.2, indicate that lipoprotein 
expression is sensitive to nutritional levels and is potentially under the control of catabolite 
repression, such as CodY or CcpA. To investigate this, a quantitative comparison between the 
lipoproteome of an insertionally inactivated codY mutant, C. difficile 630 Δerm codY::erm, and the 
parental strain, C. difficile 630 Δerm was envisioned.  
The codY::erm mutant strain has been reported to display a growth defect in TY media, which has 
been used throughout this thesis for metabolic tagging experiments; this defect is alleviated by the 
addition of Glucose to 1 % (TYG)47a. Therefore, prior to performing a proteomic profile of the 
lipoproteome it was important to ensure that the growth rate was sufficient to make a comparison 
with the parental strain, with a qualitatively equal incorporation of the probe. This would ensure 
that changes in the YnC12 tagged lipoprotein pattern could be attributed to the effect of inactivating 
codY, rather than the bacterial growth rate; the probe incorporation rate correlates with bacterial 
growth. To determine this, overnight cultures of C. difficile 630 Δerm and codY::erm, in biological 
triplicate, were sub-cultured to an OD600 of approximately 0.05 in either TY or TYG media and the 
growth rate monitored over a further 9 hours. As shown in Figure 107, when grown in TY media 
codY::erm displayed a growth defect, which was largely rescued on the addition of 1 % glucose to 
the growth medium (TYG), as previously reported47a. The codY mutant reached an OD600 of 
approximately 0.8 after 9 hours growth in TY media and, as all previous experiments have been 
performed in TY, an initial YnC12 labelling experiment was performed with both 630 Δerm and 
codY::erm being allowed to grow in the presence of the probe to a final OD600 of 0.7. 
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Figure 107: Growth curves for C. difficile 630 Δerm (blue) and codY::erm (red) in either TY (solid lines) or TYG (dashed lines) 
media; the cultures were inoculated to an OD600 of approximately 0.05 and growth followed for 9 hours. A growth defect 
was observed for codY::erm in TY media, which was only partially rescued by the addition of 1 % glucose (TYG). 
To investigate whether the incorporation efficiency of YnC12 by 630 Δerm and codY::erm was 
comparable at an OD600 of 0.7 and to visualise the anticipated changes to the C. difficile 
lipoproteome on inactivation of codY, a comparison between the parental strain and codY::erm was 
performed. Overnight cultures of both strains, in TY broth, were sub-cultured to an OD600 of 0.05 in 
duplicate and treated with either 25 µM YnC12 or 25 µM myristic acid, at an OD600 of approximately 
0.30. The cultures were allowed to grow to an OD600 of approximately 0.60 and the bacteria lysed 
and fractionated. The insoluble sub-proteome, containing the YnC12 tagged lipoproteins, was ligated 
to AzTB by CuAAC and changes in lipoprotein expression or modification visualised by SDS-PAGE and 
in-gel fluorescence analysis (Figure 108)Figure 100. The overall YnC12 incorporation efficiency 
appeared comparable under these conditions but several fluorescent bands corresponding to 
lipoproteins were of different intensity, indicating that expression of these lipoproteins maybe 
regulated by CodY. The majority of altered bands showed a reduced intensity in the codY::erm 
samples, implying a decrease in expression in the absence of CodY, however one band appeared to 
show increased expression, indicating negative regulation by CodY. The fluorescent bands 
corresponding to LTA were largely unaffected. 
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Figure 108: A comparison of the YnC12 tagged lipoproteome of 630 Δerm and codY::erm, as assessed by SDS-PAGE and 
in-gel fluorescence analysis. The cultures were treated with 25 µM YnC12 or 25 µM myristic acid; fluorescent bands that 
showed a noticeable change in intensity between spo0A::erm and the parental strain are indicated by . Coomassie 
staining (total protein, bottom) is shown as a loading control. 
7.3.2.2 Profiling the Lipoproteome of codY::erm 
To identify lipoproteins which showed altered expression, or a different modification or 
incorporation level, in the codY mutant strain a quantitative proteomic comparison between 
630 Δerm and codY::erm was conducted. Overnight cultures of C. difficile 630 Δerm and codY::erm, in 
biological triplicate, were sub-cultured to an OD600 of 0.05; one 630 Δerm subculture and two 
codY::erm subcultures were set up per biological repeat. The 630 Δerm subculture was immediately 
treated with DMSO to 1 % (v/v) and the codY::erm subcultures were treated with either DMSO or 
with 50 µM myristic acid. The inclusion of an additional codY::erm sample, where the 10 µM Ync12 
was in competition with a 5-fold excess of myristic acid, was performed as described in section 
7.3.1.2 to ensure that any lipoproteins which were expressed by codY::erm, but not detectable in the 
parental strain, could be quantified between the two codY::erm samples and their lipidation verified. 
All cultures were allowed to grow to early exponential phase (OD600 ≈0.30) before being treated with 
10 µM YnC12. The cultures were then allowed to grow to an OD600 of approximately 0.60 before 
being harvested, lysed and fractionated. 200 µg of the insoluble sub-proteome was pre-precipitated 
to deplete the LTAs and the tagged lipoproteins were ligated to AzTB by CuAAC and affinity enriched 
on Neutravidin agarose beads. To assess the pull down efficiency a comparison between an aliquot 
of the clicked sample before pull down and the supernatant from the beads was performed by SDS-
PAGE and in-gel fluorescence analysis, as shown in Figure 109. The enriched lipoproteins were then 
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reduced, alkylated and digested with trypsin on-bead. The peptides were desalted and dimethyl 
labelled on StageTips336; as previously the 630 Δerm samples, codY::erm competition samples and 
the codY::erm samples were labelled with the light, medium and heavy reagents, respectively. The 
samples were combined 1:1:1 and the differences in the enriched lipoproteome quantified by 
LC-MS/MS analysis. 
 
Figure 109: The efficiency of affinity enrichment of YnC12 tagged proteins from 630 Δerm and codY::erm, either with (+) or 
without (-) competition with a 5-fold excess of myritic acid, was assessed by comparison between an aliquot of the samples 
before pull down (-) and the supernatant (S), visualised by SDS-PAGE and in-gel fluorescence analysis. All cultures were 
treated with 10 µM YnC12; this experiment was performed in biological triplicate. Coomassie staining (total protein, 
bottom) is shown as a loading control. 
A total of 236 proteins were quantified in all three biological replicates, in at least one comparison 
(H/L or M/H), of which 46 were predicted lipoproteins and a further 10 were non-predicted hits. 
When comparing the codY mutant to the parental strain, 630 Δerm, the majority of predicted 
lipoproteins showed a reduction in enrichment (Figure 110), which correlated with the reduced 
in-gel fluorescence intensity observed for codY::erm (Figure 108). The significance of the differences 
in enrichment between the two strains was assessed using a one sample T-test; T-test value =0 (no 
change), p ≤0.05. A total of 17 predicted lipoproteins showed a highly significant reduction in 
enrichment in codY::erm when compared to the parental strain (p ≤0.01); these included 
CD630_08730 (Q18A65), an ABC-type transporter solute-binding protein which has been 
demonstrated to function as an adhesin341, CD630_09570 a phage lipoprotein, CD630_05450 an 
uncharacterised protein and CD630_19790 an ABC-type transporter solute-binding protein. 
Additionally, the non-predicted hit CD630_19300, which contains a β-lactamase domain, also 
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showed a highly significant (p ≤0.01) reduction in enrichment in codY::erm, relative to the parental 
strain. Finally, an ABC-type transporter solute-binding protein CD630_35280 was found to have an 
almost 21-fold reduction in enrichment, although this was less significant (p ≤0.05). 
The reduction in enrichment observed was an unanticipated result as CodY is typically a 
transcriptional repressor and only 19 genes have been identified in C. difficile for which transcription 
appears to be CodY activated47b. It is therefore unlikely that the majority of lipoproteins are 
positively regulated by CodY. Despite this, two predicted lipoproteins showed an increased 
enrichment in the codY mutant, indicating possible de-repression in the absence of CodY. These 
were CD630_16220 which showed a 2.2-fold increase in enrichment (p ≤0.01) and RbsB 
(CD630_03000) which showed a 1.9-fold increase in enrichment (p ≤0.05). CD630_16220 is an 
uncharacterised protein which contains pfam PepSY domains which have peptidase propeptide 
properties and RbsB is a ribose specific ABC-type transporter solute-binding protein. 
When comparing the two codY samples the predicted lipoproteins showed a reduction in 
enrichment when the YnC12 tagging was competed against a 5-fold excess of the natural lipid. The 
significance of this was assessed using a one-sample T-test, p ≤0.05 and the T-test value was set to 
zero (no change between the two samples). However, background proteins were enriched in much 
greater amounts in the YnC12 treated codY::erm samples (heavy labelled) than in the competition 
samples, so none of the predicted lipoproteins quantified could be distinguished from the 
background (Appendix D). 
 
Figure 110: A scatter plot of all quantified proteins for a comparison between 630 Δerm (L) and codY::erm (H), comparing 
the average log2 (Ratio H/L) (corresponding to codY::erm/ 630 Δerm) to the significance (-log10 T-test P Value); the 
significance cut-off was set to p= 0.05. The highly significant lipoprotein (p ≤0.01) CD630_08730, which is a known adhesin, 
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is indicated by  and the non-predicted hit CD630_19300 is indicated by ; CD630_35280, which showed a 21-fold 
reduction in enrichment (p ≤0.05), is indicated by . The predicted lipoproteins which show an increased enrichment in 
codY::erm over the parental strain which represent potential targets of CodY are indicated by  (CD630_16220) and  
(RbsB). The data was processed using MaxQuant and statistical analysis performed using Perseus, charts were plotted in 
Microsoft Excel. 
7.3.2.3 Global Proteomic Analysis 
In light of the reduction in lipoprotein enrichment on inactivation of codY, as discussed in section 
7.3.2.2, it was important to investigate whether this was due to a genuine reduction in lipoprotein 
expression levels in codY::erm, or whether this instead reflects an altered labelling efficiency due to 
reduced uptake or incorporation of the probe. To determine this, the global proteome of the codY 
mutant was compared to that of the parental strain, 630 Δerm. Overnight cultures of C. difficile 
630 Δerm and codY::erm, in biological triplicate, were sub-cultured to an OD600 of 0.05 in TY media 
and allowed to grow to an OD600 of approximately 0.60. The bacteria were then harvested, lysed, 
fractionated and the protein concentration determined; the accuracy of the determination was 
assessed by SDS-PAGE and coomassie staining (Figure 111). A number of bands were visible in the 
codY::erm samples but not in the 630 Δerm samples, especially for the insoluble sub-proteome; 
these represent proteins that are de-repressed on the inactivation of codY. 
For each biological repeat 25 µg of both the soluble and insoluble sub-proteomes was reduced, 
alkylated and digested with trypsin in solution. The peptides were de-salted and dimethly labelled 
on StageTips, according to the method reported by Li and co-workers336. The soluble and insoluble 
sub-proteomes were compared separately by duplex dimethyl labelling; the 630 Δerm and codY::erm 
samples were labelled with the light and medium reagents, respectively. The labelled peptides were 
eluted from the StageTips and combined 1:1, 630 Δerm: codY::erm and analysed by LC-MS/MS. 
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Figure 111: The global proteome of C. difficile 630 Δerm and the codY::erm, fractionated into the soluble (S) and insoluble (I) 
sub-proteomes, for three biological repeats. The protein concentration was determined and changes to the global proteome 
visualised by SDS-PAGE and Coomassie staining. Samples were standardised by protein concentration to 1 mg mL
-1
; 10 µg 
per lane. 
A total of 606 proteins were quantified in all three biological repeats in the soluble sub-proteome; 
however, for the insoluble sub-proteome very few proteins were identified in the second repeat, 
possibly due to failed digest or loss of sample from the StageTips. Consequently, proteins that were 
quantified in only two biological repeats in the insoluble sub-proteome were included in this 
analysis; a total of 825 proteins were quantified in the insoluble fraction. There was some overlap 
between the two fractions, with 376 proteins being quantified in both sub-proteomes and a total of 
1055 unique proteins were quantified across both fractions. 
Of the 825 proteins quantified in the insoluble fraction, in at least two biological repeats, 42 were 
predicted lipoproteins and 8 were non-predicted hits identified in the competition experiment. The 
distribution of the predicted lipoproteins quantified, as shown in Figure 112 A, did not correlate with 
that observed for the enriched lipoproteome (section 7.3.2.2); a larger number of lipoproteins 
showed an increase in expression in codY::erm, relative to the parental strain, indicating de-
repression in the absence of CodY. To assess which lipoproteins were expressed at a significantly 
different level in the codY mutant a one sample T-test was performed; the T-test value was set to 
zero, p ≤0.05. The lipoproteins that showed a highly significantly (p ≤0.01) increase in expression in 
the absence of CodY, indicating de-repression, included RbsB (CD630_03000), which showed a 
1.4-fold increase in expression, another ABC-type transporter solute-binding protein CD630_21770, 
which showed a 4.2-fold increase in expression, and CD630_15070, a thioredoxin, which showed a 
2-fold increase. Additionally, a number of other ABC-type transporter solute-binding proteins 
showed significantly increased expression in the codY mutant (p ≤0.05). These included OppA 
(CD630_08550) which showed a 1.8-fold increase in expression, CD630_15070 which showed a 
2-fold increase, CD630_23650 which showed a 2.4-fold increase and CD630_21740 which showed a 
5.3-fold increase in expression. The de-repression of the ABC-type transporter solute-binding 
lipoproteins, which would be expected to increase the intracellular nutrient levels, can be readily 
rationalised as a starvation response. The discovery that OppA showed increased expression in 
codY::erm  helps validate these results as the opp operon has previously been shown to be under the 
control of CodY47b. Additionally, OppD and OppB, which represent a complete ABC-type transporter 
complex (as discussed in section 7.3.1.3) were significantly increased in expression in codY::erm 
(p ≤0.05) confirming that the entire opp operon is repressed by CodY during growth in nutrient rich 
conditions. This is contrary to Spo0A regulation of the opp operon, which appears to only control the 
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expression of OppA (section 7.3.1.3). Finally, a putative lipoprotein, CD630_25380 showed a 1.5-fold 
increase in expression (p ≤0.05) in the codY mutant, relative to 630 Δerm. 
However, for a number of lipoproteins a significant reduction in expression was also observed in the 
insoluble sub-proteome. These included CD630_35280 which displayed an 8.9-fold reduction in 
enrichment (p =0.01) and was found to have a highly reduced enrichment when the lipoproteome of 
the codY mutant was compared to that of 630 Δerm (section 7.3.2.2). A number of other lipoproteins 
displayed a less significant reduction in expression (p ≤0.05); CD630_20290, an uncharacterised 
protein which features a Lumazine biding domain (pfam), displayed a 3.3-fold reduction in 
enrichment, two ABC-type transporter solute-binding lipoproteins, CD630_19790 and MetQ 
(CD630_14910) showed a 1.6- and 1.4-fold reductions in expression, respectively. Finally, 
CD630_01990, a membrane associated nucleotidase, had a 1-fold reduction in expression in 
codY::erm relative to the parental strain. It is unlikely that expression of the genes corresponding to 
these lipoproteins are all activated by CodY; instead it is possible that a negative regulator of these 
genes becomes de-repressed in the absence of CodY and therefore they are indirectly regulated. 
However, it is also possible that these changes, which in many cases are small, are the result of 
stress effects in the codY mutant. Finally CD630_16220, which showed significantly increased 
enrichment in the lipoproteome analysis, displayed a 1.3-fold increase in expression in the insoluble 
sub-proteome; however, this was not significant. 
 It is possible that the general reduction in enrichment of the lipoproteome for codY::erm, when 
compared to 630 Δerm, resulted from reduction in YnC12 incorporation, possibly due to reduced 
uptake or increased metabolism of the probe, coupled with increased biosynthesis of membrane 
phospholipids which will be discussed below. The exception to this is RbsB, which showed a highly 
significant increase in expression in the global proteome analysis and an increase of lower 
significance but similar fold change when the lipoproteome was enriched, indicating that RbsB 
expression is de-repressed in the absence of CodY. Potential CodY binding sequences exist both 
before the rbs operon and in the intergenic region upstream of the rbsB start codon, although these 
contains a number of mismatches (Figure 112 B). The remainder of the operon, composed of 
rbsRKBAC (CD630_02980 to CD630_03020), was not quantified in this experiment and it is 
impossible to hypothesise whether it is regulated by CodY. 
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Figure 112: A) A scatter plot of all proteins quantified in the insoluble sub-proteome, comparing 630 Δerm (L) to codY::erm 
(M), the average log2 (Ratio M/L) (corresponding to codY::erm/ 630 Δerm) is plotted against the significance 
(-log10 T-test p Value); the significance cut-off was set to p ≤0.05. CD630_35280, which was identified as being significantly 
reduced in the analysis of the lipoproteome (section 7.3.2.2) is indicated by . Of the lipoproteins that showed increased 
expression in codY::erm, RbsB is indicated by , OppA by  and CD630_16220 by , respectively. The data was processed 
using MaxQuant and statistical analysis performed using Perseus, charts were plotted in Microsoft Excel. B) The potential 
CodY binding sites upstream of rbsB and rbsR, compared to the consensus CodY binding sequence for C. difficile
47b
. The 
binding sequence is highlighted in red, mismatches are coloured blue; numbers refer to the distance from the rbsBor rbsR 
start codon. The alignment was produced manually. 
In general, a good correlation was observed with transcriptome analysis of codY::erm previously 
reported by Dineen and co-workers47b, with proteins corresponding to genes whose expression was 
de-repressed being expressed at an increased level in codY::erm when compared to 630 Δerm. In the 
insoluble sub-proteome (Figure 113 A) a total of 67 proteins where identified which were 
significantly de-repressed at a transcriptional level in the absence of CodY47b. Of these, 40 showed 
significantly (p ≤0.05) increased expression in the codY mutant at a proteome level, 7 of which 
showed a highly significant (p ≤0.01) increase in expression. These were the succinate-semialdehyde 
dehydrogenase, SucD (CD630_23420), which showed a 2-fold increase, butyryl-CoA dehydrogenase 
Bcd2 (CD630_10540) which showed a 2.5-fold increase in expression, an uncharacterised protein 
CD630_05770 which had a 12.2-fold increase in expression, CD630_25020 an pyridoxyl phosphate 
dehydrogenase which was 5.5-fold up regulated and a MerR family transcriptional regulator 
CD630_36150 showed a 5.3-fold increase in expression in the codY mutant, relative to the parental 
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strain. Finally, the V-type ATP Synthase components AtpK (CD630_29590) and AtpA (CD630_29560) 
were 47.4-fold and 28.3-fold increased, respectively, in the codY mutant relative to 630 Δerm. 
Proteins that corresponding to 8 genes that were shown to have increased transcription in the codY 
mutant, and are therefore potentially CodY activated47b, were quantified in the insoluble sub-
proteome. Four of these were significantly (p ≤0.05) decreased in expression in codY::erm, relative to 
the parental strain; CD630_31580, a TRAP family transcriptional regulator which showed a 4.5-fold 
reduction in expression. The remaining three proteins, which showed a more significant decreased 
in expression (p ≤0.01), were the pyruvate formate-lyase PlfB (CD630_07590) which was 8.7-fold 
decreased, a Xanthine/ uracil/ ascorbate permease CD630_21070 which was 2-fold decreased and a 
putative membrane proteins CD630_17680 which showed a 22.5-fold reduction in expression. 
The changes in expression of the MerR and TRAP family transcriptional regulators indicate that many 
of the up and down regulated proteins discovered when comparing codY::erm to 630 Δerm may not 
be subject to direct CodY regulation, especially in the case of proteins that decrease in expression in 
the absence of CodY. 
In addition to the identification of proteins corresponding to many genes which are known to be 
regulated by CodY, several other proteins showed changes in expression in the insoluble sub-
proteome level that imply regulation by CodY. The expression of a number of flagella proteins was 
reduced on the inactivation of codY; notably FliC (CD630_02390) showed a highly significant 
(p ≤0.0003) 5-fold reduction in expression. Additionally, several of other flagella proteins displayed a 
reduction in expression in codY::erm relative to 630 Δerm; these included the flagella motor switch 
protein FliG (CD630_02490) and the flagella biosynthesis protein FlhA (CD630_02630) which had a 
12.6-fold and 9.8-fold reduction in expression, respectively (p ≤0.01).  Other flagella proteins that 
were less significantly reduced in expression in the codY mutant (p ≤0.05) included the flagella motor 
rotation protein MotB (CD630_02570), the flagella basal protein FliL (CD630_02580) and the flagella 
motor switch protein FliM (CD630_02700) which were 9.3-fold, 8.7-fold and 8.3-fold down in 
expression respectively. 
As flagella biosynthesis is significantly reduced in the codY::erm mutant, it appears to be activated by 
CodY. In B. subtilis CodY represses expression of flagella during nutrient rich conditions, by binding 
directly to the promoter regions of the hag and fla/che genes. Repression of B. subtilis flagella is 
released on starvation and it has been proposed that this enables chemotaxis and allows the 
bacteria to swim to more nutrient rich environments355. The reverse appears to be true in C. difficile, 
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with flagella expression being activated, either directly or indirectly, by CodY binding in nutrient rich 
conditions; flagella expression is also repressed by Spo0A in C. difficile (section 7.3.1.3) and it 
appears that flagella expression is activated in the presence of nutrients by CodY, but repressed 
during starvation by a combination of CodY and Spo0A. This possibly reflects the different ecological 
niche C. difficile occupies, relative to B. subtilis. TcdA and TcdB are subject to de-repression by CodY 
on starvation47a, the production of which will lead to the lysis of host cells and the release of 
nutrients. Flagella motility is energy intensive therefore it is possible that, under starvation 
conditions, C. difficile conserves energy by repressing flagella production and relies on the increase 
in available nutrients in the immediate environment resulting from increased toxin secretion to 
provide nutrition. 
 
Figure 113: A) A scatter plot of all proteins quantified in the insoluble sub-proteome, comparing 630 Δerm (L) to codY::erm 
(M), the average log2 (Ratio M/L) (corresponding to codY::erm/ 630 Δerm) is plotted against the significance (-log10 T-test p 
Value); the significance cut-off was set to p = 0.05. Gene products that have been demonstrated to be de-repressed in the 
absence of CodY are coloured red, while those that are activated by CodY are coloured green
47b
. FliC is indicated by , FliG 
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and FlhA are indicated by and , respectively and MotB, FliL and FliM are indicated by, and , respectively. B) A 
scatter plot of all proteins quantified in the soluble sub-proteome, comparing 630 Δerm (L) to codY::erm (M), the average 
log2 (Ratio M/L) (corresponding to codY::erm/ 630 Δerm) is plotted against the significance (-log10 T-test p Value); the 
significance cut-off was set to p = 0.05. TcdA is indicated by  and TcdB by ; CcpA is indicated by . The data was 
processed using MaxQuant and statistical analysis performed using Perseus, charts were plotted in Microsoft Excel.  
The proteomic results for the soluble sub-proteome were also compared to the transcriptome 
analysis previously reported by Dineen and co-workers47b (Figure 113 B). As for the insoluble sub-
proteome, a good correlation between these results and the previously reported transcriptome was 
observed when comparing codY::erm to the parental strain, 630 Δerm. The majority of genes that 
were transcriptionally identified as de-repressed in the absence of CodY were significantly increased 
in expression in codY::erm (p ≤0.01); of a total of 47 transcriptionally de-repressed gene products for 
which proteins were quantified, 39 showed a significant increase in expression. These included a 
number of V-type ATP synthase subunits, AtpA (CD630_29560), AtpB (CD630_29550) and AtpE 
(CD630_29580) which were 8.4-fold, 6.7-fold and 5.1-fold increased in expression. Additionally, AtpD 
(CD630_345680) which was not found to be de-repressed by Dineen and co-workers47b, was 
increased in expression by 1.9-fold (p =0.005). 
The two LCTs, TcdA and TcdB, were also de-repressed in the codY mutant, relative to 630 Δerm; this 
was expected as the entire pathogenicity locus has been demonstrated to be repressed by CodY 
under nutrient rich conditions47a. TcdA showed a highly significant 6.2-fold increase in expression 
(p ≤0.01) while TcdB was found to have a 5.3-fold increase in expression, although this was less 
significant (p ≤0.05). 
Additionally several transcriptional regulators were found to be significantly differently expressed in 
codY::erm relative to 630 Δerm; these included CD630_36150, a MerR family transcriptional 
regulator, which was identified as being de-repressed in the absence of CodY by Dineen and co-
workers47b, and showed a 6-fold increase in expression (p =0.004). Another transcriptional regulator 
which showed differential expression, but had not previously been observed to be CodY regulated, 
was a GntR family transcriptional regulator CD630_35650 which was 5.8-fold increased in expression 
in codY::erm (p =0.004). Additionally, another nutrient sensing transcriptional regulator, Carbon 
Catabolite Protein A (CcpA, CD630_10640), showed a highly significant (p =0.001) 2.6-fold reduction 
in expression by codY::erm, relative to the parental strain. CcpA is a pleiotropic transcriptional 
regulator and is a member of the LacI family. CcpA interacts with the phosphorylated form of two 
other phosphocarrier proteins, Hpr and Chr, which are phosphorylated when high concentrations of 
glucose are present in the cell; interaction with these proteins modulates CcpA DNA binding 
specificity and allows regulation of transcription in a glucose dependant manner356. Typically, genes 
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that encode proteins required for carbon source utilisation are repressed by CcpA in high glucose 
conditions357. In C. difficile, approximately 140 genes are directly controlled by CcpA; these include 
factors required for the early stages of sporulation, including spo0A, and genes involved in sugar 
uptake, fermentation and amino acid metabolism358. C. difficile CcpA has also been shown to repress 
the expression of TcdA and TcdB in a glucose dependant manner, linking toxin production to carbon 
availablilty48. A high intracellular concentration of BCAAs may lead to a CodY dependant activation in 
the expression of CcpA. This would increase the CcpA dependant activation of the transcription of 
genes involved in sugar and amino acid uptake and metabolism, providing a link between high BCAA 
availability and the fermentation and metabolism of glucose and amino acids. 
A large number of proteins previously observed to be de-repressed in the absence of CodY47b, which 
play a role in amino acid and fatty acid metabolism and membrane biosynthesis were found to show 
increased expression in the codY mutant. This includes the butyrate metabolism operon composed 
of bcd2 (CD630_10540), etfB (CD630_10550) crt2 (CD630_10570) and hbd (CD630_10580) which 
were significantly upregulated in the codY mutant (p ≤0.01). The other members of the operon, eftA 
(CD630_10560) and thlA1 (CD630_10590), were also expressed at an increased level in codY::erm, 
but with reduced significance (p ≤0.05). This increase in butyrate production and membrane 
phospholipid synthesis may be partially responsible for the reduced incorporation of YnC12 
discussed in section 7.3.2.2; increased production of fatty acids would provide a greater pool of 
cellular lipids in competition with the probe, leading to reduced incorporation efficiency. However, 
the altered growth phase or stress factors cannot be excluded as the reason for the general 
reduction in enrichment observed for the lipoproteome of codY::erm. 
Three proteins for which the transcript was found to be CodY activated47b were found to be 
expressed at a significantly reduced level (p ≤0.01) by codY::erm, relative to 630 Δerm. These were 
an iron dependant hydrogenase CD630_08930 which was 3.7-fold reduced, a pyruvate formate-lyase 
activating enzyme PlfA (CD630_07580) and the corresponding pyruvate formate-lyase PlfB 
(CD630_07590) which were 6.6-fold and 5.5-fold reduced, respectively. 
7.4 Discussion 
In this chapter dimethyl labelling based quantitative proteomic analysis has been used, in 
combination with the metabolic tagging methodology described in Chapter 3.4.3, to analyse the 
lipoproteome of a number of C. difficile mutant strains and to compare these strains to the parental 
strain 630 Δerm. These included the lipoprotein biogenesis mutants, lgt::erm, lspA::erm and 
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lspA2::erm, for which both the lipoproteome and proteins shed or secreted into the media were 
analysed. In addition, the lipoproteome of insertionally inactivated mutants of two transcriptional 
regulators, spo0A::erm and codY::erm, were analysed to investigate the role of the C. difficile 
lipoproteome in sporulation and starvation response. For all strains studied the global proteome was 
also analysed, in comparison to 630 Δerm, to confirm that changes to the lipoproteome correlated 
with changes in expression level, rather than modification state or YnC12 incorporation rate.  
A proteomic comparison between the lipoproteome of the lipidation deficient mutant lgt::erm 
and 630 Δerm (section 7.2.1) confirmed that the majority of lipoproteins tagged by the YnC12 probe 
are genuine Lgt substrates. Of the 46 predicted lipoproteins and 10 non-predicted hits identified on 
competition between YnC12 and an excess of myristic acid, 41 predicted lipoproteins and one non-
predicted hit were significantly enriched (p ≤0.05) from 630 Δerm over the lgt mutant, indicating loss 
of lipidation on inactivation of lgt. The non-predicted hit identified was CD630_18710, which has 
been demonstrated to be a lipoprotein as part of this study. A quantitative proteomic analysis of the 
proteins shed into the media by lgt::erm was also performed; this is the classical method for 
identifying Gram-positive lipoproteins as in the absence of lipidation Lgt substrates are shed into the 
media at an increased rate129, 197. Only 22 predicted lipoproteins, and CD630_18710, were shed into 
the media at a significantly (p ≤0.05) increased level by lgt::erm, demonstrating the improved 
sensitivity of the metabolic tagging procedure over traditional methods. Analysis of the global 
proteome of lgt::erm confirmed the phenotype observed, as predicted lipoproteins were found at a 
reduced level in the insoluble sub-proteome indicating shedding into the media. For both the soluble 
and insoluble sub-proteomes the fold change for the majority of quantified proteins was less than 
2-fold, indicating that the insertional inactivation of lgt in C. difficile disrupts lipoprotein processing 
without significantly affecting protein expression. Despite this, in the soluble sub-proteome it was 
observed that there was a significant (p ≤0.05) increase in expression of TcdA by lgt::erm, possibly 
indicating a reduced nutritional uptake, and of Cwp6 (p ≤0.005), a cell wall associated amidase, 
which was also shed into the media at a significantly increased rate (p ≤0.05). 
A metabolic tagging analysis of the lspA::erm and lspA2::erm mutants, as described in section 7.2.2, 
revealed that there were few significant changes in lipoprotein expression between these strains, 
relative to the parental strain 630 Δerm. This strongly suggests that the shift of in-gel fluorescent 
bands to higher apparent MW, observed on the inactivation of lspA and lspA2, is the result of 
retention of the Type II signal peptides. The only lipoprotein to show a significant reduction in 
expression (p ≤0.01) for both lspA::erm and lspA2::erm was SsuA. However, global proteomic 
analysis revealed that the level of Spo0A in the soluble fraction of both mutants was significantly 
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(p ≤0.05) reduced in both mutants; Spo0A has been demonstrated to directly regulate the 
expression of SsuA107 and the reduction in Spo0A observed in these mutants may explain this. 
Quantitative proteomic analysis of the proteins shed into the media by the lsp mutants 
(section 7.2.3) revealed that lipoproteins are shed at a reduced rate by these strains and they may 
be retained at the membrane by their signal peptide sequence in the mutant strains. Additionally, 
TcdA was secreted into the media at an approximately 2-fold level by the lsp mutants relative to 
630 Δerm (p ≤0.05) confirming the increased secretion of TcdA observed by Toxin ELISA. 
In all three lipoprotein biogenesis mutants the expression of Spo0A was reduced when compared to 
630 Δerm; additionally, lipoprotein biogenesis pathway mutants of C. difficile display a deficiency in 
the formation of heat resistant spores, observed directly in this study (Chapter 4.4.3) and indirectly 
by others102. Complete processing of the lipoproteome is required for the expression of wild type 
levels of Spo0A and sporulation, implicating lipoproteins in the regulation of Spo0A expression. It is 
possible that lipoproteins provide a link to the external environment, such as extracellular nutrient 
levels via ABC-type transporter solute-binding proteins. However, this is unlikely as transcriptional 
regulators that respond to intracellular nutrient levels, such as CodY which has been shown to 
regulate the transcription of early sporulation genes47b, typically activate sporulation on a reduction 
in intracellular metabolites. Additionally, the increase in flagella expression and toxin production by 
the lipoprotein biogenesis pathway mutants (section 7.2.4) indicate a reduction in nutrient uptake 
on inactivation of lgt, lspA or lspA2. 
An alternative hypothesis is that lipoproteins play a direct role in the formation of C. difficile 
endospores. Spo0A is activated by phosphorylation; in B. subtilis this is via a phosphotransferase, 
Spo0B~P, which in turn is phosphorylated by the response regulator, Spo0F~P. Spo0F is 
phosphorylated by one of five histidine kinases, KinA, KinB, KinC, KinD and KinE, which form a 
phosphorelay81 . KinC, KinB and KinD feature a transmembrane sensor domain, in addition to the 
kinase domain which exists on the cytosolic side of the membrane, and the latter two require an 
accessory lipoprotein for activity. KinB is co-transcribed with a lipoprotein, KapB, deletion or 
mislocalisation of which dramatically reduces KinB function359. It has been proposed that KapB is 
required for signal transduction to KinB, possibly as the ligand recognition component of the KinB-
KapB complex359. Another lipoprotein, Med, has been reported to be required for activation of KinD 
in B. subtiltis. Med was originally identified as a being a positive regulator expression of comK, which 
encodes a competence associated protein360, and it’s surface localisation demonstrated361. However, 
Med has since been shown to interact directly with the sensor domain of KinD and phosphorylation 
of Spo0A via KinD has been demonstrated to require Med362. 
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No Spo0F or Spo0B homologues exist in C. difficile; the accepted theory is that the sporulation 
pathway in Clostridia has not evolved into a phosphorelay and instead the sensor histidine kinases 
directly phosphorylate Spo0A in a two component system. There are 5 potential sporulation 
associated histidine kinases encoded by C. difficile 630; the deletion of one of these, CD630_24920, 
reduces the sporulation level to 29 % that of the wild type51. There are no close homologues of KapB 
encoded in the C. difficile 630 genome however, Blast363 analysis revealed two homologues of Med; 
CD630_05690 and CD630_05700. CD630_05690 has 24 % identity and 45 % similarity to Med from 
B. subtilis strain 168 and CD630_05700 has 29 % identity and 49 % similarity. Both are predicted 
lipoproteins and the lipidation of CD630_05690 was confirmed by competition between YnC12 and 
myristic acid (Chapter 6.2); an alignment between Med and CD630_05690 is shown in Figure 114. 
The loss of either KapB or Med does not prevent sporulation in B. subtilis but the deletion of lgt 
prevents sporulation in B. anthracis142; it is possible that global misprocessing of lipoproteins in 
C. difficile on the inactivation of lgt, lspA or lspA2 may severely reduce sporulation by preventing the 
activation of one of the histidine kinases that phosphorylate Spo0A. This hypothesis supports the 
reduction in Spo0A expression observed for all lipoprotein biogenesis mutants (section 7.2.4) as 
Spo0A~P is a positive regulator of its own expression and a reduction in phosphorylation of Spo0A 
would also reduce Spo0A expression. However, further investigation of the potential Med-like role in 
sporulation of CD630_05700 and CD630_05690 is required, including the effect of their deletion on 
Spo0A activation. Additionally, SpoIIIAG (CD630_11980) is a predicted lipoprotein, although it was 
not detected in the proteomic analysis described in this thesis. To investigate the role of lipoproteins 
in sporulation the lipoproteome of the sporulation deficient mutant, spo0A::erm, was compared to 
the parental strain, 630 Δerm, by quantitative proteomic analysis (section 7.3.1.2). 
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Figure 114: Alignment of Med from B. subtilis strain 168 (BSU11300) with the C. difficile lipoprotein CD630_05690; 
consensus residues are highlighted with a black background (identical), a red background (charged) or a blue background 
(hydrophobic).The predicted lipobox is highlighted in yellow in the consensus sequence. The alignment was generated in 
Geneious (ClustalW) and annotated using Chroma.  
It was found that a number of ABC-type transporter solute-binding lipoproteins were enriched at a 
significantly reduced level in the spo0A::erm samples; these included SsuA and OppA (p ≤0.01) and 
ModA and CD630_07500 (p ≤0.05). In addition, CD630_19300 and SsuA2 were enriched at a 
significantly (p ≤0.05) increased level in the spo0A mutant; it is probable that SsuA2 is upregulated in 
response to the decrease in SsuA expression observed, while CD630_19300 may be negatively 
regulated by Spo0A. Analysis of the global proteome of spo0A::erm revealed that SsuA and OppA 
were expressed at a reduced level by spo0A::erm (p ≤0.005); it is likely that expression of these ABC-
type transporter solute-binding proteins is activated by Spo0A, potentially as a nutrient sensing 
system to assess whether the environment contains sufficient nutritional sources to support 
continued vegetative growth. Interestingly, it appears that Spo0A regulates OppA expression 
independently of the rest of the opp operon (section 7.3.1.3); in both this analysis and the study of 
the global proteome of codY::erm (section 7.3.2.3) only OppA, OppB and OppD were detected 
indicating that OppC may not be expressed at a significant level in C. difficile. However, it is probable 
that the sporulation defect observed for the lipoprotein biogenesis mutants is unrelated to the 
lipoproteins controlled by Spo0A and may be due to factors either upstream of Spo0A, as discussed 
above. Additionally, analysis of the global proteome of spo0A::erm showed a good correlation with 
Med B. subtilis               -MITR----LVMIFSVLLLLSGCGQTPFKGKIEKV----------------GMLFP-DTI 
CD630_05690 C. difficile 630  MRFKRILILMLTVAMIAGMLVGCANNPSNNPSSSKDNKSDISDKSNSKKSVSMILDIEGT 
Consensus/80%                 ..h.R....hhhhh.hhhhL.GCh..P.........................Mhh..chh 
 
 
Med B. subtilis               NDLVWGTKGYKGLLNIQSKYNVDVYYKEGVKTEEDIINAIEDFHKRGVNLLYGHGSEYAE 
CD630_05690 C. difficile 630  NNEAMNNSALLALNNAQKKLNIDTNKVE-SDDSSTFSNSIDILCNDNYDLIIAVGARFAK 
Consensus/80%                 N..hh...hh.hL.NhQ.KhNhDh...E..c....h.N.Ic.hh.c.h.LhhhhG.chAc 
 
 
Med B. subtilis               VFNLVGEDYPDMEFVISNAK--AKADNVTSVHFSGEAMGFFGGMTAAHMSKTNQVGVIAS 
CD630_05690 C. difficile 630  PLEMVAKKYPKQQFAIIDYEYDKQPSNITSISYEDNKSGYLAGLIAGKMTESDKVGFIGG 
Consensus/80%                 .h.hVhccYPc..FhI..hc......NhTSh.h.....GhhhGhhAhcM.c...VGhIh. 
 
 
Med B. subtilis               FT---WQPEVDGFIKGAKYENPDI-EVNTKYTDHWDDDTTAVKLYQKMKNEGADVVYPAG 
CD630_05690 C. difficile 630  TKSSSRDKFESGFREGVKFSNSSIKDISVEYADVFKDSKSVESIAKKMMDNGVDIIFSTT 
Consensus/80%                 h..........GF.cGhKh.N..I.ch.hcYhDhhcD...h..hh.KM...GhDhhh.hh 
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previously reported data337, with the flagella operon showing increased expression and the butyrate 
biosynthesis operon being repressed in the absence of Spo0A. 
Finally, to investigate the role of lipoproteins in starvation response and nutrient uptake, the 
lipoproteome of codY::erm was compared to that of 630 Δerm; a large number of lipoproteins were 
enriched at a reduced level in the codY mutant. As CodY is typically a transcription repressor it is 
unlikely that this observation results from CodY dependant activation of lipoproteins. Instead this 
may be due to reduced YnC12 uptake and incorporation by codY::erm relative to the wild type. 
Despite this, some lipoproteins were enriched at an increased level in the codY::erm samples, 
indicating potential de-repression in the absence of CodY; these included RbsB.  
To verify this, a quantitative comparison between the global proteome of codY::erm and 630 Δerm 
was performed; this is the first reported proteomic analysis of a codY mutant of C. difficile. RbsB was 
also found to be expressed at a significantly (p ≤0.01) increased level when the global proteome of 
codY::erm was compared to that of 630 Δerm. Analysis of the insoluble fraction of the codY::erm 
global proteome indicated that a number of ABC-type transporter solute-binding proteins are 
differentially regulated by CodY, with some being activated by CodY and others, including the entire 
Opp operon, repressed by CodY. The global proteome correlated well with the transcriptome 
analysis of the codY mutant reported by Dineen and co-workers47b; in particular both toxins, TcdA 
and TcdB, were de-repressed in the codY mutant47a. Additionally, a large number of flagella proteins 
were quantified in the insoluble sub-proteome and were found to be expressed at a significantly 
reduced level by codY::erm. This is the first observation of a link between flagella expression and 
CodY in C. difficile; expression of flagella is CodY activated, possibly indirectly, and increased flagella 
display is anticipated in nutrient rich conditions. In B. subtilis CodY represses flagella expression in 
the presence of BCAAs355, facilitating chemotaxis; in C. difficile the reverse appears to be true and in 
response to starvation the energetically costly flagella, are down regulated while the toxins, which 
will cause lysis of host cells and nutrient release, are upregulated. Finally, the expression of CcpA by 
codY::erm was highly significantly (p ≤0.001) reduced, indicating that CcpA may be CodY activated, 
providing a link between metabolism in nutrient rich and poor conditions. 
The following chapter will discuss the results described in this thesis and place them in context; 
where possible the proteomic results described in Chapter 6: and Chapter 7: will be used to provide 
a biochemical explanation for the phenotypes observed in Chapter 4:. Additionally, avenues for 
further research will be discussed.   
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Chapter 8: Conclusions and Future Work 
Previous chapters have described the use of bioinformatic analysis to predict lipidation in three 
C. difficile strains, the development and optimisation of metabolic tagging and the use of 
quantitative chemical proteomics to profile the C. difficile lipoproteome; this approach was then 
extended to investigate lipoprotein biogenesis and to profile the lipoproteome of spo0A and codY 
mutant strains. This chapter will describe the conclusions of this thesis and outline avenues for 
further research. This chapter is divided into five main sections which will focus on the 
methodologies developed (8.1) and their application to identify lipoproteins in C. difficile (8.2), the 
insights gained into lipoprotein biogenesis and the functions of the C. difficile lipoproteome (8.3), the 
use of quantitative proteomics to study the lipoproteome of transcriptional regulator mutants (8.4) 
and, finally, potential areas for future study (8.5). 
8.1 Metabolic Tagging of the C. difficile Lipoproteome 
8.1.1 Development of Metabolic Tagging for C. difficile 
As discussed in Chapter 1.3.1.2, metabolic chemical tagging has previously been applied to study a 
range of PTMs206, 224, 230, 234, 364, including diacylglyceryl modification in Escherichia coli199, and applied 
to a number of different species, including mammalian cell lines229, parasites such as Plasmodium 
falciparum222 and in models of infection365. Metabolic tagging is therefore broadly applicable and the 
CuAAC chemistry and enrichment techniques employed are typically robust. However, it is necessary 
to optimise the reagents and protocols used for each unique system; this is particularly true for the 
design and selection of probes to investigate PTM in new species and to target PTMs that have not 
previously been studied. This thesis has reported the extension of the metabolic chemical tagging 
approach to profile lipidation in the Gram-positive human pathogen, C. difficile.  
What follows is a description of the optimised method for the use of metabolic tagging in C. difficile. 
As little is currently known about membrane composition or the uptake and metabolism of lipids by 
C. difficile, the incorporation of a series of azide- and alkyne-tagged fatty acid analogues was tested. 
To assess a range of physiologically relevant chain lengths the synthesis of three shorter probes, 
YnC9, YnC10 and YnC11 was required (Chapter 3.2.1), based on a method previously developed in 
the Tate group224. It was found that azide-tagged probes were unstable in C. difficile culture and gave 
high non-specific labelling. However, alkyne-tagged probes showed selective tagging of potential 
lipoproteins, with incorporation efficiency increasing with chain length. Although radiolabelling of 
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bacterial lipoproteins has exclusively utilised tritiated palmitic acid analogues125, 129, no significant 
difference in metabolic labelling was observed between YnC12, a myristic acid analogue, and YnC15, 
a palmitic acid analogue. Due to the availability of YnC12 within the Tate group this probe was 
selected for use at 10 or 25 µM and ligated to AzTB by CuAAc for visualisation and enrichment, as 
previously reported by the Tate group286. 
A combination of proteolysis and Western blotting, combined with metabolic tagging, demonstrated 
that in addition to incorporation into putative lipoproteins, YnC12 was also incorporated into 
C. difficile LTA. LTA is far more abundant in the insoluble sub-proteome than lipoproteins and 
consequently blocked affinity enrichment; pre-precipitation of the samples, prior to CuAAC ligation, 
and optimisation of the resuspension buffer following CuAAC (Chapter 3.4.3) enabled efficient pull 
down of YnC12 tagged proteins. This optimised method was then employed to perform a label free 
analysis of the enriched proteins, revealing that they were predicted lipoproteins and Lgt substrates 
(Chapter 5.2). To improve discrimination between YnC12 tagged and enriched lipoproteins and the 
background, and to facilitate the identification of novel lipoproteins, quantitative proteomics was 
investigated. Dimethyl labelling, which has been applied to a spo0A mutant of C. difficile 630 Δerm337 
and to on-StageTip to affinity enriched samples336 was adapted for use with YnC12 tagged C. difficile 
proteomes. The metabolic tagging strategy developed in this thesis has been applied to a range of 
C. difficile strains and a comprehensive profile of the lipoproteome of C. difficile 630 Δerm and 
R20291 generated (Chapter 6.2). Additionally, dimethyl labelling was used to profile the 
lipoproteome of lgt::erm, lspA::erm and lspA2::erm, providing further insight into lipoprotein 
biogenesis in C. difficile. 
8.1.2 Conclusions and Implications 
The optimised method developed for the metabolic tagging and quantitative proteomic analysis of 
the C. difficile lipoproteome represents the first application of such technology to a Gram-positive 
bacterium. However, all the techniques applied, including metabolic tagging, CuAAC ligation and 
dimethyl labelling, are post genomic and as such and it is anticipated that this methodology will be 
broadly applicable to Gram-positive and Gram-negative bacteria. The quantitative chemical 
proteomic strategy described in this thesis gave superior results, both in terms of the number of 
lipoproteins identified and the confidence of these assignments, than traditional methods for the 
identification of lipoproteins129 (Chapter 7.2.3). The majority of reagents used, or close analogues 
thereof, are commercially available and the methodology reported here can be easily applied by 
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researchers without access to chemistry facilities; this method represents a useful tool for the study 
of Gram-positive bacterial lipoproteomes it is hoped that it will be widely adopted. 
8.2 Profiling the C. difficile Lipoproteome 
Having developed and optimised metabolic tagging and quantitative proteomics for application to 
C. difficile, as discussed in section 8.1.1, these tools were applied to profile the lipoproteome and to 
investigate lipoprotein biogenesis in this organism. Despite the recent increase in interest in the role 
of C. difficile lipoproteins in adhesion341 and sporulation348 no members of the predicted C. difficile 
lipoproteome have previously been experimentally validated. 
8.2.1.1 C. difficile 630 Δerm 
Across all the proteomic experiments conducted to study the C. difficile 630 Δerm lipoproteome in 
this thesis, a total of 58 lipoproteins were identified, corresponding to 82 % of the predicted 
lipoproteome (68) and two non-predicted proteins, CD630_18710 and CD630_19300. CD630_18710 
was confirmed as a lipoprotein by over expression in 630 Δerm and lgt::erm backgrounds. This 
number includes the 55 lipoproteins identified by an LFQ comparison between YnC12 and myristic 
acid treatment of 630 Δerm (EF ≥5, Chapter 5.4.2.1) and the 43 identified by an LFQ comparison 
between 630 Δerm and lgt::erm (Chapter 5.2.2). These LFQ comparisons suffered from a high 
background enrichment and therefore dimethyl labelling based quantitative proteomics was 
applied; 48 lipoproteins were confidently identified by competition between YnC12 and a 5- or 10-
fold excess of myristic acid (p ≤0.01, Chapter 6.2.1) and are included in this calculation. Additionally, 
the dimethyl labelling based quantitative comparison between the lipoproteomes of 630 Δerm and 
lgt::erm (p ≤0.05, Chapter 7.2.1), which identified 42 lipoproteins, and the quantitative comparison 
between the proteins shed into the media by 630 Δerm and lgt::erm, which identified 22 
lipoproteins (p ≤0.05, Chapter 7.2.3) are also included. A summary of the C. difficile 630 Δerm 
lipoproteins identified in this thesis is given in Figure 115 and Appendix C. 
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Figure 115: The number of lipoproteins identified in the 5 experiments conducted to profile the C. difficile 630 Δerm 
lipoproteome, divided by annotated function. A total of 58 unique lipoproteins were identified across all 5 experiments; 56 
of which were predicted to be lipidated.  55 lipoproteins identified by a LFQ comparison between YnC12 and myristic acid 
treatment of C. difficile 630 Δerm, 43 were identified by an LFQ comparison between 630 Δerm and lgt::erm, 48 were 
identified by competition between YnC12 and a 5- or 10-fold excess of myristic acid, 42 were identified by a comparison 
between the lipoproteomes of 630 Δerm and lgt::erm and a comparison between the proteins shed into the media by 
630 Δerm and lgt::erm identified 22 lipoproteins. The majority of lipoproteins are annotated as ABC-type transporter solute-
binding proteins or putative lipoproteins; however, other functions include chaperones, deacetylation of the peptidoglycan 
and adhesion to host cells.  
The majority of the C. difficile 630 Δerm lipoproteome were either ABC-type transporter solute-
binding proteins, including the adhesin CD630_08730, or of putative or uncharacterised function. In 
addition to this, a number of enzymes were identified, including a polysaccharide deacetylase, as 
were the extracellular chaperones PrsA and PrsA2. The predicted functions of the C. difficile 
lipoproteome were further investigated by pfam analysis, which allowed predicted functions to be 
assigned to some of the putative or uncharacterised proteins, summarised in Appendix C. Among 
these CD630_19300, which was identified as a lipoprotein in this study and annotated as a putative 
exported protein, was found to feature metallo-β-lactamase domain and may be involved in 
antibiotic resistance. The presence of a germane domain in CD630_36690, annotated as a putative 
exported protein, was found; germane domains have been implicated in sporulation and 
germination in B. subtilis366. Another putative lipoprotein, CD630_05690, was found to contain a 
basic membrane protein (bmp) domain which is present in surface exposed bacterial lipoproteins; as 
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discussed in Chapter 7.4, CD630_05690 is homologous to B. subtilis Med which also contains a bmp 
domain360. Finally, CD630_07070 which is annotated as a putative diguanylate kinase signalling 
protein features a GGDEF domain; GGDEF domains are ubiquitous in bacteria and synthesise cyclic 
di-GMP which is frequently used for intracellular signalling367, including the regulation of pili 
formation in C. difficile368. 
Cwp22 (CD630_27130) was identified as a lipoprotein in the LFQ comparison between YnC12 and 
myristic acid treated C. difficile 630 Δerm. Cwp22 was predicted to be a lipoprotein and features 
cwb_2 cell wall binding repeats which have been shown to bind to the cell wall polymer PSII in 
C. difficile60; Cwp22 also features Cwb_1 repeats which are known to bind to LTA in Streptococcus 
pneumoniae369; it is possible that Cwp22 plays a structural role and is anchored to the membrane by 
the diacyl-glycerol motif while binding to the cell wall via it’s cwb_2 repeats and to LTA through the 
cwb_1 repeats. However, Cwp22 was not identified in any of the other experiments performed to 
profile the lipoproteome. Additionally, Cwp27 (CD630_04400) was predicted to be lipidated, but was 
not identified in any of the experiments described in this thesis. While it is possible that Cwp22 and 
Cwp27 are expressed at a low level and therefore were not detected in other proteomic 
experiments, the lipidation status of Cwp22 remains ambiguous; the identification of Cwp22 may an 
artefact arising from the relatively high background observed for the LFQ experiment. Further 
research is required to prove or disprove the potential lipidation of Cwp22 and Cwp27. 
This study has verified the lipidation of 82 % of the predicted lipoproteome, however 12 potential 
false positives, including Cwp27, were not identified (summarised in Table 6). Some of these 
proteins were not anticipated to be lipoproteins, however, a number of them are annotated as 
putative lipoproteins or ABC-type transporter solute-binding proteins and were therefore expected 
to be lipidated. Failure to identify these proteins does not preclude their lipidation and may result 
from a low expression level under the experimental conditions used. Corroborating this hypothesis, 
the majority of these proteins were detected in the global proteome comparisons between 
630 Δerm and the lipoprotein biogenesis mutants, indicating that they are not expressed, or 
expressed at an extremely low level, under the experimental conditions used. The exceptions to this 
were Cwp27 and FuhD which were quantified in the comparison between 630 Δerm and lspA::erm 
and lspA2::erm (Chapter 7.2.4) in the soluble and insoluble sub-proteome, respectively. This 
indicates that these proteins may be false positives, although this is unexpected in the case of FuhD. 
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Table 6: The potential false positives predicted to be lipoproteins for C. difficile 630, but not identified in the proteomic 
studies described in this thesis.  
Uniprot 
Accession 
Number 
Predicted 
Lipoprotein 
Gene Name Protein Name 
Q188M7 + cwp27 CD630_04400 Putative cell wall binding protein 
Q18AX9 + CD630_11190 Putative lipoprotein 
Q18BZ5 + CD630_14760 Putative signalling protein 
Q18C05 + CD630_14860 Putative ribosome recycling factor 
Q186X7 + CD630_17660 Putative lipoprotein 
Q184D9 + CD630_29530 
ABC-type transport system, iron-family extracellular 
solute-binding protein 
Q180W3 + CD630_34640 Putative uncharacterized protein 
Q183W4 + fhuD CD630_28780 
ABC-type transport system, ferrichrome-specific 
extracellular solute-binding protein 
Q180B2 + pstS CD630_32680 
ABC-type transport system, phosphate extracellular 
solute-binding protein 
Q182G4 + CD630_24780 Putative DNA uptake transporter 
Q182G8 + CD630_24820 Putative lipoprotein 
Q18B57 + spoIIIAG CD630_11980 Stage III sporulation protein AG 
 
8.2.1.2 C. difficile R20291 
The dimethyl labelling based quantitative proteomic strategy developed to profile the C. difficile 
630 Δerm lipoproteome, which utilised the quantification of the reduction in enrichment on 
competition between YnC12 and an excess of myristic acid, was also extended to profile the 
lipoproteome of the “hypervirulent” strain C. difficile R20291 (Chapter 6.2.3). The lipoproteins 
identified for C. difficile R20291 in this thesis are summarised and compared to the predicted 
lipoproteome in Figure 116. A total of 40 lipoproteins were identified in R20291, including four 
which were not predicted to be lipidated due to misassigned start codons which disguised the Type II 
signal peptide, but are close homologues of lipoproteins from C. difficile 630, as discussed in 
Chapters 2.1.2 and 6.4. The identification of a number of misannotated lipoproteins reinforces the 
importance of biochemical validation of lipidation, rather than relying on bioinformatic predictions. 
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Figure 116: The number of lipoproteins identified in the experiment conducted to profile the C. difficile R20291 
lipoproteome, divided by annotated function. A total of 40 lipoproteins were identified by competition between YnC12 and 
a 5- or 10-fold excess of myristic acid; 35 of which were predicted to be lipidated. A total of 62 proteins were predicted to be 
lipidated in C. difficile R20291 during this study. The majority of lipoproteins identified are ABC-type transporter solute 
binding proteins or putative lipoproteins. 
The lipoproteome of C. difficile R20291 is largely conserved with that of C. difficile 630 Δerm, with 
the majority of lipoproteins having a direct homologue. As with the lipoproteome of 630 Δerm, pfam 
analysis was performed to provide insights into the function of the lipoproteins annotated as 
putative lipoproteins, which made up a larger percentage of the lipoproteome for R20291 (38 % 
compared to 31 % for 630 Δerm, Appendix C).   
In addition to the increased number of false negatives when compared to 630 Δerm more false 
positives were also predicted to be lipidated in C. difficile R20291. This study identified 57 % of the 
predicted R20291 lipoproteome, however, 26 predicted lipoproteins were not identified. These are 
annotated as putative lipoproteins, ABC-type transporter solute-binding proteins (including FhuD 
and PotD) and a β-lactamase CDR20291_2371; all would be expected to be lipidated on this basis. 
Consequently, they may not be true false positives and the failure to detect these proteins could be 
due to the relatively high background observed in the R20291 competition experiment. 
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8.2.2 Conclusions and Implications 
This thesis has described the use of quantitative chemical proteomics to tag, enrich and identify 
lipoproteins in C. difficile; this technique has been applied to create highly significant profiles of the 
lipoproteome of two strains, the laboratory strain 630 Δerm and a clinically relevant strain, R20291. 
This represents the first application of this technique to create a profile of the lipoproteome of a 
Gram-positive bacterium and the first application of such a method to a pathogenic bacterium. 
Additionally, this has led to the identification of 82 % of the predicted lipoproteome, which 
represents a significant improvement over traditional methods158-159. The use of competition 
between YnC12 and the natural lipid, myristic acid provided biochemical verification of lipidation 
and enabled the identification of non-predicted lipoproteins in both 630 Δerm and R20921, 
highlighting the risks of using a purely bioinformatic approach to identify lipoproteins. For the 
majority of the lipoproteins identified, particularly those annotated as putative proteins, this is the 
first biochemical evidence reported for their existence. 
Finally, the experimentally determined lipoproteomes for C. difficile 630 Δerm and R20291, listed 
in Table 21 and Table 22, represent a useful resource for the study of the surface proteome of 
C. difficile and enables further investigation of the role of the lipoproteome in a number of 
processes, including nutrient uptake, signalling, redox processes and sporulation. This study has 
allowed several hypotheses to be developed regarding the roles of the lipoproteome and has 
opened a number of avenues for further investigation, as discussed in section 8.5. A high degree of 
conservation, in both sequence and function, between the lipoproteomes of the two strains studied 
was observed. Based on the qualitative comparison made between strains of several representative 
ribotypes (Figure 78) the lipoproteome is potentially conserved across C. difficile, highlighting the 
importance of this little studied PTM for C. difficile’s fitness and propagation within its ecological 
niche. 
8.3 Insights into Lipoprotein Biogenesis in C. difficile 
8.3.1 The Lipoprotein Biogenesis Pathway 
As discussed in Chapter 1.2.2, lipoprotein biogenesis in Gram-positive bacteria occurs post-
translationally. Gram-positive lipoproteins are initially translated as a pre-prolipoprotein, which 
features an N-terminal Type II signal peptide sequence, typically L-3[A/S/T]-2[G/A]-1, which targets the 
protein for export. Although this has been demonstrated to occur via either the Sec or Tat 
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pathways298, in C. difficile this is presumed to be via SecA1. Following translocation the signal 
peptide remains embedded in the membrane and the lipobox motif is recognised by prolipoprotein 
diacylglyceryl transferase (Lgt, CD630_26590) which catalyses the covalent attachment of a 
membrane phospholipid substrate125 to the lipobox cysteine thiol126. Following lipid modification the 
signal peptide is then cleaved from the prolipoprotein by a Type II (lipoprotein) signal peptidase; 
C. difficile is unusual in that it has two Lsps, referred to as LspA (CD630_25970) and LspA2 
(CD630_19030). The mature lipoprotein then remains anchored to the membrane via the 
diacylglyceryl modification of the N-terminal cysteine. Metabolic tagging was used, in conjunction 
with genetic and chemical inactivation of Lgt, LspA and LspA2, to dissect the lipidation pathway in 
C. difficile 630 Δerm. The effects of the inactivation of members of the lipoprotein biogenesis 
pathway on lipidation and the insights gained into the role of the lipoproteome through this will be 
discussed in this section. 
8.3.1.1 The Role of Lgt 
To investigate the role of Lgt in lipoprotein biogenesis in C. difficile the lgt gene of 630 Δerm was 
insertionally inactivated using the ClosTron system92a (performed by Dr Andrea Kovacs-Simon, 
University of Exeter); metabolic tagging with YnC12 and chemical proteomics, as summarised in 
section 8.1.1, enabled both a qualitative and quantitative demonstration of the function of C. difficile 
Lgt. 
Metabolic tagging with YnC12 (Chapter 4.3.1.2) demonstrated the vital role of Lgt in lipoprotein 
biogenesis in C. difficile, as an almost complete loss of lipidation was observed by in-gel fluorescence 
on inactivation of lgt. Complementation in trans (lgt::erm +pTMC002) was achieved by constitutive 
expression of lgt, which restored the wild type phenotype. A quantitative proteomic comparison 
between the YnC12 tagged lipoproteome of lgt::erm and 630 Δerm (Chapter 7.2.1) confirmed the 
central role of Lgt in lipidation; 42 lipoproteins were enriched from lgt::erm at a significantly reduced 
level than from the parental strain.  The majority of lipoproteins identified by competition between 
YnC12 and myristic acid are therefore Lgt substrates and this further validated CD630_18710 as a 
canonical lipoprotein, despite its non-consensus lipobox. 
An increase in shedding of proteins into the media was observed for lgt::erm, relative to 630 Δerm; 
shedding of lipoproteins on the inactivation of lgt has been reported for Streptomyces spp.158-159 and 
Listeria monocytogenes129. A quantitative proteomic comparison between the supernatant 
proteome of lgt::erm and 630 Δerm revealed that this is also true for C. difficile; 23 lipoproteins were 
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shed at an increased level by lgt::erm. As noted in Chapter 7.2.3 and section 8.2.1.1, MS/MS 
identification of shed proteins is the traditional method for the large scale identification of Gram-
positive lipoproteins; however, when applied to C. difficile it resulted in the identification of 
considerably fewer lipoproteins than the metabolic tagging method developed during this thesis. 
Finally, low intensity residual fluorescent bands could still be observed on metabolic tagging of the 
lgt mutant with YnC12. The tagging of these bands was competed out with an excess of myristic 
acid, indicating that it was dependant on YnC12 incorporation. This raised the possibility that 
lipidation was occurring in a non-canonical manner in the absence of Lgt; the quantitative proteomic 
comparison between the lipoproteome of lgt::erm and the parental strain revealed only one protein, 
RnfG, which was equally enriched between the two strains but alos showed a significant reduction in 
enrichment on competition between YnC12 and an excess of myristic acid. An attempt was made to 
verify whether lipidation of RnfG occurred in an Lgt dependant manner (Chapter 6.3.1). However, 
detectible expression of a His6-tagged construct did not prove possible. Therefore, whether 
lipidation can occur in a non-canonical manner in C. difficile remains uncertain. 
8.3.1.2 The Roles of LspA and LspA2 
C. difficile is relatively unusual in that has more than one lipoprotein signal peptidase; these are LspA 
and LspA2 (CD630_25970 and CD630_19030, respectively). Each lsp was insertionally inactivated 
using the ClosTron system92a by Dr Andrea Kovacs-Simon, University of Exeter; the resulting mutant 
strains are referred to as lspA::erm and lspA2::erm. Metabolic tagging with YnC12 was used to 
qualitatively investigate the effect of inactivation of lspA or lspA2 on prolipoprotein processing in 
C. difficile 630 Δerm (Chapter 4.3.1.2); it was found that several fluorescent bands shifted to a higher 
apparent molecular weight (MW) on the inactivation of lspA. Complementation by constitutive 
expression of lspA in trans (lspA::erm +pTMC001) largely restored the wild type labelling pattern. In 
the absence of LspA2 a general reduction in fluorescence labelling intensity, but no distinct mass 
shifts, were observed. This indicates that some lipoproteins are unique substrates of LspA and, as all 
prolipoproteins were correctly processed by lspA2::erm, LspA is capable of processing the majority 
of lipoproteins. To determine whether LspA2 was active, a chemical genetic approach was employed 
(Chapter 4.3.2). Treatment of lspA::erm, lspA2::erm, and 630 Δerm with the specific Type II signal 
peptidase inhibitor globomycin revealed that, while LspA2 is not strongly inhibited by globomycin, in 
the absence of LspA2 (lspA2::erm) inhibition of LspA results in a global shift of lipoproteins to a 
higher MW. As inactivation of lspA alone did not lead to such a dramatic phenotype, the global 
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retention of signal peptides observed under doubly inactivated conditions (lspA2::erm + globomycin) 
indicated that LspA2 is active. 
To confirm that the changes to the in-gel fluorescence labelling pattern observed for the lsp 
inactivated mutants was due to the retention of Type II signal peptides, as opposed to changes in 
lipoprotein expression, the YnC12 tagged lipoproteome of these strains was affinity enriched and 
compared to that of the parental strain by quantitative proteomics (Chapter 7.2.2). Few large 
changes in lipoprotein expression were observed between these strains, indicating that the effects 
on the in-gel fluorescence pattern are due to retention of the Type II signal peptides. The exception 
to this was SsuA; however, expression of SsuA is under the direct control of Spo0A107, which was 
expressed at reduced levels by lspA::erm and lspA2::erm. 
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Figure 117: A) A phylogenetic tree indicating similarity between the signal peptides sequences, up to 5 residues after the +1 
cysteine, of 56 verified lipoproteins from C. difficile 630 Δerm. The signal peptides cluster into three braches of 14 
lipoproteins (balck), 4 lipoproteins (red) and 37 lipoproteins (blue). Phylogentic analysis performed using Geneious 8.0.5. B) 
The consensus lipobox sequences for the three clusters compared to the canonical lipobox (top), coloured according to A. X 
corresponds to any amino acid and J to leucine or Isoleucine. 
Peptides derived from the prolipoprotein signal peptide sequences were not found by LC-MS/MS in 
this study, possibly because they remain anchored to the beads by the YnC12 containing 
diacylglyceryl motif, preventing the facile identification of specific substrates of LspA or LspA2. 
Despite this, a cladogram of the signal peptides from 57 verified C. difficile 630 lipoproteins 
(Geneious) was generated to assess their similarity, revealing that the Type II signal peptides belong 
to three distinct clusters (Figure 117 A). The majority of predicted lipoproteins belong to the same 
cluster, however, the two smaller clusters (of 14 and 4 lipoproteins) feature conserved sequences 
surrounding the lipobox region, which could potentially direct cleavage by either LspA or LspA2 
(Figure 117 B). The lipoboxes of the two smaller clusters feature a similar TGCS motif, while the 
larger cluster features an LVGCS motif. Intriguingly, a serine in the +2 position appears to be highly 
conserved in C. difficile 630 lipoproteins. Of the 3 lipoproteins shed at a significantly reduced rate by 
lspA2::erm, AppA (CD630_26720) and CD630_21770 belonged to the cluster of 14 lipoproteins, 
raising the possibility that these are unique substrates of LspA2 and are retained at the membrane 
by the signal peptide sequence in the absence of lspA2.  
The research described in this thesis has demonstrated that both Lsp enzymes encoded by C. difficile 
are active and that some selectivity exists between them. Although it did not prove possible to 
identify unique substrates of LspA or LspA2, in-gel fluorescence analysis revealed that LspA has some 
unique substrates and is capable of processing the majority of lipoproteins in C. difficile. Despite this, 
LspA2 is active and capable of processing many lipoproteins in C. difficile 630 Δerm; the inactivation 
of both Lsps, using a combination of chemical and genetic approaches, resulted in a global retention 
of Type II signal peptides confirming that these enzymes are required for processing of 
prolipoproteins in C. difficile. 
8.3.2 Functions of the Lipoproteome 
8.3.2.1 Regulation of Flagella Expression 
S-layer extracts of lspA::erm and lspA2::erm revealed that FliC expression is increased in these strains 
(Chapter 4.4.1) and this phenotype was confirmed by proteomic analysis (Chapter 7.2.4). 
Comparison between the global proteomes of these strains and that of 630 Δerm revealed that, in 
addition to flagellin (FliC), the flagella motor switch protein (FliG) was expressed at a significantly 
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increased level by both strains and lspA::erm expressed a number of other flagella associated 
proteins at a higher level than the wild type. In B. subtilis flagella expression has been reported to 
increase under starvation conditions355; it was initially assumed that this was the case in C. difficile 
and the increase in flagella biosynthesis observed was due to reduced nutrient import on 
inactivation of either lsp. However, contrary to this hypothesis, a decrease in the expression of 
flagella proteins by C. difficile codY::erm was observed (Chapter 7.3.2.3); therefore flagella 
biosynthesis is likely to be repressed as a starvation response. 
Bis-(3’-5’)-cyclic dimeric guanosine monophosphate (c-di-GMP) is a common second messenger in 
Gram-negatives and proteobacteria367, and regulates diverse phenotypes including biofilm 
formation, modulation of virulence370 and motility371. Unusually among Firmicutes, and even among 
its close relatives, C. difficile encodes a large number of diguanylate cyclases and phosphodiesterases 
and c-di-GMP is a key signalling component in this bacterium372. Diguanylate cyclases synthesise c-di-
GMP from two molecules of GTP and feature a conserved GGDEF sequence in addition to an active 
site aspartate and guanyl binding region373. A riboswitch located upstream of the large flagella 
synthesis operon in C. difficile 630 is stabilised by binding to c-di-GMP and was demonstrated to 
function as a translational off switch in vitro and in β-galactosidase assays in B. subtilis374. High c-di-
GMP levels have been observed to repress motility and impede the transcription of the flagella 
operons, led by flgB,  in C. difficile375. Reduced flagella synthesis has also been observed at high 
c-di-CMP concentration in Vibrio cholerae376.  
Four lipoproteins identified in this study potentially play a role in c-di-GMP signalling in C. difficile; 
these are the GGDEF domain containing diguanylate kinase signalling protein, CD630_07070 
(Chapter 5.4.2.1), a nucleotidase, CD630_01990, and two nucleotide phosphodiesterases, 
CD630_06890 and CD630_06900 (Chapter 6.2.1). It is possible that retention of the signal peptide on 
inactivation of either LspA or LspA2 may affect their activity. Expression CD630_07070 in V. cholerae 
resulted in a highly significant decrease in motility and an increase in biofilm formation, 
demonstrating that it is an active diguanylate cyclase372. Diguanylate cyclases are usually non-
redundant and can contribute to highly specific phenotypes377; it is therefore possible that 
incomplete processing of pro-CD630_07070 on inactivation of lspA or lspA2 results in reduced 
activity, lower c-di-GMP levels and de-repression of flagella expression following dissociation of 
c-di-GMP from the riboswitch. However, the anticipated increase in motility resulting from the 
observed increase in flagella expression by lspA::erm and lspA2::erm requires confirmation and the 
exact role of CD630_07070 in c-di-GMP signalling remains to be investigated. Additionally, c-di-GMP 
is typically believed to be an intracellular signalling molecule, making it doubtful that a surface 
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exposed lipoprotein could play a role in c-di-GMP signalling. Despite its predicted lipobox, 
CD630_07070 was only identified in the initial LFQ analysis of the lipoproteome (Chapter 5.4.2.1); 
therefore it is possible that it plays an intracellular role in c-di-GMP signalling and is not a genuine 
lipoprotein. 
An increase in activity of the phosphodiesterases,CD630_06890 and CD630_06900,on lsp 
inactivation, resulting in reduced c-di-GMP levels, is an alternative hypothesis; however, these 
proteins lack the domains typically assoacted with phosphodiesterases that degrade c-di-GMP372. 
The exact mechanism by which the lipoproteome regulates falgella expression therefore remains 
uncertain, it is possible that other signalling systems are responsible for the increase in flagella 
expression by lspA::erm and lspA2::erm. This includes Spo0A, which represses flagella expression337, 
and was expressed at reduced levels by the lipoprotein biogenesis mutants, potentially resulting in 
the increase in flagella expression observed. 
8.3.2.2 Regulation of Toxin Production 
ABC-type transporter solute-binding proteins comprise 38 % of all predicted lipoproteins in 
C. difficile 630 and nutrient uptake is one of the major functions of the lipoproteome. On the 
inactivation of lgt, lspA and lspA2 a reduction in intracellular nutritional levels is possible, resulting 
from misprocessing and mislocalisation of ABC-type transporter solute-binding lipoproteins.  
A significant (p ≤0.05) increase in the production of TcdA by lspA::erm and lspA2::erm, when 
compared to 630 Δerm, was observed by a quantitative Toxin ELISA (Chapter 4.4.2) and lspA::erm 
also secreted TcdB at a significantly higher level. This was confirmed by proteomic analysis, as TcdA 
was found to shed into the media at a significantly (p ≤0.05) higher level by these strains and a 
comparison between the global proteome of lspA2::erm and 630 Δerm found that TcdA expression 
was significantly increased (p ≤0.05) in the lspA2 mutant. Additionally, a global proteomic 
comparison between lgt::erm and the parental strain revealed that expression of TcdA was also 
significantly increased (p =0.02) on inactivation of lgt, although this was not observed by ELISA. 
While this could be attributed to a general stress response, possibly due to an accumulation of 
prolipoproteins at the membrane, an alternative hypothesis is also possible. 
The production of the LCTs is sensitive to intracellular nutritional levels, through control of the 
pathogenicity locus expression by CodY47a and CcpA48. As discussed in Chapter 7.3.2.1, CodY acts as a 
global repressor, binding to a CodY box upstream of its targets in response to high intracellular 
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concentrations of BCAAs47b, 356, while CcpA can act as either a positive or negative regulator of gene 
expression binding to its consensus sequence in response to increasing intracellular glucose 
concentration358. Both codY47a and CcpA48 act as repressors of Toxin production when BCAA and 
readily metabolisable sugar levels, respectively, within the cell are high; an increase in TcdA and 
TcdB expression on inactivation of codY was also observed during this study. It is possible that partial 
processing of the lipoproteome results in a loss in efficiency of ABC-type transporter activity and 
intracellular nutrient levels drop, leading to de-repression of toxin expression mediated by both 
CodY and CcpA. 
However, an alternative method for regulation of toxin expression by the lipoproteome is also 
possible; a link between the flagella regulon and toxin synthesis in C. difficile has been reported, with 
mutants in fliC showing a significant increase in transcription of the PaLoc while inactivation of other 
flagella genes results in a decrease in PaLoc trasncription49. It has recently been demonstrated that 
this is mediated by the sigma factor SigD, also referred to as FliA, which is located in the flagella 
operon and regulates TcdA andTcdB expression by directly activating tcdR transcription378. As 
discussed in section 8.3.2.1, expression of the flagella operon, including sigD, is sensitive to c-di-GMP 
levels as an upstream riboswitch acts transcriptional terminator when bound to c-di-GMP374. As 
proposed above, misprocessing of CD630_07070, which is a diguanylate kinase signalling lipoprotein, 
may result in decreased c-di-GMP levels and increased expression of the flagella operon; this would 
lead to a corresponding SigD dependant increase in TcdA and TcdB expression. It is probable that the 
phenotype observed results from a combination of CodY/ CcpA dependant de-repression of toxin 
production and a SigD dependant increase in expression. 
8.3.2.3 Sporulation 
Dormant endospores are the infectious agent of C. difficile and the ability to form spores is vital for 
the survival, persistence and transmission of this pathogen79. The inactivation or deletion of lgt has 
been reported to cause a sporulation deficiency in B. anthracis142, while inactivation of B. subtilis lgt 
(also known as gerF) reduces germination efficiency186. Additionally, individual lipoproteins have 
been found to have functions required for sporulation359, 362, 366b and germination379 in B. subtilis. 
Finally, concurrently with this work a mariner-based transposon library was used to identify genes 
required for sporulation in C. difficile R20291 and both lgt and lspA mutants were underrepresented 
in the library following sporulation102. Reduced Spo0A expression was observed for all three mutant 
strains when comparing the global proteome of C. difficile 630 Δerm with that of lgt::erm, lspA::erm 
and lspA2::erm (Chapter 7.2.4). A severe defect in the formation of heat resistant colonies was found 
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for all three lipoprotein biogenesis mutants (Chapter 4.4.3) and phase contrast microscopy 
demonstrated that this was due to a failure to sporulate. These results show that correct processing 
of pre-pro- and prolipoproteins is required for efficient formation of spores in C. difficile and 
indicates that the lipoproteins required for sporulation exert their effect upstream of Spo0A. 
As such, the identification of sporulation associated lipoproteins was of interest; SpoIIIAG was 
predicted to be a lipoprotein in all three C. difficile strains analysed and forms part of the mother cell 
– forespore feeding channel composed of SpoIIIAH and the spore protein SpoIIQ, anchored to the 
outer forespore membrane184. However, SpoIIIAG was not identified in any of the proteomic 
experiments reported in this thesis, potentially as the majority of the lipoprotein tagging 
experiments were performed during exponential growth. However, the reduction in Spo0A 
expression observed for the lipoprotein biogenesis mutants implies that the lipoproteins involved in 
the phenotype observed act upstream of Spo0A and therefore should be expressed earlier in 
growth. Finally, it is unlikely that the decrease in sporulation observed is the result of a nutrient 
sensing or import defect, as the inactivation of the opp and app operons, which encode for ABC-type 
oligopeptide transporters, was observed to lead to a hypersporulative phenotype in C. difficile348. 
Lipoproteins which contain other sporulation associated domains were identified during the work 
described in this thesis. The C. difficile lipoproteins CD630_05690 and CDR20291_0493 were found 
to be homologues of the sporulation associated B. subtilis lipoprotein Med (Chapter 7.4). Med is 
required for the activation of KinD in B. subtilis, which leads to the activation of Spo0A by 
phosphorylation362. It is possible that the Med homologues in C. difficile are required for activity of 
the transmembrane kinases CD630_14920 and CD630_24920, which are believed to act directly on 
Spo0A51, as represented in Figure 118.  Additionally, germane domain containing lipoproteins, 
CD630_36690 and CDR20291_3529, were identified in C. difficile 630 Δerm and R20291. Germane 
domains are homologous to that found in the B. subtilis lipoprotein GerM, which is required for heat 
stability of spores, and is believed to be involved in peptidoglycan synthesis during spore 
development366b. GerM mutants of B. subtilis form approximately 1 % the number of heat resistant 
spores as the wild type366a, but have also been reported to display a germination defect, possibly as 
GerM is required for both the synthesis of the cortex during sporulation and its subsequent 
degradation during germination366. Consequently, germane containing proteins in C. difficile may 
function in both sporulation and germination. 
As the expression of Spo0A was reduced in all three lipoprotein biogenesis mutants, it is probable 
that the lipoproteins involved in regulation of sporulation act upstream of Spo0A; as Spo0A~P 
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activates its own expression, a reduction in kinase activity on incomplete processing of the Med-like 
lipoproteins would be anticipated to lead to a reduction in Spo0A~P levels and lower Spo0A 
expression. However, it is possible that the sporulation defect observed resulted from a combination 
of altered activity, due to misprocessing, of CD630_05690 (Med-like) and CD630_36690 (Germane). 
Supporting the latter hypothesis, three other lipoproteins were identified as being required for 
efficient sporulation by Dembek et al however, these were 2 ABC-type transporter solute binding 
lipoproteins and a putative lipoprotein, rather than the Med homologue CDR20291_0493. The 
precise roles of these proteins in sporulation and germination in C. difficile warrants further 
investigation, however, it is clear that the lipoproteome plays an important role in sporulation and 
therefore the persistence and transmission of C. difficile. 
 
Figure 118: The proposed role of the Med-like lipoproteins CD630_05690 and CD630_05700. A) In the wild type strain 
(630 Δerm) CD630_05690 or CD630_05700 are associated with the N-terminal transmembrane region of the orphan 
histidine kinases, CD630_14920 or CD630_24920. On detection of an unidentified extracellular signal by (e.g.) 
CD630_05690 the kinase is activated and auto-phosphorylates. The phosphate is directly transferred to aspartate 61 of 
Spo0A, in a two component system, and activated Spo0A~P acts as a transcription factor, increasing the expression of 
sporulation associated genes, including itself. B) In the lgt, lspA and lspA2 mutants CD630_05690 and CD630_05700 are 
incorrectly processed and retain their signal peptide; they may also be shed into the media at a higher rate. This results in 
their mislocalisation and the kinase-lipoprotein complex does not form correctly; activation of CD630_14920 or 
CD630_24920 is reduced, leading to a reduction in Spo0A~P levels and reduced sporulation. In B. subtilis the 
transmembrane histidine kinase KinB exists as a dimer and it is proposed that two molecules of the accessory lipoprotein 
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Med are associated with it
359
. The stochiometry of this putative interaction in C. difficile is unknown and they are 
represented as monomers for clarity. 
8.3.3 Conclusions and Implications 
The lipoprotein biogenesis pathway in C. difficile is composed of one Lgt enzyme and two Lsps, LspA 
and LspA2; this study has used metabolic tagging with YnC12 to demonstrate that Lgt is required for 
lipidation in C. difficile and that both Lsp enzymes are active; additionally some selectivity is 
apparent, with LspA appearing to have several unique substrates. This is the first use of a metabolic 
tagging approach in combination with genetic and chemical inactivation to profile Gram-positive 
lipoprotein biogenesis. Investigation of the phenotypes of the lgt, lspA and lspA2 mutants has 
demonstrated that inactivation of members of the lipoprotein biogenesis pathway affects the 
production of several virulence factors including the LCTs and flagella as well as in the formation of 
endospores, the transmissive agent of C. difficile. Beyond its direct functions, the lipoproteome 
evidently plays an important role in signalling and environmental sensing, with a downstream impact 
on the persistence, virulence, motility and adhesion of the bacterium. 
The exact link between these phenotypes and the lipoproteins responsible has not been fully 
elucidated in this study and it is possible that, in some cases, this is a cumulative effect resulting 
from the misprocessing of a large number of lipoproteins. For example, CodY has been reported to 
repress the expression of later stage sporulation genes in C. difficile47b, but not Spo0A, and CcpA has 
been demonstrated to repress Spo0A and SigF in a glucose dependant manner358; therefore, a 
reduction in nutrient import may play a reinforcing roles in the sporulation defect observed. 
Additionally, insertional inactivation of spo0A has been reported to lead to an increase in 
transcription of the flagella operon337; lspA::erm and lspA2::erm both display a significant reduction 
in Spo0A expression and a corresponding increase in flagella biosynthesis and these phenotypes may 
be linked. 
The profile of the C. difficile lipoproteome created during this study (Chapter 6.2) has enabled 
putative functions to be assigned to verified lipoproteins and allowed hypotheses regarding links 
between specific lipoproteins and the phenotypes observed to be considered. This thesis has 
therefore generated a number of testable hypotheses regarding the function of the lipoproteome in 
nutrient uptake and signalling; an investigation of the roles of specific lipoproteins in these 
phenotypes, discussed in section 8.5.2, will help to further unravel the role of the lipoproteome in 
virulence, motility and transmission.  
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8.4 Lipoproteins in Transcriptional Regulator Mutants 
8.4.1 630 Δerm spo0A::erm 
A significant reduction in the expression of Spo0A was observed on the inactivation of lspA and lspA2 
(Chapter 7.2.4), therefore the effect on the lipoproteome of the inactivation of spo0A in C. difficile 
Δerm was investigated (Chapter 7.3.1). Additionally, as the lipoprotein biogenesis mutants displayed 
a severe delay in the formation of heat resistant spores, relative to the parental strain, it was 
possible that sporulation associated lipoproteins that may account for this phenotype could be 
identified. It was found that a number of ABC-type transporter solute-binding lipoproteins showed a 
reduced expression in the absence of Spo0A; these included the direct Spo0A target SsuA107 and 
OppA. To compensate for the reduction in SsuA observed, the expression of SsuA2 was upregulated 
by spo0A::erm; additionally, the newly identified lipoprotein CD630_19300 was upregulated in the 
absence of Spo0A indicating that it is repressed during sporulation. 
Analysis of the global proteome of spo0A::erm confirmed the reduction in expression observed for 
SsuA and OppA was due to a highly significant decrease in their expression in the absence of Spo0A. 
These lipoproteins are not annotated as having an explicitly sporulation associated function and, as 
it is probable that the cause of the sporulation defect observed exists upstream of Spo0A, it is 
unlikely that misprocessing of SsuA or OppA is responsible for this phenotype. However, lspA::erm 
and lspA2::erm express a significantly reduced amount of Spo0A relative to the parental strain and 
this may be responsible for the significant reduction in SsuA expression levels between these strains 
and 630 Δerm (Chapter 7.2.2).  
A potential explanation for the reduced expression of SsuA, OppA, ModA and CD630_07500 by 
spo0A::erm is that they are positively regulated by Spo0A as a nutrient sensing feedback loop. In low 
nutrient conditions expression of Spo0A increases and an increased proportion is activated by 
phosphorylation. Spo0A~P then acts as a transcriptional activator increasing the expression of these 
ABC-type solute-binding proteins, which in turn increase the rate of nutrient import. This provides a 
greater sensitivity to external nutrient levels and will place a check on sporulation if extracellular 
nutrition is sufficient for vegetative growth to continue. 
Finally, a comparison between the global proteome of C. difficile 630 Δerm and spo0A::erm 
confirmed the reduction in expression of SsuA and OppA (Chapter 7.3.1.3); the results also 
correlated well with a previously reported proteomic and transcriptomic analysis of spo0A::erm337, 
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with expression of sporulation associated genes decreasing and the expression of the flagella operon 
and a butyrate biosynthesis operon being observed to increase on the inactivation of spo0A. 
8.4.2 630 Δerm codY::erm 
To further assess role of lipoproteins in nutrient uptake and to investigate the regulation of 
lipoprotein expression under starvation conditions the lipoproteome of the CodY mutant of 
C. difficile 630 Δerm, codY::erm was profiled. However, a poor correlation was found between the 
YnC12-tagged lipoproteome and the expression levels of lipoproteins quantified in the insoluble 
fraction of the global proteome (Chapter 7.3.2). The codY::erm mutant has a significant growth 
defect, an up regulation of fatty acid biosynthesis by the codY mutant has been reported47b and was 
observed during this study, both of these factors may contribute to a reduction in YnC12 uptake and 
incorporation by codY::erm. Despite this, the ribose-specific ABC-type transporter solute-binding 
protein, RbsB, showed a significant increase in enrichment from codY::erm relative to the parental 
strain; analysis of the global proteome revealed this to be a result of a de-repression of RbsB in the 
absence of CodY. 
The global proteomic analysis of codY::erm correlated well with previously reported transcriptome 
studies; this is the first reported proteomic analysis of this strain. Additionally, it was found that 
expression of flagella proteins was reduced on the inactivation of codY which has not been 
previously reported and, while the motility of this strain has not been investigated, this was 
unexpected as CodY represses flagella expression in B. subtilis355. It is possible that, as flagella 
motility requires ATP and is energy intensive, rather than utilise flagella for chemotaxis C. difficile 
down regulates flagella biosynthesis when BCAAs or GTP is limiting and instead relies on production 
of the LCTs to release nutrients from host cells in the bacterias immediate environment. 
8.4.3 Conclusions and Implications 
Investigation of the lipoproteome and global proteome of two transcriptional regulator mutants, 
spo0A::erm and codY::erm has allowed further insights into the role of the lipoproteome in 
sporulation and starvation response to be gained. In particular, the Spo0A dependant regulation of 
SsuA, which had previously been reported to be a direct target of Spo0A in vitro107, was verified in 
vivo using metabolic tagging with YnC12. Additionally, the expression of OppA is positively regulated 
by Spo0A in a highly significant manner; this was interesting as regulation of OppA expression 
occurred independently of the rest of the opp operon and the opp operon has been shown indirectly 
 261 
inhibit sporulation348. This suggested that a subset of ABC-type transporter solute binding proteins 
are utilised as a nutrient sensing feedback system during the initiation of sporulation, a hypothesis 
which requires further investigation. 
A poor correlation was observed between the metabolically tagged lipoproteome of codY::erm and 
the distribution of lipoproteins in the global proteome, in comparison to 630 Δerm; this serves to 
highlight the difficulty comparing mutant strains that display significantly altered metabolism or 
growth rate to the wild type. This also demonstrated the importance of a complementary analysis of 
the global proteome to confirm changes to the enrichment of metabolically tagged proteins 
correlates with protein expression levels. Finally, CodY dependant positive regulation of the flagella 
operon was observed, this is an unusual phenotype which requires further verification and 
investigation of the mechanism of this control is of interest. 
8.5 Avenues for Further Study 
This section will discuss proposed future work arising from the research described in this thesis and 
is divided into two distinct areas. The first will discuss potential extensions of the methods 
developed during this study and the second will address the research required to answer specific 
questions that have been raised during this study.  
8.5.1 Further Applications of this Methodology 
The metabolic tagging and quantitative chemical proteomic methodology developed for C. difficile in 
this thesis represents a highly versatile method; all the techniques used are post genomic and are 
anticipated to be easily transferable between organisms. This study has successfully applied this 
methodology to a number of strains of C. difficile and it could be readily utilised for the study of 
lipidation in other Gram-positive and Gram-negative bacteria. There are, however, a number of 
limitations to this approach; in particular identification of the site of PTM and determination of the 
modification structure was not possible and potential metabolism of the probe beyond 
incorporation into LTA was not addressed in this thesis. The main areas for further development and 
application of the metabolic tagging methodology are summarised below. 
 As discussed in section 8.2.1.1, metabolic tagging performs considerably better than 
traditional methods for the identification of Gram-positive lipoproteins. The extension of 
this strategy to other bacterial species, including Gram-positives and Gram-negatives, would 
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be anticipated to provide further insights into the composition and function of bacterial 
lipoproteomes. 
 The identification of modification sites is of interest; for canonical lipoproteins with a well-
defined lipobox motif this is easily predicted. However, for lipoproteins with less well 
defined lipoboxes, or non-canonical lipoproteins, determination of the site of PTM is 
important. This will require the use of cleavable capture reagents, which have previously 
been reported for the identification of modified peptides in metabolic tagging 
approaches380. Additionally, in the case of canonical lipoproteins, modified peptides will be 
semi-tryptic due to cleavage by an Lsp at the N-terminus; this will necessitate searching for 
non-tryptic peptides. Finally, potential metabolism of the probe in a manner that preserves 
the alkyne group, such as chain elongation, must also be considered when searching for 
modified peptides. To search for the specific mass of a PTM containing metabolised YnC12 
the major products of metabolism of the probe must be identified. 
 This thesis has demonstrated that alkyne-tagged fatty acid analogues are incorporated into 
lipoproteins and LTA in C. difficile, via conversion to membrane phospholipids. It is highly 
likely that these probes are used in other metabolic processes or to modify other 
biomolecules. The major metabolites of alkyne-tagged probes in Gram-positive bacteria are 
currently unexplored and their identification will be of increasing interest as metabolic 
tagging becomes a more broadly applied technology. Thiele et al utilised a fluorogenic dye, 
3-azido-7-hydroxycoumarin, to label alkyne-tagged lipid analogues that were incorporated 
into diacylglyceryl phosphates in E. coli and visualised by thin layer chromatography (TLC)381. 
Such an approach could rapidly be applied for the analysis of YnC12 tagged metabolites in 
C. difficile or other Gram-positive bacteria. Beavers et al have used a lipidomics approach to 
demonstrate that alkyne-tagged lipid analogues show reduced rates of enzymatic 
oxidation382. Although alkyne-tagged probes are considered to be good substrate mimetics, 
the effect of alkyne tags on probe uptake and metabolism should therefore be investigated.  
 Finally, the extension of this approach to profile to other bacterial PTMs can be envisioned. 
Lipid probes have previously been used to profile the modification of bacterial proteins by 
host enzymes111, 365 and their continued application to study PTMs in host-pathogen 
interactions is anticipated.  Additionally, the application of novel or existing probes to study 
other bacterial PTMs, such as glycosylation and AMPlyation, using methods adapted from 
those described in this thesis is of interest.  
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8.5.2 Further Work to Address Specific Questions 
The phenotypes described for the lipoprotein biogenesis pathway mutants in this thesis have 
allowed several hypotheses regarding the functions of individual lipoproteins and the lipoproteome 
in general to be suggested. In addition, the profile of the lipoproteome generated for C. difficile 
630 Δerm is not unambiguous; in particular several lipoproteins were identified by LFQ proteomic 
analysis but not in the dimethyl labelling based competition experiment, as discussed in 
section 8.2.1.1. Verification of whether they are genuine lipoproteins is therefore important. This 
section will discuss the experiments required to answer specific question raised by this thesis. 
 A number of predicted lipoproteins were found by LFQ analysis to be enriched from YnC12 
treated samples at a greater level than from myristic acid treated samples (Chapter 5.4.2.1), 
but were not identified in subsequent, higher confidence, experiments (Chapter 6.2.1). 
These included Cwp22 which potentially plays a structural role (section 8.2.1.1) and the 
putative diguanylate signalling protein CD630_07070. Verification of the lipidation of His6-
tagged constructs of possible lipoproteins has been used during this study to demonstrate 
lipidation (Chapter 6.3.1) in 630 Δerm and lgt::erm backgrounds and would be suitable for a 
rapid demonstration of lipidation for these proteins. Additionally, a number of predicted 
lipoproteins that feature consensus lipobox sequences were not identified in this study 
section 8.2.1.1) and validation of this prediction should be performed. 
 In-gel fluorescence analysis (Chapter 4.3.1.2) revealed that a number of lipoproteins appear 
to be unique substrates of LspA; although the lipoproteomes and global proteomes of 
lspA::erm and lspA2::erm were interrogated for peptides derived from the predicted Type II 
signal peptides it was not possible to identify unique substrates of either Lsp. Therefore, the 
selectivity and specificity of LspA and LspA2 remains unresolved and further investigation 
into this is required. The use of cleavable capture reagents may facilitate this by releasing 
modified peptides from the beads. Cleavage in an orthogonal manner to the tryptic digest, 
either chemically380b or via an orthogonal protease383, would further reduce sample 
complexity and aid the identification of lipoprotein N-terminal peptides, enabling 
identification of specific LspA or LspA2 substrates. 
 A comparison of the Type II signal peptide sequences for all predicted lipoproteins revealed 
that they belong to 3 distinct families, which potentially correspond to unique substrates of 
LspA and LspA2 and substrates of both Lsps. Selectivity between the Lsps could be 
investigated by N- and C-terminally tagged constructs of representative members of each 
cluster, expression in lspA::erm and lspA2::erm backgrounds would be assessed by blotting 
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for the C-terminal tag, while retention of the signal peptide in the absence of LspA or LspA2 
could be demonstrated by blotting for the N-terminal tag. 
 The increased expression of TcdA observed on the inactivation of lspA or lspA2 implicates 
the lipoproteome in the regulation of virulence in C. difficile, however the mechanism linking 
the lipoproteome to toxin regulation remains unknown. As discussed above (section 8.3.2.2), 
it is possible that this is a secondary effect due to reduced nutrient import, resulting in 
release of CodY and CcpA mediated repression of the toxin operon. This hypothesis could be 
investigated by a DNase footprinting assay, comparing the CodY/ CcpA protection of the 
toxin operon from digestion in lspA::erm and lspA2::erm to the parental strain, including 
codY::erm as a negative control.  
 An increase in expression of flagella proteins was observed for lspA::erm and lspA2::erm by 
S-Layer extraction and proteomic analysis. The effect of this phenotype on the motility of 
the lspA::erm and lspA2::erm mutants should be confirmed and the reasons for this increase 
in flagella expression investigated. The function of the diguanylate cyclase CD630_07070 in 
signalling, and its potential role in C. difficile motility, should be determined by the 
construction of a ΔCD630_07070 strain. 
 Additionally, a reduction in flagella expression by codY::erm was observed; this is the first 
report of this phenotype for this strain and it should be further validated and the motility of 
this strain, and the link between CodY and flagella expression investigated. 
 Finally, all three lipoprotein biogenesis pathway mutants displayed a striking sporulation 
defect. The identification of sporulation associated lipoproteins is therefore of interest and 
an initial profile of the lipoproteome of the asporogenous mutant spo0A::erm is described in 
this thesis. However, as discussed in section 8.3.2.3 and Figure 118, it is probable that this 
effect occurs upstream of Spo0A and a study of the effect on sporulation of inactivating the 
Med-like lipoproteins CD630_05690 and CD630_05700, and the Germane domain containing 
lipoprotein CD630_36690, is of interest. Finally, the identification of other sporulation 
associated lipoproteins by metabolic labelling at late stationary phase, when sporulation is 
more likely to occur, or in media that induces sporulation384, will aid the identification of 
sporulation specific lipoproteins such as SpoIIIAG. 
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Chapter 9. Materials and Methods 
The materials and apparatus used during this project and the microbiological, biochemical and 
proteomic techniques applied are described in this chapter. The synthesis and characterisation of 
the alkyne-tagged fatty acid analogues generated during this study, and their precursors, is detailed. 
This chapter is divided into the following sections: 
 Microbiology 
 Chemical Biology & Proteomic Analysis 
 Synthetic Chemistry 
 
9.1. Microbiology 
The growth and handling of Clostridium difficile cultures was performed according to protocols 
developed by the Fairweather Group 312. The techniques used in this project are described below. 
9.1.1. Bacterial Strains and Growth Conditions 
9.1.1.1. Bacterial Strains 
C. difficile 630 and the erythromycin sensitive derivative, 630 Δerm, were provided by Dr Peter 
Mullany, Eastman Dental Institute, London. The insertionally inactivated mutants in the lipoprotein 
biogenesis pathway, 630 Δerm lgt::erm, 630 Δerm lspA::erm and 630 Δerm lspA2::erm were 
generated by Dr Andrea Kovacs-Simon, University of Exeter, EX4 4QD; their complements were 
produced during this study. Escherichia coli NEB5α (NEB) were used as the recipient strain for 
transformation during cloning and E. coli CA434 was used as the donor strain for conjugation of 
plasmids into C. difficile. Details of all C. difficile and E. coli strains used in this study are listed in 
Appendix A. 
9.1.1.2. Clostridium difficile Culture Conditions 
C. difficile was cultured on BHIS agar composed of 3.7 % BHI (Oxoid, CM1135), 0.5 % Yeast Extract 
(BD Bacto, 211713), 0.1 % L-cysteine (Sigma Aldrich), 1.5 % Agar (BD Bacto, 214030). Cultures of 
C. difficile grown from spores were grown on BHIS agar supplemented with 0.1 % or 0.5 % sodium 
taurocholate (Sigma Aldrich).  Liquid cultures for metabolic labelling were routinely performed in TY 
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broth composed of 3 % Bacto Tryptose (BD Bacto, 211713) and 2 % Yeast Extract (BD Bacto, 210929). 
Liquid cultures for genetic manipulation and phenotypic assays (where indicated) were performed in 
BHIS broth composed of 3.7 % BHI (Oxoid, CM1135), 0.5 % Yeast Extract (BD Bacto, 210929), 0.1 % L-
cysteine (Sigma Aldrich). All cultures were grown at 37 °C under a reducing anaerobic atmosphere 
(10 % CO2, 10 % H2, and 80 % N2). All cultures were supplemented where appropriate with 
antibiotics: either erythromycin at 5 μg mL-1, thiamphenicol at 15 μg mL-1, chloramphenicol at 15 μg 
mL-1, cycloserine at 250 μg mL-1, or a combination thereof. All media was pre-reduced for at least 
2 hours prior to inoculation. Bacterial growth was monitored by measuring the Optical Density at 
600 nm (OD600) using a Spectronic Heλios ε spectrometer (Thermo Scientific, Waltham, MA). 
C. difficile cultured for the incorporation of isotopically labelled amino acids, or to be grown in the 
absence of any one amino acid, was grown in defined media (CDDM); isoleucine was replace with 
13C6
15N isoleucine for isotopically heavy cultures 324.  For selection of mutants created by allele 
coupled exchange minimal agar (CDMM) was used, supplemented with 50 µg mL-1 5-
fluorocytosine98. The composition of CDDM and CDMM is given in Table 7. 
Table 7: The composition of the defined media (CDDM) and agar (CDMM) used for C. difficile culture. 
CDDM Media CDMM Agar 
Component Concentration/ mg L-1 Component Concentration/ mg L-1 
Salts  Salts  
KH2PO4 300 KH2PO4 900 
Na2HPO4 1500 Na2HPO4 5000 
NaCl 900 NaCl 900 
CaCl2.2H2O 26 CaCl2.2H2O 26 
MgCl2.6H2O 20 MgCl2.6H2O 20 
MnCl2.4H2O 10 MnCl2.4H2O 10 
(NH4) 2SO4 40 (NH4) 2SO4 40 
FeSO4.7H2O 4 FeSO4.7H2O 4 
CoCl2.6H2O 1 CoCl2.6H2O 1 
NaHCO3 5000 NaHCO3 5000 
Glucose  Glucose  
D-Glucose 2000 D-Glucose 10000 
Vitamins  Vitamins  
Calcium-D-
pantothenate 
1 
Calcium-D-
pantothenate 
1 
Biotin 0.0125 D-Biotin 1 
Pyridoxine 0.1 Pyridoxine 0.1 
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L-Amino Acids  L-Amino Acids  
Arginine 100 Casamino acids 10000 
Cysteine 500 Tryptophan 500 
Glycine 100 Cysteine 500 
Histidine 100 Agar  
Isoleucine 100 Agar (DB Bacto) 1% (w/v) 
Leucine 1000   
Methionine 100   
Proline 800   
Threonine 100   
Tryptophan 100   
Valine 100   
 
9.1.1.3. Escherichia coli Culture Conditions 
E. coli strains were routinely cultured on LB agar (VWR); liquid cultures were grown in LB broth 
(VWR). Media was supplemented where appropriate with chloramphenicol at a concentration of 
15 µg mL-1 (Sigma Aldrich). All liquid E. coli cultures were grown overnight with shaking (225 rpm) at 
37 °C; cultures on agar were grown statically at 37 °C. 
9.1.1.4. Storage of Strains 
All bacterial strains were stored as frozen stocks by mixing 400 µL of sterile 70 % glycerol (Sigma 
Aldrich) with 1 mL of an overnight culture to give a 20 % glycerol stock, which was immediately 
frozen at -80 °C. For freezing C. difficile cultures, the 70 % glycerol was pre-reduced in the anaerobic 
cabinet for at least 1 hour prior to use. 
9.1.2. DNA Manipulation and Cloning 
9.1.2.1. Genomic DNA 
C. difficile genomic DNA (gDNA), prepared as described by Wren and Tabaqchali 385, was provided by 
Dr Stephanie Willing (Imperial College London). 
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9.1.2.2. Chelex DNA Preparation 
DNA preparations for routine colony screening were extracted using 5 % (w/v) Chelex 100 resin 
(Bio-Rad) in nuclease-free water. Single colonies were suspended in 100 µl of 5 % Chelex, boiled for 
10 minutes at 100 °C and pelleted at 10,000 x g for 1 minute. Approximately 80 % of the 
supernatant, containing DNA, was transferred to a clean tube for further analysis. 
9.1.2.3. Plasmid DNA extraction 
Plasmid DNA was extracted from 5 mL overnight cultures of E. coli using the QIAprep spin kit 
(Qiagen) according to manufacturer’s instructions, eluting in 30 to 50 µL of nuclease-free water. 
9.1.2.4. Polymerase Chain Reaction (PCR) 
All reactions were carried out using a GS2 Thermal Cycler (G-Storm) or a Prime Thermal Cycler 
(Techne). Primers used throughout this study were synthesised by Sigma Aldrich and are listed in 
Appendix A. 
Screening and colony PCR was carried out using Taq polymerase (Sigma) according to manufacturer’s 
protocol, in a total volume of 20 µL (1x PCR buffer, 2.5 mM MgCl2, 0.2 mM dNTPs, 0.3 µM forward 
and reverse primers, 0.1 µL Taq polymerase). Initial denaturation was at 94 °C for 3 min followed by 
thirty cycles of denaturation at 94 °C for 30 seconds, annealing at the lowest primers Tm for 1 
minute and extension at 72 °C for 1 minute per kb. A final extension at 72 °C for 10 minutes was 
included to ensure completion of DNA synthesis. 
Amplification of gDNA fragments for cloning purposes, or the amplification of particularly long DNA 
fragments, was carried out using KOD Hot Start polymerase (Merck). PCR was performed according 
to manufacturer’s guidelines in a total volume of 20 µL or 50 µL (1x PCR buffer, 1 mM MgSO4, 
0.2 mM dNTPs, 0.3 µM forward and reverse primers, 0.02 U KOD). Initial denaturation was at 95°C 
for 2 minutes followed by thirty cycles of denaturation at 95 °C for 20 seconds, annealing at the 
lowest primers Tm for 10 seconds and extension at 70 °C for 15 seconds per kb. A final extension at 
70 °C for 10 minutes was included to ensure completion of DNA synthesis.  
9.1.2.5. Purification of PCR Reactions 
PCR-amplified DNA fragments were purified using the QIAquick PCR purification kit according to the 
manufacturer’s guidelines. 
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9.1.2.6. Restriction Endonuclease Digestion and Fragment Purification 
All restriction endonuclease digests were carried out using enzymes provided by New England 
Biolabs (NEB) according to the manufacturer’s guidelines. PCR products and plasmid DNA were 
digested at 37 °C for at least 2 hours; digests of PCR products were purified using the QIAquick PCR 
purification kit (section 9.1.2.5), while plasmid digests were separated by agarose gel electrophoresis 
and the DNA extracted using the QIAquick Gel Extraction kit (Qiagen) according to manufacturer’s 
guidelines, eluting in 30 to 50 µL of nuclease-free water. 
9.1.2.7. Agarose Gel Electrophoresis 
Agarose gels were prepared by melting 0.8 % (w/v) agarose powder (Invitrogen) in 1x TAE (40 mM 
Tris-Acetate, 2 mM Na2EDTA, pH 8.3). SybrSafe DNA stain (1 in 10,000) was added and the gel was 
cast on a horizontal perspex plate. When fully set, gels were immersed in a tank containing 1x TAE. 
DNA samples were mixed with 0.1 volumes of 10x DNA loading buffer and loaded into the gel wells. 
10 µL of 1 kB DNA Ladder (NEB) was used to assess the size of DNA fragments run. Electrophoresis 
was performed at a constant voltage of 90 V for approximately 40 minutes. DNA was visualised on a 
UV transilluminator at 312 nm and images taken using InGenius (Syngene). 
9.1.2.8. DNA Ligation 
Ligation reactions were carried out using QuickStick ligase (Bioline) according to manufacturer’s 
guidelines; 50 ng of Vector DNA in nuclease-free water was combined with 5 μL of 4x QuickStick 
ligase buffer, 1 μL of QuickStick ligase and the required volume of insert for a 3:1 molar ration 
(insert: vector). The reaction was made up to a total volume of 20 μL with nuclease-free water and 
incubated at RT for 15 to 45 minutes. 
9.1.2.9. Transformation of E. coli 
Competent E. coli (NEB5α or CA434) cells, in 25 µl aliquots, were transformed with 2.5 µL of ligation 
reaction and incubated on ice for 30 minutes. The transformations were heat shocked at 42 °C for 
30 seconds and incubated on ice for a further 5 minutes. The E. coli cells were diluted with 150 µL 
SOC medium and incubated at 37 °C for one hour with shaking at 225 rpm. A 10 fold dilution in SOC 
media was made and 100 µL of the neat culture and the dilution spread (separately) onto LB agar 
plates supplemented chloramphenicol to 15 µg mL-1. 
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9.1.2.10. DNA Sequencing 
Sequencing was carried out by GATC Biotech (Konstanz, Germany) on purified plasmid DNA or PCR-
amplified DNA fragments. Sequencing primers were provided at a concentration of 10 pmol µL-1 or 
synthesised directly by GATC. 
9.1.2.11. E. coli to C. difficile Conjugation 
Shuttle plasmids derived from pMTL960 were transformed into E. coli CA434 as detailed above and 
conjugated into C. difficile as described by Purdy and co-workers386. Briefly, 1 mL of an overnight 
culture of the donor E. coli strain was harvested by centrifugation and gently washed with 1 mL of 
1x PBS  (4,500 x g, RT, 5 minutes).  The PBS was removed by aspiration and the pellets taken into the 
anaerobic cabinet and mixed with 200 µL of an overnight culture of the recipient C. difficile, or BHIS 
as a negative control. The resulting mixture was spotted onto non-selective BHIS agar and incubated 
anaerobically for 6 to 8 hours. The resulting colonies were re-suspended in 1 mL of sterile 1x PBS and 
200 µL spread onto BHIS agar supplemented with thiamphenicol (15 µg mL-1) to select for cells that 
contained the pMTL960-based plasmid and cycloserine (250 µg mL-1) to counter select against E. coli. 
Single colonies from the conjugation plates were re-streaked at least twice on selective BHIS plates 
to ensure eradication of the E. coli before being used for further experiments. 
9.1.2.12. ClosTron Mutagenesis 
All C. difficile ClosTron mutants were generated in C. difficile 630 Δerm by Dr Andrea Kovacs-Simon 
at the University of Exeter; a bacterial group II intron containing a retrotransposition-activated 
marker (RAM) conferring erythromycin resistance was inserted into the gene of interest using the 
ClosTron clostridial gene knockout system92a.  
9.1.2.13. Gibson Assembly 
Plasmids for the creation of clean, in-frame, deletion mutants in C. difficile 630 Δerm were generated 
by cloning PCR amplified (section 9.1.2.4) 1,200 bp upstream and downstream homologous regions 
into pMTL-SC7315 using the Gibson Assembly kit (NEB) according to the manufacturer’s guidelines. 
9.1.2.14. Deletion Mutagenesis by Allele Coupled Exchange (ACE) 
ACE mutants were generated using plasmids produced by Gibson Assembly, which were conjugated 
into C. difficile 630 as described above. The selection of ACE mutants was performed as described by 
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Cartman and co-workers 98. Briefly, transconjugants were re-streaked on BHIS supplemented with 
15 µg mL-1 thiamphenicol and 250 µg mL-1 cycloserine; single crossover integrant clones were 
identifiable as larger, faster growing colonies after 18 to 24 hours. Single crossover clones were 
selected and re-streaked to purity, which was assessed and confirmed by Chelex preparation and 
Kod PCR as described above. Pure single crossovers were re-streaked onto nonselective BHIS 
medium and incubated for 4 days to allow a second recombination event to occur. The colonies 
were scraped into 1 mL of PBS and serial dilutions were made, down to 10-6; 100 µL of each dilution 
was spread onto CDMM agar supplemented with 50 µg mL-1 5-fluorocytosine. After 6 days of 
incubation, 5-fluorocytosine resistant colonies were re-streaked onto CDMM agar and BHIS 
supplemented with 15 µg mL-1 thiamphenicol and 250 µg mL-1 cycloserine. Fluorocytosine resistant, 
thiamphenicol sensitive colonies were mutant candidates and were screened by PCR to distinguish 
double crossover recombinant clones from wild-type revertants. The candidate double cross-overs 
were confirmed by sequencing using primers external and internal to the homologous regions. 
9.1.3. Phenotypic Assays 
9.1.3.1. Toxin ELISA 
Secreted Toxin A and B were detected and quantified, relative to a positive control, using an ELISA 
kit (tgcBIOMICS, Product TGC-E002-1) according to the manufacturer’s guidelines. 
9.1.3.2. Sporulation Efficiency Assay 
Overnight cultures of the required C. difficile strains, in pre-reduced BHIS broth, were sub-cultured, 
normalising to an OD600 of 0.10 in pre-reduced BHIS broth and allowed to grow up to an OD600 of 
approximately 0.60. A second sub-culture in pre-reduced BHIS was performed, diluting to an OD600 
of 0.10 and these cultures were allowed to grow to an OD600 of approximately 0.60; these steps were 
taken to minimise any spore carry over from the initial culture and to ensure synchronously growing 
cultures. The second sub-culture was then diluted again to an OD600 of 0.10 in 30 mL of BHIS and 
allowed to grow overnight to stationary phase, at which the first time point was taken. 
Colony forming units were counted as follows, for the inoculated culture and then every 24 hours 
from stationary, for a total of 120 hours. Total viable counts were performed by preparing 10-fold 
serial dilutions, down to 10-7, in sterile pre-reduced PBS and spotting 10 µL in technical triplicate 
onto pre-reduced BHIS agar supplemented with 0.1 % sodium taurocholate. Spores counts were 
assessed by heat treating an aliquot of the culture at 80 °C for 45 minutes prior to dilution and 
 272 
plating aerobically as described above. In order to differentiate between sporulation and 
germination defects the entire experiment was followed by phase-contrast microscopy; 1 mL of the 
culture was removed at each time point and slides prepared as described below (section 9.1.3.3). 
9.1.3.3. Phase-Contrast Microscopy  
 Slides were prepared by harvesting a 1 mL aliquot of the culture at 6,800 x g, RT, 1 minute. The 
pellet was washed twice with 1 mL of PBS (6,800 x g, RT, 1 minute), and fixed in 1 mL of 8 % 
formaldehyde in PBS and incubated at room temperature for 1 hour. The samples were washed 
twice with 500 µL of 18 MΩ water and spotted onto glass slides. Slides were allowed to dry 
overnight, mounted in 18 MΩ water and imaged using a Nikon Eclipse E600 microscope fitted with a 
Retiga 2000R Fast 1394 camera. 
9.1.4. Protein Manipulation and Metabolic Tagging 
9.1.4.1. S-Layer Extraction 
S-layer extracts were prepared using a low pH glycine method 312. An overnight C. difficile culture in 
TY broth, grown for no more than 18 hours, was harvested by centrifugation (3,550 x g, 10 minutes, 
RT). The supernatant was discarded into disinfectant and the pellet washed with 1/10 volume of 
PBS. The supernatant was discarded, the pellet re-suspended in 1/100 volume of 0.2 M glycine-HCl, 
pH 2.2, and incubated at RT with gentle agitation for 20 minutes. The suspension was centrifuged 
(25,000 x g, 10 minutes, 4 °C), the supernatant containing the SLPs was transferred to a clean 
microfuge tube and neutralised to pH 7-8 by the addition of 2 M Tris base. 
9.1.4.2. Treatment of C. difficile Cultures with Fatty Acid Analogues 
An overnight culture of C. difficile in TY broth was sub-cultured to an OD600 of 0.05. The subculture 
was allowed to grow to early exponential phase (OD600 ≈0.3) before being split into aliquots, if 
required. Each culture or aliquot was treated with a DMSO solution containing an azide- or alkyne-
tagged fatty acid analogue (e.g. YnC12); both the probe and the concentration were varied between 
samples and experiments with the final concentration of DMSO for each culture fixed at 1 %. 
Typically a final YnC12 concentration of 25 µM was used for metabolic tagging. The cultures were 
then allowed to grow to stationary phase over 7 to 8 hours before cell lysis. 
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9.1.4.3. Cell Lysis and Fractionation 
Cell lysis and fractionation was performed via a freeze-thaw protocol optimised from that previously 
reported by the Fairweather group58. Overnight cultures of C. difficile were harvested by 
centrifugation (5,000 x g, 10 minutes, RT) and the media poured off into disinfectant. The bacterial 
pellets were washed twice with 500 μL of PBS (5,000 x g, 10 minutes, RT) and the pellets frozen 
at -20 °C overnight. The bacterial pellets were re-suspended in PBS containing 1.4 mg mL-1 lysozyme, 
0.12 µg mL-1 DNase I and 30 µg mL-1 of a C. difficile specific phage endolysin347b, to a relative OD600 of 
80. The samples were incubated at 37 oC for 1 hour. The membranes and insoluble proteome were 
harvested by centrifugation (25,000 x g, 10 minutes, 4 oC) and the supernatant was removed; this 
fraction contains the soluble cytoplasmic proteins. The insoluble membrane pellets were washed 
twice with 500 μL of PBS, re-suspended in PBS to a final OD600 of 80 and solubilised by the addition of 
SDS to a final concentration of 1 %. Any aggregates were pelleted by centrifugation at 17,000 x g, 10 
minutes, RT and approximately 80 % of the supernatant removed to clean tubes. The protein 
concentration of the samples was then determined as described in section 9.1.4.4. 
For the detection of His-tagged proteins the after harvest and washing with PBS, as described above, 
the bacterial pellets were frozen at -80 °C for 15 minutes then thawed at RT for 15 minutes. This 
freeze-thaw was cycle repeated a total of 3 times and the endolysin, which featured a His-tag, was 
then be omitted from the lysis step while still achieving consistent lysis. Following the freeze-thaw 
cycle the bacterial pellets were re-suspended in PBS containing 1.4 mg mL-1 lysozyme and 
0.12 µg mL-1 DNase I, to a relative OD600 of 80. The samples were incubated at 37 
oC for 1 hour and 
the membranes and insoluble proteome were harvested, washed and solubilised as described 
above. 
9.1.4.4. Protein Concentration Determination 
Protein concentration was determined using the BioRad DC Protein Concentration Assay using Bio-
Rad standard reagents and measuring the absorbance at 750 nm. BSA (Sigma Aldrich) was used to 
generate a standard curve. 
9.1.4.5. SDS-PAGE and Gel Visualisation 
SDS-PAGE was performed using Mini-PROTEAN 3 apparatus (Bio-Rad Laboratories). Acrylamide gel 
solutions (14 %) were prepared as outlined below in Table 8. Following the addition of the APS and 
TEMED to the resolving gel mix approximately 4.5 mL of the solution was pipetted between the glass 
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plates and 0.5 mL of isopropanol layered on top. The resolving gel was allowed to polymerise for 
30 minutes, the isopropanol poured off and the gel allowed to dry. The APS and TEMED were added 
to the stacking gel and the solution layered on top of the resolving gel. The desired comb was 
inserted and the stacking gel allowed to polymerise for 30 minutes.  
Once the polymerisation was complete the comb was removed and the gel running apparatus 
assembled; approximately 450 mL of Running Buffer (25 mM Tris Base, 192 mM glycine, 0.1 % SDS) 
was used to immerse the gel, completely filling the upper compartment. Samples were diluted using 
2x Sample Loading Buffer (Neupage) to the desired concentration, 1x Sample Loading Buffer. 
10 to 15 μL of each protein sample was loaded per well, with at least one well reserved for the 
protein size marker (3 μL of Precision Plus “All Blue” Standards, Bio-Rad Laboratories). An equal 
volume of 1x Sample Loading Buffer was added to any empty wells. Gels were run at 200 V for 
55 minutes. 
Table 8: Recipe for SDS-PAGE resolving & stacking gels. Sufficient for two 1.0 mm mini-gels
312
. 
14% SDS-PAGE Resolving Gel 5% SDS-PAGE Stacking Gel 
30 % Acrylamide/ bis-acrylamide 4.7 mL 30 % Acrylamide/ bis-acrylamide 833 μL 
1.5 M Tris-HCl, pH 8.8 2.5 mL 1.5 M Tris-HCl, pH 8.8 1.25 mL 
18 mΩ Water 2.7 mL 18 mΩ Water 2.87 mL 
10 % SDS 100 μL 10 % SDS 50 μL 
10 % APS 50 μL 10 % APS 25 μL 
TEMED 10 μL TEMED 5 μL 
 
Gels were imaged by in-gel fluorescence and Coomassie staining. Prior to imaging, gels were fixed 
for 30 minutes in 45 % methanol (v/v), 10 % acetic acid (v/v) and rehydrated for at least 15 minutes 
in 10 % acetic acid. Visualisation by fluorescence was carried out using an Ettan™ DIGE Imager (GE 
Healthcare); the Cy3 channel was used to detect TAMRA-labelled proteins and the Cy5 channel to 
detect the molecular weight markers. The results were analysed with ImageQuant™ TL software. For 
detection of all proteins the gels were covered in Coomassie stain (0.25 % (w/v) Coomassie Brilliant 
Blue R-250, 45 % (v/v) methanol, 10 % (v/v) acetic acid) and incubated for at least an hour with 
gentle agitation. The gels were then washed and covered with 45 % methanol (v/v), 10 % acetic acid 
(v/v) solution and incubated at room temperature until the background staining had been reduced 
to an acceptable level. The gels were rehydrated with 10 % acetic acid prior to imaging. 
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9.1.4.6. Semi-Dry Transfer 
Following separation by SDS-PAGE proteins were semi-dry transferred onto PVDF membranes for 
Western-immunoblot analysis. The gel was equilibrated in Cathode buffer (40 mM glycine; 25 mM 
Tris-HCl in 10 % methanol, pH 9.4) for approximately 10 minutes and the PVDF membrane wet with 
methanol, washed with water and soaked in anode II buffer (25 mM Tris-HCl in 10 % methanol, 
pH 9.4) for approximately 5 minutes. The transfer stack was then assembled as follows; two pieces 
of Whatman 3 mm filter paper soaked in anode I buffer (300 mM Tris-HCl in 10 % methanol, 
pH 10.4) were placed on the anode, followed by one piece of filter paper soaked in anode II buffer, 
the membrane and the equilibrated gel, followed by three pieces of filter paper soaked in cathode 
buffer. The proteins were transferred at a constant voltage of 15 V for 15 minutes for one gel, or 
25 minutes for the simultaneous transfer of two gels. To assess the efficiency of the transfer and 
visualise the molecular weight marker membranes were stained (0.1 % Ponceau S (w/v) in 5 % acetic 
acid), destained in water, dehydrated with methanol and dried at RT for 30 minutes. 
9.1.4.7. Western blotting 
Membranes were incubated with primary antibodies in 3 % non-fat milk in PBS for 1 hour at RT. The 
membrane was washed four times with approximately 50 mL of PBS and the membrane covered 
with the HRP-conjugated secondary antibody in 3 % milk in PBS. The membranes were incubated at 
RT for 30 minutes and washed with PBS as above. The membrane was dried briefly on absorbent 
paper and covered with Enhanced Chemiluminescent Substrate (SuperSignal West, Pico). The 
membrane was exposed using a Las 4000 imager (Fuji). 
9.1.5. Bioinformatic Analysis 
9.1.5.1. DNA Analysis 
Geneious 6.1.6 (Biomatters Ltd, New Zealand) was used for visualisation and analysis of C. difficile 
genomes, in silico PCR, restricition digest, cloning, primer and plasmid design. The genome viewer 
Artemis (http://www.sanger.ac.uk/resources/software/artemis/)283 was also used to analyse 
C. difficile genomes. NEBuilder (http://nebuilder.neb.com/) was used to design primers for use in 
Gibson Assembly (section 9.1.2.13) 
 276 
9.1.5.2. Protein Analysis 
The pattern matching tool ScanProsite (http://prosite.expasy.org/scanprosite/)277 was used to 
identify proteins that feature a Type II signal peptide; these were also identified using the online tool 
LipoP (http://www.cbs.dtu.dk/services/LipoP/)278. Type I signal peptides were predicted using the 
online tool SignalP (http://www.cbs.dtu.dk/services/SignalP/)279; predictions of transmembrane 
helices were made  using the online tools Phobius (http://phobius.sbc.su.se/)280 and TMMHMM 
(http://www.cbs.dtu.dk/services/TMHMM/). Protein alignments were created using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) via Geneious and annotated using Chroma 
(http://www.llew.org.uk/chroma/)387. Protein annotations and FASTA files were extracted using 
Uniprot (http://www.uniprot.org/) and BLAST searches conducted using the online tool available at 
http://www.uniprot.org/blast/. Proteins of unknown function were further investigated using the 
Protein Families database, pfam (http://pfam.xfam.org/). Analysis of proteomic data is described in 
section 9.2.11. 
9.2. Chemical Biology & Proteomic Analysis 
9.2.1. General Reagents 
All reagents and buffers were purchase from Sigma Aldrich, Fisher Scientific or VWR Scientific, unless 
otherwise indicated. Streptavidin Dynabeads and neutravidivin agarose beads were purchased from 
Invitrogen (3 Fountain Drive, Paisley, UK). Ultrapure water (18.2 MΩ) was used for the preparation 
of all solutions and buffers and obtained from a Millipore Elix Q-gard purification system. 
Globomycin was purchased from Sigma Aldrich and used without any further purification. All 
dimethyl labelling reagents were purchased from Sigma Aldrich and used without further 
purification. All buffers were filtered (0.2 µM) before use in proteomic applications and low protein 
binding tubes (Protein LoBind tubes, Eppendorf) used during the enrichment and digestion of 
protein for proteomic analysis, as well as to dry the digested peptides under vacuum. LC-MS grade 
acetonitrile and water for proteomic analysis were purchased from Fisher Scientific and 
supplemented with 0.5% TFA. 
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9.2.2. Protein Precipitation 
9.2.2.1. Methanol 
Protein samples were diluted in 10 volumes of ice cold methanol, vortexed briefly and stored at -
80 °C overnight. The proteins were pelleted by centrifugation (17,000 x g, 4 °C, 30 minutes) and 
washed with ice cold methanol. The supernatant was carefully removed and the pellet air dried to 
remove the remaining methanol. 
9.2.2.2. Tri-Chloroacetic Acid (TCA) 
10 % (v/v) of a 100 % TCA solution was added and the sample, typically culture supernatants, 
vortexed briefly then incubated on ice for 30 minutes. The sample was centrifuged (25,000 x g, 4 °C, 
10 minutes), the supernatant discarded and the pellet re-suspended with 1 mL of ice cold 90 % 
acetone. The protein suspension was vortexed for 15 minutes then centrifuged (25,000 x g, 4 °C, 
10 minutes). The supernatant was discarded and the pellet washed with 1 mL of ice cold 90 % 
acetone. The protein was harvested by centrifugation (25,000 x g, 4 °C, 15 minutes) and the 
supernatant carefully removed. The pellet was dried at 50 °C for 5 minutes then re-suspended in PBS 
to the desired concentration, following the addition of approximately 3 % (v/v) 2 M Tris base to 
quench any residual TCA. 
9.2.2.3. Chloroform/ Methanol Precipitation 
The sample was diluted consecutively with 4 volumes of ice cold methanol, 1 volume of chloroform 
and finally 3 volumes of water; the sample was vortexed after each addition. The proteins were 
precipitated to the interface by centrifugation (17,000 x g, RT, 10 minutes) and the 
aqueous/methanol layer removed. A further 4 volumes of methanol were added and the sample 
vortexed. The proteins were pelleted by centrifugation (17,000 x g, RT, 10 minutes) and the 
supernatant was carefully removed. The pellets were washed twice with 4 volumes of cold methanol 
(17,000 x g, RT, 10 minutes) and air dried at room temperature for approximately 10 minutes.  
9.2.2.4. Pre-precipitation to Deplete LTAs 
A double chloroform/ methanol precipitation was performed prior to click chemistry, if required, to 
deplete the samples of lipoteichoic acids and enable efficient pull down of labelled proteins. Protein 
precipitation was performed twice sequentially, as described above (section 9.2.2.3), with the 
omission of the wash steps. Following both precipitations the pellets were air dried at room 
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temperature for approximately 10 minutes and re-suspended to 10 mg mL-1 in 2 % SDS in PBS by 
vortexing and sonication, then sequentially diluted to 1 mg mL-1 by the addition of PBS. 
9.2.3. Click Chemistry 
Click Chemistry reagents were made up as described below 206. The click reaction was typically 
carried out on 100 to 200 μL of a 1 mg mL-1 protein solution in 0.2 % SDS in PBS. Components 1 to 4 
were premixed in the order shown, vortexing after the addition of each reagent and allowing 2 
minutes following the addition of the TCEP to reduce the copper. The click solution was then added 
to the samples to give the final concentration indicated and the reaction shaken at RT for 1 hour. 
The click reaction was quenched by the addition of EDTA to a final concentration of 10 mM and the 
protein recovered by chloroform/ methanol precipitation. The samples were then re-suspended in 
2 % SDS, 3 % IGEPAL-CA630 (Sigma Aldrich), 10 mM DTT and 10 mM EDTA to 10 mg/mL by vortexing 
and sonication, then sequentially diluted to 1 mg mL-1 by the addition of PBS. 
Table 9: Click reagents and their stock solutions; stored at -20 °C. 
 Reagent Stock Concentration Final Concentration 
1 Capture reagent (Azide) 10 mM in DMSO 100 μM 
2 CuSO4 50 mM in H2O 1 mM 
3 TCEP 50 mM in H2O 1 mM 
4 TBTA 10 mM in DMSO 100 μM 
  
9.2.4. Pull Down 
Avidin-coupled beads (Invitrogen), at 300 μL per mg of protein, were washed three times with 10 
volumes of 0.2 % SDS in PBS, centrifuging at 3000 x g, 2 minutes, RT. The “clicked” protein samples 
were added to the beads and incubated at room temperature with gentle shaking for 2 hours. For 
SDS-PAGE analysis the supernatant was removed and the beads washed four times with 10 volumes 
of 0.2 % SDS in PBS. The bound proteins were eluted by boiling at 95 °C for 10 minutes in 2 % SDS in 
PBS. For proteomic analysis the beads were washed (3000 x g, 2 minutes, RT) with 10 volumes of 1 % 
SDS in PBS (x3), 4 M urea in PBS (x2) and 50 mM ammonium bicarbonate solution (AMBIC, x5), with 
vortexing between each wash. Approximately 10 µg equivalent of the beads were removed prior to 
the final wash for a control SDS-PAGE gel, if required. The beads were stored under approximately 
50 µL of 50 mM AMBIC at 4 oC prior to reduction, alkylation and on-bead digest. 
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9.2.5. On Bead Reduction, Alkylation and Tryptic Digest 
Enriched proteins were reduced by the addition of 100 mM DTT in 50 mM AMBIC to the beads, at a 
final concentration of 10 mM DTT.  The proteins were incubated at 55 oC for 30 minutes. The beads 
were washed twice with 10 volumes of 50 mM AMBIC (3000 x g, 2 minutes, RT) and left under 
approximately 50 µL of 50 mM AMBIC. The proteins were then alkylated by the addition of 100 mM 
iodoacetamide in 50 mM AMBIC to a final concentration of 10 mM iodoacetamide. The samples 
were stored in the dark at RT for 30 minutes. The beads were washed twice with 10 volumes of 
50 mM AMBIC (3000 x g, 2 minutes, RT) and left under approximately 50 µL of 50 mM AMBIC. For 
each 50 µL of beads in 50 mM AMBIC, 1 µg of Trypsin was added (from a 20 µg/100 µL solution in 
50 mM AMBIC). The samples were spun down briefly and incubated with shaking at 37 oC overnight. 
The beads were then washed with 80 µL of 50 mM AMBIC by vortex mixing for 10 minutes at RT and 
centrifuging at 3000 x g, 2 minutes, RT. The supernatant containing the peptide mixture was 
removed to a clean microcentrifuge tube and the beads washed with 80 µL of 0.1 % formic acid. The 
supernatant was removed, combined with the above and the peptides desalted using StageTips. 
9.2.6. Proteomic Digest of Lysates 
Prior to digest 25 µg of lysate was precipitated to remove detergents present in the sample; 100 µL 
of methanol, 25 µL of chloroform and 100 µL of water were added, the sample vortexed and the 
proteins were precipitated to the interface by centrifugation (17,000 x g, RT, 10 minutes). The 
aqueous/methanol top layer removed and a further 100 µL of methanol was added and the sample 
vortexed. The proteins were pelleted by centrifugation (17,000 x g, RT, 10 minutes) and the 
supernatant was carefully removed. The pellet was air dried at RT for 10 minutes then resuspended 
in 40 µL of 5 mM DTT in 50 mM AMBIC by vortex mixing and sonication. The sample was spun down 
briefly and incubated at 55 oC for 30 minutes. Next, 2 µL of 100 mM iodoacetamide in 50 mM AMBIC 
was added to each sample (to 0.2 mM) and the samples incubated at RT in the dark for 30 minutes. 
5 µL of trypsin (20 µg/ 100 µL in 50 mM AMBIC) was added, the samples spun down briefly and 
incubated with shaking at 37 oC overnight.  The digests were quenched by the addition of TFA to 
0.5 % and the peptides desalted using StageTips. 
9.2.7. StageTip Desalting for Label Free and SILAC Proteomic Analysis 
Digested peptides were desalted on StageTips, following a method developed from that described 
by Rappsilber and co-workers329. C18 SDB-XC disks (3M) were cut and fitted into p200 pipette tips as 
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described. The StageTips were washed with 150 µL of methanol, centrifuging at 2000 x g, 2 minutes, 
RT to draw the methanol through the C18 disks. The StageTip was then equilibrated with 150 µL of 
water, centrifuging at 2000 x g, 2 minutes, RT, before the peptides were loaded by centrifugation 
(2000 xg, 2 minutes, RT). The peptides were desalted by washing with 150 µL of water (2000 x g, 
2 minutes, RT) then eluted into a clean eppendorf tube with 60 µL of 79 % acetonitrile, centrifuging 
at 2000 x g, 2 minutes, RT. The eluted peptide solution was dried under vacuum and the dry 
peptides were stored at -80 oC until LC-MS/MS analysis. The peptides were then dissolved in 30 µL of 
0.5 % TFA, 2 % acetonitrile in water by vortex mixing for 5 minutes and sonication for 20 minutes. 
The samples were then centrifuged at 17,000 x g, 10 minutes, 7 oC to remove any aggregates and 
approximately 60 % of the samples transferred to auto-sampler vials for LC-MS/MS analysis. 
9.2.8. In-Solution Dimethyl Labelling 
Whole proteome digests were dimethyl labelled in solution following the method developed by 
Boersema and co-workers 274b. For duplex labelling light and medium dimethylation conditions were 
used; for triplex labelling heavy samples were included, labelling as described in Table 10. Following 
tryptic digest the peptides were StageTipped and dried under reduced pressure; the peptides were 
then re-suspended in 100 µL of 100 mM TEAB by vortex mixing and sonication and the pH adjusted 
to within the 5 to 8.5 range with 5 % formic acid, if required. To the samples 4 µL of 4 % 
formaldehyde, or deuterated formaldehyde for medium and heavy samples, was added and the 
samples were mixed briefly and spun down. 4 µL of 0.6 M sodium cyanoborohydride for light and 
medium, or sodium cyanoborodeuteride for heavy samples, was added and the dimethyl labelling 
reactions shaken at room temperature for 1 hour. The reactions were quenched with 16 µL of 1 % 
ammonia, vortex mixed and spun down; 8 µL of 5 % formic acid was added to the samples on ice. An 
equal volume of the labelled samples were combined and desalted on StageTips. 
Table 10: In solution dimethyl labelling conditions. 
Dimethyl Label Components 
Light 4 µL of 4 % (v/v) CH2O solution and 4 µL 0.6 M NaBH3CN 
solution, in 100 mM TEAB, for 100 µL of sample. 
Medium 4 µL of 4 % (v/v) CD2O solution and 4 µL 0.6 M NaBH3CN 
solution, in 100 mM TEAB, for 100 µL of sample. 
Heavy 4 µL of 4 % (v/v) 13CD2O solution and 4 µL 0.6 M NaBD3CN 
solution, in 100 mM TEAB, for 100 µL of sample. 
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9.2.9. On StageTip Dimethyl Labelling 
Dimethyl labelling on StageTips was performed on peptides producted by on-bead digestion, 
building on work by Li and co-workers 336. 
Table 11: The following solutions were used for on StageTip dimethyl labelling. 
Buffer Name Components 
PB 7.5 A mix of 2 mL of 50 mM Na2HPO4 and 7 mL of 50 mM NaH2PO4 
Light Labelling Buffer A mix of 90 % (v/v) PB 7.5, 5 % (v/v) of a 4 % (v/v) CH2O 
solution in water and 5% of a 0.6 M NaBH3CN solution in 
water. 
Medium Labelling Buffer A mix of 90 % (v/v) PB 7.5, 5 % (v/v) of a 4 % (v/v) CD2O 
solution in water and 5 % of a 0.6 M NaBH3CN solution in 
water. 
Heavy Labelling Buffer A mix of 90 % (v/v) PB 7.5, 5 % (v/v) of a 4 % (v/v) 13CD2O 
solution in water and 5 % of a 0.6 M NaBD3CN solution in 
water. 
 
The samples were prepared on StageTips as described in section 9.2.7. Before elution 20 µL of 
freshly prepared light, medium or heavy labelling buffer was added to the top of the StageTips. The 
samples were centrifuged at 200 x g, 5 minutes, RT; this speed was adjusted as required such that it 
took at least 5 minutes for 20 µL of labelling buffer to flow through the StageTips. This was repeated 
a further four times so that the peptides on the StageTips were exposed to the labelling buffer for at 
least 25 minutes. The StageTips were then centrifuged at 2000 x g, 2 minutes, RT, to pull any excess 
labelling buffer through and the labelled peptides washed with 150 µL of water (2000 x g, 1 minute, 
RT). The labelled peptides were eluted into a clean microcentrifuge tube by adding 60 µL of 79 % 
acetonitrile to the top of the tip and centrifuging at 2000 x g, 2 minutes, RT. An equal volume of each 
sample was mixed (either 1:1, light: medium or 1:1:1 light: medium: heavy). The mixed dimethyl 
labelled peptide solutions were dried under vacuum and the dry peptides stored at -80 °C until LC-
MS/MS time became available. The peptides were then dissolved in 30 µL of 0.5 % TFA, 2 % 
acetonitrile in water as described in section 9.2.7. 
9.2.10. UHPLC-MS/MS 
Samples for proteomic analysis were prepared as described above and the peptide mixtures 
separated on an Easy-Nano LC1000 (Thermo Scientific) equipped with an Acclaim Pepmap 100 pre-
column and an EASY-Spray 50 cm x 75 µm Pepmap C18 column (Thermo Scientific) eluting running a 
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gradient of 2 % Acetonitrile, 0.1 % FA, to 98 % Acetonitrile, 0.1 % TFA in water at a flow rate of 
250 nL min-1, over 2 hours. All solvents used were LCMS grade; a typical injection volume of 2 to 3 µL 
of samples was used for samples prepared by on-bead digest, from 200 µg of protein pre-pull down, 
or 1 µL for a digest of 25 µg of lysate. The nano-LC was connected directly to a Q-Exactive 
Quadrupole-Orbitrap Mass Spectrometer (Thermo Scientific) for MS/MS analysis, via a heated EASY-
Spray source (Thermo Scientific) operated at a spray voltage of 1.7 kV. The Q-Exactive was run in 
positive ion mode, using data dependant (Top 10) acquisition with an isolation window of 3.0 m/z. 
Ions were fragmented by HCD with normalized collision energies of 25 W; the ion target value was 
set to 106 for MS and 105 for MS/MS. The nano-LC-MS/MS was set up, calibrated and controlled by 
Tune and Xcalibur used to load samples (both Thermo Scientific). 
9.2.11. Proteomic Data Analysis 
Thermo .RAW files generated by Xcalibur were processed using MaxQuant 1.3.0.5330, searching 
against the corresponding database using the Andromeda search engine340. All databases to search 
against were created by extracting the complete proteome of the relevant C. difficile strain from 
Uniprot; common contaminants were included in the search. Methionine oxidation and N-terminal 
acetylation were included as variable modifications and cysteine S-carbamidomethylation was set as 
a fixed modification. The multiplicity and labels were set depending on the experiment, allowing a 
maximum of 3 labelled amino acids per peptide. A total of 5 modifications per peptide, 2 missed 
cleavages and a maximum charge of +7 was allowed. A false discovery rate of 0.01 for peptides, 
proteins and sites was used for identification; the minimum peptide length allowed was 7 amino 
acids. For protein identification the minimum number of peptides and razor + unique peptides 
allowed was set to 1. Razor peptides are non-unique peptides which are assigned to a group of 
proteins, rather than to an individual protein; both razor and unique peptides were used for 
quantification. All other parameters were left as pre-set; when possible (for biological or technical 
repeats) the match between runs feature was selected, with a time window of 2 minutes. 
9.3. Synthetic Chemistry 
9.3.1. Reagents and Apparatus 
All general chemicals and reagents, including 5-hexynoic acid, 17-octadecynoic acid and caproic 
(hexanoic), myristic and palmitic acids, were obtained from chemical suppliers (Sigma Aldrich, Fisher 
Scientific or VWR International) and used without further purification. Reactions that required an 
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inert atmosphere were performed under nitrogen (N2) gas. YnC12, YnC15 and the tri-functional 
capture reagents AzTB and YnTB were provided by Dr Megan Wright and Dr Emmanuelle Thinon, 
Imperial College London. 
Flash Column Chromatography: was performed using silica gel (Merck, Geduran 560, 40-63 μm). Thin 
layer chromatography (TLC) analysis was performed using aluminium backed silica gel sheets (Merck, 
TLC Silica Gel 60, F254) with detection by UV absorption at 254 and 365 nm or by chemical staining. 
NMR Spectroscopy: 1H and 13C NMR spectra were recorded on a Bruker AM-400 spectrometer. All 
spectra were recorded in deuterated solvents, as stated, and referenced to either the internal 
tetramethylsilane standard at 0 ppm or to the solvent residual peak. Chemical shifts are given in 
parts per million. For 1H NMR the coupling constants are assigned in Hz, where possible. 
Mass Spectroscopy: Low resolution mass spectra were recorded using a Waters LC-MS system, 
equipped with a Waters HPLC system, an XBridge C18 column (Waters, 4.6 mm × 100 mm for 
analytical and 19 mm × 100 mm for preparative), a Waters 2998 Photodiode Array (detection at 
180–700 nm) and a Waters 3100 mass spectrometer with ESI. Samples were eluted with 5 % to 95 % 
MeOH in H2O over 15 minutes at a flow rate of 1.2 mL min
-1 for analytical and 20 mL min-1 for 
preparative; both solvents were supplemented with 0.1 % formic acid and were degassed with 
helium. 
9.3.2. Synthesis of YnC9 
All the alkyne-tagged fatty acid analogues produced as part of this thesis were synthesised in four 
steps, following a procedure developed in the Tate group and optimised by Dr Emmanuelle Thinon, 
Imperial College London224. YnC9 was synthesised from the commercially available 9-bromononanoic 
acid as described below. 
9.3.2.1. 9-Iodononanoic acid 
 
To a clear solution of 9-bromononanoic acid (1 g, 3.77 mmol, 1 eq.) in dry acetone (18.85 mL) was 
added sodium iodide (3.16 g, 21.09 mmol, 5 eq.) and the reaction stirred under inert atmosphere for 
approximately 19 hours. The reaction mixture was diluted with DCM (100 mL) and water (200 mL) 
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and separated; the aqueous layer was extracted with DCM (2x 70 mL). The combined organic layers 
were washed with sodium thiosulfate (100 mL) and brine (100 mL), dried (MgSO4) and concentrated 
under reduced pressure. The product, 9-iodononanoic acid (1.18 g, 4.14 mmol, 98 %), was used in 
the following reaction without any further purification. Rf = 0.39 (75 % hexane, 20 % ethyl acetate, 
5 % acetic acid). δH/ppm (400 MHz, CDCl3) 3.16 (2H, t, JH-H=7.01 Hz), 2.33 (2H, t, JH-H=7.49 Hz), 1.79 
(2H, m), 1.61 (2H, m), 1.30 (8H, m). δC/ppm (100 MHz, CDCl3) 180.00, 33.84, 33.29, 30.22, 28.82, 
28.73, 28.12, 24.40, 7.04. 
9.3.2.2. 11-(trimethylsilyl)undec-10-ynoic acid 
 
Trimethylsilyl-acetylene (1.10 mL, 7.81 mmol, 2 eq.) was placed under inert atmosphere and 
dissolved in anhydrous THF (7.97 mL) and the solution cooled to -78 oC. n-Butyl lithium (1.6 M, 
4.88 mL, 2 eq.) was added dropwise over 10 minutes and the reaction stirred at -78 oC for one hour. 
DMPU (9.92 mL, 82.02 mmol, 21 eq.) was added dropwise, followed by 9-iodononanoic acid (1.11 g, 
3.91 mmol, 1 eq.) in THF (9.78 mL). The reaction was allowed to warm to room temperature and 
stirred for 2 hours. The reaction was cooled to -78 oC and quenched with 20 mL of saturated 
aqueous ammonium chloride solution. The mixture was diluted with diethyl ether (100 mL) and 
water (50 mL). The layers were separated and the aqueous layer washed with diethyl ether (2x 
50 mL). The organic layers were combined and washed with water (100 mL), brine (100 mL), dried 
(MgSO4) and the solvents removed under reduced pressure. The residue was purified by flash 
column chromatography (75 % hexane, 20 % ethyl acetate, 5 % acetic acid) to give 11-
(trimethylsilyl)undec-10-ynoic acid (496 mg,1.95 mmol, 50 %) containing 9-iodononanoic acid 
(approx. 16 %, as assessed by 1H NMR). Rf = 0.37 (75 % hexane, 20 % ethyl acetate, 5 % acetic acid). 
δH/ppm (400 MHz, CDCl3) 2.33 (2H, t, JH-H=7.49 Hz), 2.19 (2H, m), 1.61 (2H, m), 1.49 (2H, m) 1.29 (8H, 
m), 0.12 (9H, s). HRMS found, 272.2056; C14H30NO2Si [M+NH4]
+ requires 272.2046. 
9.3.2.3. Un-dec-10-ynoic acid, YnC9 
 
 285 
Crude 1-(trimethylsilyl)undec-10-ynoic acid (676 mg, 2.66 mmol), containing 9-iodononanoic acid, 
was dissolved in methanol (16.12 mL) and potassium carbonate (735 mg, 5.32 mmol, 2 eq.) was 
added in one portion; the reaction mixture was stirred overnight. The solvents were removed under 
reduced pressure and the residue re-dissolved in 2 M HCl (50 mL) and diethyl ether (50 mL), 
separated and the aqueous layer extracted with diethyl ether (50 mL). The organic layers were 
combined, washed with water (50 mL), brine (50 mL) and dried (MgSO4). The solvents were removed 
under reduced pressure to give crude Un-dec-10-ynoic acid (304 mg, 1.67 mmol) which contained 
residual 9-iodononanoic acid. Un-dec-10-ynoic acid (397 mg, 1.67 mmol), containing 9-iodononanoic 
acid (0.46 mmol 1 eq.), was dissolved in DMSO (557 μL) and amino ethanol (693 μL, 11.48 mmol, 
25 eq.) was added; the reaction mixture was heated to reflux (120 oC) and stirred for two hours. The 
reaction was cooled to room temperature and diluted with diethyl ether (100 mL) and 2 M HCl 
(100 mL). The layers were separated and the aqueous layer extracted with diethyl ether (2x 50 mL). 
The combined organic layers were washed with 2 M HCl (50 mL) and brine (100 mL) and dried 
(MgSO4). The solvents were removed under reduced pressure and the residue purified by flash 
column chromatography (75 % hexane, 20 % ethyl acetate, 5 % acetic acid) to yield pure Un-dec-10-
ynoic as a pale yellow solid (190 mg, 1.04 mmol, 39 % over two steps). Rf = 0.39 (75 % hexane, 20 % 
ethyl acetate, 5 % acetic acid). δH/ppm (400 MHz, CDCl3) 2.32 (2H, t, JH-H= 7.50 Hz), 2.15 (2H, td, JH-H= 
7.11 Hz, JH-H= 2.64 Hz), 1.91 (1H, t, JH-H=2.65 Hz), 1.60 (2H, m), 1.50 (2H, m), 1.29 (8H, m). δC/ppm 
(100 MHz, CDCl3) 180.36, 84.91, 68.32, 34.34, 29.29, 29.19, 29.08, 28.85, 28.63, 24.87, 18.58. HRMS 
found, 200.1660; C11H22NO2 [M+NH4]
+ requires 200.1651. 
9.3.3. Synthesis of YnC10 
YnC10 was synthesised using the same procedure as detailed above for YnC9 (section 9.3.2); 10-
bromodecanoic acid was used as the starting material. 
9.3.3.1. 10-Iododecanoic acid 
 
Synthesised following the procedure detailed for 9-Iodononanoic acid to give 10-iododecanoic acid 
(1.04 g, 3.50 mmol, 88 %). Rf = 0.36 (75 % hexane, 20 % ethyl acetate, 5 % acetic acid). δH/ppm (400 
MHz, CDCl3) 3.16 (2H, t, JH-H= 7.03 Hz), 2.33 (2H, t, JH-H= 7.50 Hz), 1.79 (2H, m), 1.61 (2H, m), 1.28 
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(10H, m). δC/ppm (100 MHz, CDCl3) 179.66, 33.80, 33.34, 30.28, 29.00, 28.94, 28.80, 28.27, 24.45, 
7.12. HRMS found 316.0781; C10H23NO2I [M+NH4]
+ requires 316.0774. 
9.3.3.2. 12-(trimethylsilyl)dodec-11-ynoic acid 
 
Synthesised following the procedure detailed in for 11-(trimethylsilyl)undec-10-ynoic acid to yield a 
mixture of 12-(trimethylsilyl)dodec-11-ynoic acid (529 mg, 1.97 mmol, 58 %) and 10-iododecanoic 
acid (approx. 13 %, as assessed by 1H NMR). Rf = 0.50 (75 % hexane, 20 % ethyl acetate, 5 % acetic 
acid). δH/ppm (400 MHz, CDCl3) 2.33 (2H, m), 2.19 (2H, t, JH-H= 7.16 Hz), 1.61 (2H, m), 1.49 (2H, m), 
1.27 (10H, m), 0.12 (9H, s). HRMS found, 267.1786; C15H27O2Si [M+H]
+ requires 267.1780. 
9.3.3.3. Dodec-11-ynoic acid, YnC10 
 
Synthesised following the procedure detailed for Un-dec-10-ynoic acid, to yield a mixture of dodec-
11-ynoic acid and residual 10-iododecanoic acid (approx. 14 %, as assessed by 1H NMR). Dodec-11-
ynoic acid was purified following the conversion of residual 10-iododecanoic acid to the amino 
alcohol, as detailed above (190 mg, 0.97 mmol, 40 % over two steps). Rf = 0.33 (75 % hexane, 20 % 
ethyl acetate, 5 % acetic acid). δH/ppm (400 MHz, CDCl3) 2.33 (2H, t, JH-H= 7.51 Hz), 2.16 (2H, td, JH-H= 
2.65 Hz, JH-H= 7.08 Hz), 1.91 (1H, t, JH-H= 2.66 Hz), 1.61 (2H, m), 1.50 (2H, m), 1.28 (10H, m). δC/ppm 
(100 MHz, CDCl3) 180.3, 85.0, 68.3, 34.2, 29.5, 29.4, 29.2, 28.9, 28.7, 24.7, 18.6. 
9.3.4. Synthesis of YnC11 
YnC11 was synthesised using the same procedure as detailed above for YnC9 (section 9.3.2), using 
11-bromoundecanoic acid as the starting material. Only residual 11-iodoundecanoic acid was 
present after the second step however, treatment with amino ethanol in refluxing DMSO was 
performed as previously described to remove the residue. 
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9.3.4.1. 11-Iodoundecanoic acid 
 
Synthesised following the procedure detailed for 9-Iodononanoic to give 11-iodoundecanoic acid 
(952 mg, 3.05 mmol, 81 %). Rf = 0.13 (95 % hexane, 4 % ethyl acetate, 1 % acetic acid). δH/ppm 
(400 MHz, CDCl3) 3.17 (2H, q, JH-H= 7.04 Hz), 2.33 (2H, t, JH-H= 7.51 Hz), 1.79 (2H, m), 1.61 (2H, m), 
1.26 (12H, m). δC/ppm (100 MHz, CDCl3) 179.85, 34.01, 33.54, 30.49, 29.33, 29.30, 29.18, 29.02, 
28.50, 24.65, 7.35. 
9.3.4.2. 13-(trimethylsilyl)tridec-12-ynoic acid 
 
Synthesised following the procedure detailed for 11-(trimethylsilyl)undec-10-ynoic acid to yield 13-
(trimethylsilyl)tridec-12-ynoic acid (297 mg, 1.05 mmol, 41 %) containing only residual 11-
iodoundecanoic acid by 1H NMR. Rf = 0.52 (75 % hexane, 20 % ethyl acetate, 5 % acetic acid). 
δH/ppm (400 MHz, CDCl3) 2.32 (2H, t, JH-H= 7.53 Hz), 2.18 (2H, m), 1.60 (2H, m), 1.49 (2H, m), 1.25 
(12H, m), 0.12 (9H, s). HRMS found, 283.2093; C16H31O2Si [M+H]
+ requires 283.2093. 
9.3.4.3. Tridec-12-ynoic acid, YnC11 
 
Synthesised following the procedure detailed for un-dec-10-ynoic acid to yield tridec-12-ynoic acid, 
which contained only residual 11-iodoundecanoic acid by 1H NMR. Purified following the conversion 
of the residual 11-iodoundecanoic acid to the amino alcohol, as described for un-dec-10-ynoic acid, 
to yield pure dodec-11-ynoic acid (YnC11) (64 mg, 0.31 mmol, 50 % over two steps). Rf = 0.37 (75 % 
hexane, 20 % ethyl acetate, 5 % acetic acid). δH/ppm (400 MHz, CDCl3) 2.32 (2H, t, JH-H= 7.52 Hz), 2.16 
(2H, td, JH-H= 2.65 Hz, JH-H= 7.09 Hz), 1.92 (2H, t, JH-H= 2.64 Hz), 1.61 (2H, m), 1.50 (2H, m), 1.26 (12H, 
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m). δC/ppm (100 MHz, CDCl3) 179.81, 84.61, 67.88, 33.86, 29.23, 29.17, 29.08, 29.02, 28.88, 28.55, 
28.31, 24.49, 18.22. HMRS found, 228.1957; C13H26NO2 [M+NH4]
+ requires 228.1964. 
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Appendices 
A. Additional Materials 
Appendix A contains additional experimental materials supplementary to Chapter 9.1, as follows: 
Table Number  Brief Description 
Table 12 A list of all C. difficile strains used in this study. 
Table 13 A list of all E. coli strains used during this study 
Table 14 A list of all plasmids generated or used during this study. 
Table 15 A list of all primers used during this study. 
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Table 12: C. difficile Strains used during this study. 
Strain Name Alternative Strain Name Plasmid name Source Ribotype Comments 
630 Δerm - - Peter Mullany 012 Spontaneous erythromycin sensitive isolate of C.difficile 630 
630 ∆erm spo0A::erm 630 Δerm CD630_24920::erm - Robert Fagan 012 
 
630 Δerm - pMTL960 Cate Reynolds 012 
 
630 - - Brendan Wren 012 Zurich, 1982, human isolate. 
R20291 - - Brendan Wren 027 London, 2006, human isolate. 
Liv22 - - Brendan Wren 106 Liverpool, 2009, human isolate. 
M68 - - Brendan Wren 017 Dublin, 2006, human isolate. 
M120 - - Brendan Wren 078 U.K., 2007, human isolate. 
BI-9 - - Brendan Wren 001 From the Gerding collection. 
Ox247 - - Kate Dingle 005 Oxford clinical isolate with putative S-layer glycosylation locus. 
630 Δerm lgt::erm 630 Δerm CD630_26590::erm - Andrea Kovacs-Simon 012 
 
630 Δerm lspA::erm 630 Δerm CD630_25970::erm - Andrea Kovacs-Simon 012 
 
630 Δerm lspA2::erm 630 Δerm CD630_19030::erm - Andrea Kovacs-Simon 012 
 
630 Δerm CD630_08730::erm - - Andrea Kovacs-Simon 012 
 
630 Δerm CD630_08730::erm - pAKS001 Andrea Kovacs-Simon 012 
 
630 Δerm lspA::erm 630 Δerm CD630_25970::erm pMCD03 This Study 012 
 
630 Δerm lspA2::erm 630 Δerm CD630_19030::erm pTMC001 This Study 012 
 
630 Δerm lgt::erm 630 Δerm CD630_26590::erm pTMC002 This Study 012 
 
630 Δerm ΔilvD 630 Δerm ΔCD630_20140 - This Study 012 Bases 10 to 1556 of ilvD deleted using the CodA system 
630 Δerm codY::erm - - Bruno Dupuy  012 
 
630 Δerm - pTMC004 This Study 012 
 
630 Δerm - pTMC005 This Study 012 
 
630 Δerm - pTMC006 This Study 012 
 
630 Δerm lgt::erm 630 Δerm CD630_26590::erm pTMC004 This Study 012 
 
630 Δerm lgt::erm 630 Δerm CD630_26590::erm pTMC005 This Study 012 
 
630 Δerm lgt::erm 630 Δerm CD630_26590::erm pTMC006 This Study 012 
 
630 Δerm lgt::erm 630 Δerm CD630_26590::erm pMTL960 This Study 012 630 Δerm lgt::erm vector control 
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630 Δerm - pTMC007 This Study 012 
 
630 Δerm - pTMC008 This Study 012 
 
630 Δerm - pTMC009 This Study 012 
 
630 Δerm - pASF85 This Study 012 630 Δerm inducible vector control 
630 Δerm lgt::erm 630 Δerm CD630_26590::erm pTMC007 This Study 012 
 
630 Δerm lgt::erm 630 Δerm CD630_26590::erm pTMC008 This Study 012 
 
630 Δerm lgt::erm 630 Δerm CD630_26590::erm pTMC009 This Study 012 
 
630 Δerm lgt::erm 630 Δerm CD630_26590::erm pASF85 This Study 012 630 Δerm lgt::erm inducible vector control 
 
Table 13: E. coli strains used during this study. 
Host strain Plasmid Name Plasmid Description Vector Backbone Vector Use 
CA434 pTMC003 pMTL-SC7215::ΔilvD pMTL-SC7215 To create an ilvD deletion mutant in 630 Δerm 
 
Table 14: Plasmids created during this study. 
Plasmid Name Plasmid Description Vector Backbone Vector Use 
pMCD03 pRPF144::CD630_19030 pMTL960 Constitutive expression of LspA2 
pTMC001 pRPF144::CD630_25970 pRPF144 Constitutive expression of Lgt 
pTMC002 pRPF144::CD630_26590 pRPF144 To create an ilvD deletion mutant (Gibson assembly) in 630 Δerm 
pTMC003 pMTL-SC7215::ΔilvD pMTL-SC7215 Constitutive expression of LspA 
pTMC004 pMTL960::pcwp2-CD630_18710-His pHAS005 Constitutive expression of CD630_18710 with a C-terminal His tag 
pTMC005 pMTL960::pcwp2-CD630_11390-His pHAS005 Constitutive expression of CD630_11390 (RnfG) with a C-terminal His tag 
pTMC006 pMTL960::pcwp2-CD630_19300-His pHAS005 Constitutive expression of CD630_19300 with a C-terminal His tag 
pTMC007 pMTL960::ptet-CD630_18710-His pECC17 Inducible expression of CD630_18710 with a C-terminal His tag 
pTMC008 pMTL960::ptet-CD630_11390-His pECC17 Inducible expression of CD630_11390 (RnfG) with a C-terminal His tag 
pTMC009 pMTL960::ptet-CD630_19300-His pECC17 Inducible expression of CD630_19300 with a C-termnal His tag 
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Table 15: primers used during this study. Primers were synthesised by Sigma Aldrich. 
Primer Number Direction Sequence 5' to 3' Restriction sites Uses and Comments  
2182 Forward GATC GAGCTC GGTTTTTAAATAATTTATAGGGGG SacI Clone CD630_25970 
2183 Reverse GATC GGATCC TCACCTACTTTTACTTTCAAAAAATAAAAC BamHI Clone CD630_25970 
2204 Forward GATC GAGCTC TATTTTCAATTAATACAAAG SacI Clone lgt CD630_26590 
2205 Reverse GATC GGATCC CTATTCTTCACTAATATTATTTTTATTTTTC BamHI Clone lgt CD630_26590 
2242 Forward GATC CCATGG GC CTATATATATTAATAATAATTCTACTC NcoI Cloning CD630_25970 (lspA) 
2243 Reverse GATC CTCGAG CCTACTTTTACTTTCAAAAAATAAAAC XhoI Cloning CD630_25970 (lspA) 
2244 Forward GATC CCATGG GC CAAGGAGGTGTTAATATCAG NcoI Cloning CD630_19030 (lspA2) 
2245 Reverse GATC CTCGAG TCTTTTAAACTGACGATAG XhoI Cloning CD630_19030 (lspA2) 
2599 Forward GTTTTTTTGTTACCCTAACTTTATCCTGGTAAAATAATTAGTGTC - pMTL-SC7315 - left arm; for deletion of ilvD 
2600 Reverse ATGAGAAGTTTAAAATTTAAACCTTTAGAACCGAAAATAAAG - right arm - left arm; for deletion of ilvD 
2601 Forward TTTAAATTTTAAACTTCTCATAATATTACCTCTTTCTTAC - left arm - right arm; for deletion of ilvD 
2602 Reverse GATTATCAAAAAGGAGTTTAGGTAGTAAAAATCCTAAAGGC - pMTL-SC7315 - right arm; for deletion of ilvD 
2603 Forward GCTTATATCTAAAAGCAAAAGCAATCG - for screening ΔilvD candidates 
2604 Reverse CTAATGAAAAACCTAATCCAGTTAATG - for screening ΔilvD candidates 
2960 Forward GATC GAGCTC GTGTAAAAAATAAAGGAGG SacI To clone CD630_18710 
2961 Reverse GATC CTCGAG TTTATTTTTTATTTTTTCCAATTCTTTTTC XhoI To clone CD630_18710 
2962 Forward GATC GAGCTC GTATTTGGGGAGGTG SacI To clone CD630_11390 
2963 Reverse GATC CTCGAG TTTATTAAGAGCACTATTGAAAACATC       XhoI To clone CD630_11390 
2964 Forward GATC GAGCTC TTATGAATATGGAGG  SacI To clone CD630_19300 
2965 Reverse GATC CTCGAG TTTTCCATAACATATATCAC XhoI To clone CD630_19300 
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B. Additional Bioinformatic Tables 
Appendix B contains complete lists of the lipoproteins predicted by bioinformatics analysis, grouped 
into probable (high confidence prediction) and possible (lower confidence prediction) lipoproteins as 
described in Chapter 2.1. The contents of this appendix are as follows: 
Table Number  Brief Description 
Table 16 The predicted lipoproteome of C. difficile 630. 
Table 17 The predicted lipoproteome of C. difficile R20291. 
Table 18 The predicted lipoproteome of C. difficile M120. 
Table 19 The predicted lipoproteome of B. subtilis strain 168. 
Table 20 Lipoprotein homologs between C. difficile 630, R20291 and M120. 
Table 16: The predicted lipoproteome of C. difficile 630. For signal, Y indicates the presence and N the absence of a 
predicted signal peptide sequence. For Phobius, Y indicates the presence and 0 the absence of a predicted signal peptide 
sequence. All predicted lipoproteins have a Type II signal peptide sequence (lipoP), which features a lipobox. 
Uniprot 
Entry Gene names Protein names Si
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Probable Lipoproteins (61) 
Q183A6 appA CD630_26720 
ABC-type transport system, oligopeptide-family solute-
binding protein 
Y SpII  Y 
Q18CR2 CD630_01730 Putative lipoprotein Y SpII  Y 
Q18CT7 CD630_01990 Putative membrane-associated nucleotidase Y SpII  Y 
Q188M7 CD630_04400 Putative cell wall binding protein Y SpII  Y 
Q188Y7 CD630_05450 Putative uncharacterized protein Y SpII  Y 
Q189B5 CD630_05690 Putative lipoprotein Y SpII  Y 
Q189N2 CD630_06890 Putative nucleotide phosphodiesterase Y SpII Y 
Q189N6 CD630_06900 Putative nucleotide phosphodiesterase Y SpII Y 
Q189U5 CD630_07470 Putative lipoprotein Y SpII  Y 
Q189U7 CD630_07500 
ABC-type transport system, amino acid-family extracellular 
solute-binding protein 
Y SpII  Y 
Q18A65 CD630_08730 
ABC-type transport system, sugar-family extracellular 
solute-binding protein 
Y SpII  Y 
Q18A71 CD630_08760 
ABC-type transport system, sugar-family extracellular 
solute-binding protein 
Y SpII  Y 
Q183Z1 
CD630_09570 
CD630_29070 
Putative phage lipoprotein Y SpII Y 
Q18AJ9 CD630_09990 
ABC-type transport system, nitrate/sulfonate/taurine 
extracellular solute-binding protein 
Y SpII  Y 
Q18AT3 CD630_10800 Putative lipoprotein Y SpII  Y 
Q18AX9 CD630_11190 Putative lipoprotein Y SpII  Y 
Q18AZ4 CD630_11310 Putative solute-binding lipoprotein Y SpII  Y 
Q18B93 CD630_12320 Putative lipoprotein Y SpII  Y 
Q18BL3 CD630_13480 Putative lipoprotein Y SpII  Y 
Q18BZ5 CD630_14760 Putative signalling protein Y SpII Y 
Q18C05 CD630_14860 Putative ribosome recycling factor Y SpII  Y 
Q18C25 CD630_15070 Putative thioredoxin Y SpII  Y 
Q18C31 CD630_15090 Putative lipoprotein Y SpII  Y 
Q18C77 CD630_15570 Putative peptidylprolyl isomerase (EC 5.2.1.8) Y SpII Y 
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Q186E4 CD630_15890 
ABC-type transport system, sugar-family extracellular 
solute-binding protein 
Y SpII  Y 
Q186H8 CD630_16220 Putative uncharacterized protein Y SpII  Y 
Q186K7 CD630_16530 Putative Probable D-methionine-binding lipoprotein Y SpII  Y 
Q186P2 CD630_16870 Putative uncharacterized protein Y SpII Y 
Q186X7 CD630_17660 Putative lipoprotein Y SpII  Y 
Q186Y3 CD630_17740 
ABC-type transport system, amino acid-family extracellular 
solute-binding protein 
Y SpII  Y 
Q186Z3 CD630_17810 Putative lipoprotein Y SpII  Y 
Q187U0 CD630_19790 
ABC-type transport system, extracellular solute-binding 
protein 
Y SpII  Y 
Q187V2 CD630_19920 Putative lipoprotein Y SpII  Y 
Q187Z8 CD630_20290 Putative uncharacterized protein Y SpII  Y 
Q188C2 CD630_20520 Putative lipoprotein Y SpII  Y 
Q185W2 CD630_21740 
ABC-type transport system, cysteine/amino acid-family 
extracellular solute-binding protein 
Y SpII  Y 
Q185W5 CD630_21770 
ABC-type transport system, cysteine/amino acid-family 
extracellular solute-binding protein 
Y SpII  Y 
Q185I4 CD630_23110 
ABC-type transport system, molybdenum-like extracellular 
solute-binding protein 
Y SpII  Y 
Q185N5 CD630_23650 
ABC-type transport system, nitrate/sulfonate/taurine 
extracellular solute-binding protein 
Y SpII  Y 
Q181Z0 CD630_24060 Putative lipoprotein Y SpII  Y 
Q182M5 CD630_25380 Putative lipoprotein Y SpII  Y 
Q182N7 CD630_25500 
ABC-type transport system, sugar-family extracellular 
solute-binding protein 
Y SpII  Y 
Q182Y0 CD630_26450 
ABC-type transport system, sugar-family extracellular 
solute-binding protein 
Y SpII  Y 
Q183E7 CD630_27130 Putative cell wall protein Y SpII  Y 
Q183F4 CD630_27190 Putative polysaccharide deacetylase Y SpII  Y 
Q183J7 CD630_27630 Putative lipoprotein Y SpII  Y 
Q184D9 CD630_29530 
ABC-type transport system, iron-family extracellular solute-
binding protein 
Y SpII  Y 
Q180R1 CD630_34140 
ABC-type transport system, sugar-family extracellular 
solute-binding protein 
Y SpII Y 
Q180W3 CD630_34640 Putative uncharacterized protein Y SpII  Y 
Q181C3 CD630_35250 
ABC-type transport system, iron-family extracellular solute-
binding protein 
Y SpII  Y 
Q181C7 CD630_35280 
ABC-type transport system, iron-family extracellular solute-
binding protein 
Y SpII  Y 
Q181S4 CD630_36690 Putative exported protein Y SpII  Y 
Q183W4 fhuD CD630_28780 
ABC-type transport system, ferrichrome-specific 
extracellular solute-binding protein 
Y SpII  Y 
Q18C11 metQ CD630_14910 
ABC-type transport system, methionine-specific substrate-
binding lipoprotein 
Y SpII  Y 
Q18A64 modA CD630_08690 
ABC-type transport system, molybdenum-specific 
extracellular solute-binding protein 
Y SpII  Y 
Q18A51 oppA CD630_08550 
ABC-type transport system, oligopeptide-family extracellular 
solute-binding protein 
Y SpII  Y 
Q18AM5 potD CD630_10270 
ABC-type transport system, spermidine/putrescine solute-
binding protein 
Y SpII  Y 
Q180Z8 prsA CD630_35000 Peptidylprolyl isomerase PrsA-like (EC 5.2.1.8) Y SpII  Y 
Q180B2 pstS CD630_32680 
ABC-type transport system, phosphate extracellular solute-
binding protein 
Y SpII  Y 
Q18C04 ssuA CD630_14840 
ABC-type transport system, alkane sulfonates-family 
extracellular solute-binding protein 
Y SpII  Y 
Q184I1 ssuA2 CD630_29890 
ABC-type transport system, sulfonate-family extracellular 
solute-binding protein 
Y SpII  Y 
Potential Lipoproteins (7) 
Q184J0 CD630_29990 
ABC-type transport system, iron-family extracellular solute-
binding protein 
N SpII  Y 
Q183D5 CD630_27010 Putative lipoprotein N SpII  Y 
Q182G4 CD630_24780 Putative DNA uptake transporter N SpII  Y 
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Q18D38 rbsB CD630_03000 
ABC-type transport system, ribose-specific extracellular 
solute-binding protein 
N SpII  Y 
Q182G8 CD630_24820 Putative lipoprotein N SpII  Y 
Q189Q1 CD630_07070 Putative diguanylate kinase signalling protein N SpII  Y 
Q18B57 
spoIIIAG 
CD630_11980 
Stage III sporulation protein AG Y SpII  0 
Table 17: The predicted lipoproteome of C. difficile R20291. For signal, Y indicates the presence and N the absence of a 
predicted signal peptide sequence. For Phobius, Y indicates the presence and 0 the absence of a predicted signal peptide 
sequence. All predicted lipoproteins have a Type II signal peptide sequence (lipoP), which features a lipobox. 
Uniprot 
Entry Gene names Protein names Si
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Probable Lipoproteins (53) 
C9YHY3 CDR20291_0174 Putative lipoprotein Y SpII Y 
C9YLR7 CDR20291_1520 Putative lipoprotein Y SpII Y 
C9YJV2 CDR20291_0852 ABC transporter, substrate-binding lipoprotein Y SpII Y 
C9YPB1 CDR20291_2425 Putative lipoprotein Y SpII Y 
C9YNU0 CDR20291_2252 
Putative sulfonate ABC transporter, solute-binding 
lipoprotein 
Y SpII Y 
C9YMK3 CDR20291_1811 ABC transporter substrate-binding protein Y SpII Y 
C9YNC1 CDR20291_2080 
Probable amino-acid ABC transporter, substrate-binding 
protein 
Y SpII Y 
C9YJQ5 CDR20291_0805 ABC transporter, substrate-binding lipoprotein Y SpII Y 
C9YND3 CDR20291_2092 Putative lipoprotein Y SpII Y 
C9YNC4 CDR20291_2083 
Probable amino-acid ABC transporter, substrate-binding 
protein 
Y SpII Y 
C9YJN5 oppA CDR20291_0785 Oligopeptide ABC transporter, substrate-binding lipoprotein Y SpII Y 
C9YPU3 CDR20291_2608 Probable polysaccharide deacetylase Y SpII Y 
C9YLN4 CDR20291_1487 
Putative ribose ABC transporter, substrate-binding 
lipoprotein 
Y SpII Y 
C9YPL9 CDR20291_2533 Putative extracellular solute-binding protein Y SpII Y 
C9YM65 CDR20291_1669 Amino acid ABC transporter, substrate-binding protein Y SpII Y 
C9YLA6 CDR20291_1358 Putative lipoprotein Y SpII Y 
C9YM72 CDR20291_1676 Putative lipoprotein Y SpII Y 
C9YJC5 CDR20291_0675 Putative lipoprotein Y SpII Y 
C9YQA9 fhuD CDR20291_2774 
Putative ferrichrome ABC transporter, substrate-binding 
protein 
Y SpII Y 
C9YJC8 CDR20291_0678 Amino acid ABC transporter, substrate-binding protein Y SpII Y 
C9YNN9 CDR20291_2200 ABC transporter, substrate-binding protein0 Y SpII Y 
C9YK66 CDR20291_0967 Putative solute-binding lipoprotein Y SpII Y 
C9YJ67 CDR20291_0615 Putative nucleotide phosphodiesterase Y SpII Y 
C9YJQ2 CDR20291_0802 ABC transporter, substrate-binding lipoprotein Y SpII Y 
C9YL89 metQ CDR20291_1341 
Putative D-methionine ABC transporter, substrate-binding 
lipoprotein 
Y SpII Y 
C9YPY6 CDR20291_2651 Putative lipoprotein Y SpII Y 
C9YLA3 CDR20291_1355 Putative thioredoxin Y SpII Y 
C9YMU3 CDR20291_1902 ABC transporter, substrate-binding protein Y SpII Y 
C9YM57 CDR20291_1661 Putative lipoprotein Y SpII Y 
C9YK38 CDR20291_0939 Putative lipoprotein Y SpII Y 
C9YIU9 CDR20291_0493 Putative outer membrane lipoprotein Y SpII Y 
C9YRB1 CDR20291_3129 
Putative phosphate ABC transporter, substrate-binding 
protein 
Y SpII Y 
C9YRT2 CDR20291_3300 Putative lipoprotein Y SpII Y 
C9YKG8 CDR20291_1069 Putative lipoprotein Y SpII Y 
C9YRL8 CDR20291_3236 ABC transporter, solute-binding protein Y SpII Y 
C9YMJ4 CDR20291_1801 Putative exported protein Y SpII Y 
C9YQF9 CDR20291_2824 ABC transporter, substrate-binding protein Y SpII Y 
C9YQW5 CDR20291_2983 
Abc-type fe3+ transport system periplasmic component-like 
protein 
Y SpII Y 
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C9YRZ4 CDR20291_3362 Putative iron ABC transporter, solute-binding protein Y SpII Y 
C9YMY3 CDR20291_1942 Putative lipoprotein Y SpII Y 
C9YMV7 CDR20291_1916 Putative lipoprotein Y SpII Y 
C9YME8 CDR20291_1753 Uncharacterized protein Y SpII Y 
C9YRZ5 CDR20291_3363 Putative iron ABC transporter, solute-binding lipoprotein Y SpII Y 
C9YJP8 modA CDR20291_0798 
Putative molybdenum ABC transporter, substrate-binding 
protein 
Y SpII Y 
C9YIS6 CDR20291_0470 Putative lipoprotein Y SpII Y 
C9YLY2 CDR20291_1585 Putative lipoprotein Y SpII Y 
C9YSG1 CDR20291_3529 Putative exported protein Y SpII Y 
C9YKT8 CDR20291_1190 Putative lipoprotein Y SpII Y 
C9YLU8 CDR20291_1551 Lipoprotein Y SpII Y 
C9YJY3 potD CDR20291_0883 
Spermidine/putrescine ABC transporter, substrate-binding 
lipoprotein 
Y SpII Y 
C9YII7 CDR20291_0381 Cell surface protein Y SpII Y 
C9YPT6 CDR20291_2601 Cell surface protein Y SpII Y 
C9YL83 CDR20291_1335 Putative lipoprotein Y SpII Y 
Possible Lipoproteins (9) 
C9YN00 CDR20291_1959 Putative lipoprotein N SpII Y 
C9YNY3 CDR20291_2296 Putative lipoprotein N SpII Y 
C9YPS4 CDR20291_2589 Putative lipoprotein N SpII Y 
C9YP58 CDR20291_2371 Metallo beta-lactamase superfamily lipoprotein N SpII Y 
C9YIB0 rbsB CDR20291_0303 D-ribose ABC transporter, substrate-binding protein N SpII Y 
C9YK49 CDR20291_0950 Putative lipoprotein Y SpII 0 
C9YPC3 CDR20291_2437 Putative sugar transporter, substrate-binding lipoprotein N SpII Y 
C9YP62 CDR20291_2375 Putative lipoprotein N SpII Y 
C9YKD5 
spoIIIAG 
CDR20291_1036 
SpoIIIAG protein Y SpII 0 
Table 18: The predicted lipoproteome of C. difficile M120. For signal, Y indicates the presence and N the absence of a 
predicted signal peptide sequence. For Phobius, Y indicates the presence and 0 the absence of a predicted signal peptide 
sequence. All predicted lipoproteins have a Type II signal peptide sequence (lipoP), which features a lipobox. 
Gene names Protein names Si
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Probable Lipoproteins (59) 
M120_RT078_01951 Putative Lipoprotein Y SpII Y 
M120_RT078_27421 putative polysaccharide deacetylase Y SpII Y 
M120_RT078_09851 
ABC-type transport system, nitrate/sulfonate/taurine extracellular solute-
binding protein 
Y SpII Y 
M120_RT078_24141 Putative Lipoprotein Y SpII Y 
M120_RT078_25541 Putative Lipoprotein Y SpII Y 
M120_RT078_20501 Putative Lipoprotein Y SpII Y 
M120_RT078_10871 Putative Lipoprotein Y SpII Y 
M120_RT078_18521 Fragment of ABC-type transport system, substrate-binding protein Y SpII Y 
M120_RT078_21901 
ABC-type transport system, cysteine/ amino acid-family extracellular solute-
binding protein 
Y SpII Y 
M120_RT078_21931 
ABC-type transport system, cysteine/ amino acid-family extracellular solute-
binding protein 
Y SpII Y 
M120_RT078_09181 
ABC-type transport system, oligopeptide-family extracellular solute-binding 
protein  oppA 
Y SpII Y 
M120_RT078_07441 MPP Superfamily; Putative Nucleotide Phosphodiesterase  Y SpII Y 
M120_RT078_07471 Putative Nucleotide phosphodiesterase Y SpII Y 
M120_RT078_23691 
ABC-type transport system, nitrate/sulfonate/taurine extracellular solute-
binding protein 
Y SpII Y 
M120_RT078_09381 ABC-type transport system, sugar-family extracellular solute-binding protein Y SpII Y 
M120_RT078_26591 ABC-type transport system, sugar-family extracellular solute-binding protein  Y SpII Y 
M120_RT078_06371 Putative Lipoprotein Y SpII Y 
M120_RT078_23151 
ABC-type transport system, molybdenum-like extracellular solute-binding 
protein    
Y SpII Y 
 322 
M120_RT078_17871 Putative Lipoprotein Y SpII Y 
M120_RT078_17801 
ABC-type transport system, amino acid-family extracellular solute-binding 
protein 
Y SpII Y 
M120_RT078_14991 Putative Lipoprotein Y SpII Y 
M120_RT078_08091 Putative Lipoprotein Y SpII Y 
M120_RT078_16141 Conserved Hypothetical protein Y SpII Y 
M120_RT078_14851 Tro-A Like Superfamily; Zinc ABC Transporter Solute Binding Protein Y SpII Y 
M120_RT078_08121 ABC-transport System, Amino acid-family-extracellular solute-binding protein Y SpII Y 
M120_RT078_09311 
ABC-type transport system, molybdenum-specific extracellular solute-binding 
protein  modA 
Y SpII Y 
M120_RT078_12071 Conserved Hypothetical Protein Y SpII Y 
M120_RT078_29041 
ABC-type transport system, ferrichrome-specific extracellular solute-binding 
protein  fhuD  
Y SpII Y 
M120_RT078_11051 Putative Solute-binding Lipoprotein Y SpII Y 
M120_RT078_09351 ABC-type transport system, sugar-family extracellular solute-binding protein   Y SpII Y 
M120_RT078_27091 Oligopeptide Binding ABC Transporter Solute Binding Protein Y SpII Y 
M120_RT078_14761 
ABC-type transport system, methionine-specific substrate-binding lipoprotein  
metQ    
Y SpII Y 
M120_RT078_19451 ABC-type transport system, extracellular solute-binding protein   Y SpII Y 
M120_RT078_27881 putative lipoprotein Y SpII Y 
M120_RT078_10761 Putative Lipoprotein Y SpII Y 
M120_RT078_17231 Iron Compound ABC transporter substrate-binding protein Y SpII Y 
M120_RT078_34111 Conserved Hypothetical protein Y SpII Y 
M120_RT078_00471 
TPR Superfamily; TPR Repeats Containing Protein & Aspatate Retropepsin 
Domain 
Y SpII Y 
M120_RT078_33571 ABC-type transport system, sugar-family extracellular solute-binding protein Y SpII Y 
M120_RT078_19781 Putative Lipoprotein Y SpII Y 
M120_RT078_32461 ABC-type transport system, phosphate extracellular solute-binding protein  pstS Y SpII Y 
M120_RT078_17721 Putative Lipoprotein Y SpII Y 
M120_RT078_02241 MPP Superfamily; Putative Membrane Associated Nucelotidase Y SpII Y 
M120_RT078_29561 
ABC-type transport system, sulfonate-family extracellular solute-binding protein  
ssuA2 
Y SpII Y 
M120_RT078_31111 Fe3+ ABC transporter periplasmic component-like protein  Y SpII Y 
M120_RT078_14971 Putative Thioredoxin Y SpII Y 
M120_RT078_06141 Conserved Hypothetical protein Y SpII Y 
M120_RT078_14601 Putative Signalling Protein Y SpII Y 
M120_RT078_20321 Conserved Hypothetical protein Y SpII Y 
M120_RT078_25681 ABC-type transport system, sugar-family extracellular solute-binding protein Y SpII Y 
M120_RT078_14711 Putative Ribosome Recycling Factor Y SpII Y 
M120_RT078_36221 Putative Exported Protein Y SpII Y 
M120_RT078_16771 Conserved Hypothetical protein Y SpII Y 
M120_RT078_16421 Putative Probable D-methionine-binding lipoprotein Y SpII Y 
M120_RT078_13251 Putative Lipoprotein Y SpII Y 
M120_RT078_26851 ABC-type transport system, oligopeptide-family solute-binding protein  appA Y SpII Y 
M120_RT078_12081 Putative Cell Surface Protein Y SpII Y 
M120_RT078_29181 ABC-type transport system, iron-family extracellular solute-binding protein Y SpII Y 
M120_RT078_10181 ABC-type transport system, spermidine/putrescine solute-binding protein  potD Y SpII Y 
Possible Lipoproteins (5) 
M120_RT078_03041 
ABC-type transport system, ribose-specific extracellular solute-binding protein  
rbsB   
N SpII Y 
M120_RT078_24941 Putative Lipoprotein N SpII Y 
M120_RT078_27201 Putative Lipoprotein N SpII Y 
M120_RT078_29671 ABC-type transport system, iron-family extracellular solute-binding protein  N SpII 0 
M120_RT078_11731 Stage III sporulation protein AG  spoIIIAG   Y SpII 0 
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Table 19: The predicted lipoproteome of B. subtilis strain 168. For signalP, Y indicates the presence and N the absence of a 
predicted signal peptide sequence. For Phobius, Y indicates the presence and 0 the absence of a predicted signal peptide 
sequence. All predicted lipoproteins have a Type II signal peptide sequence (lipoP), which features a lipobox. 
Uniprot 
Entry Gene names Protein names Si
gn
al
P
 
Li
p
o
P
 
P
h
o
b
iu
s 
Probable Lipoproteins (79) 
P42061 
appA BSU11381/BSU11382 
BSU11380 
Oligopeptide-binding protein AppA Y SpII Y 
O32001 yokF BSU21610 
SPBc2 prophage-derived endonuclease YokF (EC 3.1.-
.-) 
Y SpII Y 
O05497 ydhF BSU05730 Uncharacterized protein YdhF Y SpII Y 
O31942 yonS BSU21010 
SPBc2 prophage-derived uncharacterized lipoprotein 
YonS 
Y SpII Y 
O34538 ycdA BSU02780 Uncharacterized lipoprotein YcdA Y SpII Y 
O34629 yerH BSU06630 Uncharacterized lipoprotein YerH Y SpII Y 
O32208 yvgL yvsD BSU33380 
Putative ABC transporter substrate-binding 
lipoprotein YvgL 
Y SpII Y 
O34805 yvrC BSU33180 
Uncharacterized ABC transporter substrate-binding 
lipoprotein YvrC 
Y SpII Y 
O34482 ansZ yccC BSU02690 
L-asparaginase 2 (L-ASNase 2) (EC 3.5.1.1) (L-
asparagine amidohydrolase 2) 
Y SpII Y 
O34563 glnH BSU27440 ABC transporter glutamine-binding protein GlnH Y SpII Y 
P46338 pstS yqgG yzmB BSU24990 Phosphate-binding protein PstS (PBP) Y SpII Y 
P54952 yxeM BSU39500 LP9E Probable amino-acid-binding protein YxeM Y SpII Y 
O31567 yfiY BSU08440 Probable siderophore-binding lipoprotein YfiY Y SpII Y 
P54941 yxeB BSU39610 HS74BR Iron(3+)-hydroxamate-binding protein YxeB Y SpII Y 
P37580 fhuD BSU33320 Iron(3+)-hydroxamate-binding protein FhuD Y SpII Y 
P94492 yncB BSU17620 Endonuclease YncB (EC 3.1.-.-) Y SpII Y 
O34594 cccB BSU35270 
Cytochrome c-551 (Cytochrome c B) (Cytochrome 
c551) 
Y SpII Y 
O06989 mdxE yvdG BSU34610 Maltodextrin-binding protein MdxE Y SpII Y 
P40409 feuA BSU01630 Iron-uptake system-binding protein Y SpII Y 
P54535 artP yqiX BSU23980 Arginine-binding extracellular protein ArtP Y SpII Y 
P37966 lipO lplA BSU07100 Lipoprotein LipO (Lipoprotein LplA) Y SpII Y 
P96619 ydcC BSU04630 Sporulation protein YdcC Y SpII Y 
P24327 prsA BSU09950 Foldase protein PrsA (EC 5.2.1.8) Y SpII Y 
O34725 yjhA BSU12180 Uncharacterized lipoprotein YjhA Y SpII Y 
P94517 yscB BSU28890 Uncharacterized protein YscB Y SpII Y 
O34348 yfmC BSU07520 
Fe(3+)-citrate-binding protein YfmC (Ferric-citrate-
binding protein) 
Y SpII Y 
O05252 yufN BSU31540 Uncharacterized lipoprotein YufN Y SpII Y 
Q02112 lytA lppX BSU35640 Membrane-bound protein LytA Y SpII Y 
O07009 cycB yvfK BSU34160 Cyclodextrin-binding protein Y SpII Y 
P42199 tcyA yckK BSU03610 L-cystine-binding protein TcyA Y SpII Y 
P96667 ydeJ BSU05220 Uncharacterized lipoprotein YdeJ Y SpII Y 
P94361 yxkH BSU38800 Putative polysaccharide deacetylase YxkH (EC 3.-.-.-) Y SpII Y 
O34960 yjgB BSU12150 Uncharacterized protein YjgB Y SpII Y 
O34968 yerB yecC BSU06570 Putative lipoprotein YerB Y SpII Y 
O05410 yrpE BSU26830 Probable metal-binding protein YrpE Y SpII Y 
O34966 znuA adcA ycdH BSU02850 High-affinity zinc uptake system binding-protein ZnuA Y SpII Y 
P40766 ypmR yzjA BSU21740 Uncharacterized protein YpmR Y SpII Y 
P94421 yclQ BSU03830 
Uncharacterized ABC transporter solute-binding 
protein YclQ 
Y SpII Y 
P42400 yckB BSU03380 
Probable ABC transporter extracellular-binding 
protein YckB (ORF2) 
Y SpII Y 
O34866 yodJ yokZ BSU19620 Putative carboxypeptidase YodJ (EC 3.4.-.-) Y SpII Y 
P46922 opuAC BSU03000 Glycine betaine-binding protein OpuAC Y SpII Y 
O34385 mntA ytgA BSU30770 Manganese-binding lipoprotein MntA Y SpII Y 
O32156 yurO BSU32600 
Uncharacterized ABC transporter extracellular-binding 
protein YurO 
Y SpII Y 
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O06965 yvcA yvrA BSU34850 Putative lipoprotein YvcA Y SpII Y 
O32167 metQ yusA BSU32730 Methionine-binding lipoprotein MetQ Y SpII Y 
P26906 dppE dciAE BSU12960 Dipeptide-binding protein DppE Y SpII Y 
P24141 oppA spo0KA BSU11430 
Oligopeptide-binding protein OppA (Stage 0 
sporulation protein KA) 
Y SpII Y 
C0SP94 yhfQ BSU10330 
Putative ABC transporter substrate-binding 
lipoprotein YhfQ 
Y SpII Y 
O34406 tcyJ ytmJ BSU29380 L-cystine-binding protein TcyJ Y SpII Y 
P42971 pbpC ycsM yzsA BSU04140 
Penicillin-binding protein 3 (PBP 3) (PSPB20) 
(Penicillin-binding protein C) 
Y SpII Y 
C0SP80 yteS BSU30110 Putative lipoprotein YteS Y SpII Y 
P96647 yddJ BSU04990 Uncharacterized protein YddJ Y SpII Y 
Q45462 opuBC proX BSU33710 Choline-binding protein Y SpII Y 
P36949 rbsB BSU35960 D-ribose-binding protein Y SpII Y 
O31851 yojM BSU19400 Superoxide dismutase-like protein YojM Y SpII Y 
P94446 coxA yrbB BSU27830 Sporulation cortex protein CoxA Y SpII Y 
O32128 yutC BSU32320 Uncharacterized lipoprotein YutC Y SpII Y 
P39072 gerM BSU28380 Spore germination protein GerM Y SpII Y 
Q795R2 ytcQ BSU30160 
Putative ABC transporter peptide-binding protein 
YtcQ 
Y SpII Y 
P39596 efeM ywbM BSU38270 ipa-28d Probable iron uptake system component EfeM Y SpII Y 
Q01625 misCA spoIIIJ BSU41040 
Membrane protein insertase MisCA (Foldase YidC 2) 
SpoIIIJ 
Y SpII Y 
O34852 tcyK ytmK BSU29370 L-cystine-binding protein TcyK Y SpII Y 
P16450 gerD BSU01550 Spore germination protein GerD Y SpII Y 
P54598 yhcN BSU09150 Lipoprotein YhcN Y SpII Y 
P94528 araN yseC BSU28750 Probable arabinose-binding protein Y SpII Y 
O31835 yobA BSU18810 Uncharacterized protein YobA Y SpII Y 
O32005 yokB BSU21650 
SPBc2 prophage-derived uncharacterized lipoprotein 
YokB 
Y SpII Y 
C0SP99 yciB BSU03350 Putative L,D-transpeptidase YciB (EC 2.-.-.-) Y SpII Y 
P54498 yqgU BSU24820 Uncharacterized lipoprotein YqgU Y SpII Y 
O07013 ganB galA yvfO BSU34120 Arabinogalactan endo-beta-1,4-galactanase Y SpII Y 
P40400 ssuA ygbA yzeA BSU08840 Putative aliphatic sulfonates-binding protein Y SpII Y 
O31518 yesO BSU06970 
Putative ABC transporter substrate-binding protein 
YesO 
Y SpII Y 
P42307 yxiP S3B BSU39090 Uncharacterized protein YxiP Y SpII Y 
C0SP84 
ytlA ytlB BSU30595 
BSU30590/BSU30600 
Putative binding protein YtlA Y SpII Y 
P54594 yhcJ BSU09110 Uncharacterized lipoprotein YhcJ Y SpII Y 
O32189 yusW BSU32950 Uncharacterized protein YusW Y SpII Y 
O31486 ydaJ BSU04270 Putative lipoprotein YdaJ Y SpII Y 
O07634 ylaJ BSU14800 Uncharacterized lipoprotein YlaJ Y SpII Y 
P39571 gerBC BSU35820 Spore germination protein B3 Y SpII Y 
Possible Lipoproteins (15) 
P54945 yxeF BSU39570 HS74F Uncharacterized protein YxeF N SpII Y 
O32436 med BSU11300 Transcriptional activator protein med N SpII Y 
O35028 yfkR BSU07780 Putative spore germination protein YfkR N SpII Y 
O32243 opuCC yvbC BSU33810 
Glycine betaine/carnitine/choline-binding protein 
OpuCC 
N SpII Y 
O31810 yndF BSU17770 Spore germination protein YndF N SpII Y 
P39911 yphF johF BSU22810 Uncharacterized protein YphF (ORF1) N SpII Y 
P24011 ctaC BSU14890 Cytochrome c oxidase subunit 2 N SpII Y 
P40773 yfjL yztA BSU08050 Uncharacterized protein YfjL (PSPB19') N SpII Y 
P07870 gerAC gerA3 BSU33070 Spore germination protein A3 N SpII Y 
P21884 ykyA ykrC BSU14570 Uncharacterized lipoprotein YkyA N SpII Y 
P37488 yybP BSU40560 Uncharacterized lipoprotein YybP N SpII Y 
C0H3R7 yvzJ BSU34729 Uncharacterized lipoprotein YvzJ N SpII Y 
P54451 yqeF BSU25700 Uncharacterized lipoprotein YqeF N SpII Y 
P54178 ypmQ BSU21750 SCO1 protein homolog (BsSco) N SpII Y 
P39910 slp pal BSU14620 Pal-related lipoprotein N SpII Y 
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Table 20: A table of homologues to predicted lipoproteins in C. difficile 630, identified by amino acid sequence similarity to predicted lipoproteins in R20291 and M120. Phylogenetic analysis 
was performed using ClustalΩ; homologues which were not predicted to be lipidated but identified as lipoproteins manually (Chapter 2.2 and 6.4) are included, indicated by *.  
C. difficile 
630 Uniprot 
Accession 
Number C. difficile 630 Protein names 
Homologous Gene Names 
630 
Homologous Gene Names 
R20291 
Homologous Gene Names 
M120 
Q183A6 
ABC-type transport system, oligopeptide-family solute-binding 
protein 
appA CD630_26720 appA CDR20291_2560* appA_M120_RT078_26851 
Q18CR2 Putative lipoprotein CD630_01730 CDR20291_0174 M120_RT078_01951 
Q18CT7 Putative membrane-associated nucleotidase CD630_01990 - M120_RT078_02241 
Q188Y7 Putative lipoprotein CD630_05450 CDR20291_0470 M120_RT078_06141 
Q189B5 Putative lipoprotein CD630_05690 CDR20291_0493 M120_RT078_06371 
Q189N2 Putative nucleotide phosphodiesterase CD630_06890 CDR20291_0615 M120_RT078_07441 
Q189N6 Putative nucleotide phosphodiesterase CD630_06900 - M120_RT078_07471 
Q189Q1 Putative diguanylate kinase signaling protein CD630_07070 CD630_14760 - 
Q189U5 Putative lipoprotein CD630_07470 CDR20291_0675 M120_RT078_08091 
Q189U7 
ABC-type transport system, aminoacid-family extracellular 
solute-binding protein 
CD630_07500 CDR20291_0678 M120_RT078_08121 
Q18A65 
ABC-type transport system, sugar-family extracellular solute-
binding protein 
CD630_08730 CDR20291_0802 M120_RT078_09351 
Q18A71 
ABC-type transport system, sugar-family extracellular solute-
binding protein 
CD630_08760 CDR20291_0805 M120_RT078_09381 
Q183Z1 Putative phage lipoprotein CD630_09570 - - 
Q18AJ9 
ABC-type transport system,nitrate/sulfonate/taurine 
extracellular solute-binding protein 
CD630_09990 CDR20291_0852 M120_RT078_09851 
Q18AT3 Putative lipoprotein CD630_10800 CDR20291_0939 M120_RT078_10761 
Q18AX9 Putative lipoprotein CD630_11190 CDR20291_0950 M120_RT078_19871 
Q18AZ4 Putative solute-binding lipoprotein CD630_11310 CDR20291_0967 M120_RT078_11051 
Q18B93 Putative lipoprotein CD630_12320 CDR20291_1069 - 
Q18BL3 Putative lipoprotein CD630_13480 CDR20291_1190 M120_RT078_13251 
Q18BZ5 Putative signaling protein CD630_14760 - M120_RT078_14601 
Q18C05 Putative lipoprotein CD630_14860 CDR20291_1335 M120_RT078_14711 
Q18C25 Putative thioredoxin CD630_15070 CDR20291_1753 M120_RT078_14971 
Q18C31 Putative lipoprotein CD630_15090 CDR20291_1358 M120_RT078_14991 
Q18C77 Putative peptidylprolyl isomerase (EC 5.2.1.8) CD630_15570 CDR20291_3337* M120_RT078_15501* 
Q186E4 
ABC-type transport system, sugar-family extracellular solute-
binding protein 
CD630_15890 CDR20291_1487 M120_RT078_17231 
Q186H8 Peptidase propeptide and ypeb domain protein CD630_16220 CDR20291_1520 M120_RT078_16141 
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Q186K7 Putative Probable D-methionine-binding lipoprotein CD630_16530 CDR20291_1551 M120_RT078_16421 
Q186P2 Putative lipoprotein CD630_16870 CDR20291_1585 M120_RT078_16771 
Q186X7 Putative lipoprotein CD630_17660 CDR20291_1661 M120_RT078_17721 
Q186Y3 
ABC-type transport system, aminoacid-family extracellular 
solute-binding protein 
CD630_17740 CDR20291_1669 M120_RT078_17801 
Q186Z3 Putative lipoprotein CD630_17810 CDR20291_1676 M120_RT078_17871 
Q187U0 ABC-type transport system, extracellular solute-binding protein CD630_19790 CDR20291_1902 M120_RT078_19451 
Q187V2 Putative lipoprotein CD630_19920 CDR20291_1916 M120_RT078_19781 
Q187Z8 Putative lipoprotein CD630_20290 CDR20291_1942 M120_RT078_20321 
Q188C2 Putative lipoprotein CD630_20520 CDR20291_1959 M120_RT078_20501 
Q185W2 
ABC-type transport system,cystine/aminoacid-family 
extracellular solute-binding protein 
CD630_21740 CDR20291_2080 M120_RT078_21901 
Q185W5 
ABC-type transport system,cystine/aminoacid-family 
extracellular solute-binding protein 
CD630_21770 CDR20291_2083 - 
Q185I4 
ABC-type transport system, molybdenum-like extracellular 
solute-binding protein 
CD630_23110 CDR20291_2200 M120_RT078_23151 
Q185N5 
ABC-type transport system,nitrate/sulfonate/taurine 
extracellular solute-binding protein 
CD630_23650 CDR20291_2252 M120_RT078_23691 
Q181Z0 Putative lipoprotein CD630_24060 CDR20291_2296 M120_RT078_24141 
Q182G4 Putative DNA uptake transporter CD630_24780 CDR20291_2371 - 
Q182G8 Putative lipoprotein CD630_24820 CDR20291_2375 M120_RT078_24941 
Q182M5 Putative lipoprotein CD630_25380 CDR20291_2425 M120_RT078_25541 
Q182N7 
ABC-type transport system, sugar-family extracellular solute-
binding protein 
CD630_25500 CDR20291_2437 M120_RT078_25681 
Q182Y0 
ABC-type transport system, sugar-family extracellular solute-
binding protein 
CD630_26450 CDR20291_2533 M120_RT078_26591 
Q183D5 Putative lipoprotein CD630_27010 CDR20291_2589 M120_RT078_27201 
Q183F4 Putative polysaccharide deacetylase CD630_27190 CDR20291_2608 M120_RT078_27421 
Q183J7 Putative lipoprotein CD630_27630 CDR20291_2651 M120_RT078_27881 
Q184D9 
ABC-type transport system, iron-family extracellular solute-
binding protein 
CD630_29530 - M120_RT078_29181 
Q184J0 iron ABC transporter substrate-binding protein CD630_29990 CDR20291_2835* M120_RT078_29671 
Q180R1 
ABC-type transport system, sugar-family extracellular solute-
binding protein 
CD630_34140 CDR20291_3236 M120_RT078_33571 
Q180W3 Putative lipoprotein CD630_34640 CDR20291_1355 M120_RT078_34111 
Q181C3 
ABC-type transport system, iron-family extracellular solute-
binding protein 
CD630_35250 CDR20291_3362 - 
Q181C7 
ABC-type transport system, iron-family extracellular solute-
binding protein 
CD630_35280 CDR20291_3363 - 
Q181S4 Putative exported protein CD630_36690 CDR20291_3529 M120_RT078_36221 
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Q183E7 Putative cell wall protein cwp22 cwp22 CD630_27130 CDR20291_2601 - 
Q188M7 Putative cell wall binding protein cwp27 cwp27 CD630_04400 CDR20291_0381 M120_RT078_12081 
Q183W4 
ABC-type transport system, ferrichrome-specific extracellular 
solute-binding protein 
fhuD CD630_28780 fhuD CDR20291_2774 M120_RT078_29041 
Q18C11 
ABC-type transport system, methionine-specific substrate-
binding lipoprotein 
metQ CD630_14910 metQ CDR20291_1341 metQ_M120_RT078_14761 
Q18A64 
ABC-type transport system, molybdenum-specific extracellular 
solute-binding protein 
modA CD630_08690 modA CDR20291_0798 M120_RT078_09311 
Q18A51 
ABC-type transport system, oligopeptide-family extracellular 
solute-binding protein 
oppA CD630_08550 oppA CDR20291_0785 oppA_M120_RT078_09181 
Q18AM5 
ABC-type transport system,spermidine/putrescine solute-
binding protein 
potD CD630_10270 potD CDR20291_0883 potD_M120_RT078_10181 
Q180Z8 Peptidylprolyl isomerase PrsA-like (EC 5.2.1.8) prsA1 CD630_35000 CDR20291_1406* M120_RT078_34491* 
Q180B2 
ABC-type transport system, phosphate extracellular solute-
binding protein 
pstS CD630_32680 CDR20291_3129 pstS_M120_RT078_32461 
Q18D38 
ABC-type transport system, ribose-specific extracellular solute-
binding protein 
rbsB CD630_03000 rbsB CDR20291_0303 rbsB_M120_RT078_03041 
Q18B57 Stage III sporulation protein AG spoIIIAG CD630_11980 spoIIIAG CDR20291_1036 spoIIIAG_M120_RT078_11731 
Q18C04 
ABC-type transport system,alkanesulfonates-family 
extracellular solute-binding protein 
ssuA CD630_14840 ssuA CDR2029_1333* - 
Q184I1 
ABC-type transport system, sulfonate-family extracellular 
solute-binding protein 
ssuA2 CD630_29890 CDR20291_2824 ssuA2_M120_RT078_29561 
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C. Experimentally Verified Lipoproteomes 
This appendix contains curated lists of the lipoproteins identified by proteomic quantification of the 
competition between YnC12 and an excess of myristic acid, for C. difficile 630 Δerm and R20291 
(Chapter 6.2). In the case of 630 Δerm verification from all proteomic experiments is included; this 
comprises the optimised LFQ comparisons between YnC12 and myristic acid tagged lipoproteomes 
and betwee YnC12 treated 630 Δerm and lgt::erm (Chapter 5.2.2 and 5.4.2.1). Also included are the 
results of quantitative proteomic experiments using dimethyl labelling that verify lipidation, 
comprised of the comparison between YnC12 tagged lipoproteins from 630 Δerm and lgt::erm 
(Chapter 7.2.1) and the comparison of the proteins shed into the media between 630 Δerm and 
lgt::erm (Chapter 7.2.3). Proteins names and gene IDs were extracted from Uniprot 
(http://www.uniprot.org) and further domain information from the Pfam database 
(http://pfam.xfam.org). 
Table Number  Brief Description 
Table 21 The experimentally verified lipoproteome of C. difficile 630 Δerm. 
Table 22 The experimentally verified lipoproteome of C. difficile C. difficile R20291. 
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Table 21: The experimentally validated lipoproteome of C. difficile 630 Δerm. Identification and significant enrichment, or loss thereof, for each protein is indicated by + for the given 
experiments. A total of 58 lipoproteins were identified in at least one experiment, corresponding to 82 % of the predicted lipoproteome and 2 non-predicted lipoproteins. 
Uniprot Accession 
Number Gene names Uniprot Protein Names Pfam Domains Pfam Domain Names Pr
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Q183A6 
appA 
CD630_26720 
ABC-type transport system, 
oligopeptide-family solute-binding 
protein 
SBP_bac_5 
Bacterial extracellular solute-
binding protein 
+ + + + + + 
Q18CR2 CD630_01730 Putative lipoprotein PGA_cap 
Bacterial capsule synthesis protein 
PGA_cap 
+ + + + +   
Q18CT7 CD630_01990 
Putative membrane-associated 
nucleotidase 
Metallophos Calcineurin-like phosphoesterase + + + + +   
Q188Y7 CD630_05450 Uncharacterized protein 
  
+ + + + + + 
Q189B5 CD630_05690 Putative lipoprotein Bmp Basic membrane protein + + + + +   
Q189N2 CD630_06890 
Putative nucleotide 
phosphodiesterase 
PGA_cap, Metallophos 
Bacterial capsule synthesis protein 
PGA_cap, Calcineurin-like 
phosphoesterase 
+ + + + +   
Q189N6 CD630_06900 
Putative nucleotide 
phosphodiesterase 
PGA_cap, Metallophos 
Bacterial capsule synthesis protein 
PGA_cap, Calcineurin-like 
phosphoesterase 
+ +         
Q189Q1 CD630_07070 
Putative diguanylate kinase 
signalling protein 
SBP_bac_3, GGDEF 
Bacterial extracellular solute-
binding protein, Cyclic di-GMP 
synthesis  
+ + 
   
  
Q189U5 CD630_07470 Putative lipoprotein SBP_bac_8 
Bacterial extracellular solute-
binding protein 
+ + + + + + 
Q189U7 CD630_07500 
ABC-type transport system, 
aminoacid-family extracellular 
solute-binding protein 
SBP_bac_3 
Bacterial extracellular solute-
binding protein 
+ + + + +   
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Q18A65 CD630_08730 
ABC-type transport system, sugar-
family extracellular solute-binding 
protein 
ABC_sub_bind 
ABC transporter substrate binding 
protein 
+ + + + + + 
Q18A71 CD630_08760 
ABC-type transport system, sugar-
family extracellular solute-binding 
protein 
ABC_sub_bind 
ABC transporter substrate binding 
protein 
+ +       + 
Q183Z1 
CD630_09570 
CD630_29070 
Putative phage lipoprotein 
  
+ + + + +   
Q18AJ9 CD630_09990 
ABC-type transport 
system,nitrate/sulfonate/taurine 
extracellular solute-binding protein 
NMT1_2 
Closely related to NMT1/ THI5-like 
domains 
+ + + + + + 
Q18AT3 CD630_10800 Putative lipoprotein 
  
+ + + + +   
Q18AZ4 CD630_11310 Putative solute-binding lipoprotein SBP_bac_5 
Bacterial extracellular solute-
binding protein 
+ + + + + + 
Q18B93 CD630_12320 Putative lipoprotein TPR_11, TPR_1 Tetratricopeptide repeat (TPR) + + + + +   
Q18BL3 CD630_13480 Putative lipoprotein 
  
+ + 
   
  
Q18C25 CD630_15070 Putative thioredoxin Redoxin Redoxin  + + + + +   
Q18C31 CD630_15090 Putative lipoprotein 
  
+ + 
 
+ +   
Q18C77 CD630_15570 
Putative peptidylprolyl isomerase 
(EC 5.2.1.8) 
SurA_N_3, Rotamase_3 
 N-terminus of the chaperone SurA, 
Peptidylprolyl isomerase 
+ +   +     
Q186E4 CD630_15890 
ABC-type transport system, sugar-
family extracellular solute-binding 
protein 
Peripla_BP_4 Periplasmic binding protein domain + + + + +   
Q186H8 CD630_16220 Uncharacterized protein PepSY 
Peptidase propeptide and YPEB 
domain 
+ + + + +   
Q186K7 CD630_16530 Lipoprotein Lipoprotein_9 NLPA lipoprotein + + + + + + 
Q186P2 CD630_16870 Uncharacterized protein     + +   + +   
Q186Y3 CD630_17740 
ABC-type transport system, 
aminoacid-family extracellular 
solute-binding protein 
SBP_bac_3 
Bacterial extracellular solute-
binding protein 
+ + + + +   
Q186Z3 CD630_17810 Putative lipoprotein     + + + + +   
Q187I1 CD630_18710 
Putative oxidoreductase Tn1549-
like,CTn5-Orf30 
AhpC-TSA 
Alkyl hydroperoxide reductase 
(AhpC) and thiol specific antioxidant 
(TSA) related 
 
  + + +   
Q187P0 CD630_19300 Uncharacterized protein Lactamase_B Metallo-beta-lactamase protein fold   +   +     
Q187U0 CD630_19790 
ABC-type transport system, 
extracellular solute-binding protein 
NMT1 
NMT1/ THI5-like; biosynthesis of 
the pyrimidine moiety of thiamine 
+ + + + + + 
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Q187V2 CD630_19920 Putative lipoprotein Lumazine_bd, TPR_1 
Lumazine-binding domain, 
Tetratricopeptide repeat (TPR) 
+ +   +     
Q187Z8 CD630_20290 Uncharacterized protein Lumazine_bd Lumazine-binding domain + + + + +   
Q188C2 CD630_20520 Putative lipoprotein     + + + + +   
Q185W2 CD630_21740 
ABC-type transport 
system,cystine/aminoacid-family 
extracellular solute-binding protein 
SBP_bac_3 
Bacterial extracellular solute-
binding protein 
+ + + + + + 
Q185W5 CD630_21770 
ABC-type transport 
system,cystine/aminoacid-family 
extracellular solute-binding protein 
SBP_bac_3 
Bacterial extracellular solute-
binding protein 
+ + + + + + 
Q185I4 CD630_23110 
ABC-type transport system, 
molybdenum-like extracellular 
solute-binding protein 
SBP_bac_11 
Bacterial extracellular solute-
binding protein 
+ + 
 
+ 
 
  
Q185N5 CD630_23650 
ABC-type transport 
system,nitrate/sulfonate/taurine 
extracellular solute-binding protein 
NMT1_2 
Closely related to NMT1/ THI5-like 
domains 
+ + + + + + 
Q181Z0 CD630_24060 Putative lipoprotein HlyD_2 HlyD family secretion protein + + + + + + 
Q182M5 CD630_25380 Putative lipoprotein     + +   +     
Q182N7 CD630_25500 
ABC-type transport system, sugar-
family extracellular solute-binding 
protein 
SBP_bac_1 
Bacterial extracellular solute-
binding protein 
+   +       
Q182Y0 
CD630_25500;CD6
30_26450 
ABC-type transport system, sugar-
family extracellular solute-binding 
protein;ABC-type transport system, 
sugar-family extracellular solute-
binding protein 
SBP_bac_1 
Bacterial extracellular solute-
binding protein 
+ + 
 
+ + + 
Q183D5 CD630_27010 Putative lipoprotein DUF3798 
Bacterial lipoprotein of unknown 
function 
+ + + + + + 
Q183F4 CD630_27190 Putative polysaccharide deacetylase Polysacc_deac_1 polysaccharide deacetylase + + + + +   
Q183J7 CD630_27630 Putative lipoprotein DUF4358 
Bacterial domain of unknown 
function 
+ + + + +   
Q184J0 CD630_29990 
ABC-type transport system, iron-
family extracellular solute-binding 
protein 
Peripla_BP_2 Periplasmic binding protein + + + + + + 
Q180R1 CD630_34140 
ABC-type transport system, sugar-
family extracellular solute-binding 
protein 
SBP_bac_1, SBP_bac_8 
Bacterial extracellular solute-
binding protein 
+ +         
Q181C3 CD630_35250 
ABC-type transport system, iron-
family extracellular solute-binding 
SBP_bac_6 
Bacterial extracellular solute-
binding protein 
+   + 
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protein 
Q181C3;Q181C7 CD630_35280 
ABC-type transport system, iron-
family extracellular solute-binding 
protein;ABC-type transport system, 
iron-family extracellular solute-
binding protein 
SBP_bac_6 
Bacterial extracellular solute-
binding protein 
+ +   + +   
Q181S4 CD630_36690 Putative exported protein Germane 
GerMN domain; implicated in both 
sporulation and spore germination 
+ + + + + + 
Q183E7 
Cwp22 
CD630_27130 
Putative cell wall protein CW_binding_1, YkuD 
Putative cell wall binding repeat, 
L,D-transpeptidase catalytic 
domain; beta-lactam antibiotic 
resistance 
+ + 
   
  
Q18C11 
metQ 
CD630_14910 
ABC-type transport system, 
methionine-specific substrate-
binding lipoprotein 
Lipoprotein_9 NLPA lipoprotein + + +   + + 
Q18A64 
modA 
CD630_08690 
ABC-type transport system, 
molybdenum-specific extracellular 
solute-binding protein 
SBP_bac_11 
Bacterial extracellular solute-
binding protein 
+ + + + 
 
  
Q18A51 
oppA 
CD630_08550 
ABC-type transport system, 
oligopeptide-family extracellular 
solute-binding protein 
SBP_bac_5 
Bacterial extracellular solute-
binding protein 
+ + + + + + 
Q18AM5 
potD 
CD630_10270 
ABC-type transport 
system,spermidine/putrescine 
solute-binding protein 
SBP_bac_8 
Bacterial extracellular solute-
binding protein 
+ + + + 
 
  
Q180Z8 
prsA 
CD630_35000 
Peptidylprolyl isomerase PrsA-like 
(EC 5.2.1.8) 
SurA_N_3, Rotamase_3 
 N-terminus of the chaperone SurA, 
Peptidylprolyl isomerase 
+ + + + + + 
Q18D38 
rbsB 
CD630_03000 
ABC-type transport system, ribose-
specific extracellular solute-binding 
protein 
Peripla_BP_4 Periplasmic binding protein domain + + + + +   
Q18C04 
ssuA 
CD630_14840 
ABC-type transport 
system,alkanesulfonates-family 
extracellular solute-binding protein 
NMT1 
NMT1/ THI5-like; biosynthesis of 
the pyrimidine moiety of thiamine 
+ + + + + + 
Q184I1 
ssuA2 
CD630_29890 
ABC-type transport system, 
sulfonate-family extracellular 
solute-binding protein 
NMT1 
NMT1/ THI5-like; biosynthesis of 
the pyrimidine moiety of thiamine 
+ + + 
  
+ 
  
 
     Total Proteins: 56 55 43 48 42 22 
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Table 22: The experimentally validated lipoproteome of C. difficile R20291. Identification and significant loss of enrichment on competition between YnC12 and an excess of myristic acid is 
indicated by + for each protein; a total of 40 lipoproteins were identified, corresponding to 57 % of the predicted lipoproteome and 5 non-predicted lipoproteins. 
Uniprot 
Accession 
Number 
Gene names Uniprot Protein Names Pfam Domains Pfam Domain Names 
P
re
d
ic
te
d
 L
ip
o
p
ro
te
in
 
R
2
0
2
9
1
 C
o
m
p
e
ti
ti
o
n
 (
p
 ≤
0
.0
1
) 
C9YPP5 appA CDR20291_2560 
Oligopeptide ABC transporter, substrate-binding 
protein 
SBP_bac_5 Bacterial extracellular solute-binding protein   + 
C9YIS6 CDR20291_0470 Putative lipoprotein 
  
+ + 
C9YIU9 CDR20291_0493 Putative outer membrane lipoprotein Bmp Basic membrane protein + + 
C9YJ67 CDR20291_0616;CDR20291_0615 
Putative nucleotide phosphodiesterase;Putative 
nucleotide phosphodiesterase 
PGA_cap, 
Metallophos 
Bacterial capsule synthesis protein PGA_cap, 
Calcineurin-like phosphoesterase 
+ + 
C9YJC5 CDR20291_0675 Putative lipoprotein SBP_bac_8 Bacterial extracellular solute-binding protein + + 
C9YJC8 CDR20291_0678 
Amino acid ABC transporter, substrate-binding 
protein 
SBP_bac_3 Bacterial extracellular solute-binding protein + + 
C9YJV2 CDR20291_0852 ABC transporter, substrate-binding lipoprotein NMT1_2 
NMT1/THI5 like required for the biosynthesis 
of the pyrimidine moiety of thiamine 
+ + 
C9YK38 CDR20291_0939 Putative lipoprotein 
  
+ + 
C9YK66 CDR20291_0967 Putative solute-binding lipoprotein SBP_bac_5 Bacterial extracellular solute-binding protein + + 
C9YKG8 CDR20291_1069 Putative lipoprotein TPR_11, TPR_1 TPR repeat + + 
C9YLA3 CDR20291_1355 Putative thioredoxin Redoxin Redoxin    + 
C9YLA6 CDR20291_1358 Putative lipoprotein 
  
+ + 
C9YLF4 CDR20291_1406 Putative peptidyl-prolyl isomerase 
SurA_N_3, 
Rotamase_3 
SurA N-terminal domain, peptidylprolyl 
isomerase 
+ + 
C9YLN4 CDR20291_1487 
Putative ribose ABC transporter, substrate-
binding lipoprotein 
Peripla_BP_4 Periplasmic binding protein domain  + + 
C9YLR7 CDR20291_1520 Putative lipoprotein PepSY Peptidase propeptide and YPEB domain + + 
C9YLU8 CDR20291_1551 Lipoprotein Lipoprotein_9 NLPA lipoprotein + + 
C9YLY2 CDR20291_1585 Putative lipoprotein Pfam-B_6545   + + 
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C9YM65 CDR20291_1669 
Amino acid ABC transporter, substrate-binding 
protein 
SBP_bac_3 
Bacterial extracellular solute-binding 
proteins, family 3  
+ + 
C9YM72 CDR20291_1676 Putative lipoprotein     + + 
C9YMJ4 CDR20291_1801 Putative exported protein AhpC-TSA AhpC/TSA family + + 
C9YMU3 CDR20291_1902 ABC transporter, substrate-binding protein NMT1 NMT1/THI5 like + + 
C9YNC1 CDR20291_2080 
Probable amino-acid ABC transporter, substrate-
binding protein 
SBP_bac_3 
Bacterial extracellular solute-binding 
proteins, family 3  
+ + 
C9YNC4 CDR20291_2083 
Probable amino-acid ABC transporter, substrate-
binding protein 
SBP_bac_3 
Bacterial extracellular solute-binding 
proteins, family 3  
+ + 
C9YNN9 CDR20291_2200 ABC transporter, substrate-binding protein Pfam-B_15444 
 
+ + 
C9YNU0 CDR20291_2252 
Putative sulfonate ABC transporter, solute-
binding lipoprotein 
NMT1_2, 
SBP_bac_11 
NMT1-like family;  Bacterial extracellular 
solute-binding protein 
+ + 
C9YPB1 CDR20291_2425 Putative lipoprotein 
  
+ + 
C9YPC3 CDR20291_2437 
Putative sugar transporter, substrate-binding 
lipoprotein 
SBP_bac_1 Bacterial extracellular solute-binding protein + + 
C9YPL9 CDR20291_2533 Putative extracellular solute-binding protein SBP_bac_1 Bacterial extracellular solute-binding protein + + 
C9YPS4 CDR20291_2589 Putative lipoprotein DUF3798 
Protein of unknown function 
(DUF3798)Provide 
+ + 
C9YPU3 CDR20291_2608 Probable polysaccharide deacetylase Polysacc_deac_1 Polysaccharide deacetylase + + 
C9YPY6 CDR20291_2651 Putative lipoprotein DUF4358 Domain of unknown function (DUF4358) + + 
C9YQG9 CDR20291_2835 
Putative iron ABC transporter, substrate-binding 
protein 
Peripla_BP_2 Periplasmic binding protein   + 
C9YQW5 CDR20291_2983 
Abc-type fe3+ transport system periplasmic 
component-like protein 
SBP_bac_6 Bacterial extracellular solute-binding protein + + 
C9YSG1 CDR20291_3529 Putative exported protein Germane Sporulation and spore germination + + 
C9YL89 metQ CDR20291_1341 
Putative D-methionine ABC transporter, 
substrate-binding lipoprotein 
Lipoprotein_9 NLPA lipoprotein + + 
C9YJP8 modA CDR20291_0798 
Putative molybdenum ABC transporter, 
substrate-binding protein 
SBP_bac_11 Bacterial extracellular solute-binding protein + + 
C9YJN5 oppA CDR20291_0785 
Oligopeptide ABC transporter, substrate-binding 
lipoprotein 
SBP_bac_5 Bacterial extracellular solute-binding protein + + 
C9YRW9 prsA CDR20291_3337 
Putative foldase lipoprotein (Late stage protein 
export lipoprotein) 
SurA_N_3, 
Rotamase_3 
SurA N-terminal domain; peptidylprolyl 
isomerase 
  + 
C9YIB0 rbsB CDR20291_0303 
D-ribose ABC transporter, substrate-binding 
protein 
Peripla_BP_4 Periplasmic binding protein domain + + 
C9YL81 ssuA CDR20291_1333 
Putative aliphatic sulfonates ABC transporter, 
substrate-binding lipoprotein 
NMT1 
NMT1/THI5 like required for the biosynthesis 
of the pyrimidine moiety of thiamine 
  + 
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     Total Proteins:  35 40 
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D. Supplementary Electronic Information 
Appendix D contains a guide to the supplementary electronic information. Supplementary proteomic 
information is provided as searchable excel spreadsheets, containing all proteins identified in a 
defined number of biological repeats, as described in the main text. Each file contains a key, which 
explains the data contained in the workbook in further detail. Proteomics data were generated as 
described in Chapter 9.2.10 and processed using MaxQuant (Chapter 9.2.11); further analysis was 
performed using Perseus and the data exported into Excel for inclusion in the supplementary 
information. 
Table 23: A guide to the supplementary electronic information associated with this thesis. 
Number File Name Brief Description 
Associated 
Chapter 
S1 
 
Initial LFQ Data 
Initial label free proof of principle proteomic experiments, including a 
comparison between YnC12 and myristic acid fed C. difficile 630 Δerm 
and a comparison between YnC12 treated 630 Δerm and lgt::erm. 
5.2 
S2 
SILAC 
Development 
Peptide data, heavy to light ratios and percentage incorporation for Ile(7) 
SILAC C. difficile 630 and 630 Δerm ΔilvD; heavy only and a 1:1 mixture of 
heavy to light labelled samples for both strains. 
5.3.1 
S3 
Dimethyl 
Development 
Peptide data for the assessment of dimethyl labelling efficiency (light 
reagents only) and a proof of principle experiment comparing YnC12 and 
myristic acid treated C. difficile 630 Δerm by duplex dimethyl labelling. 
5.4 
S4 
Optimised LFQ 
Analysis 
All proteins identified in an optimised LFQ experiment comparing YnC12 
treated 630 Δerm to myristic acid treated 630 Δerm. 
5.4 
S5 
Competition 
Experiments 
Proteomic identification of lipoproteins from 630 Δerm and R20291 by 
quantification (triplex dimethyl labelling) of the competition between 
YnC12 and a 5- or 10- fold excess of myristic acid. 
6 
S6 
Lgt Mutant 
Proteomics 
A quantitative (duplex dimethyl labelling) comparison between the 
lipoproteome and soluble and insoluble sub-proteomes of C. difficile 630 
Δerm and lgt::erm. 
7.1.1 & 7.1.4 
S7 
LspA and LspA2 
Mutant 
Proteomics 
A quantitative (triplex dimethyl labelling) comparison between the 
lipoproteome and soluble and insoluble sub-proteomes of C. difficile 630 
Δerm, lspA::erm and lspA2::erm. 
7.1.2 & 7.1.4 
S8 
Shed 
Proteomes of 
the Lipoprotein 
Biogenesis 
Mutants 
Quantification of the differences in proteins shed into the media by 
lgt::erm (duplex dimethyl labelling), lspA::erm and lspA2::erm (triplex 
dimethyl labelling), relative to 630 Δerm. 
7.1.3 
S9 
Spo0A Mutant 
Proteomics 
A quantitative comparison between the lipoproteome and soluble and 
insoluble sub-proteome of spo0A::erm and 630 Δerm. Quantification of 
the competition between YnC12 and a 5-fold excess of myristic acid, for 
spo0A::erm.  
7.2.1 
S10 
CodY Mutant 
Proteomics 
A quantitative comparison between the lipoproteome and soluble and 
insoluble sub-proteome of codY::erm and 630 Δerm. Quantification of 
the competition between YnC12 and a 5-fold excess of myristic acid, for 
codY::erm. 
7.2.2 
 
